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ABSTRACT 
 
Design, Syntheses and Applications of Fluorescent Dyes. 
(August 2009) 
Liangxing Wu, B.S., University of Science and Technology of China 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
 New methodologies for the efficient syntheses of 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacenes (BODIPYs) and rosamines were developed. A serendipitous discovery 
led to a new reaction which afforded BODIPYs in high yields. Systematic studies of the 
kinetics and mechanisms of the new reaction were performed. A series of BODIPYs 
were successfully prepared using the new approach. A simple and efficient synthesis of 
rosamines with cyclic-amine substituents was devised. These new rosamines showed 
interesting anti-tumor activities. 
Several types of novel fluorescent compounds were prepared. Highly fluorescent 
GFP-chromophore analogs were designed and synthesized. The correlation between the 
optical properties and the structures was investigated. New pyronin dyes with meso-
heteroatom substituents were efficiently prepared. The fluorescence properties of these 
compounds were highly dependent on the nature of the meso-substituents. A set of 
BODIPY dyes that fluoresce brightly above 600 nm were made. They were then used as 
acceptors to prepare water-soluble through-bond energy transfer cassettes. All the 
cassettes had complete energy transfer and high quantum yields in MeOH. A few also 
had good fluorescence properties in aqueous media and even on proteins. 
The through-bond energy transfer cassettes were used to monitor protein-protein 
interactions. In order to test our hypothesis, an artificial protein interaction system was 
built by utilizing the biotin/(strept)avidin interactions. Thus Atto425-BSA-biotin, 
streptavidin-cassette1 and avidin-cassette2 were prepared. The interactions between 
Atto425-BSA-biotin and cassette labeled (strept)avidin were successfully detected in 
vitro and in living cells by fluorescence techniques. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Fluorescence  
 Fluorescence detection is highly sensitive and easy to operate. There has been 
dramatic growth in the use of fluorescence in the past few decades. Fluorescence 
technology has now been widely used by scientists from many different disciplines.
 Fluorescence is the emission of light from any substance and occurs from 
electronically excited singlet states. Emission of light from triplet excited states is 
phosphorescence.1 The processes that occur between the absorption and emission of 
light are usually illustrated by the Jablonski diagram (Figure 1.1.). Absorption of 
photons will excite a fluorophore into singlet excited states S1 or S2. This process is very 
quick and happens within 10-15s. Fast internal conversion (10-12s) brings the fluorophore 
to the lowest vibrational level of S1. Emission of light around 10-8s returns the molecules 
to the ground state. Molecules in the S1 state can also undergo spin conversion to the 
first triplet state T1. Transition from T1 to S1 is forbidden, thus emissions from T1 are 
much slower (ms to s). 
 
0
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Figure 1.1. A typical Jablonski diagram. 
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Since the energy spacing between the vibrational levels in S0 and S1 is similar, 
there often exists mirror image symmetry between the emission spectrum and the S0→S1 
absorption spectrum. Another general property of fluorescence is that the same 
fluorescence emission spectrum is generally observed regardless of the excitation 
wavelength.  
 
S0
S1
hv2
hv1
hvF
Fluorescence
Internal Conversion
hv2
two-photon
absorpt ion
one-photon
absorption
 
 
Figure 1.2. Jablonski diagram for two-photon excitation. 
 
A fluorophore can also be excited by absorbing two photons simultaneously 
(Figure 1.2.). This process is two-photon excitation.2 Irrespective of the excitation 
wavelength, the fluorophore still emits from the lowest energy level of the relaxed S1 
state. Two-photon absorption cross-section describes the probability of the simultaneous 
absorption of two photons and transition of the fluorophore to an excited state that 
differs energetically from the ground state by the energy of the two photons.3 The 
physical origin of the two-photon cross-section can be understood by some simple 
comparison.1 For one-photon absorption, the absorption coefficients are usually 
expressed as the molar extinction coefficients in units of M-1cm-1. The single molecule 
one photon absorption σ1 can be described in units of cm2, which is the effective area 
over which a single molecule absorbs the incident light.  The number of photons 
absorbed per second (NA1) is given by: 
NA1 (photon/s) = σ1 (cm2) I(photon/cm2s) 
where I is the light intensity and σ1 is the cross-section for one-photon absorption. The 
units are given within the parentheses. Similarly, for two-photon absorption: 
NA2 (photon/s) = σ2 I2(photon/cm2s)2 
 3
In order for the units to match, the units of two-photon cross-section σ2 must be 
cm4s/photon. The values of σ2 are usually reported in terms of GM (Gopper-Mayer) 
units, where 1 GM = 10-50 cm4s/photon. 
The important spectroscopic characteristics for fluorescent compounds are listed 
in Table 1.1. These parameters can be used as guidelines for selecting appropriate 
fluorophores for different applications. 
 
Table 1.1. Important spectroscopic characteristics of fluorophores 
 
terms description 
Molar extinction 
coefficient 
(ε: M-1cm-1) 
A measurement of how strongly a fluorophore absorbs light at a 
given wavelength; absorbance divided by the absorption pathlength 
and the concentration of the fluorophore 
Stokes shift 
(cm-1) 
Difference (usually in frequency unit) between the spectral positions 
of the maxima of the lowest energy absorption and the fluorescence 
arising from the same electronic transition 
Fluorescence 
quantum yield 
(Φf) 
The number of emitted photons relative to the number of absorbed 
photons; typically determined relative to a fluorophore of known 
fluorescence quantum yield 
Fwhm: nm Fluorescence full width at half maximum height (fwhm): measurement of fluorescence sharpness 
Brightness 
(εΦf) 
Product of molar extinction coefficient multiplied by fluorescence 
quantum yield; a measurement for the intensity of the fluorescent 
signal obtained upon excitation at a specific wavelength 
Fluorescence 
lifetime 
(τ: ns) 
The average time the molecule spends in the excited state prior to 
return to the ground state; after a pulsed excitation, the time-
dependent fluorescence intensity I(t) is measured. The lifetime is 
calculated from the slope of a plot of logI(t) versus t 
TPA 
cross-section 
(σ2: GM) 
Two-photon absorption (TPA) cross-section: the probability of the 
simultaneous absorption of two photons and transition of the 
fluorophore to an electronically excited state 
Photobleaching Photochemical decompositioin of fluorophores; complex mechanisms 
Blinking The fluorophore randomly enter transient, non-fluorescent states; reversible 
Fluorescence 
anisotropy 
Measure for the polarization of the emitted light upon excitation with 
linearly polarized light; reflects the rotational freedom of 
fluorophores 
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1.2 Multiplexing with FRET and TBET 
 In biological studies especially high throughput screening, it is often desirable to 
simultaneously detect several fluorescently tagged components, ie multiplexing, using a 
single excitation source. Ideally, the fluorescent tags for multiplexing should emit very 
strongly at significantly different wavelengths when irradiated at the source wavelength 
so that the labeled tags can be easily detected and distinguished. However, multiplexing 
with one excitation source inevitably results in less intense fluorescence from the long 
wavelength emitting tags. This is because dyes that emit further into the red usually have 
red-shifted absorption and absorb less photons at the excitation wavelength (Figure 1.3.). 
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Figure 1.3.  (a) Scheme for multiplexing; (b) ideal multiplexing output; (c) common multiplexing output; 
(d) reasons for the diminished fluorescence output as the emission maxima occur further from excitation 
source. 
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Combinations of dyes arranged to maximize fluorescence resonance energy 
transfer (FRET) have been used to alleviate the above mentioned problems.4,5 FRET 
occurs between an excited donor (D) molecule and a ground state acceptor (A) as a 
result of long-range dipole-dipole interactions. The donor molecules typically emit at 
shorter wavelengths that overlap with the absorption spectrum of the acceptor. The rate 
of the energy transfer for a donor and acceptor separated by a distance r is given by6,7 
( ) λ)⎥⎦
⎤⎢⎣
⎡= (
128
10ln9000)( 456
2
J
Nnr
Qr
D
D
T πτ
κk                                                                        
where DQ  is the quantum yield of donor in the absence of the acceptor. Dτ  is the 
lifetime of donor in the absence of the acceptor. r is the distance between donor and 
acceptor. N is Avogadro’s number (6.02 x 1023). n is the refractive index of the medium. 
The overlap integral )(λJ expresses the degree of spectral overlap between the donor 
emission and the acceptor absorption and can be calculated from  
∫
∞
=
0
4)()()( λλλελλ dFJ AD  
where )(λDF  is the normalized donor fluorescence intensity at wavelength λ in the 
corrected fluorescence spectrum. )(λε A is the extinction coefficient of the acceptor at 　
wavelength λ .  
 2κ is a factor describing the relative orientation in space of the donor and 
acceptor transition dipoles. The orientation factor 2κ can be given by 
2κ  = (cosθT – 3cosθDcosθA)2        or 
     2κ  = (sinθTsinθAcosφ – 2cosθDcosθA)2 
where θT is the angle between the emission transition dipole of the donor and the 
acceptor absorption dipole, θD and θA are the angles between these dipoles and the 
vector joining the donor and the acceptor, and φ is the angle between the planes (Figure 
1.4.). 2κ  can range from 0 to 4. For head to tail parallel dipoles 2κ  = 4, and for parallel 
dipoles 2κ  = 1. If the dipoles are perpendicular to each other, 2κ  = 0. 2κ  is generally 
 6
assumed to be 2/3, which is appropriate for dynamic random averaging of the donor and 
acceptor. 
φθA
θD
θA
θT
D
A
r
 
Figure 1.4. Dependence of the orientation factor 2κ on the direction of the dipoles. 
 
 The Förster distance ( 0R ) is the distance at which half the donor molecules decay 
by energy transfer and half decay by usual radiative and non-radiative pathways. So 
when r = 0R , KT = (1/ Dτ ).  Thus 
∫∞⎥⎥⎦
⎤
⎢⎢⎣
⎡
=
0
4
45
2
6
0 )()(
128
)10(ln9000 λλλελπ dFNn
kQR ADD  
 0R  is typically in the range of 20 to 60 A
o for organic fluorophores. R0 is usually 
reported for an assumed 2κ  value (2/3). Once the R0 is known, the rate of energy 
transfer can be easily calculated using 
6
01 ⎟⎠
⎞⎜⎝
⎛=
r
R
D
T τk  
 The efficiency of energy transfer E is the fraction of photons absorbed by the 
donor that are transferred to the acceptor. E is given by 
TD
TE
k
k
+= −1τ  
which is the ratio of the energy transfer rate to the total decay rate of the donor. E can 
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The efficiency of energy transfer is typically measured using the relative fluorescence 
intensity or fluorescence lifetime of the donor, in the absence and presence of acceptor.  
Since energy transfer is governed by the spectra overlap and dipole orientations, 
FRET systems are only partial solutions to the multiplexing problems. On the other 
hand, through-bond energy transfer (TBET) cassettes (Figure 1.5.), in which donor and 
acceptor systems are connected via a twisted but conjugated linker, might solve all these 
problems. In such cassettes, rapid energy transfer from the donor to the acceptor may 
occur though bonds. Extensive studies by our group and others showed that the through-
bond energy transfer is mechanistically different to the Förster basis for FRET, and there 
is no requirement for overlap of the emission of the donor part with the absorption of the 
acceptor fragment.8-11 It therefore is possible to design dyes that absorb strongly at a 
short wavelength and emit brightly with similar intensities at several long wavelengths 
which are critical for multiplexing. 
 
 
Figure 1.5. A typical diagram for through-bond energy transfer cassette. 
 
The exact mechanism for through-bond energy transfer is still not clear. But it is 
thought to occur via Dexter energy transfer or conjugated linker mediated 
superexchange. Dexter energy transfer is an electron-exchange interaction between 
donor and acceptor.12 In dexter energy transfer, the excited electron from the donor is 
transferred to the acceptor with concomitant transfer of a ground state electron from the 
acceptor to the donor. Dexter energy transfer depends on the orbital energy levels and 
symmetries of the donor relative to those of the acceptor. It is a short-range process 
compared with FRET. Superexchange is a stepwise energy transfer process in which the 
n
hv
donor acceptor
hv'
energy transfer
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electron is transferred through the conjugated bridge, thus superexchange takes place 
over longer distances than Dexter energy transfer.13 
  Even though they are referred to as “through-bond energy transfer cassettes”, the 
energy transfer process in such systems is usually the combination of FRET, through-
bond and other transfer mechanisms. It is not possible to determine how much energy is 
transferred via FRET or through-bond. The observed energy transfer efficiency is the 
overall transfer via all possible pathways. Our group is interested in such energy transfer 
cassettes for biological applications. 
 
1.3 Labeling of proteins 
 Labeling of proteins with fluorescent probes has facilitated the studies of protein 
structures, functions, intracellular locations, dynamics and protein-protein interactions. 
Traditionally this has been done by in vitro labeling of proteins with fluorescent probes, 
followed by transferring them back into cells and monitoring them in real time using 
advanced imaging techniques such as confocal microscopy and others. Recent advances 
in genetic engineering have made it possible to directly generate fluorescently labeled 
proteins in living cells. A brief summary of the available protein labeling methods is 
described in this section. 
 
1.3.1 Covalent labeling techniques 
(1) Direct fluorescent labeling of target proteins 
 The widely used labeling strategies rely on selective reaction of fluorescent 
probes with amino acid side chains in the proteins of interest (Figure 1.6.). For instance, 
the primary amine in lysine sidechains are often targeted by fluorescent N-
hydroxysuccinimidyl ester, isocyanates or aldehydes to give amides, ureas or reductive 
amination products. Carboxylic acid groups from Asp or Glu side chain can also be used 
to react with amino-fluorophores. Similarly, fluorescent maleimides, iodoacetamides or 
disulfides are used to react with cysteine sidechains to afford the corresponding 
bioconjugates.14 Recent development expands the labeling scope to different amino acid 
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side chains such as tyrosine, tryptophan and so on by choosing appropriate reactions and 
carefully controlling the reaction conditions (Figure 1.6.).15 However, these methods are 
not site-specific and only good for in vitro labeling, because the same amino acid can 
appear at different locations in the target protein and it will also be present in many other 
proteins.  
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Figure 1.6. Labeling of proteins by modification of amino acid sidechains. Modification of a lysines; b 
cysteines; c aspartic acids or glutamic acids; d tryptophans; e tyrosines. 
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Selective modification of the terminal amino acid can be used to alleviate the 
problems (Figure 1.7.). For instance, N-terminal tryptophan residues can be modified by 
aldehydes through Pictet-Spengler reaction.16 Oxidation of N-terminal serine and 
threonine residues can form reactive aldehydes/ketones allowing further selective 
derivatization.17 The N-terminal amino group can also be oxidized by pyridoxal-5-
phosphate (PLP) to form an imine, tautomerization followed by hydrolysis of the 
resulting glyoxyl imine to yield an aldehyde or ketone specifically at the N terminus for 
further functionalization.18 Since endogenous N-terminal cysteine-containing proteins 
are rare, protein ligation has been used for site-specific labeling of proteins.19 The 
protein of interest with an N-terminal cysteine is expressed inside a live cell by using 
intein-mediated protein splicing, methionyl aminopeptidases, the ubiquitin-fusion 
strategy or selective proteolysis with highly specific proteases like the TEV (tobacco 
etch virus) protease. Incubation of the cell with a thioester-containing, cell-permeable, 
fluorescent probe leads to chemoselective native chemical ligation reaction between the 
thioester of the probe and the N-terminal cysteine of the protein, giving rise to the 
resulting specifically labeled protein. Muir et al successfully adopted intein-mediated 
splicing to selectively label proteins by expressing a target protein with the first half of 
the naturally occurring Ssp DnaE split intein fused to its C-terminus. The second half of 
the split intein was covalently tagged by a fluorescent probe. Upon combining the split 
intein halves, self-splicing occurred, leaving the protein of interest labeled at its C-
terminus with the probe (Figure 1.8.a).20 Although modification of terminal amino acids 
are more selective than labeling of amino acid sidechains, these labeling protocols still 
lack generality as it is difficult to achieve selective labeling of the protein of interest in 
protein mixtures, because several proteins might have the same terminal amino acid. 
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Figure 1.7. Labeling of proteins by modification of terminal amino acids. Modifcations of: a tryptophan; 
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More specific labeling methods are usually achieved by genetic incorporation of 
unnatural functional groups into the proteins of interest (Figure 1.8.b). The first 
demonstration of this concept was by Dibowski and Schimdtchen in 1998 through 
introducing a p-iodophenylalanine residue into an undecapeptide using reverse 
proteolysis.21 This residue was modified through metal catalyzed coupling reactions with 
different probes. Important extensions of this approach were made by Schultz et al.22 
They have successfully incorporated various unnatural amino acids with different 
functional groups into proteins with high efficiency and site-specificity. For instance, 
unnatural amino acids bearing ketones, azide or alkynes have been incorporated, 
allowing further derivatization using hydrazone formation, Staudinger ligation or 
azide/alkyne cycloaddition reactions. The major advantages of unnatural amino acid 
labeling are the excellent specificity, versatility and minimal structural perturbation to 
the target protein. However, unnatural amino acid mutagenesis is not yet broadly 
applicable in all cell types. 
Recently, a ligand-directed protein labeling method has been reported by 
Hamachi and co-workers.23 In this approach, the ligand binds to the target protein with 
high affinity, driving a chemical reaction of the reactive group on the ligand with an 
amino acid located on the protein surface through the proximity effect (Figure 1.8.c). 
The reactive group used by Hamachi is an electrophilic phenylsulfonate ester group. The 
surface of the target protein is specifically labeled using tosyl chemistry: an SN2-type 
reaction with the concomitant release of the ligand molecule. This approach was 
successfully used to label proteins in living cells, tissues and mice. However, a high 
affinity ligand for the protein of interest needs to be identified in order to apply this 
labeling method, which is usually not convenient especially for the unknown proteins.  
 The most prominent method of protein labeling is to genetically encode green 
fluorescent protein (GFP) or one of its variants as a fusion to the protein of interest24 
(Figure 1.8.d). The resulting fusion gene is expressed and the fluorescence of GFP is 
detected microscopically.25 Although GFP and its variants have proven to be extremely 
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useful for in vivo studies, these probes are limited by their large size and thus may 
interfere with the structure and function of the target proteins to which they are fused. 
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Figure 1.8. Other direct labeling methods. a split intein labeling (IN, N-terminal portion of a split intein; Ic,  
C-terminal fragment); b functionalization of incorporated unnatural amino acids; c ligand-directed 
labeling; d labeling with GFP. 
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 (2) Enzyme-catalyzed labeling by post-translational modification 
 More recent approaches have employed transferase and ligases for covalent 
labeling of target proteins (Figure 1.9.). Recongnition between the enzyme and its 
protein substrate ensures that the labeling reaction is fast and specific. 
 Acyl carrier protein (ACP) and peptide carrier protein (PCP) have been used to 
specifically label proteins of interest by fusion to the target proteins followed by 
modification by the enzyme phosphopantetheine transferase (PPtase).26,27 PPtase 
transfers 4′-phosphopantetheine-linked probes from coenzyme A (CoA) to a serine 
sidechain of ACP or PCP to form a specific covalent attachment. 
 Biotin ligase has also been exploited as an alternative strategy for covalent 
protein labeling. A 15 amino acid peptide sequence (‘acceptor peptide’, or AP) was 
identified by Ting for specific biotinylation of proteins.28,29 The biotin ligase catalyzed 
the ligation of biotin to the AP which can be fused to proteins of interest. A ketone 
isostere of biotin was also transferred to the AP, providing a unique functionality for 
subsequent derivatization with different probes. 
 Transglutaminases (TGases) are enzymes that catalyze amide bond formation 
between the γ-carboxyamide group of an acceptor glutamine (Gln or Q) residue and a 
primary amine donor, with the loss of ammonia.30 TGase exhibits high specificity for its 
glutamine-containing protein substrate, but wide tolerance for the structure of the amine 
donor, which makes it ideal for protein labeling applications. Recently, Ting and co-
workers have utilized a seven-amino-acid tag (PKPQQFM, ‘Q tag’) that is substrate for 
a TGase.31 Target proteins were expressed as fusions with Q tag then site-specifically 
labeled by TGase with amine-containing probes. 
Several other enzymes have also been utilized to achieve specific labeling of 
proteins by post-translational modification, such as farnesyltransferase (FTase)32 and 
formylglycine-generating enzyme (FGE).33 FTase catalyzes the covalent attachment of 
modified farnesyl moieties through a thioether bond to a cystein residue in the C-
terminal four-aminoacid farnesylation motif “CAAX”, where “C” is a cysteine residue, 
“A” is an aliphatic residue, and “X” is usually serine, methionine, glutamine, alanine or 
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threonine. Farnesyl analogs with azide/alkyne functional groups were successfully 
incorporated into proteins with high specificity. The products were subsequently labeled 
with different probes. Formylglycine generating enzyme can generate the sulfatase 
active site by converting a conserved cysteine to formyl glycine. A six-residue sulfatase 
motif (LCTPSR) containing this cystein has been used as a genetic tag to introduce the 
aldehyde functionality into proteins for subsequent labeling with aminooxy- or 
hydrazide-functionalized probes.34 
 Most of the above mentioned methods are restricted to the cell surface, because 
of the use of membrane impermeable dyes or competition from endogenous substrates. 
A covalent system that can be used intracellulary relies on the self-alkylation reaction of 
human O6-alkylguanine transferase (hAGT or SNAP-tag) to label hAGT fusion proteins 
with a number of cell permeable, fluorescent O6-benzylguanine (BG) substrates.35-37 The 
irreversible self-labeling reaction involves transfer of the functionalized benzyl groups 
from the BG substrates to an active site cysteine in hAGT to form a stable covalently 
modified protein. BG can be derivatized with a wide range of probes without influencing 
the efficiency of the reaction. Labeling of SNAP-tag fusion proteins in different cellular 
compartments such as nucleus, cytoplasm, endoplasmic reticulum (ER), cytoplasmic and 
extracellular face of the plasma membrane have been successfully illustrated. 
 Another self-labeling protein tag (HaloTag) has also been developed for specific 
protein labeling.38 The engineered halogen dehydrogenase cleaves the carbon halogen 
bond of fluorescent ligands to become covalently labeled with the fluorophore. Covalent 
bond formation between HaloTag and the fluorescent alkylhalides is highly specific, 
occurs rapidly under physiological conditions and essentially irreversible. This system 
was successfully used to specifically label HaloTag fusion proteins in vitro and in living 
cells. 
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Figure 1.9. Illustrative examples of enzyme catalyzed labeling of proteins. a ACP (PCP)/PPtase; b Q-
tag/TGase; c AP/biotin ligase; d farnesyl/FTase; e BG/AGT (SNAP-tag); f Halo-tag. 
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Figure 1.9. Continued. 
 
1.3.2 Non-covalent labeling methods 
 The most straightforward method for targeting a small molecule tag to a protein 
sequence is to use a specific, high-affinity non-covalent binding interaction between a 
ligand and its corresponding receptor (Figure 1.10.). In this approach, the protein of 
interest is expressed as fusion to a protein tag that is capable of binding to a small-
molecule ligand. 
One of the first ligand-receptor pairs for in vivo protein labeling was reported by 
Farinas and Verkman, who used antibody tags fused to localization signal sequences to 
target various hapten-fluorophore conjugates to specific subcellular compartments in 
living cells.39 Similar strategy was exploited to label avidin fusion proteins with 
fluorescent biotin derivatives using the biotin-avidin interactions.40 More recent 
approaches have employed the interaction between an FKBP12 mutant (F36V) and a 
synthetic ligand (SLF’).41 The specific interaction between dihydrofolate reductase 
(DHFR) and its small molecule-ligand methotrexate was also used to specifically label 
DHFR fused proteins with fluorescently labeled methotrexates.40,42,43 
The tetracysteine/biarsenical method introduced by Tsien and coworkers is one 
of the most used strategies to target chemical labels to specific proteins in living cells.44 
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The membrane-permeant fluorogenic biarsenical (FlAsH) compounds become strongly 
fluorescent upon high-affinity binding (Kd : 2-4 pM) to the six amino acid tetracysteine 
motif (CCXXCC, where X is any amino acid except cysteine) in the target protein.45 The 
FlAsH method has already made significant contributions to cell biology. 
 In addition to the FlAsH tag, several groups have developed conceptually similar 
approaches. For example, Nolan has evolved a 38 amino acid peptide (‘fluorette’) that 
binds to Texas Red fluorophore with a Kd of 25 pM.46,47 Labeling of this sequence fused 
protein in cells with Texas Red derivatives was demonstrated. In a separate approach, 
Vogel used nickel-nitrilotriacetic acid (Ni-NTA) functionalized fluorophores to label 
hexahistidine tagged cell-surface proteins.48 Another system consisting of a 
polyaspartate tag for labeling of cell-surface proteins with fluorescent zinc conjugates 
has also been reported.49 
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Figure 1.10. Illustrative examples of non-covalent labeling of proteins. a DHFR/methotrexate; b 
tetracysteine/biarsenical (FlAsH). 
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Table 1.2. Summary of protein labeling methods 
labeling method tag size (aa) comments 
Covalently labeling 
(1) direct attachment to proteins 
modification of amino acid 
side chains (Lys, Cys, Glu, 
Asp, Trp, Tyr) 
0 selective but not specific, only for in vitro labeling 
terminal amino acids 
modification (Ser, Thr, 
Cys, Trp) 
0 specific but only for in vitro labeling 
unnatural amino acids 0 excellent specificity, not yet broadly applicable in all cell types 
intein mediated protein 
splicing 
~ 150 
(temporary)
specific, tag size problem even though 
temporary 
ligand-directed labeling 0 high affinity ligand is needed 
GFP 238 excellent specificity, tags are big 
(2) enzyme catalyzed labeling 
ACP (PCP)/PPTase 77 (80) specific but tags are big and only for cell surface protein labeling 
AP/biotin ligase 12 cell surface protein labeling 
Q-tag/TGase 6 moderate specificity, background labeling 
CAAX/FTase 4 specificity needs improvement 
Sulfatase motif/FGE 6 specificity needs improvement 
BG/hAGT 182 specific and intracellular labeling, but tag is big 
Alkylhalide/HaloTag 296 tag size problem 
Non-covalently labeling 
Hapten (phOx)/antibody 
(sFv) 25 KDa tag size problem 
biotin/avidin 516 tag is big 
SLF’/FKBP12 (FK36V) 108 protein-ligand dissociation, tag size problem 
Methotrexate/DHFR 157 protein-ligand dissociation, tag size problem 
Biarsenicals/tetracystein 4 background labeling, only for reducing environment 
Texas Red/fluorette 38 Texas Red only 
Ni-NTA/His6 6 low affinity 
Zn labels/polyaspartate 12 low affinity 
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1.3.3 Summary 
 In summary, a diverse set of protein labeling systems are available (Table 1.2.). 
As each labeling method has its advantages and restrictions, successful experiments 
require selection of a labeling approach that is matched with the biology of the research 
question. The approaches reported to date point the way toward effective design criteria 
for site-specific labeling of proteins in living systems.40 Receptors must be amenable to 
genetic encoding as fusions to the protein of interest. The receptors must be small so as 
not to perturb protein functions. Probes should bind (or be covalently attached to) 
receptors with high specificity and stability. The kinetics of the binding or attachment 
should be fast enough to facilitate the applications to study fast biological processes. 
  
1.4 Delivery of proteins into cells 
 The in vitro labeled proteins generally can not enter cells by passive diffusion, 
but require active transport. Cell-penetrating peptides (CPPs) are very attractive for this 
purpose because of their ability to mediate cellular uptake of proteins. The most widely 
used CPPs are derived from HIV-1 tat (TAT) and Drosophila Antennapedia 
homoprotein.50,51 However, the delivery with these CPPs requires covalent attachment of 
proteins of interest to the CPPs thus the processes are experimentally inconvenient, time 
consuming and restrictive with respect to the scope of the experiments that can be 
performed. Conversely, carrier vehicles that can import proteins without being 
covalently attached have the potential to circumvent all these problems. The most 
common “Non-covalent carriers” include “Pep-1” (also known as Chariot)52,53, oligo-
arginine54,55 and polyethyleneimine (PEI)56. Pep-1 and oligo-arginine have been used in 
our group to import proteins into cells. 
 Pep-1 is a synthetic peptide carrier capable of introducing proteins into cells.  
The peptide has 21 amino acid residues (KETWWETWWTEWSQPKKKPKV), which 
can be divided into three different domains with specific functions: (i) a hydrophobic 
tryptophan-rich motif, forming the main interactions with macromolecules and required 
for efficient targeting to the cell membrane; (ii) a hydrophilic lysine-rich domain derived 
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from the nuclear localization sequence (NLS) of simian virus 40 (SV-40) large T 
antigen, required to improve intracellular delivery and solubility of the peptide vector; 
and, (iii) a spacer domain, which improves the flexibility and the integrity of both the 
hydrophobic and hydrophilic domains.57  
Pep-1 associates with the protein cargo via its tryptophan-rich motif through 
noncovalent interactions to form the Pep-1/cargo complex.  The cellular translocation 
mechanism of the Pep-1/cargo complexes has become very controversial.  Deshayes et 
al. postulated that the membrane crossing process involved formation of a transient 
transmembrane pore-like structure.57  In contrast, Henriques et al. found no evidence for 
pores or other lytic structures using photophysical techniques.  Their work suggested that 
the main driving force for the peptide translocation was charge asymmetry between the 
outer and inner leaflet of biological membranes.58 Zerbe et al. proposed a model which 
was compatible both with the active endocytic mechanism and with the passive inverted 
micelle pathway.59  
The Pep-1 peptide is non-toxic and has high transport efficiency (65-95%).  It 
has been shown to rapidly co-transport large fluorescent proteins (>119kDa, and mAb’s 
ca. 250 kDa) into cells. Once internalized, the fluorescent protein/Pep-1 complex rapidly 
dissociates, thereby allowing the fluorescent-tagged protein to proceed to its intracellular 
target while concomitantly the Chariot peptide is rapidly degraded.52,53  
 
1.5 Detection of protein-protein interactions 
 Protein-protein interactions (PPIs) are known to play an important role in all 
cellular functions, and thus technologies for identifying and characterizing PPIs are 
extremely important. PPIs are commonly detected by two-hybrid systems, reconstitution 
methods, immunoprecipitations, protein mass spectrometry and more recently FRET-
based systems.60,61 
 The two-hybrid system is a method that uses transcriptional activity as a measure 
of protein-protein interactions.62,63 The system relies on the modular organization of 
many transcription factors which have separable domains for DNA-binding and 
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transcriptional activation. One of the target proteins (often termed the “bait”) is fused to 
DNA-binding domain (DBD). The other protein of interest (often termed the “prey”) is 
fused to the activation domain (AD) of the transcription factor. Interactions between the 
“prey” and “bait” bring the AD close to the DBD resulting in activation of transcription 
then expression of a reporter gene.  
 Reconstitution of a split protein’s function can also be used to detect PPIs. For 
example, the N terminal fragment and C-terminal fragment of β-galactosidase were 
fused to interacting protein partners. Upon interaction, β-galactosidase was reconstituted 
and detected histochemically.64 Interaction-mediated reconstitution has also been 
described for ubiquitin, mouse dihydrofolate reductase (DHFR) and so on.60 
 Immunoprecipitation is another commonly used method to detect PPIs.61 In this 
approach, an antibody that is specific for one of the target proteins is used to precipitate 
that particular protein out of a solution. The interacting partners will also be pulled out 
of the solution as intact protein complexes which can be further identified by mass 
spectrometry or other methods. 
Fluorescence technologies have been used extensively for assaying PPIs in living 
cells and in real time since they are highly sensitive even at very low protein 
concentrations and easy to operate. Fluorescence assays for protein interaction have 
usually been designed based on relative changes in the photophysical parameters such as 
anisotropy, lifetime, emission wavelength and quantum yield of the fluorescence 
emission upon interaction. 
Intermolecular FRET between two spectrally overlapping fluorophores attached 
to two different host proteins offers a unique opportunity to monitor real-time protein-
protein interactions. This is usually performed with a pair of fluorescent proteins used 
for FRET such as BFP-GFP and CFP-YFP.65 Several approaches, such as mathematical 
correction, internal calibration, external calibration, donor lifetime measurement and 
acceptor bleaching, have been employed to quantify of the extent of FRET in the 
interacting protein mixtures.  
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 The strong spectral overlap of the donor and acceptor that is required for FRET 
leads to a substantial fluorescence background (eg spectral bleedthrough or cross-talk) 
that interferes with the detection of the FRET signals and makes the quantification even 
more complicated. Moreover, the spectral overlap requirement makes it extremely 
difficult to detect multiple PPIs simultaneously because it is hard to find several 
acceptors that have strong spectral overlap with the same donor but emit at significantly 
different wavelengths.  
The through-bond energy transfer cassettes can strongly fluoresce at a much 
longer wavelength than the excitation source, effectively giving a much larger Stoke’s 
shifts, and more intense fluorescence from a single excitation source than is possible via 
FRET. Therefore, the through-bond energy transfer cassettes have the potential to 
increase both the resolution and fluorescence intensities obtained from several tags 
excited by the same laser source operating at a single wavelength. Sets of energy-
transfer cassettes can then be used to monitor communication between proteins in cells.   
Combination of FRET with through-bond energy transfer cassettes enables several 
contacts to be detected using one laser excitation source; several through-bond energy 
transfer cassettes can be observed simultaneously due to their identical absorption 
maxima, high quantum yields and huge (different) Stoke’s shifts. As showed in Figure 
1.11., target protein 1 is labeled with a FRET donor and the interacting partner proteins 
are attached with different through-bond energy transfer cassettes. After excitation of the 
FRET donor on protein 1, it will be close enough for the FRET donor to transfer energy 
through space to the FRET acceptors, which are also donors in the through-bond energy 
transfer cassettes, on the interacting partner(s), then the energy will be transferred again 
through bond to the cassette acceptor and the fluorescence of that acceptor is going to be 
detected. So the interacting partner(s) can be determined simply by the fluorescence 
detected. This method also enables multiple protein-protein interactions to be observed 
simultaneously.   
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Figure 1.11. Proposed system for detecting protein-protein interactions. 
 25
CHAPTER II 
DESIGN AND SYNTHESES OF HIGHLY FLUORESCENT 
GFP-CHROMOPHORE ANALOGS* 
 
2.1 Introduction 
 The green fluorescent protein (GFP) from the jellyfish Aequorea victoria is one 
of the most widely studied and exploited proteins in biochemistry and cell biology due to 
its strong intrinsic visible fluorescence, which is easily detectable by fluorescence 
spectroscopy.66,67 The phenomenon of green fluorescence from jellyfish has been known 
for years.68 However, the material that causes the fluorescence is not known until 1962 
when it was isolated from Aequorea victoria and identified as a protein by Osamu 
Shimomura.69 Since then, this green fluorescent protein (GFP) has been extensively 
studied. Shimomura was only interested in GFP’s bioluminescence and wanted to 
understand the biochemistry involved in the process. Prasher was the first person to 
realize the potential of GFP as a tracer molecule. He was able to isolate and characterize 
GFP gene.70 Two years later in 1994, Charlfie successfully expressed GFP in E. coli so 
that they fluoresced green when irradiated with blue light.24 For the first time, Chalfie 
demonstrated the value of GFP as a biological marker. While they were all interested in 
GFP and demonstrated that it can be used as a fluorescent tag, it is Roger Tsien who is 
responsible for much of our understanding of how GFP works and for developing 
mutants of GFP. His group has developed mutants that are brighter and have different 
colors.71-73 In fact, most of the GFP samples used today are products from Tsien’s lab. 
For their discovery and development of the green fluorescent protein, Shimomura, 
Chalfie and Tsien were awarded the 2008 Nobel Prize in Chemistry. 
 
 
____________ 
*Reprinted in part with permission from “Syntheses of Highly Fluorescent GFP-
chromophore Analogues”, Liangxing Wu, Kevin Burgess, J. Am. Chem. Soc., 2008, 103,  
4089-4096. Copyright 2009 American Chemical Society. 
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The primary sequence of GFP was deduced from the nucleotide sequence of its 
cDNA by Prasher in 1992.70 Wild type GFP is made up of 238 amino acids residues in a 
single polypeptide with a calculated molecular weight ca 26.9 KDa. The structure of the 
GFP chromophore from Aequorea victoria was first proposed by shimomura in 197974 
and was further confirmed and corrected by Prasher in 1993.75 The chromophore is a p-
hydroxybenzylideneimidazolinone formed from residue 65-67, which are Ser-Tyr-Gly in 
the native protein. The crystal structure of GFP was solved in 1996.76 GFP has a unique 
eleven β-sheets barrel-like structure with a diameter of ca 24 Å and a height of 42 Å. 
The β-sheets form the walls of the can and an α-helix runs diagonally through the 
cylinder. The chromophore is attached to the α-helix and is buried in the center of the β-
can (Figure 2.1.a). Several polar residues and water molecules comprise a complex 
hydrogen-bonding network around the chromophore67,76 (Figure 2.1.c). This network 
permits the transfer of protons between the chromophore and residue sidechains, the 
direction of which determines the ionization state of the chromophore. In the neutral 
form, Glu222 and Ser205 help to buffer and neutralize the chromophore. When exposed 
to UV light, Glu222 donates its charge to the chromophore by proton extraction through 
the H-bond network involving Ser205 and water, thereby generating the ionized form of 
the chromophore. The H-bond pattern in the chromophore vicinity is thought to change, 
stabilizing the chromophore in its ionized state. His148 now stabilizes the Tyr-derived 
portion of the chromophore by H-bonding directly to the phenolic oxygen. The side 
chain of Thr203 now hydrogen bonds directly to this oxygen as well. The H-bond 
between Glu222 and Ser205 is lost in the ionized form of chromophore. The 
reestablishment of the original hydrogen bond network allows the chromophore to return 
the charge back to Glu222 regenerating the neutral isomer.66 
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Figure 2.1. (a) X-ray strucrure; (b) chromophore of GFP; (c) schematic diagram of the interactions 
between the chromophore and its surroundings in the S65T mutant. Possible hydrogen bonds are drawn as 
blue dashed lines. 
 
 
 The generally accepted mechanism for the biosynthesis of GFP chromophore is 
autocatalytic posttranslational cyclization and oxidation of the polypeptide backbone, 
involving Ser65, Tyr66 and Gly67 residues66,77,78 (Figure 2.2.). First, GFP folds into a 
native conformation which is non-fluorescent and called “apo-GFP”. Then nucleophilic 
attack of the amide in Gly67 on the carbonyl of residue Ser65 followed by dehydration 
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to form the imidazolinone. Finally, oxidation by molecular oxygen put the aromatic 
group of Tyr66 into conjugation with the imidazolinone. Only at this stage, the GFP is 
highly fluorescent.  
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Figure 2.2.  Biogenesis of the chromophore in wild-type GFP. 
 
Chemical synthesis of GFP model chromophore is straight forward. The model 
compound was prepared via Erlenmeyer azlactone synthesis79 as shown in Scheme 2.1. 
Reaction of N-acetylglycine, 4-hydroxybenzaldehyde and anhydrous sodium acetate in 
acetic anhydride provided the corresponding azlactones which was reacted with 
methylamine in the presence of potassium carbonate to afford the imidazolinone model 
compound.78 Libraries of model chromophores of GFP and mutant proteins have been 
prepared similarly and the structure-property relationships were systematically studied in 
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order to figure out the photophysical parameters that defines the GFP spectroscopic 
properties.80,81 
 
Scheme 2.1. Chemical synthesis of model chromophore of GFP. 
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The absorption spectrum of wild-type GFP contains two main bands at ca 395 
and 475 nm, and these are usually assigned to the neutral and anionic forms of the 
chromophore, respectively. Excitation of either neutral or anionic species results in a 
similar emission spectrum centered at 508 nm with a high quantum yield (Φ = 
0.8).67,82,83 This is presumably due to the fact that the phenolic oxygen of Tyr66 is more 
acidic in the excited state than in the ground state; excited-state proton transfer (ESPT) 
occurs resulting in a common anionic excited state that is responsible for the observed 
emission spectrum.84  
The substitution of one or more amino acids within the chromophore or in its 
immediate proximity has allowed the development of GFP mutants with different 
absorption and emission properties. The first major improvement was a single point 
mutation (S65T: Ser65 → Thr) reported by Tsien in 1995.72 This mutation dramatically 
improved the spectral characteristics of GFP, resulting in increased fluorescence, 
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photostability and a shift of the major excitation peak to 488 nm with the emission peak 
kept ca 508 nm. Further mutation (F64L: Phe64 → Leu) to this scaffold generated 
enhanced GFP (EGFP) with improved folding efficiency. Many other mutants have also 
been made such as blue fluorescent protein (BFP), cyan fluorescent protein (CFP) and 
yellow fluorescent protein (YFP). BFP derivatives contain the Y66H (Tyr66 → His) 
mutation which gave blue shifted absorption (383 nm) and emission (448 nm). 
Substitution of Tyr66 with Trp caused the chromophore to form with an indole 
component giving CFP which absorbed ca 440 nm and emitted ca 490 nm.71 The red-
shifted wavelength of the YFP derivatives is achieved by the T203Y (Thr203 → Tyr) 
mutation and is due to π-stacking interactions between the substituted tyrosine residue 
and the chromophore.66 The recent discovery of red fluorescent protein (RFP) from a 
non-bioluminescent reef coral launched a second revolution of fluorescent proteins due 
to its significantly red-shifted excitation and emission maxima (λex 558 nm, λem 583 nm, 
Φ 0.7).73 The chromophore in RFP DsRed (Figure 2.3.) shares the same 4-
hydroxybenzylidene- imidazolinone core with GFP chromophore, but with an acylimino 
group at the 2-position of the imidazolinone ring. The resulting additional conjugation 
from the acylimino group in the chromophore is responsible for the red-shifted 
spectroscopic properties of DsRed compared to those of GFP. 
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Figure 2.3. Structure of the red fluorescent protein (DsRed) chromophore. 
 
It is now well known that the denatured-GFP and the chromophore isolated from 
the native protein will totally lose their fluorescence. Molecules representing the 
chromophores of GFP (A78 and B83), and point mutants (C for Y66F mutant of GFP; D 
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for CFP representing the Y66W mutant of GFP; E for BFP representing the Y66H 
mutant of GFP)78 or naturally occurring analogs (F for red fluorescent protein RFP)85 
have been prepared and studied in solution.86,87 They fluoresce at somewhat shorter 
wavelengths than their parent proteins and with extremely low quantum yields. This 
striking difference in quantum yields has been much discussed in the literature, but the 
consensus opinion is relatively simple.80 Loss of fluorescence energy from the synthetic 
chromophores in solution is mainly the result of radiationless transfer arising from free 
rotation about the aryl-alkene bond (blue arrows, Figure 2.4.). Isomerization of the 
alkene (red arrows) and the polar nature of media relative to the apolar environment 
within the β-barrel protein structures may also be contributing factors, but the main one 
is that free rotation parameter. Steric and electronic factors prevent free rotation of the 
aryl substituents when the chromophores are encapsulated in the proteins. The 
environment also disfavors E:Z-isomerization, and provides an apolar medium that is 
often conducive to fluorescence. 
 
 
 
 
 
Figure 2.4.  Some synthetic analogs of chromophores in fluorescent proteins (FP). 
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The research discussed in this chapter explores a hypothesis that highly 
fluorescent analogs of the GFP chromophore could be made by including boron. The 
conceptual genesis of these analogs 1, and the particular compounds that in fact have 
now been made, are represented in Figure 2.5. It was supposed that inclusion of the 
boron atom would preclude free rotation of the aryl-alkene bond so these chromophore 
analogs would be highly fluorescent in solution. Thus the specific aims for this work are: 
(i) design and syntheses of highly fluorescent GFP-chromophore analogs 
(ii) studies of the structure-property relationships 
(iii) preparation of water-soluble derivatives for biomolecular labeling 
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Figure 2.5.  Thought process that led to the design of analogs 1 and the derivatives discussed in this 
chapter. 
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2.2 Results and discussions 
2.2.1 Syntheses of the highly fluorescent GFP-chromophore analogs 
To the best of our knowledge, nearly83 all the syntheses of GFP-chromophore 
analogs are based on condensation of hippuric or aceturic acid derivatives with 
aldehydes (the “Erlenmeyer azlactone synthesis”79).78,80,81,85,87,88 However, at least one 
report indicates these conditions do not work well for pyrrole-2-carbaldehyde89 which 
gives a mixture of products, and in fact our attempts to use them for similar substrate 
were also unsuccessful, which led to complex mixtures and very low yield of the desired 
product (Scheme 2.2.).  Consequently, a new strategy was developed that began with the 
synthesis of an imidazolinone90, then condensation of this with the pyrrole-aldehyde.  
That route was successful for compounds 1a – e. 
 
Scheme 2.2. Routes to target compounds 1.  a conventional condensation approaches were unsuccessful 
for pyrrole-2-carboxaldehyde;89 b the strategy developed here involving condensation of imidazolinones. 
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Scheme 2.2. continued. 
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We initially believed the main challenge in the synthesis described in Scheme 
2.2. was that compounds 4 tended to form as mixtures of E:Z-isomers, but later it was 
determined that these materials isomerized under the reaction conditions to form 1 and 5.  
This conclusion was reached in the following way. Compound 1c and the corresponding 
intermediates 4c were chosen as models for the series. First, evidence was collected for 
assignment of E- or Z- stereochemistry for 4c and related materials.91,92 Table 2.1. shows 
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selected spectroscopic parameters for the two isomers of 4c. Coupling between the C6-H 
proton and the C5=O carbonyl carbon was probably the most definitive stereochemical 
probe: a larger coupling constant was observed for one isomer, which was therefore 
assigned an E-configuration. This assignment was supported by observation of a reduced 
wavenumber for stretching of the carbonyl group in the putative E-isomer, as would be 
expected from internal H-bonding. Having made this assignment, then chemical shift 
differences of the protons at H6, H1’, H4’ and the carbon at C5 were noted as possible 
indicators of E- or Z- stereochemistry. 
 
Table 2.1. Spectroscopic properties of Z- and E-4c isomers 
 
H-bond weakens
C=O IR stretch
NH N
N
O
N O
N
N
I
I
1
23
4 5
6
1'
2'3'
4'
5'
Z-4c E-4c
H
 
 
 
 
3JH6, C5 
(Hz) 
νC=O 
(cm-1) 
δH6 
(ppm) 
δC5 
(ppm) 
δH1’ 
(ppm) 
δH4’ 
(ppm) 
       
Z-4c 3.8 1686 7.17 169.8 10.62 5.87 
E-4c 8.9 1663 7.33 168.6 13.01 5.99 
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Work by others on syntheses of GFP-chromophore analogs (via approaches 
analogous to that shown in Scheme 2.2.a) leading to compounds like A78 and G88 could 
have led to isomeric mixtures but apparently that was not a problem for those structures.  
Thus the Z-isomer of compound A was shown to be more stable than the E-form by 2.1 
kcal•mol-1 via experimental measurements.91 Similarly, B3LYP calculations for 
molecule G indicated that the Z-isomer was thermodynamically preferred by 1.66 
kcal•mol-1.93  However, the same B3LYP method was applied to compound 4c in the 
current work and this led to the wrong conclusion. Specifically, the E-isomer was 
calculated to be more stable both in vacuo and in a medium of the same dielectric 
constant as DMSO (by 1.33 and 0.61 kcal•mol-1 at 25 oC, and 0.82 and 0.60 kcal•mol-1 at 
100 oC, respectively), whereas NMR experiments in d6-DMSO showed that the Z-isomer 
was in fact the thermodynamically preferred one. Details of the calculations are given in 
the appendix material, and spectra for the thermal isomerization studies are shown in 
Figure 2.6.a.  In fact, the thermal isomerization in d6-DMSO at 100 °C was quite slow 
(the reaction approaches equilibrium after 51 h indicative of a very high energy barrier 
to E,Z-isomerization).  The E,Z-ratio at equilibrium was ca 0.6:1.0 indicating the Z-
isomer was more stable by 0.41 kcal•mol-1 at 100 oC. Photoisomerization of two 
different E:Z mixtures of 4c in CDCl3 radiated at 360 nm was also studied, the data 
(Figure 2.6.b) indicates the E-isomer is dominant in the photostationary state.   
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a                                                                                     
             0 h                51 h
E:Z  1.52 : 1.00     0.60 : 1.00
              0 h               27 h
E:Z   2.13 :1.00    0.59 : 1.00
 
b 
                 0 h                      4 h
E:Z      0.39 : 1.00         2.95 : 1.00
       
              0 h                 4 h
E:Z   1.30 : 1.00     3.04 : 1.00
 
 
Figure 2.6.  Isomerization of E,Z-mixtures of compound 4c. a thermally in d6-DMSO at 100 oC; b, and 
photochemically in CDCl3 at 25 oC and 360 nm radiation. 
 
The next step in this project was to make the final products 1 from the 
intermediates 4.  Two isomeric products could be formed, 1 and 5, and the spectroscopic 
strategies used to differentiate them were similar but not identical to those applied to 
compound 4c. Coupling between the C6-H proton and the C5=O carbonyl carbon is 
complicated by additional spin-pairings involving the B- and F-nuclei. Consequently, 
that particular spectroscopic probe is not so conveniently measured, however the E-
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isomer is easily identified by the presence of coupling between the 19F to C5=O atoms.  
Further, the carbonyl stretch for compounds 5 is less than that for 1; in this case this is 
because the boron atom is directly coordinated with the carbonyl C=O only for 
compounds 5.  Single crystal X-ray analyses were also obtained for compound 1c and 
5c, confirming the assignment in this case (see below).  Table 2.2. shows the key 
spectroscopic parameters for compounds 1c and 5c.  In retrospect, the magnitude and 
direction of small chemical shift differences for these two series of compounds show 
consistent trends (Figure 2.7.) that could be used to make tentative assignments for new 
compounds in the series. 
 
Table 2.2. Spectroscopic properties of 1c and 5c 
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νC=O 
(cm-1) 
δC5 
(ppm) 
δH6 
(ppm) 
δH4’ 
(ppm) 
δF 
(ppm) 
      
1c 1705 160.7 7.41 6.01 37.02 
5c 1610 
158.4 
(t, JCF = 6.1Hz) 
7.64 6.28 34.20 
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Figure 2.7.  Trends in chemical shift differences for compounds 5 relative to compounds 1 illustrate that 
these can be used to differentiate between them.  Here the zero line is the chemical shift values for 
compounds 1, and the relative chemical shift difference for the corresponding compound 5 is indicated.  
The chemical shift differences for the 19F signals shown here are 0.1 x their actual values. 
 
The X-ray structures of molecules 1c and 5c (Figure 2.8.) have at least two 
interesting features, one is relevant to the spectroscopic assignments made above, and 
the other relates more to their fluorescence properties.  First, the C=O bond length for 
compound 1c is 1.226(3) Å whereas the corresponding distance in compound 5c is 
1.311(5) Å.  The first of these carbonyls is not complexed, so the bond length is shorter, 
and the bond is presumably stronger than in 5c where its bond order is reduced by 
interaction with the BF2-entity.  Second, the pyrrole-derived ring in compound 1c is 
almost exactly co-planar with the one originating from an imidazolinone; in fact, the 
dihedral angle between those two rings is only 0.51°.  However, for compound 5c the 
corresponding dihedral angle is 9.94°.  Electronic spectra of compounds 1 and 5 are 
described in the next section. Briefly, compounds 1 tend to absorb at longer wavelengths 
than their isomers 5, with higher extinction coefficients, and they also fluoresce at longer 
wavelengths. All these properties are consistent with 1 being the more planar, 
conjugated structure. Moreover, fluorescence quantum yields for 5 are, without 
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exception, 10 to 100 times less than for the corresponding structures 1. It may be that 
one contributing factor to this is rapid equilibration between the two enantiomeric 
twisted conformations serving as a pathway for radiationless decay.  
Interestingly, similar phenomenon has also been observed in Dronpa, a GFP 
homolog evolved from a Pectiniidae coral. Dronpa can be repeatedly and reversibly 
switched between a fluorescent on- and a non-fluorescent off-state by irradiation with 
light.94 Recently, it was found out that the fluorescent on-state of Dronpa is due to the 
cis-deprotonated (anionic) chromophore, whereas the non-fluorescent off-state 
corresponds to the protonated (neutral) trans-isomer.95 On the basis of structural 
comparisons of the on- and off-states from NMR studies, Mizuno proposed that in a 
fluorescent state the chromophore is tethered to the opposite β-barrel by the hydrogen 
bond between the chromophore phenolate oxygen and the neighboring Ser142 hydroxyl 
group. This hydrogen bond holds the two rings of the chromophore in a cis-
configuration. The His193 imidazole ring, which is located below the chromophore 
phenyl moiety, stabilizes the entire chromophore planar conformation. This rigid 
structure favors the radiative relaxation process from the first electronic state to the 
ground state. By contrast, the trans-chromophore in the non-fluorescent state lacks both 
the hydrogen bond with Ser142 and chromophore stacking with His193. These structural 
changes increase the flexibility not only of the chromophore but also a part of the 
corresponding β-barrel which might lead to the fluorescence loss and give the off-
state.96,97 
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a                            top                                    side 
1.226 Å
  
nearly perfect planar
 
b                            top                                       side 
1.311 Å
  
twisted by ~ 10o
 
C N O B F I H   
Figure 2.8.  Top and side views of structures based on single molecule X-ray diffraction analyses of: (a), 
compound 1c; and, (b) compound 5c. 
 
In the event, E,Z-isomerization of compounds 4 apparently does not significantly 
impact the syntheses of products 1 because the isomers seem to interconvert under the 
conditions used in the final step, as supported by the following observations.  Synthesis 
of 4c via condensation mediated by HBr/TFA (conditions ii in Scheme 2.2.b) in fact 
gave E-4c almost exclusively. However, when this material was converted to the boron-
containing final products, compound 5c and 1c were formed in a ratio of approximately 
2:1. Similarly, when a 1:1 mixture of E-4c and Z-4c was converted to the boron-
containing products via the same reaction conditions, 5c and 1c were formed in a ratio of 
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approximately 2:1.  It appears that formation of compound 1c from 4c is a stereorandom 
process, ie little or no stereochemical information in the starting material is retained. 
The pathway outlined in Scheme 2.2.b worked well for syntheses of compound 
1a-e, but there was a problem when the same protocol was applied to the 4-
nitrobenzene-substituted product 1f. Specifically, the intramolecular “aza-Wittig” 
closure did not afford the desired azlactone 3f; instead, a complex mixture of products 
formed.  Consequently, the route described in Scheme 2.3. was devised. Here the 
azlactone was formed via an intramolecular condensation of the hippuric acid 
derivative;79 this intermediate was not isolated, but instead was condensed with 3,5-
dimethyl-2-pyrrolaldehyde to give the azlactone-derivative 6.  Conversion of 6 to the 
corresponding imidazolinone 4f was achieved via reaction with methylamine.78 Finally, 
the BF2-entity was introduced using the same conditions as outlined for the other 
compounds in the series in Scheme 2.2.b.   
 
Scheme 2.3.  Revised procedure for synthesis of compounds 1f and 5f. 
 
NO2
H
NO COOH
N
H
CHO
6
E/Z ~1:1
46 %
(i) Ac2O, 90 oC, 1.5 h
(ii) 90 oC, 1.5 h NH N
O
O
NO2
 
 
 43
Scheme 2.3.  Continued. 
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Compounds 1f and 5f were crystallized and studied by X-ray diffraction.  They 
show the same features as outlined for the structures of 1c and 5c.  Thus the carbonyl of 
1f is shorter than that in 5f, and the molecular shape is almost perfectly flat whereas 5f is 
twisted.  Further details are given in the appendix material. 
For synthetic convenience in preparing compounds 1, concurrent formation of 
compounds 5 is a nuisance. Conditions to form compounds 1 with high selectivities were 
not identified in this study, but it was shown that the less fluorescent material 5 could be 
stripped of the BF2-group giving intermediates 4 that could thereby be “recycled” 
(Scheme 2.4.). Thus, for our most studied compounds, those in series c, treatment of 5c 
with sulfuric acid gave removal of the BF2-group to regenerate intermediate 4c.  If this 
 44
intermediate is not heated above room temperature or radiated with relatively intense 
and energetic light (eg 360 nm) then 4c will be isolated as a pure E-isomer.  However, as 
outlined above, this has no real consequence on the formation of compound 1c because 
5c is invariably also formed.    
 
Scheme 2.4.  Method to recycle the undesired compounds 5 into the target materials 1. 
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Review of the literature on BODIPY dyes leads to the conclusion that there are 
an abundance of lypophilic probes of that general type, but relatively few water-soluble 
ones.98 Consequently, there was a strong motivation to prepare the first water-soluble 
variants of dyes 1. Compound 1c was chosen as a starting point because this material 
was conveniently obtained in gram amounts, and because it contains an aryl iodide 
functionality that can also be manipulated. Sulfonation of compound 1c was achieved by 
treatment with excess chlorosulfonic acid at 0 °C (Scheme 2.5.). Practically, isolation of 
such sulfonic acids can be difficult. Here the crude reaction mixture was quenched with 
NaHCO3 (aq) and the dye accumulated in the aqueous phase. The dichloromethane layer 
was removed, and the sodium salt of the product was extracted back into an organic 
medium (1:1 CH2Cl2/iPrOH). After removal of the solvents the crude residue contained 
over 90% of the desired product. This material was then further purified by flash column 
chromatography on silica using 10% MeOH in CH2Cl2. Overall, the extraction and 
chromatography procedure is relatively easy because the products are so strongly 
colored. 
Scheme 2.5. also shows how the sulfonated product 1g was coupled with 5-
hexynoic acid via a Sonogashira reaction.99 Again, the sulfonated product could be 
isolated via column chromatography on silica (20% MeOH in CH2Cl2). Compounds 1g 
and 1h are soluble in aqueous media, and 1h contains a carboxylic acid functionality that 
could be used as a point of attachment to biomolecules. To illustrate this, and to measure 
the spectroscopic properties of this probe on a protein, 1h was coupled to streptavidin. 
Measurement of the dye:protein ratio via UV100,101 indicated this was almost exactly 
3.0:1.0.  
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Scheme 2.5.  Syntheses of the water-soluble probes 1g and 1h. 
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The thiol functional group is not very common in most proteins and can be 
labeled with high selectivity. Thiol-reactive probes often provide a means of modifying a 
protein at a defined site. Scheme 2.6. shows how a thiol-reactive analog 1i was easily 
prepared from compound 1c. Sonogashira reaction of 1c with bromoacetamide 
derivative gave a mixture of bromo- and iodo- substituted derivatives 7. After 
sulfonation and halide exchange, thiol-reactive probe 1i was obtained in almost 
quantitative yield. 
 
Scheme 2.6. Synthesis of water-soluble thiol-reactive analog 1i. 
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2.2.2 UV and fluorescence properties of the GFP-chromophore analogs 
The central hypothesis of this work is that the fluorescence quantum yields of 
“unconstrained” GFP analogs like 4 will be greatly increased in compounds such as 1 
that are conformationally locked by a boron atom.  This was verified, and illustrative 
data are shown in Table 2.3. 
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f ree rotation as in GFP
chromophore models
outside the protein
"constrained" as in GFP
increased quantum
yield?
 
 
The unconstrained molecule Z-4c has a very low quantum yield (0.0005) 
compared to the locked analog 1c (0.86); this is a dramatic illustration of the 
hypothesized effect. Several other differences in the electronic spectra of these materials 
were also observed. The UV absorbance and fluorescence emissions of compound 1c are 
both red-shifted relative to Z-4c, and the fluorescent emission from 1c is sharper (Figure 
2.9.). For further comparisons, data for the trans-unconstrained intermediate E-4c, and 
the isomeric locked product 5c are also given in Table 2.3.  The UV and fluorescence 
properties of E-4c are almost identical to those of Z-4c.  The locked compound 5c has a 
quantum yield that is approximately 30-fold greater than E-4c, and its absorbance and 
emission wavelengths are also red shifted.  The quantum yield of 5c is, however, 86-fold 
less than 1c, possibly for the reason implied in the discussion of the X-ray structures of 
1c and 5c, ie rapid conformational equilibria between ring-puckered forms leading to 
radiationless decay pathways.  Other consequences of deviation from planarity for 5c are 
that the absorbance is blue-shifted, and the extinction coefficient is less.  
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Table 2.3. Spectroscopic properties of 4c, 1c and 5c in MeOH 
 
 
λmax abs 
(nm) 
ε 
(M-1cm-1) 
λmax emiss 
(nm) 
fwhma 
(nm) 
Φb 
      
Z-4c 458 40200 515 69 0.0005 
1c 492 57300 532 54 0.86 ± 0.02 
E-4c 458 48000 515 73 0.0003 
5c 463 42700 530 54 0.01 
 
a Fluorescence full width at half maximum peak height (fwhm); b Fluorescein in 0.1M NaOH as standard 
(φ = 0.92).102  
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Figure 2.9.  Normalized UV absorbance and fluorescence of Z-4c and 1c in MeOH, (ca 10-6 M for UV and 
10-6 - 10-7 M for fluorescence). 
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Table 2.4. gives the UV absorbance and fluorescence data for all the compounds 
1 and 5.  The UV and fluorescence properties of the lypophilic compounds 1a - f and 5a 
– f are quite similar; Figure 2.10. shows illustrative spectra for compounds 1a - f and 5a 
– f. 
The data in Table 2.4. show that the UV absorbance maxima for all the lipophilic 
compounds 1a – f in MeOH are very similar (λmax abs = 494 + 4 nm) except for 
compound 1a which has a methyl- rather than an aryl-substituent on the core.  
Measurements of fluorescence full width at half-maximum peak heights (fwhm) show 
that the methyl substituted compound 1a gives the sharpest fluorescence in the series. 
Fluorescence emission maxima for compounds 1b – e are in a 10 nm range (λmax emis = 
526 + 5 nm). The outliers in terms of fluorescence are 1a (because it does not have an 
aryl substituent) and the nitroaryl-substituted compound 1f.  Compound 1f, fluorescing 
at 598 nm, has a much larger Stoke’s shift than the others in the series, but a much lower 
quantum yield. The anomalously low quantum yield is most probably due to 
photoinduced electron transfer from the excited state of the fluorescent core to the 
LUMO of the nitroaryl group (ie d-PeT). When hexane was used as a medium in place 
of methanol then the quantum yield of the nitroaryl-substituted compound 1f was only 
about 33 % less than 1a – e in MeOH. This implies the d-PeT quenching mechanism is 
not dominant in apolar media, reflecting changes of the oxidation potentials in this 
molecule. The absorption and fluorescence maxima of 1a – e were shifted by up to 20 
nm to the red when a less polar media (dichloromethane) was used (see appendix for an 
expanded version of Table 2.4.).  
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Figure 2.10. UV absorbance and fluorescence spectra for: (a) GFP-chromophore analogs 1 in MeOH; and, 
(b) GFP-chromophore analogs 5 in MeOH. Throughout: 10-6 M for UV and 10-7 M for fluorescence. 
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Figure 2.10. Continued. 
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Table 2.4. Spectroscopic properties of GFP-chromophore analogs 
 
 
λmax abs 
(nm) 
ε 
(M-1cm-1) 
λmax emiss 
(nm) 
fwhm 
(nm) 
Φa solvent 
       
1a 477 57300 485 19 0.89 ± 0.01 MeOH 
5a 426 37000 485 25 0.0007 MeOH 
1b 490 58700 521 46 0.87 ± 0.01 MeOH 
5b 463 50500 517 64 0.006 MeOH 
1c 492 57300 532 54 0.86 ± 0.02 MeOH 
5c 463 42700 530 54 0.01 MeOH 
1d 493 51300 521 38 0.85 ± 0.03 MeOH 
5d 455 38600 528 69 0.03 MeOH 
1e 495 37900 531 48 0.80 ± 0.01 MeOH 
1f 492 44000 598 120 0.0004 MeOH 
1f 498 n.d. 587 53 0.53 ± 0.01 Hexanes 
5f 473 35500 527 73 0.005 MeOH 
5f 486 n.d. 545 97 0.05 Hexanes 
1g 488 48100 531 53 0.88 ± 0.01 MeOH 
1g 481 46500 518 50 0.87 ± 0.01 Phos 7.4b 
1h 488 35000 538 58 0.84 ± 0.01 MeOH 
1h 482 34800 526 56 0.82 ± 0.01 Phos 7.4b 
1i 489 26200 542 61 0.87 ± 0.01 MeOH 
1i 483 26900 528 59 0.87 ± 0.01 Phos 7.4b 
1s 482 n.d. 529 56 n.d. Phos 7.4b 
 
a Fluorescein in 0.1M NaOH as standard (φ=0.92); b 0.1M lithium phosphate buffer (pH=7.4). 
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Table 2.4. also gives data for the water-soluble dyes 1g, 1h, 1i and 1s.  The 
absorbance and emission maxima for 1g, 1h, and 1i were slightly blue-shifted in 
phosphate buffer relative to the same dyes (and to 1c) in MeOH.  Quantum yields for 1g 
1h and 1i were also high in phosphate buffers, just as in MeOH. The spectra of 
compound 1s (Figure 2.11.), ie 1h on streptavidin, was not significantly different to the 
parent dye; in other words, conjugation to this particular protein does not have 
significant effect on the fluorescent properties. 
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Figure 2.11. Normalized UV absorbance and fluorescence of 1h and the labeled streptavidin 1s in 0.1 M 
lithium phosphate buffer, pH 7.4. 
 
 
2.3 Conclusions 
Compounds 1 in this chapter are conceptual hybrids of GFP chromophore 
analogs and BODIPY dyes. The data presented prove that addition of the BF2-entities to 
the open chain intermediates 4 greatly increases the quantum yields across a range of 
compounds. Overall, this provides more evidence for the assertion that GFP 
chromophores within the protein have enhanced quantum yields due to conformational 
locking within the β-barrel cocoon. 
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The fluorescence properties of compounds 1 tend to be very similar to BODIPY 
dyes.  Both compounds are neutral, uncharged, highly fluorescent molecules that absorb 
with high extinction coefficients and emit in around 520 – 530 nm (unless high 
conjugating substituents are added).  BODIPY dyes have many applications in chemistry 
and biology.  Probes 1 could presumably be used in the same ways, and there may be 
some advantages to doing this, in terms of intellectual property at the very least.  
Further, the data presented here show that dyes 1 can be sulfonated and modified to 
include a point of attachment to biomolecules. The water-soluble modifications to 1 
retain their fluorescent properties in aqueous media and when attached to a model 
protein (streptavidin).  
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CHAPTER III 
A NEW SYNTHESIS OF SYMMETRIC BORAINDACENE (BODIPY) DYES* 
 
3.1 Introduction  
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene, or BODIPY® (hereafter abbreviated 
to BODIPY) dyes are extremely fluorescent materials and have become the preferred 
fluorophores in new fluorescent probes that have found numerous applications in 
biochemistry and molecular biology.  This is due to their superior characteristics, such as 
(i) their relatively high absorption coefficients and fluorescence quantum yields; (ii) 
narrow emission bandwidth and therefore higher peak intensity and good signal/noise 
ratio; (iii) insensitivity to the polarity and pH of their environment; (iv) greater chemical 
and photochemical stabilities; (v) optical properties can be tuned by small modifications 
to their structures; (vi) relatively short synthesis to the simple derivatives.98 The first 
member of BODIPY family was reported by Treibs and Kreuzer in 1968,103 although 
relatively little attention was given to the discovery until the end of the 1980s.104 Then, 
the potential use of this dye for biological labeling was recognized. Tons of patents and 
papers were published based on BODIPY dyes in the past two decades. Today, BODIPY 
dyes have become one of the most popular dyes in biological studies. 
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____________ 
*Reprinted in part with permission from “A New Synthesis of Boraindacene (BODIPY) 
Dyes”, Liangxing Wu, Kevin Burgess, Chem. Commun., 2008, 40, 4933-4935. 
Copyright 2009 Royal Society of Chemistry. 
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 Synthesis of BODIPY is based on the well-known pyrrole condensation reaction 
which was originally developed for the synthesis of certain porphyrins. Symmetric 
BODIPYs with meso-substituents are formed via condensation of a highly electrophilic 
carbonyl compound such as acetyl chloride, aldehyde or acid anhydride with two pyrrole 
units.98,104  
8-Substituted BODIPY dyes (ie ones with substituents in the meso position) tend 
to be relatively easy to prepare via condensation of acyl chlorides with pyrroles (Scheme 
3.1.a). These transformations involve unstable dipyrromethene hydrochloride salt 
intermediates.  The intermediate dipyrromethene hydrochlorides are easier to handle and 
purify as C-substitution increases but, even so, these are not generally isolated in 
syntheses of BODIPY dyes.   
Other activated carboxylic acid derivatives could be used in place of acid 
chlorides. In the particular case of acid anhydrides, this concept has been reduced to 
practice. Scheme 3.1.b shows how a BODIPY derivative was prepared from glutaric 
anhydride.105 An attractive feature of this chemistry is that a free carboxylic acid is 
produced, and this may later be used to attach the probe to target molecules. 
Syntheses similar to those depicted in Scheme 3.1.a and 3.1.b but which use 
aromatic aldehydes (to the best of our knowledge, aliphatic aldehydes have not been 
reported in this reaction) require oxidation steps.   The reagents for these oxidations can 
introduce experimental complications.  Thus in Scheme 3.1.c the oxidant used was p-
chloranil or DDQ and eventually the byproducts from this had to be removed (in fact, 
this was done after complexation with the boron).  
 
Scheme 3.1. Typical syntheses of symmetric BODIPYs with meso-substituent from (a) acyl chloride; (b) 
anhydride; (c) aldehyde. 
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Scheme 3.1. Continued. 
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 α,β-Unsubstituted BODIPYs (eg R1 = R2 = R3 = H in Scheme 3.1.c) can also be 
prepared from aldehydes using neat conditions.106 The aldehyde is dissolved in excess 
pyrrole at room temperature, and the dipyrromethane intermediate (the reduced form of 
the dipyrromethene) was formed and isolated.  The BODIPY dye was obtained after 
oxidation with DDQ and complexation with boron.  Acid chlorides probably would be 
too reactive to use with pyrrole (since it is unsubstituted and more reactive) so this 
aldehyde-based approach is the method of choice.   
It is unusual to use any aldehydes that are not aromatic to prepare BODIPY 
derivatives. In this sense the vinylic thioether probe as shown in the following reaction 
was exceptional. A catalytic amount of ytterbium (III) trifluoromethane sulfonamide was 
used to mediate the condensation process, the intermediate dipyrromethane was oxidized 
with DDQ, and complexation with boron trifluoride gave the product, though in very 
poor yield.107 
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Condensations of pyrroles with acid chlorides or with benzaldehyde derivatives, 
as outlined above, are direct and convenient methods to access symmetrically substituted 
BODIPY dyes. However, another approach is required to form unsymmetrically 
substituted ones. Generally, this is achieved via preparations of ketopyrrole 
intermediates, followed by a Lewis acid mediated condensation of these with another 
pyrrole fragment. Schemes 3.2.a shows reactions of magnesium anions of pyrroles with 
activated carboxylic acid derivatives to give the corresponding 2-ketopyrroles.108,109 In 
part b, one such ketopyrrole is condensed with another pyrrole unit to give a BODIPY 
framework.  This method is particularly valuable for unsymmetrical ones. 
 
Scheme 3.2. (a) Two different methods for production of ketopyrroles from magnesium derivatives of 
pyrrole, and (b) application of these starting materials in the production of unsymmetrical BODIPYs. 
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Scheme 3.2. Continued. 
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 The syntheses of BODIPYs without meso-substituents (eg R4 = H in Scheme 
3.2.b) are usually achieved by Lewis acid mediated condensation of pyrrole-2-CHO with 
another pyrrole molecule that is not substituted at the 2-position. The conditions are very 
similar to the ones shown in Scheme 3.2.b. Only difference is that, in order to synthesize 
meso-unsubstituted BODIPYs, a pyrrole-2-CHO is used in place of the ketopyrrole. 
Many simple BODIPY derivatives are prepared using this method.98 
 This work describes a serendipitous discovery that symmetric BODIPY 
derivatives without meso-substituents can be prepared from the pyrrole-2-CHO 
component alone. Further the yield can be superior for this new approach. Thus the 
specific aims for this project are: 
(i) optimization of conditions for the new reaction 
(ii) investigation of the mechanism and kinetics of the new transformation 
(iii) preparation of BODIPY derivatives using this new approach 
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3.2 A new approach to symmetric BODIPYs 
  When 3,5-dimethylpyrrole-2-carboxaldehyde 8a in CH2Cl2 was treated with 
POCl3 as indicated in Scheme 3.3.b, a yellow solution resulted, and evolution of gas 
was observed.  1H, 13C, 31P NMR and MS analyses of the crude reaction mixture 
showed that it contained the known110-112 dipyrromethenium cation 10 and the 
dichlorophosphate counterion. This intermediate 10 was converted to the BODIPY 
product 9a without isolation by adding BF3•OEt2 to the reaction mixture.  
 
Scheme 3.3.  (a) Conventional synthesis of tetramethyl-BODIPY 9a; and, (b) the new approach described 
here. 
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 The reaction occurred efficiently with 3,5-dimethylpyrrole-2-carboxaldehyde 8a 
(0.2 M in CH2Cl2) using only 1.2 equivalents of POCl3 at room temperature. Almost 
complete conversion of the starting pyrrole-2-CHO 8a to the dipyrromethene 
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intermediate 10 was observed within 30 min and no obvious by-product was detected by 
NMR. After installing the boron center, the desired product tetramethyl BODIPY 9a was 
obtained in 92 % yield which was higher than the conventional approach yield (70 %). 
The reaction with 8a was also carried out on 1-3 grams scale and the product 9a was 
isolated with similar yields by recrystallization. Thus no further optimization of the new 
reaction condition was performed.  
 
Scheme 3.4. Synthesis of pyrrole-2-aldehyde 8. 
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Table 3.1. Synthesis of symmetric BODIPYs 9 
S.M BODIPY product 9 Yield (%) S.M BODIPY product 9 
Yield 
(%) 
8a N
B
F2
N
 
92 8f N
B
F2
N
Et Et  
28 
8b 
N
B
F2
N
 
91 8g N
B
F2
N
 
22 
8c 
N
B
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N
MeO OMe
 
85 8h 
N
B
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N
Ac Ac
 
0b 
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N
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N
Ph
Ph
Ph
Ph  
21 8i 
N
B
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N
MeO OMe
 
0b 
8e 
N
B
F2
N
Et Et
 
75a 
 
   
a Literature reported yield was 45 %;113,114 b complex mitures; trace amount of desired product. 
 
The pyrrole-2-aldehyde substrates needed for the new reaction were prepared via 
Vilsmeyer-Haack reaction from the corresponding pyrroles in good yields (Scheme 3.4.). 
The standard new reaction condition (0.1-0.2 M substrate in CH2Cl2, 1.2 equivalents of 
POCl3, room temperature, overnight; then addition of BF3OEt2) was used to prepare 
series of BODIPY derivatives 9 from the pyrrole-2-CHO substrates 8 (Table 3.1.). 
Various substituents were tolerated in the synthesis. Product yields were substrate 
dependent and tended to be good except where there were steric issues from a C3-
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substituent (compare 9b and 9d), where the pyrrole was less electron rich (compare 9e 
and 9h), or for reasons which cannot be explained simply (9f, 9g and 9i). Further 
optimization of the reaction condition with respect to each substrate might improve the 
product yield. 
 
Table 3.2. Photophysical properties of BODIPYs 9 in CH2Cl2 
 
 
λmax abs 
(nm) 
ε 
(M-1cm-1) 
λmax emiss 
(nm) 
fwhma 
(nm) 
Φfl 
      
9a 505 83200 516 - 0.80b 
9b 629 161500 637 23 0.78 ± 0.03c 
9c 651 149100 662 27 0.71 ± 0.04c 
9d 564 78000 593 - 1.00d 
9e 531 87000 538 21 0.86 ± 0.03e 
9f 512 110200 516 17 0.96 ± 0.02e 
9g 547 92000 553 20 0.90 ± 0.02e 
a Full width at half maximum height of fluorescence (fwhm); b data were obtained from reference;115  
c Nile blue (Φ 0.27 in EtOH)116 was used as a  standard; d data were obtained from reference117; e 
Rhodamine 6G (Φ 0.94 in EtOH)118 was used as a standard.  
 
 
Characteristically, all the new BODIPY dyes emit bright, sharp fluorescent 
signals (Table 3.2. and Figure 3.1.).  Substituents at 3 and 5 positions of BODIPY shift 
the absorption and emission to the red (compare 9a, 9f and 9e). Aryl substituents 
dramatically shift the absorption and emission maxima to the longer wavelengths 
(compare 9a and 9d). Constrained derivatives gave even more red-shift (compare 9e and 
9g, 9d and 9b, 9c). 
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Figure 3.1. Spectra of BODIPYs 9 in CH2Cl2. a absorbance (10-6 M); b fluorescence (10-7 M, excited at 
λmax abs). 
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3.3 Kinetic and mechanistic studies of the new reaction 
  3,5-dimethylpyrrole-2-carboxaldehyde 8a was chosen as the substrate to study 
the kinetics and mechanism of the new reaction. The self-condensation process from 
8a to 10 as shown in Scheme 3.1.b (but in CDCl3, at 0.2 M of substrate) was 
followed by 1H, 13C, and 31P NMR over 10 min intervals at room temperature.  More 
than 95 % conversion was observed in less than 20 min, and no by-products were 
observed by NMR (see Appendix Information).  Gas evolution occurred, possibly 
due to loss of CO and HCl from the system. 
  The reaction shown in Scheme 3.1.b was also followed via continual UV 
measurements. This experiment required a considerably more dilute solution (6.7 x 
10-5 M). Excess phosphorus oxychloride was used in this experiment, so the 
concentration of that reagent was effectively invariant throughout the transformation.  
Absorbance peaks for phosphorus oxychloride, the pyrrole-2-carboxaldehyde 8a and 
the product 10 were well resolved under these conditions (Figure 3.2.a). As the 
reaction progressed the concentration of the pyrrole-2-CHO 8a declined and the 
dipyrromethene 10 was formed. No intermediates or byproducts were detected 
assuming no coincident UV absorption characteristics (Figure 3.2.b).  
  Kinetic data extracted from the UV experiment are plotted in Figure 3.2.c.  
Over the first 20 min of the transformation it is second order with respect to the 
pyrrole-2-CHO 8a (6.43 L•mol-1•s-1). This analysis assumes that there were no 
intermediates having coincident UV absorption characteristics.  
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Figure 3.2.   UV study of the self-condensation reaction in CH2Cl2 at 25 oC, and 6.7 x 10-5 M of pyrrole-2-
CHO 8a.  (a) Reaction components and their UV spectra; (b) UV profile for the reaction; (c) plot used to 
deduce the rate of the reaction. 
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Figure 3.2.   Continued. 
   
  The data collected on this reaction type was quite extensive, but still no 
clearly favored mechanism emerges.  All the evidence indicates that phosphorus 
oxychloride seems to be intimately involved in this reaction; when this reagent is 
replaced with another Lewis acid (specifically, TFA or BF3•OEt2) the 
dipyrromethenium cation 10 did not form.  One possibility is that POCl3 reacts with 
pyrrole-2-carboxyaldehyde to give a vinylogous Vilsmeyer-Hack reagent (Figure 
3.3.a, where alternatively the chloride could be a P-based leaving group).  Formation 
of the product then relies on electrophilic attack of this reagent on the C2-atom of 
another pyrrol-2-carboxaldehyde molecule. However, it is somewhat surprising if 
this is the regioselectivity of the attack in that step for some of the substrates. 
Another possiblity is that in the presence of POCl3, pyrrole-2-aldehyde deformylated 
to generate the free pyrrole which condensated with another molecule of pyrrole-2-
aldehyde to give the product (Figure 3.3.b). However, this transformation is quite 
unusual and it is hard to draw a plausible mechanism for the deformylation step. 
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Figure 3.3.  (a) and (b) Two possible mechanisms for the formation of dipyrromethene. 
 
3.4 Conclusion   
  In summary, a novel synthesis of symmetric BODIPY dyes was discovered. 
The new reaction condition was optimized and gave superior yield of tetramethyl-
BODIPY (92 %) than the conventional synthesis (70 %). Systematic investigation on 
the kinetics and mechanism for the new reaction was carried out. Several possible 
mechanisms were proposed for the transformation. The new condition was applied on 
various pyrrole-2-CHO substrates with a diversity of alkyl and aryl substituents and  
afforded the desired product in moderate to good yields. A few NIR BODIPY 
derivatives were also prepared using this new approach. 
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CHAPTER IV 
ROSAMINES WITH CYCLIC AMINE SUBSTITUENTS: SYNTHESES, 
SPECTROSCOPIC PROPERTIES AND APPLICATIONS* 
 
4.1 Introduction  
Rhodamine and rosamine dyes are highly fluorescent xanthylium chromophores 
that have been widely used in many different fields of research, from the lasing medium 
in dye lasers to fluorescent markers in biological studies.119 The structural difference 
between rhodamines and rosamines is that rhodamines carry an additional 2′-carboxylic 
acid which constrains the rotation of the meso-phenyl substituents and also offers a 
handle for attachment to biomolecules. 
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-CO2H
meso
carbon
2'
 
 
 Noelting and Dziewonsky first reported the preparation of rhodamine in 1905.120 
Many rhodamine derivatives have been synthesized since then. Among them, 
Rhodamine B, rhodamine 6G, rhodamine 110, Texas Red and Alex Fluor dyes (Figure 
4.1.) are the most commonly used ones. Their fluorescence characteristics are highly 
dependent on the substituents and ring conjugation. The meso-substituents are not 
significantly conjugated to the xanthylium core so that they do not have much effect on 
 
 
____________ 
*Reprinted in part with permission from “Synthesis and Spectroscopic Properties of 
Rosamines with Cyclic Amine Substituents”, Liangxing Wu, Kevin Burgess, J. Org. 
Chem., 2008, 73, 8711-8718. Copyright 2009 American Chemical Society. 
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the emission wavelength. But the nature and flexibility of the meso-substituents affect 
the fluorescence quantum yields and stability of the rhodamine derivatives. Substituents 
on the nitrogen will red-shift the absorption and emission. For example, rhodamine 110 
absorbs at 502 nm and emits at 527 nm while the ethyl-substituted derivative (rhodamine 
B) absorbs ca 550 nm and emits ca 570 nm.119 The additional conjugation of the 
xanthylium π-system, as well as formation of rigid rings in rhodamines can shift their 
absorption and emission maxima to longer wavelengths.121 The rigidity shifts the 
emission of Texas Red to 615 nm and additional conjugation in Alexa594 also red-shifts 
the fluorescence to 617 nm.122 
 
O NHEtEtHN
CO2
O NEt2Et2N
CO2
O NH2H2N
CO2
rhodamine B rhodamine 6G rhodamine 110  
O NN
SO3
SO2Cl
Texas Red
O NH2H2N
CO2H
SO3H SO3
CO2H
Alexa 488
O NN
CO2H
CO2H
SO3HO3S
Alexa 594  
Figure 4.1. Structures of some common rhodamines. 
 
 Rhodamine dyes are highly favorable fluorophores because of their excellent 
photophysical properties, such as high extinction coefficient, excellent quantum yields 
(often near 1), great photostability and relatively long emission wavelength (> 550nm) 
compared to fluorescein.119 Additionally, their fluorescence spectra are pH-independent 
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over a broad range (low to neutral pH). In contrast to fluorescein, which exists in a non-
fluorescent spiro form at acidic pH, rhodamines exist in a fluorescent quinine form at 
neutral and acidic pH, and a non-fluorescent spiro form only at strong basic condition.123 
 
O NEt2Et2N
CO2H
O NEt2Et2N
O
O
OH-
H+
open, "quinone f orm"
fluorescent
closed, "spiro form"
non-fluorescent  
 
 Due to its remarkably high photostability, high quantum yield and low cost, 
rhodamine 6G is often used as a laser dye and as a fluorescence quantum yield 
standard.119 Rhodamine B is frequently used in biology as a staining fluorescent dye, 
sometimes in combination with auramine O, as the auramine-rhodamine stain (AR). The 
AR is a histological technique used to visualize acid-fast bacilli notably species in the 
Mycobacterium genus using fluorescence microscopy.124 Acid-fast organisms display a 
reddish-yellow fluorescence. Rhodamine B can also be used as a layer dye and 
fluorescence quantum yield standard. Rhodamine 110 especially its sulfonated analog 
Alexa 488 is used extensively for biological labeling in place of fluorescein since they 
absorb and emit at similar wavelengths but are far more photostable. In fact, Alexa Fluor 
dyes are probably the most used rhodamine derivatives in biochemistry and cell biology. 
Alexa dyes are highly water-soluble which facilitate the applications under physiological 
conditions. Furthermore, they give exceptionally bright and photostable conjugates with 
biomolecules. The fluorescence emission even of dyes with the highest possible 
quantum yield and great water-solubility, such as fluorescein and sulforhodamine (Texas 
Red), is considerably quenched on conjugation to biological molecules, particularly to 
proteins. However, conjugation does not affect the optical properties of Alexa dyes. 
Actually, diverse protein conjugated of Alexa dyes tend to be brighter and more resistant 
to photobleaching than those of any alternative dyes that have similar spectral properties. 
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In addition, Alexas dyes are insensitive to pH in the 4-10 range. All the above 
characteristics facilitate the wide use of Alexa dyes in biological studies.122 
 Rhodamine derivatives can also be used as substrates for the multidrug resistance 
(MDR) transporter assays.125,126 Multidrug resistance (MDR), mediated by the plasma 
membrane protein P-glycoprotein127 (Pgp), has been identified as a major impediment to 
successful chemotherapy for a variety of cancers.128 Pgp pumps a variety of structurally 
and mechanistically unrelated chemicals and chemotherapeutic agents from tumor cells, 
resulting in treatment failures.129,130 The mechanism by which Pgp overexpression is 
induced during exposure to chemotherapeutics is still not fully understood.131,132 
Attempts have been made to alleviate the function of Pgp using modulators such as 
verapamil, quinidine, cuclosporin A, PSC833, and others.133-135 These modulators bind 
to the drug-transport sites on the protein and impede the binding and subsequent efflux 
of agents of interest, thus allowing their accumulation. Studies of the efflux function of 
Pgp have traditionally use Pgp transport molecules that are either intrinsically 
fluorescent or tagged with a fluorescent marker. Among the best transport molecules for 
Pgp are the xanthylium dyes rhodamine 123 (the methyl ester of rhodamine 110), 
rhodamine 6G and tetramethylrosamine.136-138 Such studies usually monitor the efflux of 
a specific molecule, such as rhodamine 123, from cells by measuring the decrease in 
intracellular fluorescence.125,131 These dyes have also been used as fluorescent markers 
to determine the efficacy of Pgp modulators.139 
Rhodamine 123 has also been extensively used as a mitochondrial stain for 
studying cellular functions.140 Mitochondria are the main energy generators that maintain 
cell life and essential cell functions.141 As a powerhouse, mitochondria generate energy 
through oxidative phosphorylation where oxidation of respiratory substrates is coupled 
to the synthesis of ATP under aerobic conditions.142 This process involves a sequence of 
electron transfers from respiratory substrates to oxygen, concurrent with proton 
translocation from the mitochondrial inner compartment to the intermembrane space 
through a series of respiratory chain complexes located on the inner membrane. The 
electrochemical proton gradient thus formed, also designated as the proton motive force, 
 74
is the driving force for ATP synthesis through the back flow of protons through the ATP 
synthase complex.  Importantly, this mitochondrial transmembrane proton-motive force 
which results in a negative potential inside the mitochondrial matrix selectively 
accumulates lipophilic cations such as rhodamine 123 which are membrane-permeable 
compounds with cationic characteristics.143,144  
High concentrations of lipophilic cations in mitochondria often results in cell 
death by decreasing cellular ATP production,145 rendering mitochondria a unique target 
for cellular toxicity.143 Numerous studies have shown that the mitochondrial membrane 
potentials of carcinoma cells are higher than in normal epithelial cells and that the 
accumulation and retention of lipophilic cations correlated with the mitochondrial 
membrane potential. This increase in mitochondrial membrane potential in carcinoma 
cells which leads to selective accumulation of toxic lipophilic cations provides a 
rationale for selective chemotherapy of cancer cells. Rhodamine 123 was the first 
example of lipophilic cation to exhibit selective anti-tumour activity.146-148 In in vitro 
experiments, this compound markedly induced cell death in 9/9 of carcinoma cell types 
while 6/6 of non-tumorigenic epithelial cell types remained unaffected when tested at 
similar concentrations.149-151 Rhodamine 123 also displays selective toxicity in certain 
carcinoma cells in vivo and prolongs the survival of mice bearing experimentally 
induced Ehrlichs ascites tumor or MB49 bladder carcinoma, but not that of mice bearing 
L1210 leukemia or B16 melanoma.152 The moderate selectivity and systemic toxicity 
limit the usefulness of rhodamine 123. 
In spite of their wide applications, there are not many available rhodamine or 
rosamine derivatives. There is considerable potential for modulating the chemical and 
biochemical properties of rosamines by varying the substituents, but the scope of such 
research is limited by synthetic constraints. The first syntheses of rosamines center 
around condensation reactions of the type shown in Figure 4.2.a.121,153-155 Such 
approaches tend to involve high temperatures. They can be facilitated via microwave 
heating,156 but even in those cases the conversion to product is not very efficient. Other 
work deals with modification of the 2-carboxylate group of rhodamines (not 
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shown),123,157 but the parent systems are also made via condensation reactions at elevated 
temperatures. An alternative approach to syntheses of rosamine dyes is to add an organo-
lithium or -magnesium compound to the carbonyl group of a xanthone, then protonate to 
cause loss of water and generate the product158 (Figure 4.2.b). That approach has been 
applied extensively by Detty and co-workers to make tetramethylrosamine derivatives 
(and especially S-, Se-, and Te-analogs)159-162 for their photodynamic and other medicinal 
properties.125,126,163-165 Similarly, attack of aryl Grignards on solid-supported xanthones 
was used in a supported parallel synthesis approach to a library of rosamine 
derivatives.166 However, the preparation of rosamine derivatives using the addition 
approach has been limited by the paucity of synthetic routes to 3, 6-diaminesubstituted-
xanthones. The reported approaches to 3,6-diamino-xanthone usually require many step 
synthesis and only lead to low yield of the desired products.166-172 Some routes only 
work for certain substrates and are not general173-178 (Figure 4.3.).  
 
a 
R2N OH CHO
R'
+
(i) heat
(ii) oxidize
R'
OR2N N+R2  
 
b 
OR2N NR2
O
(i) ArMgBr
(ii) acid OR2N N+R2
Ar
 
 
Figure 4.2. Syntheses of rosamine dyes via: (a) the conventional condensation approach; and, (b) 
nucleophilic additions to 3,6-diamino-xanthones. 
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a 
O NMe2Me2N
Cl-
(i) KCN, H2O, relfux, 18 h
(ii) FeCl3, HCl, H2O, 90 oC, 12 h
(iii) NaHCO3, H2O, reflux, 72 h
22 %  
O NMe2Me2N
O
 
b 
Me2N OH
OHC
HO NEt2
+
(i) HCl, H2O, EtOH, 25 oC, 18 h
(ii) H3PO4, H2O, ref lux, 2 h  
O NEt2Me2N
O
 
c 
XMe2N NMe2
NEt2
O
(i) POCl3, Et3N, CH2Cl2
0 to 25 oC, 48 h
(ii) NaOH, H2O, 25 oC X NEt2Me2N
O
X = S, Se or Te  
d 
O2N Cl
O
OH
HY N
H
O
+
(i) K2CO3, Cu, DMF, 130 oC
(ii) H2SO4, 80 oC
(iii) alkylation
(iv) SnCl2, EtOH, 90 oC  
Y NR2H2N
O
Y = O, NR' or S  
Figure 4.3. Reported syntheses of 3,6-diaminesubstituted-xanthones. 
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For several years, work in our laboratory has focused on a solution phase 
approach to the rosamine dyes. This chapter shows the efficient synthesis of rosamine 
cores 11 – 15 with a variety of meso-substituents a - i.  The specific aims for this work 
are: 
(i) development of an efficient synthesis of 3, 6-diamino-xanthone 
(ii) preparation of rosamines from the synthesized aminoxanthones 
(iii) functionalization to prepare water-soluble derivatives 
(iv) photophysical property studies and applications 
(v) biological activity test for the new rosamines 
 
O
R2
R12N N+R12
R1 = N
11
O
N
12
BocN
N
14
N
13
HN
N
15
Me
a cb
R2 =
d e f
MeOI
OMe
g h
S
OMeMeO
i
Me
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4.2 Syntheses of aminoxanthones and rosamines 
The ditriflate 16 was easily prepared on a multigram scale without 
chromatography via a slight modification of a known procedure.179,180 This reacted with 
piperidine, morpholine, Boc-piperazine, and pyrrolidine to give the symmetrical 
products 17 – 20 as indicated in Table 4.1.  Stepwise addition to give an unsymmetrical 
product was also explored briefly, and this proved to be feasible (reaction 4.1), 
presumably because the product of the first addition (a vinylogous amide) is less reactive 
than the starting material. 
 
Table 4.1.  Amination of the ditriflyl xanthone 16 
O
O
TfO OTf
amine
DMSO, 90 °C, 12 h
16  
O
O
R2N NR2
17 - 20   
 
product NR2 yield (%) 
   
17 N
 
89 
18 NO
 
93 
19 NBocN
 
60 
20 N
 
18 
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O
O
TfO OTf
DMSO, 25 °C, 1.5 h
16
NH
(i) 5 eq.
 
 
 
O
O
N N
21 84 %
DMSO, 90 °C, 12 h
O
NH
(ii) 5 eq.
O
 
 
reaction 4.1 
 
Ketones 17 to 21 are not exceptionally reactive, they are vinylogous ureas, but 
they combined efficiently with organolithium and Grignard reagents to give tertiary 
alcohols.  These adducts were not isolated; instead they were treated with aqueous acid 
to give the desired products as indicated in Table 4.2.  All the compounds were isolated 
in tens to hundreds of milligram amounts via flash chromatography.  However, in three 
cases (11d, 11h and 14d) several grams of product were isolated via recrystallization of 
crude materials obtained on a larger scale.  The benzenoid compounds shown in Table 
4.2 have methyl-, iodo-, and one or two methoxy substituents on the meso-aryl group.  
Steric effects associated with ortho-substitution did not seem to have any significant 
adverse effects on the syntheses of any compounds in this series. 
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Table 4.2. Synthesis of rosamine derivatives 
O
O
R12N NR22
(i) R3M, THF
(ii) 2M HCl
M = Li or MgX  
O
R3
R12N NR
2
2
Cl  
entry NR12 NR22 R3M product 
yield 
(%) 
      
1 N
 
N
 
CH3MgBr 11a 89 
2 N
 
N
 
PhCH2MgCl 11b 70 
3 N
 
N
 
PhMgBr 11c 100 
4 N
 
N
 
I MgCl
 
11d 90 
5 N
 
N
 
MeO MgBr
 
11e 100 
6 N
 
N
 MgBr
OMe
 
11f 100 
7 N
 
N
 S MgBr  
11g 74 
8 N
 
N
 
Li
OMe
OMe  
11h 96 
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Table 4.2. Continued 
entry NR12 NR22 R3M product 
yield 
(%) 
9 N
 
N
 MgCl
Me
 
11i 99 
10 NO
 
NO
 MgCl
Me
 
12i 98 
11 N
 
N
 MgCl
Me
 
13i 53 
12 N
 
NO
 MgCl
Me
 
22i 98 
13 NBocN
 
NBocN
 MgCl
Me
 
14i 90 
14 NBocN
 
NBocN
 
LiI
 
14d 68 
15 NBocN
 
NBocN
 
Li
OMe
OMe  
14h 94 
 
None of the compounds shown in Table 4.2. are water-soluble, but several 
modifications were tested to demonstrate that water soluble derivatives are accessible 
from some of the products.  Reaction 4.2, for instance, illustrates how the piperazine 
derivative 14d could be unmasked to give a bisammonium salt.  That salt was not 
isolated but aqueous solution of it was strongly fluorescent, and it was neutralized then 
reacted with tert-butyl bromoacetate to give the diester 23.  Treatment of diester 23 with 
trifluoroacetic acid gave a product that was water-soluble and fluorescent but difficult to 
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isolate.  The inference of these experiments is that the intermediate ammonium salt and 
the diacid derived from it could be prepared via deprotection of their precursors then 
used to couple to biomolecules. 
 
O NN
BocN NBocCl-
I (i) 1:1 TFA/CH2Cl2
25 oC, 1 h
(ii) K2CO3, DMF
100 oC, 4 h
14d
O
Br
OtBu
 
O NN
N NCl- CO2
tBuButO2C
I
23 76 %  
reaction 4.2 
 
The dimethoxy compound 11h was also modified to give a water soluble analog.  
Scheme 4.1. outlines how this was achieved via a demethylation procedure to give the 
phenolate 24. That derivative has no functional group for direct attachment to a 
biomolecule, and in any case it is only slightly water-soluble.  Consequently, the two 
phenolate groups were alkylated with tert-butyl bromoacetate, then the esters were 
deprotected to give the diacid 25.  Diacid 25 is a polar, water-soluble compound that was 
conveniently isolated by washing away residual starting materials using 
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acetonitrile/ether. This derivative was conjugated to avidin to explore how its 
spectroscopic properties are modulated by coupling to this protein (see below). 
 
Scheme 4.1. Synthesis of water-soluble rosamine 25. 
 
O NN
OMeMeO BBr3, CH2Cl2
-78 to 25 oC
12 h
Cl
11h  
O NN
OHHO
24 87 %
(i) Cs2CO3, Bu4NI, DMF
25 oC, 12 h
(ii) 1:1 TFA / CH2Cl2
25 oC, 1 h
(iii) ion-exchange (Cl)
O
Br
OtBu
X-
 
O NN
OO COOHHOOC
25 75 %
Cl-
 
 
Interestingly, rosamine 24 was easily sulfonated in concentrated sulfuric acid to 
give a water-soluble derivative 26 along with an unexpected product 27 which was 
mono-brominated and sulfonated product probably arising from the mixture Cl/Br 
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counterion (reaction 4.3). Both 26 and 27 were unambiguously assigned by NMR, MS 
and X-ray diffraction analysis (Figure 4.4.). 
 
O NN
HO OH
X-
conc'd H2SO4
0 to 25 oC, 12 h
24  
 
O NN
HO OH
Br SO3
O NN
HO OH
HO3S SO3
+
26 27  
 
reaction 4.3 
  
The X-ray structure shows that in rosamine 26 the two nitrogens are essentially 
flat and coplanar with the xanthene core structure. The piperidine rings adopt perfect 
chair conformations and the meso-phenyl substituent is almost perpendicular to the 
xanthene core structure (dihedral angle: 71.90 o) indicating that the meso-substituents are 
not conjugated with the rosamine cores. Similar conformations were also observed in 
rosamine 27. Details of the X-ray structure parameters are listed in the Appendix 
information. 
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a 
 
b 
 
Figure 4.4. X-ray structures for rosamines (a) 26 and (b) 27. 
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Another modification to give a water-soluble probe is shown in reaction 4.4.  
Here the two tert-butyloxycarbonyl groups of rosamine 14h were removed with acid to 
give, after neutralization and ion exchange, the bisamine 15h. Compound 15h dissolves 
easily in water; its spectroscopic properties in buffers were explored extensively (see 
below). 
 
ON N
MeO OMe
BocN NBocCl
14h
(i) 1:1 TFA/CH2Cl2
25 oC, 1 h
(ii) NaHCO3
(iii) ion-exchange (Cl)
 
 
ON N
MeO OMe
HN NHCl
15h 83 %  
reaction 4.4 
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4.3 Spectroscopic properties of rosamine derivatives 
Table 4.3. shows UV-Vis absorption wavelength maxima, molar extinction 
coefficients, fluorescence emission maxima, fluorescence peak broadness (measured by 
full width at half maximum height, fwhm), and quantum yields for the target 
compounds.  These data were collected for all the compounds when dichloromethane 
was used as solvent.  However, we observed that the meso aliphatic compounds 11a and 
11b tend to be less stable in polar media. 
The UV and fluorescence properties of all the rosamine derivatives are quite 
similar. They all absorb in the range of 555-570 nm except for the meso-thiophene 
derivative 11g which gives red-shifted absorption and fluorescence maxima (see next 
paragraph for detailed discussion), indicating that the meso-aryl groups are not 
significantly conjugated to the xanthene core, presumably because steric factors 
involving these substituents make it energetically unfavorable for the molecules to 
become planar. The fluorescence maxima fall in the range of 580 ± 10 nm. The emission 
peak broadness values in this series range from 31 – 44 nm (CH2Cl2); these values are 
comparable with a typical rhodamine, rhodamine B (36 nm in CH2Cl2).  
Several trends emerge from the spectroscopic data recorded for the compounds 
dissolved in dichloromethane. Relative to the other compounds, the meso-methyl 
derivative 11a has slightly blue-shifted absorption and fluorescence maxima, but the 
extinction coefficient and the quantum yield are comparable with the rosamines having 
aromatic meso-substituents. Curiously, the benzyl compound 11b is spectroscopically 
more similar to the meso-phenyl compound 11c than to the methyl derivative 11a. 
Compound 11g is most red-shifted in terms of the wavelengths for absorption maxima 
and the fluorescence emission maxima.  However, the quantum yield for this compound 
was about a third of that observed for other members in this series; this observation 
might be attributed to partial fluorescence quenching via electron transfer from the S-
containing heterocycle.181 Quantum yields for the Boc-piperazine derivatives were also 
low relative to other members of the series. The very best quantum yield observed was 
for the pyrrolidine derivative 13i.  
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Differences between the piperidine derivatives 11 and the pyrrolidine derivative 
13i are accentuated in a more polar medium (ethanol, second section of Table 4.3.). For 
example, the fluorescence quantum yield of piperidine derivatives 11i varies from 0.89 
in CH2Cl2 to 0.28 in EtOH, while pyrrolidine derivative 13i has very high quantum 
yields in both solvents (1.00 in CH2Cl2 and 0.95 in EtOH). To the best of our 
knowledge, this work is the first to uncover a relationship between the ring size of the 
peripheral amines in rosamines and their fluorescent quantum yields, but others have 
commented on similar effects in the context of 4-amino-1,8-napthalimide182 and 4-
aminophthalimide derivatives.183 The origin of these effects is thought to be that smaller-
ring cyclic amine substituents are less inclined to invert at nitrogen atom in the excited 
state, so this pathway for non-radiative loss is disfavored and the overall quantum yields 
are higher.184 More polar solvents favor intramolecular charge transfer from cyclic 
amines where the N-atom more closely approximates a planar arrangement as a result of 
facile interconversion between ring forms. The interconversion is more rapid for 
piperidine derivatives than the pyrrolidine-based compounds. Overall, the quantum yield 
data for the compounds in ethanol are, in all the cases measured, less than that in 
dichloromethane. This is a somewhat unexpected finding since other rosamines are 
known to be very highly fluorescent even in alcohols; for instance, tetramethyl rosamine, 
has a quantum yield of 0.84 in MeOH.101,172  
 Quantum yields of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes 
with meso-aryl substituents are thought to be increased if the aryl group has an ortho-
substituent, or if rotation of the aryl is otherwise restricted.98 Similarly, fluorescein and 
derivatives with 2-substituted meso-aryl groups are far more fluorescent than the 
corresponding meso-phenyl compound.185,186 However, it is surprising that in the series 
outlined in Table 4.3., unlike the analogous BODIPY dyes, rosamines with ortho-
substituted meso-aryl groups (11i: 2-Me, 11f: 2-OMe, 11h: 2,6-OMe) have similar 
quantum yields to the phenyl derivative (11c). The rotation of meso-substituents did not 
reduce the rosamine quantum yields. 
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Table 4.3. Spectral properties of rosamines 
 λmax abs (nm) εmax 
λfluor 
(nm) 
fwhm 
(nm)a Φfb 
  
 CH2Cl2 
11a 555 101900 570 35 0.91 ± 0.05 
11b 566 95900 582 34 0.87 ± 0.01 
11c 565 106000 585 37 0.89 ± 0.01 
11d 570 115400 590 38 0.85 ± 0.01 
11e 562 116700 582 35 0.91 ± 0.02 
11f 566 118000 585 37 0.92 ± 0.03 
11g 582 107600 603 41 0.33 ± 0.01c 
11h 565 87300 586 36 0.86 ± 0.04 
11i 565 123600 582 34 0.89 ± 0.01 
12i 554 106900 575 37 0.80 ± 0.01 
13i 558 127400 573 31 1.00 ± 0.09 
22i 559 111000 579 36 0.59 ± 0.01 
14i 555 120800 577 40 0.47 ± 0.01 
14d 561 77900 585 42 0.41 ± 0.01 
14h 555 109300 580 40 0.49 ± 0.02 
23 564 62800 586 44 0.007 
  
 EtOH 
11c 564 86700 588 39 0.30 ± 0.01 
11d 568 70700 592 40 0.28 ± 0.01 
11e 561 100400 582 37 0.31 ± 0.01 
11f 564 115600 586 37 0.36 ± 0.01 
11g 581 56500 606 43 0.10 ± 0.01c 
11i 564 119500 584 36 0.28 ± 0.01 
12i 556 98600 582 38 0.16 ± 0.01 
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Table 4.3. Continued 
 λmax abs (nm) εmax 
λfluor 
(nm) 
fwhm 
(nm)a Φfb 
 
EtOH 
13i 558 120500 576 33 0.95 ± 0.01 
22i 560 97000 582 38 0.14 ± 0.01 
14i 556 108000 580 39 0.19 ± 0.01 
24 557 71000 580 37 0.26 ± 0.01 
25 557 84800 580 38 0.49 ± 0.02 
15h 561 81000 582 45 0.008 
26 562 82400 589 37 0.28 ± 0.01 
27 553 117200 592 38 0.02 
  
 0.1 M Phosphate buffer, pH = 7.4 
15h 542 71500 568 41 0.14 ± 0.02 
25 567 76500 594 42 0.13 ± 0.01 
26 564 73600 602 44 0.009 
a Full width at half-maximum height: a measure of the sharpness of the fluorescence peaks; b Average of 
three measurements and Rhodamine 101 was used as a standard (Φ = 1.0 in EtOH)187; c Cresyl Violet (Φ = 
0.54 in MeOH)188  was used as a standard. 
 
 The only non-symmetrical compound (with respect to a plane through the meso-
substituent) is the piperidine/morpholine derivative 22i.  This has a lower quantum yield 
than similar symmetrical compounds (ie 11i and 12i).  The water-soluble derivatives 25 
and 15h had quantum yields of approximately 0.13 in 0.1 M phosphate buffer (pH 7.4). 
It is somewhat unexpected that bis-sulfonated rosamine derivative 26 is almost non-
fluorescent in aqueous buffer, while a similar sulforhodamine (Texas Red) is highly 
fluorescent in water. It is also surprising that sulfonated/brominated derivative 27 lost its 
fluorescence even in EtOH. All these data suggested that the cyclic amine substituents 
except for pyrrolidine as described in this work somehow affected the fluorescence 
properties.  
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Figure 4.5.  Normalized (a) UV-Vis absorption (10-6 M); and, (b) fluorescence spectra (10-7 M, excited at 
λmax abs), for representative rosamines in CH2Cl2. 
 
Some illustrative UV-Vis absorption and fluorescence emission spectra for 
molecules of Table 4.2. are shown in Figure 4.5. These data show that the meso-
thiophene derivative 11g is red-shifted, both in terms of absorption and fluorescence, 
relative to the other compounds.  Absorption and emissions from all the other probes are 
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clustered in a relatively narrow wavelength range, with the meso-methyl derivative 11a 
at the blue end of the scale. 
The piperidine derivative 11i was chosen as a typical dye to study solvent-effects 
on absorption maxima, fluorescence emission maxima, and quantum yields (Table 4.4.).  
It emerged that the fluorescence efficiency of the rosamines is quite dependent on the 
solvent used. Two of those with small dipole moments (CH2Cl2 and CHCl3, the 
compounds are not soluble in aliphatic hydrocarbons) gave optimal fluorescence 
quantum yields. No significant differences were observed in the UV-Vis absorption 
maxima for these compounds.  Similarly, the Stokes shifts observed are all within the 
range 14 – 24 nm. 
 
Table 4.4. Spectral properties of rosamine 11i in different solvents 
 
Solvent Spectral Properties 
 
Dielectric 
Constant 
Dipole 
Moment 
λmax abs 
(nm) 
λfluor 
(nm) 
Φfa 
      
CHCl3 4.8 1.04 566 580 0.95 ± 0.02 
EtOAc 6.1 1.78 567 586 0.19 ± 0.01 
THF 7.5 1.75 567 588 0.32 ± 0.01 
CH2Cl2 8.9 1.60 565 582 0.89 ± 0.01 
Acetone 21.0 2.88 564 587 0.15 ± 0.01 
EtOH 24.3 1.69 564 584 0.28 ± 0.01 
MeOH 33.0 1.70 562 582 0.19 ± 0.01 
CH3CN 36.6 3.92 562 586 0.14 ± 0.01 
DMF 38.3 3.82 570 594 0.20 ± 0.01 
a Rhodamine 101 (Φ = 1.0 in EtOH) was used as a standard. 
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Data presented in Table 4.4. indicate the intensity of fluorescence emission from 
11i can be used as a probe for solvent polarity.  This assertion was confirmed via series 
of measurements in a dichloromethane/methanol mixed solvent system (Figure 4.6.).  
The intensity of the fluorescence of this compound (at 1.4 x 10-7 M) increased nearly 
linearly with the proportion of dichloromethane (see Appendix Information).  
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Figure 4.6. Fluorescence intensity (excited at 562 nm) of 11i at 1.4 x 10-7 M in a CH2Cl2/MeOH mixed 
solvent system. The shoulder observed at around 560 nm is an artifact caused by the excitation source 
which was necessarily close in wavelength. 
 
The fact that the molecules were most fluorescent in two less polar solvents 
could be due to aggregation in polar media.  This possibility was tested by measuring 
fluorescence wavelength maxima for 11i as a function of concentration in ethanol (a 
representative polar solvent; Figure 4.7.a).  In fact, the wavelength for emission maxima 
did not change significantly over a concentration range of 5 x 10-9 to 5 x 10-6 M.  This 
implies aggregation is not significant at those concentrations. Experiments with the non-
ionic detergent Triton-X 100 gave no appreciable change in the fluorescence spectra of 
the dye in this concentration range (Figure 4.7.b), further supporting the assertion that 
11i does not aggregate.  At a relatively high concentration of the dye, 2 x 10-5 M, there 
 94
was a 7 nm red shift in the emission maximum for the fluorescence spectrum, indicating 
aggregation may only be a problem under such conditions. 
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Figure 4.7. (a) Fluorescence spectra of 11i in EtOH at different concentrations (excited at 564 nm); (b) 
effect of triton X-100 on the fluorescence of 11i in EtOH (10-6 M, ex. 564nm). 
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Predictably, the quantum yields of the piperazine derivatives 14, 15h, and 23 are 
somewhat dependent on the nitrogen atoms at the periphery of the molecule.  
Derivatives for which this nitrogen is protected with a tert-butyloxycarbonyl group have 
moderate quantum yields. However, the free secondary amine of compound 15h, for 
example, almost completely quenches the fluorescence unless it is protonated; this is 
because photoinduced electron transfer (PET) mechanisms may be possible for the 
amine.181 Similarly, compound 23 in the free base form is almost completely non-
fluorescent in dichloromethane, but solutions of this dye become strongly fluorescent 
upon protonation. The photophysical properties of rosamine 15h are pH dependent.  The 
absorption and fluorescence maxima of dye 15h slightly shifted to the red with 
increasing pH from 2 to 12 (Table 4.5.). Figure 4.8. shows how the fluorescence of 15h 
drops dramatically when the pH is raised above ca 6 and these fluorescence changes are 
reversible. 
 
Table 4.5. UV absorption and fluorescence maxima of 15h in phosphate solutions 
 
 
pH λmax abs (nm) 
λmax emiss 
(nm) pH 
λmax abs 
(nm) 
λmax emiss 
(nm) 
  
2.00 538 565 8.12 551 571 
3.00 538 565 8.43 555 574 
4.08 538 565 9.09 559 582 
5.18 539 565 10.22 560 584 
6.04 539 565 10.67 560 584 
7.08 541 567 11.13 560 584 
7.55 544 568 11.98 560 584 
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Figure 4.8. Dependence of electronic spectra of 15h on pH. a Absorption (9.8 x 10-6 M); b fluorescence 
(5.7 x 10-7 M; excitated at λmax abs); c Fluorescence intensities (λmax emiss, excited at λmax abs, 5.7 x 10-7 M) vs 
pH in phosphate solutions (50 mM, H3PO4+NaOH); d reversibility (excitation at λmax abs 538 nm and 
detection at λmax emiss 565 nm for pH 2.9; excitation at λmax abs 560nm and detection at λmax emiss 584 nm for 
pH 11.3: throughout the dye was used at 5.7 x 10-7 M and the pH was adjusted with 2M HCl or NaOH). 
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Figure 4.8. Continued. 
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Finally, the water soluble probe 25 was conjugated with avidin via activation of 
the dye-carboxylic acids (N-hydroxysuccinimide and N,N’-diisopropylcarbodiimide in 
DMF) then addition of the activated probe to the protein in 0.1 M NaHCO3 at pH 8.3.  
The dye:protein ratio was calculated to be 0.8 by UV-Vis when three equivalents of the 
dye was used; this corresponds to 27 % labeling efficiency.  When 5 eq. of dye was used 
then a dye protein ratio of 1.4 (28 % labeling efficiency) was observed.  The latter 
sample was used to obtain the spectral data shown in Figure 4.9.  The UV-Vis absorption 
and fluorescence emission maxima of 25 on avidin were observed to be within a few nm 
of the dye in phosphate buffer. The quantum yield of the protein conjugate was 0.06 in 
phosphate buffer compared with 0.13 for the free dye 25. 
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Figure 4.9. UV-Vis absorption and fluorescence spectra of rosamine 25 and 25 labeled avidin in 0.1 M 
phosphate buffer, pH 7.4. 
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4.4 Biological activity test 
The in vitro antiproliferative activity of rosamine derivatives (Table 4.6.) against 
a promyelocytic leukemia cell-line, HL60 was determined using a 24 h endpoint MTT 
assay.189 Results were expressed as IC50: the concentration of compound (in μM) that 
inhibits proliferation rate by 50 % as compared to control untreated cells. From the 
assay, compounds 11, 13i, 14i, 22i demonstrated their anti-tumour activity with IC50 
values in the sub-micromolar range. Compound 11g which had a thiofuran and the para-
iodo aryl substituted 11d showed the highest activity among the analogues (IC50 of 0.10 
and 0.09 μM respectively). In contrast, compounds 11a, 12i, 24, 25, and 28 displayed 
moderate to poor activity from single-digit micro-molar IC50 values to undeterminable 
IC50 up to 100 μM. 
 
Table 4.6. The structure-activity relationship (SAR) and in vitro cytotoxicity of rosamine analogues in 
HL60 cells 
 
OR1 R2
R3
Cl-  
 
Compd R1 R2 R3 IC50 (μM) ± S.D.a in HL60 
13i N
 
N
  
0.72 ± 0.09 
11i N
 
N
  
0.76 ± 0.03 
22i N
 
N O
  
0.35 ± 0.01 
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Table 4.6. Continued 
Compd R1 R2 R3 IC50 (μM) ± S.D.a in HL60 
12i N O
 
N O
  
8.27 ± 2.16 
14i N NBoc
 
N NBoc
  
0.62 ± 0.07 
28 N NH
 
N NH
  
53.3 ± 0.30 
11a N
 
N
 
CH3  3.86 ± 1.46 
11b N
 
N
 Ph  
0.82 ± 0.04 
11c N
 
N
  
0.47 ± 0.13 
11g N
 
N
 S  
0.10 ± 0.04 
11d N
 
N
 
I
 
0.09 ± 0.01  
11e N
 
N
 
OMe
 
0.66 ± 0.17 
11f N
 
N
 
MeO  
0.95 ± 0.01 
11h N
 
N
 
MeO
MeO
 
0.25 ± 0.22 
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Table 4.6. Continued 
Compd R1 R2 R3 IC50 (μM) ± S.D.a in HL60 
24 N
 
N
 
HO
HO
 
2.91 ± 1.86 
25 N
 
N
 
HO2CH2CO
HO2CH2CO
 
>100 
aMean IC50 and standard deviation of triplicate determination assessed in vitro at 24 h post-treatment using 
MTT assay. 
 
The influence of the cyclic amine substituents on the anti-proliferative activity of 
the compounds was evident from studying compounds with 2-methyl phenyl at the meso 
position (Table 4.6. and Figure 4.10.). Regardless of the size of the ring, the derivatives 
containing hydrophobic cyclic amines from pyrrolidine (13i), piperidine (11i) to Boc-
piperazine (14i) exhibited moderate anti-proliferative activity with IC50 values of 0.62-
0.76 μM. On the other hand, the derivatives with cyclic amines that contain exposed 
oxygen or NH isosteres as in the case of compounds 12i and 28 had 10- to 50-fold higher 
IC50 of 8.27 or 53.3 μM respectively.  The unsymmetrical rosamine 22i, which had a 
combination of piperidine and morpholine substituents interestingly had the lowest IC50 
value among compounds with 2-methyl phenyl at the meso position, alluding to the 
possible importance of an amphilic structure with contrasting hydrophobic and 
hydrophilic halves. 
For the effect of meso-substitution on anti-proliferative activity of rosamines, 
compounds that have symmetrical piperidine-substituted dye cores with a variety of 
meso-substituents were studied (Table 4.6. and Figure 4.10.). Similar to compounds 12i 
and 28, the derivatives with hydrophilic substituents such as the phenolic 24 and the 
carboxylic 25 had higher IC50 values than the unsubstituted meso-aryl 11c.  Having an 
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aryl substituent at the meso position, whether directly (11c-h) or through an alkyl spacer 
(11b), was important for anti-proliferative activity and was convincingly demonstrated 
in the lower activity observed in compound 11a which had only a simple methyl 
substituent at the meso position.  Among the aryl substituted compounds, the thiofuran 
(11g) and the para-iodo aryl (11d) structures had the lowest IC50 values compared to a 
simple phenyl-substituted compound 11c, while 4-methoxy aryl (11e), mono-2-methoxy 
(11f) and di-2-methoxy (11h) aryl substitutions did not confer additional activity. 
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Figure 4.10. Structure-activity relationship of rosamine derivatives in HL60 cells. 
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The in vitro antiproliferative activity of the most active compounds 11d and 11g 
were assessed against a panel of cell-lines derived from human solid tumors including 
colon cancer, breast cancer, oral squamous cell carcinoma and nasopharyngeal 
carcinoma (Table 4.7.).  A 48 h assay endpoint which is more typical of cytotoxicity 
studies was used.  The anti-proliferative activity of rhodamine 123 (Rh123) was also 
simultaneously determined for comparison. Both 11d and 11g exhibited at least 10-fold 
lower IC50 values compared to Rh123. In addition, the thiofuran-substituted compound 
(11g) consistently showed between 1.5-fold to 4-fold lower IC50 values across all four 
types of solid tumors compared to compound 11d. 
 
Table 4.7. Cytotoxic effects of rhodamine analogues on carcinoma and immortalized normal human 
epithelial cell types 
 
 
IC50 (μM) ± S.D.a Cell line Tissue Origin 
11d 11g Rh123 
HCT116 Colon 0.39 ± 0.11 0.15 ± 0.06 7.92 ± 0.95 
MCF-7 Breast 0.39 ± 0.22 0.27 ± 0.16 5.61 ± 0.61 
HSC2 Oral 0.25 ± 0.12 0.12 ± 0.09 4.48 ± 2.23 
OKF6b Oral  0.41 ± 0.07 0.25 ± 0.10 9.84 ± 3.46 
HK1 Nasopharyngeal 0.42 ± 0.06 0.09 ± 0.01 5.86 ± 0.15 
NP69b Nasopharyngeal 0.51 ± 0.16 0.33 ± 0.20 6.28 ± 0.21 
aMean IC50 and standard deviation of triplicate determination assessed in vitro at 48 h post-treatment using 
MTT assay. bImmortalized normal human epithelial cells 
 
 
To investigate whether rosamines 11d and 11g have greater anti-proliferative 
effects on cancer cells compared to normal cells, two immortalized epithelial cell-lines 
from oral (OKF6) and nasopharyngeal (NP69) origin were also included in the study.  
Gratifyingly, both 11d and 11g were more cytotoxic towards the cancer cell-lines than 
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the immortalized normal cell-lines, as demonstrated in the 1.25-fold to 3-fold higher IC50 
values in the normal compared to the cancer cell-lines. 
Even though both compound 11d and 11g have equally potent anti-proliferative 
activity with similar IC50 values in the low sub-micromolar range, the fluorescence 
quantum yield of 11g is low, at a value that is approximately 3-fold lower compared to 
11d (0.10 vs 0.28 in ethanol). Therefore, only the intracellular localization of compound 
11d in HSC2 cells was examined via confocal microscopy using dual staining 
techniques (Figure 4.11.). 
Co-staining images and topographic profiles of cells containing compound 10d 
and a mitochondria-specific dye Rh123 revealed an almost identical overlap, suggesting 
that compound 11d localized particularly well in mitochondria (Figure 4.11.a and b).  In 
comparison, compound 11d displayed only partial co-localization with ER and 
lysosomes, according to the confocal images and topographic profiles of compound 11d 
with ER-Tracker (Figure 4.11.c and d) and with LysoTracker (Figure 4.11.e and f) 
respectively.  Staining of the cytoplasmic or nuclear membrane by compound 11d was 
not detected, indicating that compound 11d does not react non-specifically with 
biological membranes.  Furthermore, the nucleus remained free of compound 11d (dark 
nuclear area) indicating that this class of compounds would not be expected to directly 
damage DNA. 
 105
a          b 
  
0
500
1000
1500
2000
2500
3000
3500
Lenght
Fl
ur
os
ce
nc
e 
In
te
ns
ity
0
500
1000
1500
2000
2500
3000
3500
Rh123
11
 
 
c                     d 
 
0
1000
2000
3000
4000
5000
6000
7000
Lenght
Fl
ur
os
ce
nc
e 
In
te
ns
ity
0
200
400
600
800
1000
1200
1400
1600
ER-Tracker
11
 
 
e           f 
   
0
500
1000
1500
2000
2500
3000
3500
Lenght
Fl
ur
os
ce
nc
e 
In
te
ns
ity
0
500
1000
1500
2000
2500
3000
3500
4000
Lyso-Tracker
11
 
 
 
Figure 4.11.  Intracellular localization of compound 11d in HSC2 cells. Confocal images (a,c,e) and 
fluorescence topographic profiles (b,d,f) of HSC2 cells double-stained with 100 nM of compound 11d and 
respective organelle probes.  (a,b) Mitochondria were labeled with 100 nM of Rh123 and excited at 494 
nm. (c,d) Endoplasmic reticulum were labeled with 100 nM ER-Tracker and excited at 365 nm. (e,f) 
Lysosomes were labeled with 500 nM of LysoTracker and excited at 365 nm.  Compound 11d was excited 
at 575 nm.  Line segment indicates the longitudinal transcellular axis analyzed to generate the topography 
fluorescence profiles. Objective magnification × 63. 
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The induction of apoptosis was quantified in flow cytometry experiments 
measuring the externalization of membrane phosphatidylserine through annexin V-FITC 
staining, which is an event considered characteristic of cells undergoing apoptosis 
(Figure 4.12.).  Flow cytometric analysis of HSC2 cells treated with compound 11d at 
IC50 value (0.25 μM) showed the onset of apoptosis at 8 h of compound incubation with 
16% of the cells staining positive for annexin V compared to less than 10% at 0 h or 4 h 
time-points. The proportion of cells undergoing apoptosis continued to increase rapidly 
to 58 % within 24 h. 
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Figure 4.12. Compound 11d induced apoptosis. (a) A representative histograms of event and (b) mean 
percentage of annexin V-FITC binding to PS as an indicator of apoptosis in HSC-2 cells treated with 0.5 
μM compound 11d at different duration. 
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Figure 4.13. Effects of 11d on cell cycle. HSC2 cells were treated with 0.25 µM of compound 11d for 
various times and samples were harvested for flow cytometry analysis. 
 
The cell cycle profile of HSC2 when treated with an IC50 concentration (0.25 
mM) of compound 11d was examined in a time course experiment (Figure 4.13.).  From 
4 h to 48 h, the cell cycle profile remained unchanged, indicating cell death caused by 
compound 11d did not occur as a result of cell cycle arrests.       
 
4.5 Conclusions 
This chapter describes efficient solution phase syntheses of rosamines with cyclic 
amine substituents.  It is amenable to scale-up and purification of the products.  Further, 
water-soluble derivatives can be prepared via modification of the initial products.  The 
rosamine products are shown to be more fluorescent in dichloromethane and chloroform 
than in more polar solvents. However, this is not observed for some commercially 
available rosamines with acyclic amine substituents such as tetramethyl rosamine. This 
control 4 h 8 h
12 h 24 h 48 h
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solvent dependence might be useful to probe the media polarity. Further, the data 
collected here illustrate that the ring size of the cyclic amine substituents has significant 
effects on the quantum yields; this trend has not been noted previously for rosamine 
dyes.  Finally, the spectroscopic properties of the water soluble rosamine 25 conjugated 
to a protein was not significantly different to that of the free dye in aqueous media. 
The anti-proliferative activity of the new rosamine derivatives against a panel of 
cell-lines from leukemia and solid tumors were studied. Structure activity relationship 
study indicated the importance of having hydrophobic substituents at the peripheral 
cyclic amines as well as at the meso-aryl groups.  Structures with aryl substituents at the 
meso position, either directly attached or via a -CH2- spacer conferred extra activity.  
The most active compounds 11d and 11g were at least 10-fold more potent than 
rhodamine123, a structurally similar compound whose anti-cancer properties have been 
extensively investigated.  Furthermore, our study also showed that compounds 11d and 
11g showed greater cytotoxicity towards oral and nasopharyngeal cancer cells compared 
to immortalized normal cells of the same organ type. 
Fluorescence microscopy studies showed that compound 11d localizes 
exclusively within the mitochondria. This, together with data from cell cycle analysis 
and onset of apoptosis studies, suggests that compound 11d induced cell death through 
mitochondria-dependent apoptosis rather than through damage to nucleic materials.  The 
intracellular localization data here also agrees with literature reports where higher 
mitochondrial transmembrane potential have been noted in cancer cells compared to 
normal epithelial cells, to result in accumulation of lipophilic cations, such as the 
rosamine derivatives studied here, in mitochondria. Overall, our results suggest that 
these compounds may offer a unique potential for the design of mitochondrial targeting 
agents that either directly kill or deliver cytotoxic drugs to selectively kill cancer cells. 
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CHAPTER V 
NEW PYRONIN DYES WITH MESO-HETEROATOM SUBSTITUENTS: 
SYNTHESIS AND SPECTROSCOPIC PROPERTIES* 
 
5.1 Introduction  
Pyronin dyes differ from rhodamines or rosamines in that the meso-substituent 
for pyronins is usually an H-atom instead of phenyl derivatives. Since the meso-
substituents usually do not affect the optical properties, pyronin dyes have very similar 
fluorescence properties with the corresponding rhodamine derivatives. 
 
 
 
 A typical feature of the dye character of pyronins is their ability to be used as pH 
indicators since pyronin dyes hydrolyze in water especially under basic conditions which 
convert them into 9-ol-3,6-bisamino-9H-xanthene (xanthyldrols).190 The color of their 
acidic and neutral solution is red (xanthylium 3,6-bis(dimethylamino) chloride PY: λmax 
abs = 547 nm; λmax emiss = 566 nm), while their alkaline solutions are colorless (PY: λmax 
abs = 390 nm; λmax emiss = 463 nm); a reversible change results from the variation in pH 
from basic to acidic. Extinction coefficients of the red solutions are much higher than 
these measured for the corresponding colorless solutions. 
 
 
____________ 
*Reprinted in part with permission from “Fluorescent Amino- and Thiopyronin Dyes”, 
Liangxing Wu, Kevin Burgess, Org. Lett., 2008, 10, 1779-1782. Copyright 2009 
American Chemical Society. 
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OH
OH-
H+
pyronin Y (PY)
cationic: R+
xanthydrols
neutral: ROH
λmax emiss: 566 nm λmax emiss: 463 nm  
 
 Photophysical properties of pyronin dyes are sensitive to the local environment 
and the photophysics of pyronins such as pyronin B (diethyl substituted derivative) has 
been well studied. The nonradiative S1→S0 internal conversion of pyronins has been 
studies in different solvent systems.191,192 This process is associated with the rigidity of 
the xanthene-amine bond, solvent polarity and structures. Several models have been 
proposed to explain the effect of solvent and molecular structure on internal conversion 
in pyronin and rhodamine dyes: the intramolecular rotation model,193 the twisted 
intramolecular charge-transfer (TICT) model194-196 and the umbrella-like-motion (ULM) 
model.197 In the intramolecular rotation model, internal conversion is mainly governed 
by rotation about the xanthene-amine bond. The rate of internal conversion should 
decrease as the solvent viscosity and size of the amino groups are increased. However, 
this situation has not been observed for the most rhodamine dyes as well as pyronins in 
solution.191,192 In TICT model, internal conversion occurs via TICT state in dye 
compounds. TICT state is characterized by electron transfer from amino groups to the 
xanthene ring and by rotation about the xanthene-amine bond. In this model, internal 
conversion is controlled mainly by solvent polarity and the donor-acceptor properties of 
the amino group and xanthene ring.198 In the TICT model, the energy of the TICT state 
mainly determines the nonradiative rate. Increasing the solvent polarity decreases the 
energy of the TICT state and increases the nonradiative rate. In addition, the structure of 
the dye molecule and solvent viscosity can also influence the formation of TICT state in 
this model because intramolecular rotation is involved. However, experimental studies 
do not confirm the TICT model for pyronin B in polar aprotic and protic solvent 
systems.191,192 In the ULM model, a structural change in the amino groups from a planar 
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structure (a) to a pyramidal structure (b) results in internal conversion in the excited 
state.197,199,200 This umbrella-like motion changes the xanthene-amine bond from a 
double bond to a single bond and moves the positive charge from the amino group to the 
xanthene ring. Here, solvent polarity has to be taken into account for internal conversion 
process but the main factor is the specific solute-solvent interactions. This type of 
interactions results from hydrogen bonding formation between solute (dyes) and solvent 
molecules. The stability of the resonance structures of pyronins is directly related to the 
internal conversion because specific solute-solvent interactions are effective on either 
ground state or excited state structure. The ULM model is able to explain the behavior of 
pyronin B in different solvent systems.191,192 
 
O NN O NN
a b
pyronin B pyronin B  
 
 Pyronin dyes tend to form aggregates in aqueous solutions and in matrix systems 
as the dye concentration is increased. This behavior is extensively studied theoretically 
and experimentally in aqueous solutions and matrix systems such as cyclodextrans 
(CDs), cucurbiturils (CBs), zeolites and colloidal suspensions.201-207 
 Besides the photophysics, the pyronin dyes have also been well known for its 
biological applications. Pyronin dyes such pyronin Y (PY) have been widely used to 
stain biomolecules especially RNA and DNA.208 When used alone, pyronin Y stains 
both DNA and RNA and the staining capabilities of the nucleic acids vary depending 
upon the pyronin Y concentration at equilibrium.209 Specificity of the staining reaction is 
assayed by testing sensitivity of the stainable material to RNase or DNase. The colored 
complexes detected by light absorption in fixed cells stained with pyronin Y are non-
fluorescent and are most likely the products of condensation of single-stranded (ss) RNA 
or DNA by PY. The products of PY interaction with double-stranded (ds) nucleic acids 
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are fluorescent and can be detected in cells by cytofluorometry.210 The interactions of 
pyronin Y with nucleic acids are complex process.211  PY binds by intercalation to ds 
nucleic acids. Its binding affinity to ds RNA is sevenfold higher than to ds DNA. 
Binding of PY to ss nucleic acids is initiated by PY intercalation between neighboring 
bases, neutralization of the polymer charge by the cationic dye and subsequent 
condensation and agglomeration (precipitation) of the product. In the final product, PY 
molecules are interspaced with bases, forming stacks of alternating dye-base 
composition. PY fluorescence is nearly totally quenched in these complexes. PY can 
denature the ds sections of nucleic acids, rendering them single-stranded and causing 
their condensation and precipitation. Therefore, at increasing PY concentration, the 
fluorescence of PY bound to ds nucleic acid is suppressed because of the progressive 
denaturation of the ds sections. The binding of PY to DNA can be suppressed by DNA-
specific ligands such as Hoechst 33342 and methyl green.208 In the presence of these 
dyes, PY can be used as a specific RNA fluorophore.209 However, PY also stains 
mitochondrial membranes in live cells just like other cationic dyes, therefore, the RNA 
specificity obtained with PY staining needs to be further confirmed with alternative 
methods. Furthermore, the cytotoxicity of PY to certain cell-lines also limits its wide 
applications.210 
 Pyronins have also been used as laser dyes and to detect trace proteins and 
determine species such as As(III)212, Cr(VI)213 and tannins.214 Despite all these activities, 
only a few pyronin derivatives are available and investigations on the structure-property 
relationships of pyronins are rare. There is almost no literature on any fluorescent dyes 
of structure A where X = NR2 or SR.  In fact, to the best of our knowledge, the only 
reported compound in this category is “Pyronin 12”, ie structure B.  Dyes that have been 
christened with a trivial name are often well known and frequently used.  However,  
Pyronin 12 was mentioned peripherally in a paper on dimerization of dyes in aqueous 
solution,215,216 but its synthesis and spectroscopic properties were not reported. 
Moreover, there do not appear to be any reports of others using this dye, or any like it, 
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since it was first described.  This chapter outlines syntheses and the spectroscopic 
properties of a range of dyes A where the X substituent is an amine or a thiol. 
 
O
NH2
N
H
N
H
B
Pyronin 12
O
X
R2N NR2
A
X = aryl or alkyl: well known
X = NR2 or SR: unexplored  
 
5.2 Syntheses of new pyronin derivatives 
The approach used in this work was based on reactions of a ditriflyl xanthone 16 
with piperidine derivatives as shown in Scheme 5.1. The starting material for this 
transformation is a known compound179 that we prepared via a slight modification of the 
literature procedure (see chapter IV and Appendix information); this modification was 
scalable to at least 13 g since, unlike the original method, no chromatography was 
required. Amines related to 17 and 29 have been prepared via condensation procedures 
that involve several steps;158,166,172,176-178 the reaction outlined below is more direct once 
the common ditriflyl xanthone starting material has been made. The product precipitates 
from the reaction mixture after addition of water, and is then recrystallized. There are, 
however, restrictions on the amines that can be used; less nucleophilic ones (eg HNBu2, 
HNEt2) tended to give mostly monosubstitution under the conditions studied (DMSO, 90 
°C). 
 
Scheme 5.1. Synthesis of 3,6 diamino-xanthones 17 and 29. 
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Scheme 5.2. Failed attempt to synthesize new pyronin dyes. 
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The ketone functionality of compounds 17 and 29 is less reactive because of the 
arylamine substituents; it may be considered as a vinylogous urea.  Thus no reaction was 
observed when piperidine was heated with the ketones under mildly acidic conditions 
(Scheme 5.2.). Conversely, the nucleophilicity of the oxygen atom is increased for the 
same reason hence it can be triflated. These triflates were red fluorescent in CH2Cl2 but 
unfortunately they not stable. Thus they were not isolated and used to react with amines 
or benzyl thiol to give the fluorescent compounds 30a – f (Table 5.1.). Reaction of the 
triflate with alcohols such as MeOH and EtOH also occurred smoothly to give yellow 
fluorescent solutions. However, the products formed with alcohols were not stable 
enough to be isolated. 
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Table 5.1. Synthesis of new pyronin dyes 
 
 
 
 
 
 
 
entry Y NuH yield (%) 
    
30a H NH
 
81 
30b H Et2NH  61 
30c H 
H2N  
98 
30d H 
H2N CO2tBu  
80 
30e H 
BnSH  23 
30f MeO2C NH
 
86 
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 A single-crystal X-ray structure of compound 30c was obtained (Figure 5.1.).  
This provided two pieces of evidence that all three nitrogen atoms are involved in 
delocalization of the positive charge from the aromatic core.  Firstly, all three nitrogens 
are essentially planar (deviation of the nitrogen away from the plane formed by the three 
substituents was observed to be 0.062 Å for the central amine and 0.175/0.223 Å for the 
terminal ones).  Secondly, the deviation of that plane from the one which encapsulated 
the aromatic segment of the molecule was 9 - 22°, and the C-N distances for the bonds 
that connect the amine substituents to the pyronin core were 1.35 – 1.37 Å (whereas 
other C – N single bonds in the same molecule were 1.45 – 1.47 Å).  These observations 
are indicative of lone pair donation from the pyronin amine-substituents into the core 
heterocyclic framework. 
 
N-atoms essentially flat
and in aromatic
plane
triflate
 
C N O F S H  
 
Figure 5.1. X-ray structure of novel pyronin 30c. 
 
5.3 Photophysical properties of new pyronin dyes 
Selected spectral properties of the molecules 30 are shown in Table 5.2.  The 
compounds formed from nitrogen nucleophiles, 30a – d and 30f, absorb in the range 456 
– 499 nm with high extinction coefficients (51,000 – 62,000).  They emit in the range 
537 – 562 nm with quite sharp emissions (fwhm = 41 – 55 nm; cf the same parameter for 
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rhodamine B in CH2Cl2 is 36 nm, and rhodamines are generally recognized to give sharp 
fluorescent emissions). Quantum yields are least in the series for the compounds from 
secondary amines (30a, 30b, and 30f), and these emit at longer wavelengths. Other 
compounds in the series that were derived from primary amines (30c and 30d) had 
markedly higher quantum yields (0.85 and 0.90, respectively). The S-containing 
compound 30e absorbs and emits at significantly longer wavelengths, and with a sharper 
output; for these reasons this is possibly the most interesting dye in the series. 
 
Table 5.2. Spectral properties of 30 measured in CH2Cl2 
 
 
 
λmax 
(nm) 
εmax 
(L·mol-1·cm-1) 
λf 
(nm) 
fwhm 
(nm) a 
Φf b 
30a 491 60400 562 55 0.14 ± 0.01 
30b 499 51000 558 41 0.11 ± 0.02 
30c 456 52400 537 52 0.85 ± 0.01 
30d 462 62000 544 52 0.90 ± 0.02 
30e 598 82600 619 38 0.79 ± 0.02 c 
30f 482 54900 552 47 0.02 ± 0.01 
 
a Full width at half-maximum height: a measurement of the sharpness of the fluorescence spectra; b 
Average of three measurements; Fluorescein in 0.1 M NaOH (Φ = 0.92)102 was used as a standard; c 
Cresyl violet in MeOH (Φ = 0.54)217 was used as a standard. 
 
 Normalized spectra that correspond to the data in Table 5.2. are shown in Figure 
5.2. Compounds 30c and 30d absorb UV and fluoresce at shorter wavelengths than the 
others.  Conversely, the absorption and fluorescence of compound 30e is further to the 
red of the others in the series. 
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Figure 5.2. Normalized (a) UV absorbance and (b) fluorescence (excited at λmax abs) of novel pyronins 30 
in CH2Cl2 (ca 10-6 M for absorbance; 10-7 M for fluorescence). 
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Compounds 30a, 30c, and 30e were selected for pH dependence studies; data for 
30c  are shown here. The UV absorption of this compound was uneffected by addition of 
TFA, but was decreased by addition of NEt3 (Figure 5.3.a and b). The fluorescent 
emission characteristics of this compound followed the same trend (Figure 5.3.c and d).  
Figure 5.3.e shows that the impact of NEt3 on the fluorescence of this compound is 
essentially reversible. Dye 30a, that has a tertiary amine meso-substituent, showed a 
different pH dependence  (see Appendix Information) possibly because it does not have 
a relatively acidic proton.  Thiol derivative 2e showed no UV or fluorescence change on 
addition of TFA, but addition of NEt3 caused decomposition (see Appendix 
Information). 
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Figure 5.3. Dependence of electronic spectra of 30c on pH. UV absorbance for 30c under: a acidic; and, b 
basic conditions (CH2Cl2, 1.1 x 10-5 M).   Fluorescence pH dependence of 30c under: c acidic; and, d basic 
conditions (CH2Cl2, 2.5 x 10-7 M, excited at 456 nm).  e Fluorescence intensity of 30c under alternating 
basic (Et3N) and acidic (TFA) conditions (CH2Cl2, 2.5 x 10-7 M, excited at 456 nm). 
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Figure 5.3. Continued. 
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Figure 5.3. Continued. 
 
basic acidic basic acidic basic acidic
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The spectral data summarized above are consistent with reversible deprotonation 
of the central amine under mildly basic conditions. That proton loss gives a less 
conjugated and non-fluorescent imine derivative (Figure 5.4.).   
 
30c
f luorescent f orm
O
HN
N N+
NEt3
H+ O
N
N N
30c
deprotonated
non-f luorescent f orm  
Figure 5.4. Likely acid/base equilibrium for 30c. 
 
5.4 Conclusion 
In summary, a direct route to novel heteroatom analogs of rhodamine and 
rosamine systems is described here. Spectral properties of the compounds are highly 
dependent on the nature of the nucleophile that is used to add to the central carbon atom.  
In that regard, the S-containing compound 30e is of particular interest to the community 
seeking fluorophores that emit above the 600 nm mark. However, just like normal 
pyronin dyes, the stability of the new pyronin derivatives might be a concern for wide 
applications. Further improvement on the stability of such dyes is still needed. 
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CHAPTER VI 
WATER-SOLUBLE THROUGH-BOND ENERGY TRANSFER CASSETTES: 
SYNTHESES, SPECTROSCOPIC PROPERTIES AND APPLICATIONS 
 
6.1 Introduction  
Multiplexing of fluorescent labels is a common requirement in biotechnology. A 
convenient approach to multiplex is to tag each component with a fluorescent label, and 
then excite the labels at a single wavelength using a commercial laser source eg an argon 
laser (488nm). The best-known examples of multiplexing are FRET7 based cassettes in 
which the donor and acceptor units are connected via non-conjugated linkers (Figure 
6.1.a). In these systems, a donor fragment harvests energy from an excitation source and 
transfers it through space, via dipole-dipole coupling, to an acceptor that then fluoresces. 
Well spaced fluorescence emissions over a range of wavelengths, ie resolution, could be 
achieved by choosing appropriate acceptors. Unfortunately, the sensitivity of emission 
with multiplexed, FRET-based cassettes is still constrained by the requirement that the 
fluorescence of the donor must overlap with the absorption of the acceptor. The dyes that 
emit at longer wavelengths usually absorb at the excitation wavelength less effectively, 
so their fluorescence intensities are diminished.  
 
through-bond energy transfer
hv
donor acceptor
hv'
through-space energy transfer
a
hv
donor acceptor
hv'
b
 
Figure 6.1. (a) Through-space and (b) through-bond energy transfer cassettes. 
 
Our research focuses on energy transfer cassettes in which the donor is connected 
to acceptors via electronically conjugated linkers (Figure 6.1.b)8,9,218-220 and energy 
transfer may occur via through-bond pathways such as Dexter energy transfer12 and 
others. Through-bond energy transfer is not constrained by the same parameters such as 
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spectra overlap as the corresponding through-space mechanisms. It may, therefore, be 
possible to separate the donor absorption from the acceptor fluorescence by many 
wavenumbers without compromising the intensity of the light emitted. Thus 
multiplexing with good resolution and high sensitivity may be achieved with sets of 
appropriate through-bond energy transfer cassettes. 
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O
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NN+ O
OHO O
O
O
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O
O OHO
NN+
O
O
-O2C
Ex. 488 nm
Em. 538 nm Em. 582 nm Em. 603 nm Em. 616 nm  
Figure 6.2. Through-bond energy transfer cassettes based on fluorescein and rosamines. 
 
 As a proof of concept, sets of through-bond energy transfer cassettes based on 
fluorescein donor and rosamine acceptors (Figure 6.2.) have been prepared and reported 
by previous group members.11 These cassettes absorb strongly at 488 nm corresponding 
to the argon laser source. Excitation of the cassettes at 488 nm produces fluorescence 
characteristic of only the acceptor component indicating complete energy transfer in 
such systems. These cassettes fluoresce at 538, 582, 603 and 616 nm, respectively; hence 
their emissions are dispersed over a 78 nm wavelength range, and their fluorescence 
signals are well separated and easily differentiated. Moreover, these cassettes all 
fluoresce strongly when excited at the donor. Thus, these through-bond energy transfer 
cassettes have good resolution and sensitivity which are required for multiplexing. 
Further studies show that the energy transfer from donor to acceptor in these cassettes is 
extremely fast (6-7 ps) and is about four times faster than the corresponding FRET 
cassettes.221 Due to the fast energy transfer, these cassettes are far more photostable than 
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the fluorescein donor when excited at 488 nm. This can be explained as follows. 
Fluorescein decomposes via intersystem crossing to a relatively long-lived triplet state 
then reactions with surrounding molecules. The fluorescein donor in these cassettes, 
however, rapidly transfers energy to the more photostable rosamine acceptors before 
such intersystem crossing can occur. 
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Figure 6.3. Indication of the directions of the S1↔S0 transition moments in different through-bond energy 
transfer cassettes. 
 
In order to understand the through-bond energy transfer process and facilitate 
design of better through-bond energy transfer cassettes, studies on the correlation of 
energy-transfer rates with structures for a wide range of through-bond energy transfer 
cassettes were carried out by our group and collaborators.10 Our observations indicate 
that energy transfer is fastest (< 0.2 ps) when the transition moments of the donor and 
acceptor are aligned with the linker axis as in C (Figure 6.3.). The study shows that the 
energy transfer in through-bond energy transfer cassettes such as A is much faster than 
the corresponding FRET cassettes (6.8 and 35 ps, respectively). Several findings also 
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suggest that Förster energy transfer is not the prevalent mechanism in such cassettes. 
First, the transition dipole moments of the donor and acceptor in cassettes like B are 
perpendicular to each other. According to Förster theory, FRET should not occur. 
However, complete and ultrafast (0.47 ps) energy transfer was observed in cassette B 
and similar derivatives. Second, the studies showed no systematic correlation of the 
energy transfer rate with the nature of the acceptor, despite the difference in donor-
acceptor energy gap. This also argues against the FRET mechanism, which depends 
critically on the overlap integral of the donor emission and acceptor absorption spectra. 
Third, experiments with cassettes having reduced donor-acceptor distances showed no 
significant increase in transfer rates, as would be predicted from Förster theory. 
Energy transfer cassettes designed to transfer energy through bonds will always 
transfer a certain amount of the energy through space as well. Unfortunately, it is usually 
not possible to ascertain how much energy transfer occurs via through-bond mechanisms 
relative to the through-space pathways. This is very likely to be the case when the donor 
and acceptor fragments are relatively close together. Nevertheless, the overall rates of 
energy transfer can be measured; they in turn will be influenced by the structure of the 
donor, acceptor, linker fragments and the orientation of the donor-linker-acceptor 
connectivity. 
All of the above mentioned through-bond energy transfer cassettes have poor 
water solubilities and this is likely to make their conjugation to biomolecules difficult, 
thus limits their applications in biological studies. The first water-soluble through-bond 
energy transfer cassette (Figure 6.4.) was reported by our group in 2006.222 This cassette 
was successfully attached to a protein (ACBP) and the conjugate was transferred back 
into cell by a cell-penetrating peptide Chariot. The conjugate was successfully detected 
in COS-7 cells by fluorescence microscope. Even though it is water-soluble and has 
been successfully used for intracellular imaging, this cassette still has several 
disadvantages. First, the energy transfer in the conjugate is only about 60 %. Secondly, 
the emission of the acceptor is less than 600 nm and is still complicated by the cell 
autofluorescence. Third, there are multiple carboxylic acid handles in the cassettes which 
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may react with proteins and cause cross coupling between different protein molecules 
thus might affect the protein structure and functions. Last, the synthesis of this cassette is 
extremely difficult, giving very low yield and requiring tedious reverse phase HPLC 
purification. So further effort is still needed to design and prepare better water-soluble 
through-bond energy transfer cassettes. 
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Figure 6.4. A water-soluble through-bond energy transfer cassette. 
 
 This chapter describes the design and syntheses of a series of new water-soluble 
through-bond energy transfer cassettes 31-33 (Figure 6.5.). Correlation between optical 
properties and cassette structures is investigated. Applications of these new water-
soluble cassettes are also demonstrated. Thus, the specific aims of this project are to: 
(i) design and synthesize water-soluble cassettes that emit above 600 nm 
(ii) prepare sets of water-soluble cassettes for multiplexing 
(iii) study the correlation between optical properties and cassette structures 
(iv) demonstrate applications in biomolecular labeling and intracellular 
imaging 
(v) monitor protein-protein interactions with these new cassettes 
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Figure 6.5. Structures of through-bond energy transfer cassettes 31-33. 
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6.2 Syntheses of water-soluble through-bond energy transfer cassettes 
6.2.1 Syntheses of donor fragments 
 The structures of the donor fragments that are used to prepare cassette 31-33 are 
showed in Figure 6.6. They are soluble in water and absorb strongly at ca 500 nm which 
makes them ideal donors for the water-soluble cassettes. 
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Figure 6.6. Donor fragments for water-soluble cassettes. 
 
 The synthesis and properties of compound 1g were described in Chapter II.223 
This compound is soluble in water and highly fluorescent. BODIPY 34 was prepared 
and studied by a previous group member.224 The synthesis of this compound is 
summarized in Scheme 6.1. 
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Scheme 6.1. Synthesis of donor fragment 34. 
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 Scheme 6.2. describes the synthesis of a new compound 35. Condensation of 2,4-
dimethyl-pyrrole with a benzaldehyde derivative gave BODIPY 36. Functionalization of 
36 via “Click” reaction225-227 leads to the water soluble derivative 35. Interestingly, the 
click reaction did not proceed at room temperature even in the presence of tris-
(benzyltriazolylmethyl)amine (TBTA) ligand. However, the desired product 35 was 
obtained in excellent yield after raising the temperature to 50 oC. 
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Scheme 6.2. Synthesis of donor 35. 
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6.2.2 Syntheses of acceptor parts 
 A series of BODIPYs 37 that emit above 600 nm have been prepared and 
exploited as acceptor fragments for water-soluble through-bond energy transfer 
cassettes. The structures of these BODIPY acceptors are summarized in Figure 6.7. 
Similar BODIPYs have been reported in literature.228-230 However, the ones shown here 
all have a carboxylic acid handle which can be used as an attach point for coupling to 
biomolecules. They also have an alkyne functional group which allows further 
derivatization via cross coupling reactions such as Sonogashira and “Click” reactions to 
prepare through-bond energy transfer cassettes. Moreover, some of the BODIPY 
acceptors are water-soluble thus can be used for protein labeling and intracellular 
imaging. 
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Figure 6.7. BODIPY acceptor fragments for cassettes. 
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Scheme 6.3. Syntheses of pyrrole fragments 38-40. 
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Scheme 6.3. Continued. 
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The first steps necessary for syntheses of BODIPY acceptors 37 were preparation 
of the starting pyrroles 38-40 and iodobenzaldehyde derivatives 44-46. Scheme 6.3. 
describes the syntheses of the pyrrole derivatives. Pyrrole 38a is a known compound and 
its synthesis has been reported.229 Compounds 38b-c were prepared using similar 
conditions reported for 38a (Scheme 6.3.a). Pyrrole 39c was synthesized according to a 
known procedure228 developed for 39a-b (Scheme 6.3.b). Analogs of pyrrole 40a-b have 
also been reported.230 Attempt to synthesize 40a-b using the literature procedures failed 
to give the final products. Thus a new approach was devised (Scheme 6.3.c). In the new 
synthesis, a common intermediate furapyrrole was synthesized from 5-bromo-2-
furaldehyde231 and then protected by tert-butyloxylcarbonyl (Boc) group to afford 
compound 42 which was stable and easy to manipulate. Suzuki coupling of 42 with 
arylboronic acid followed by decarboxylation and removal of Boc under microwave 
irradiation gave pyrroles 40a-b. Compared with the reported conditions, the new 
approach described here is more convergent and easier to work with because the 
intermediates involved are stable and easy to handle.  Scheme 6.4. shows the syntheses 
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of iodobenzaldehyde derivatives 44-46. They were obtained in high yields by alkylation 
of the phenol precursors. 
 
Scheme 6.4. Syntheses of iodo-benzaldehyde fragments 44-46. 
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 With the pyrroles and iodobenzaldehydes in hand, BODIPY acceptors can be 
prepared from corresponding precursors by standard BODIPY synthesis. Illustrative 
synthesis of a BODIPY acceptor 37a is showed in Scheme 6.5. Condensation of pyrrole 
38a with aryl aldehyde 44 followed by oxidation with chloranil or DDQ afforded the 
dipyrromethene (DIPY) intermediate, which was passed through a short pad of alumina 
to remove most of the by-products. Subsequent chelation of DIPY with boron gave the 
BODIPY 47a. Palladium catalyzed Sonogashira reaction of iodo-BODIPY 47a with 
trimethylsilyl acetylene occurred smoothly, giving compound 48a in excellent yield. 
Removal of trimethylsilyl protecting group and hydrolysis of methyl ester in BODIPY 
48a were achieved in a single step by stirring a solution of this compound in a mixture of 
solvents (MeOH/THF/H2O) in the presence of potassium carbonate. BODIPY acceptors 
37b-g were successfully prepared using similar conditions.  
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Scheme 6.5. Illustrative synthesis of BODIPY acceptor fragment 37a. 
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 There was a problem for the synthesis of BODIPY acceptors 37h-i. Compounds 
48h-i were efficiently prepared using the above described procedures. However, the 
deprotection step did not work well for 48h-i. A mixture of products were formed when 
compound 48h-i were stirred with K2CO3 in MeOH/THF/H2O (Scheme 6.6.). Attempt to 
isolate products 37h-i from the reaction mixture was failed due to close polarity of the 
product with unknown by-products. Further optimization of the reaction was not carried 
out at this stage. 
 
Scheme 6.6. Syntheses of acceptors 37h-i. 
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6.2.3 Syntheses of cassettes 
 Cassettes 31 were prepared via copper-mediated azide/alkyne cycloadditions, 
which is also called “Click” reaction, from the corresponding azido-BODIPY donor 34 
and alkynyl-BODIPY acceptors 37. The click reaction occurred smoothly in the 
presence of a tris-(benzyltriazolylmethyl)amine “TBTA” ligand232 to give a 1,2,3-
triazole based linker. One illustrative systhesis of such cassettes was described for 31a in 
Scheme 6.7. Cassettes 31b-g were prepared using similar conditions.  
 
Scheme 6.7. Illustrative synthesis of BODIPY cassettes. 
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 Cassettes 32 and 33 were prepared to test the effect of the linkers and donor parts 
on optical properties of the cassettes. These two cassettes were prepared from the 
corresponding donor and acceptor fragments via Palladium catalyzed Sonogashira 
reactions. An aryl-alkyne linker was formed to join the donor and acceptor parts. The 
synthesis for cassette 32 was demonstrated in Scheme 6.8. Cassette 33 was made 
similarly from donor 35 and acceptor 37c in 45 % yield. 
 
Scheme 6.8. Synthesis of cassette 32. 
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Table 6.1. summarizes the yields for the syntheses of cassettes 31, corresponding 
BODIPY acceptors 37 and the intermediates 47-48. 
 
Table 6.1. Summary of the yields for preparation of 47, 48, 37 and cassettes 31 
 
yield (%) a b c d e f g h i 
47 69 15 64 50 88 80 47 75 41 
48 92 86 100 83 88 87 80 100 94 
37 85 76 67 95 80 100 80 N/A N/A 
31 75 78 80 48 60 35 25 N/A N/A 
 
 
6.3 Spectroscopic properties of BODIPY acceptors and cassettes 
The absorption and fluorescence emission properties of BODIPY acceptors are 
summarized in Table 6.2. BODIPY 37a and its water-soluble derivative 37b have 
similar absorption and emission maxima. They also have almost the same quantum 
yield. The absorption and emission wavelengths for compound 37d are almost the same 
as its regioisomer 37a. However, BODIPY 37d has much higher quantum yield than 37a 
(0.81 and 0.48 in MeOH, respectively). The oxygen atom at para-position of the aryl 
substituent shifts the emission maxima ca 25 nm to the red (compare 37c and 37b, 37f 
and 37e). Molecular constraints in compound 37e extend the conjugation and cause red 
shift of the absorption and emission wavelengths compared with uncyclized derivatives. 
BODIPYs 37b, 37c and 37g are water-soluble. Their properties in aqueous buffer are 
also summarized in Table 6.2. The absorption and emission maxima of these compounds 
in buffer are very similar to that in MeOH. However, the quantum yield and extinction 
coefficient for these compounds are slightly lower than that in MeOH. Illustrative 
absorbance and fluorescence spectra of the BODIPY acceptors and the donor fragment 
34 are showed in Figure 6.8. 
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Table 6.2. Photophysical properties of BODIPY acceptors 
 
 λmax abs (nm) log (εmax)  
λmax emiss 
(nm) fwhm (nm) Φ 
MeOH 
37a 543 4.61 598 49 0.48 ± 0.01a 
37b 553 4.71 605 47 0.50 ± 0.01a 
37d 542 4.70 599 47 0.81 ± 0.02a 
37c 585 4.71 627 44 0.76 ± 0.02a 
37e 626 5.12 642 32 0.75 ± 0.02b 
37f 650 4.98 669 37 0.57 ± 0.01b 
37g 653 5.10 672 36 0.69 ± 0.02b 
0.1 M PBS buffer (pH 7.4) 
37b 544 4.65 604 56 0.44 ± 0.02a 
37c 582 4.52 629 50 0.66 ± 0.01a 
37g 660 4.84 678 40 0.48 ± 0.02b 
 
a Cresyl Violet (Φ=0.54 in MeOH); b Nile Blue (Φ = 0.27 in EtOH) were used as standards. 
 
 
 
a                                                                       b 
 
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650 700 750 800
Wavelength (nm)
No
rm
al
iz
ed
 A
bs
or
ba
nc
e
 34
 37b
 37c
 37e
 37g
   
0
0.2
0.4
0.6
0.8
1
1.2
400 450 500 550 600 650 700 750 800
Wavelength (nm)
No
rm
al
iz
ed
 F
lu
or
es
ce
nc
e
 34
 37b
 37c
 37e
 37g
 
  
Figure 6.8. Normalized (a) absorbance; and (b) fluorescence spectra of BODIPY donor 34 and illustrative 
acceptors 37 in MeOH (10-6 M for absorbance; 10-7 M for fluorescence).  
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The absorption spectra of all the cassettes display two distinct peaks. One stong 
absorption band around 500 nm corresponds to the λmax of the donor component. The 
other peak is due to the absorption of the acceptor fragment. The absorption spectra of 
the cassettes resemble those that would be obtained by superimposing the donor and 
acceptor spectra, indicative of two independent dye fragments. However, when 
irradiated at the absorption maxima of the donor, the donor fluorescence is almost 
completely quenched and only acceptor fluorescence is observed in MeOH. Thus energy 
is absorbed at wavelengths corresponding to the donor part and emitted at wavelengths 
governed by the acceptor fragment, hence gives large pseudo-Stokes’ shift. Complete 
energy transfer from donor to acceptor is observed for all the cassettes when MeOH is 
used as solvent. However, some energy leak from the donor fragment is detected for 
cassettes 31f and 31g when they are dissolved in aqueous media. Illustrative absorption 
and emission spectra of these cassettes are shown in Figure 6.9. 
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Figure 6.9. Normalized (a) absorbance, (b) fluorescence in MeOH; (c) absorbance, (d) fluorescence in 0.1 
M phosphate buffer (pH 7.4) of BODIPY donor 34 and cassettes 31. Throughout, 10-6 M for absorbance, 
10-7 M for fluorescence, ex. at 488nm. 
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Salient photophysical properties of the BODIPY-BODIPY cassettes are shown in 
Table 6.3. Through-bond energy transfer cassettes are usually designed to absorb light at 
the donor excitation wavelength, relay it to the acceptor part, then emit fluorescence 
from there.  The term “energy transfer efficiency” (ETE %) quantifies this and it is 
defined as follows: 
 
ETE % =
quantum yield of the acceptor fragment in the cassette
excited at the donor
quantum yield of the acceptor fragment in the cassette
excited at the acceptor
X 100
 
 
ETE % is a measure of the energy transfer of the cassette when irradiated at the 
donor. It reflects the extent of energy transfer which is emitted as photons by the 
acceptors. This term eliminates the negative effects of non-radiative loss in the transfer 
process.  
The fluorescence quantum yields of the acceptor fragments in the cassettes were 
determined when excited at the donor and acceptor parts. Values of the ETE % for the 
cassettes were calculated using these quantum yields. In MeOH, the quantum yields 
were almost the same whether the donor or the acceptor parts were excited, indicating 
nearly complete energy transfer from the donor to the acceptor. The ETE % values for 
all the cassettes are summarized in Table 6.3. The results in Table 6.2. and Table 6.3. 
also show that the quantum yields of the acceptor fragments were almost the same in the 
presence and absence of the donor parts. The absorption and emission maxima of the 
acceptor fragments in the cassettes were also very similar to that of the BODIPY 
acceptors alone. However, in aqueous buffer, the quantum yields were significantly 
reduced. Cassettes 31c, 31d, 31f, 31g were almost non-fluorescent in aqueous media. 
The ETE % for all the cassetttes were also lower than that in MeOH. Several cassettes 
have obvious energy leak from the donor fragment in aqueous media (Table 6.3.). The 
absorption and emission wavelengths were similar whether MeOH or aqueous buffer 
was used as solvent. Another observation was that the extinction coefficients were also 
less in aqueous media. Cassettes 32 and 33 also have complete energy transfer and high 
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quantum yields in MeOH (see Appendix Information). However, they were not soluble 
in aqueous media, thus their photophysical properties were not further studied. 
Interestingly, cassettes 31a, 31b and 31e still have moderate quantum yields (0.24-0.30) 
and almost complete energy transfer in aqueous media. Cassettes 31a and 31b emit in 
the same range (ca 600 nm) while cassette 31e fluoresce at longer wavelength (ca 650 
nm). Thus cassettes 31b and 31e were chosen to monitor protein-protein interactions 
(see next section). 
 
Table 6.3. Photophysical properties of BODIPY cassettes 
 
log(εmax) Φ of acceptor 
 
λabs D 
(nm) 
λabs A 
(nm) 
λemiss A 
(nm) D A Ex. Da Ex. A 
E.T.E (%)d 
MeOH 
31a 506 542 595 4.96 4.52 0.50 0.50a 100 
31b 506 552 601 5.15 4.74 0.46 0.47b 98 
31c 506 584 623 5.02 4.73 0.69 0.73b 95 
31d 506 542 594 5.02 4.58 0.77 0.79a 97 
31e 506 626 640 4.67 4.72 0.69 0.71c 97 
31f 506 649 666 4.81 4.86 0.47 0.51c 92 
31g 506 652 668 4.90 4.95 0.55 0.58c 95 
0.1M PBS buffer, pH 7.4 
31a 500 535 594 4.94 4.41 0.25 0.27a 93 
31b 501 556 599 5.06 4.58 0.30 0.32b 94 
31c 503 589 628 4.94 4.53 0.030 0.035b 86 
31d 500 535 592 4.95 4.42 0.069 0.077a 90 
31e 499 631 645 4.52 4.39 0.24 0.26c 92 
31f 500 655 674 4.65 4.48 0.032 0.037c 86 
31g 503 654 673 4.82 4.63 0.008 0.012c 67 
a Rhodamine 6G (Φ=0.94 in EtOH) ; b Cresyl Violet (Φ=0.54 in MeOH); c Nile Blue (Φ = 0.27 in EtOH) 
were used as standards; d energy transfer efficiency (E.T.E) was calculated by dividing the quantum yield 
of acceptor when excited at donor by the quantum yield of acceptor when excited at acceptor. 
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6.4 Protein-protein interaction studies 
 FRET donor Atto425 and through-bond energy transfer cassettes 1 (cassette 31b) 
and 2 (cassette 31e) were used to study protein-protein interactions and test our 
hypothesis that combination of FRET and TBET will enable detection of multiple 
protein-protein interacctions simutaneously (See Chapter I, Figure 1.11.). The structures 
and spectral properties of Atto425, cassettes 1 and 2 are shown in Figure 6.10. Several 
key spectral data make Atto425 a good FRET donor for cassettes 1 and 2. First, the 
fluorescence emission of Atto425 overlaps perfectly with absorbance of the donor part in 
cassettes 1 and 2. Second, cassettes 1 and 2 do not absorb at Atto425’s absorption 
maxima. Thus cassettes 1 and 2 will not be directly excited during the FRET studies. 
 
 
a 
 
 
Figure 6.10. FRET donor Atto425, cassette 1 and cassette 2: (a) structures; (b) absorbance and 
fluorescence spectra in 0.1 M phosphate buffer (pH 7.4). 
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Figure 6.10. Continued. 
 
 
A well-behaved system for studying protein-protein interactions was needed to 
test cassettes 1 and 2.  This was generated via the interaction of biotin-functionalized 
bovine serum albumin (BSA) with avidin or streptavidin.233-235 The vitually irreversible 
nature of the interaction was ideal for this proof of concept study.  Thus, BSA was 
reacted with N-hydroxysuccinimide (NHS) activated forms of: (i) the FRET donor Atto-
425 (a coumarin derivative; Sigma); then, (ii) biotin.  The dye:biotin:BSA ratio was 
measured101,236 as 5.2:6.6:1.0.  Cassette 1 was activated (di-isopropylcarbodiimide, 
NHS) then coupled to streptavidin (dye:protein 2.5:1.0). Similarly, cassette 2 was 
coupled to avidin (dye:protein 1.6:1.0).  The strategy followed was to mix these proteins, 
excite the Atto425 donor, and observe emissions from cassettes 1 and 2.  Strong 
enhancements mean that binary complexes like A and B, three-component tertiary 
complexes like C, and/or higher order assemblies were formed (Figure 6.11.).  This 
experiment would not be possible using Atto425 as a FRET donor and single dyes based 
on the acceptor components of 1 and 2 because the fluorescence emission from Atto425 
(centered on 480 nm) has minimal overlap with the absorbance spectrum of the TBET-
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acceptor from 1 and almost none with that in 2 (λmax abs 556 and 631 nm, respectively, in 
pH 7.4 phosphate buffer). 
 
avidin streptavidin BSAFRET donor
(Atto 425)
cassette
1
cassette
2
biotin
+ +
A B C
+ +
 
Figure 6.11. FRET from one protein can be used to excite the donors of TBET-cassettes on another 
protein to reveal interactions. 
 
 
 Interactions between two proteins were studied in a fluorescence cuvette to test 
our hypothesis and the artificial protein interaction system. Several precautions were 
necessary before the key energy transfer experiment could be performed and interpreted.  
First, 1-streptavidin and 2-avidin were pretreated with BSA to suppress non-specific 
interactions. Second, steps were taken to correct for variations of dye fluorescence 
properties in different protein environments. This was done by observing each probe for 
each relevant protein-protein interaction, one dye at a time to give the baseline “before 
FRET” values. Cassettes 1 and 2 were slightly influenced by the protein environment, 
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but Atto425 showed more marked changes. The “after FRET” values were direct 
fluorometer reading for the protein mixtures. The difference between “before FRET” 
and “after FRET” values were the changes due to FRET during protein interactions.  
The fluorescence profiles for the two protein interactions were summarized in 
Figure 6.12. Experiment (i) tested the interaction between Atto425-BSA-biotin and 1-
streptavidin. Mixing of these two proteins gave significant fluorescence enhancement at 
around 600 nm corresponding to cassette-1 and the fluorescence of Atto425 (ca 480 nm) 
decreased accordingly. The biotin/streptavidin interactions brought the proteins together 
such that the FRET donor was able to relay energy to the TBET cassette donor parts. 
Thus, the fluorescence output of this experiment clearly showed that Atto425-BSA-
biotin and 1-steptavidin were interacting. Experiment (ii) represented a control study for 
experiment (i). In this experiment, Atto425-BSA and 1-streptavidin were mixed in a 
fluorescence cuvette. Since the BSA was not functionalized with biotin hence no 
protein-protein interactions were expected. This was confirmed by the fluorescence 
output. No obvious changes between “before FRET” and “after FRET” were observed in 
this experiment. The interactions between Atto425-BSA-(biotin) and 2-avidin were 
studied similarly as shown in Figure 6.12. c and d (experiment iii and iv, respectively). 
The results showed that the interactions between these two proteins were also 
successfully detected using our through-bond energy transfer cassettes and a FRET 
donor Atto425. Our method was further validated by testing the interactions between 
Atto425-BSA-(biotin) with 1-BSA (experiment v and vi, Figure 6.12.e and f). Whether 
Atto425-BSA was functionalized with biotin or not, no interactions were expected 
between these two proteins thus no significant changes in the fluorescence intensities 
should be detected. This was confirmed by the experimental data as shown in Figure 
6.12.e and f. All these studies proved our hypothesis and showed that combination of 
FRET and TBET can be used to monitor protein-protein interactions. 
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Figure 6.12. In vitro two protein interaction studies. (i) Atto425-BSA-biotin and 1-streptavidin; (ii) 
Atto425-BSA and 1-streptavidin; (iii) Atto425-BSA-biotin and 2-avidin; (iv) Atto425-BSA and 2-avidin; 
(v) Atto425-BSA-biotin and 1-BSA; and, (vi) Atto425-BSA and 1-BSA. a spectra for experiment (i); b for 
experiment (ii); c for experiment (iii); d for experiment (iv); e for experiment (v); f for experiment (vi). 
Throughout, the mixtures were excited at 430 nm.  The concentrations of the proteins used were (x 10-7 M, 
in pH 7.4 phosphate buffer): Atto-425-BSA, 2; Atto-425-BSA-biotin, 2; 1-streptavidin, 3; 2-avidin, 9; 1-
BSA, 3. 
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 The next step is to test our method by studying more complex protein-protein 
interactions such as interactions between three proteins. Figure 6.13. describes four key 
experiments of observing protein-protein interactions between three proteins. 
Experiment (i) represents a critical control wherein Atto-425-BSA and 1-streptavidin 
and 2-avidin were mixed. In this experiment the BSA was not functionalized with biotin 
hence no protein-protein interactions were expected. The slight changes in fluorescence 
intensities were due to errors from quantification calibration and/or residual non-specific 
interactions (even though all samples were pretreated with BSA). Experiment (ii) was 
the most important one. Here the combination of Atto-425-BSA-biotin, 1-streptavidin 
and 2-avidin gave significant fluorescence enhancements for cassettes 1 and 2 relative to 
experiment (i), and the fluorescence of the Atto-425 FRET donor decreased accordingly. 
These observations indicate the biotin-to-avidin/streptavidin interactions brought the 
proteins together such that the FRET donor was able to relay energy to the TBET 
cassette donor parts. Exactly the same combination was used in experiment (iii) except 
that 1-streptavidin and 2-avidin were pretreated with biotin. This was a negative control 
in which the BSA/avidin (or streptavidin) interaction was blocked by pretreating with 
biotin. This almost completely suppressed the fluorescence enhancements that were 
observed in experiment (ii). In experiment (iv), cassette 1, bound this time to BSA, did 
not show significant energy transfer enhancement, while 2-avidin did, proving that the 
origin was the biotin/avidin (or streptavidin) interaction. 
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Figure 6.13. In vitro three protein interactions. a Deconvoluted fluorescence changes for combination of 
(i) Atto-425-BSA, 1-streptavidin and 2-avidin; (ii) Atto-425-BSA-biotin, 1-streptavidin and 2-avidin; (iii) 
1-streptavidin and 2-avidin were pretreated with excess biotin then Atto-425-BSA-biotin was added; and, 
(iv) 1-BSA, 2-avidin and Atto-425-BSA-biotin.  b spectra for experiment (i); c for experiment (ii); d for 
experiment (iii); and, e for experiment (iv), (before deconvolution).  Throughout, the mixtures were 
excited at 430 nm.  The concentrations of the proteins used were (x 10-7 M, in pH 7.4 phosphate buffer): 
Atto-425-BSA, 2; Atto-425-BSA-biotin, 2; 1-streptavidin, 3; 2-avidin, 9; 1-BSA, 3. 
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 The protein-protein interactions were then investigated in live COS-7 cells using 
Pep-152,53,57,237 to import the labeled proteins inside the cells at 37 oC (see Appendix for 
detailed information). No significant fluorescence upon excitation at 458 nm, where 
FRET donor Atto425 absorbs, was observed in the acceptors channels (565-615 nm and 
640-704 nm), when Atto425-BSA-biotin, 1-streptavidin and 2-avidin were imported into 
cells individually (Figure 6.14.a-c). However, significant signal from the acceptor 
proteins (1-streptavidin or 2-avidin) was observed upon excitation at 458 nm when the 
donor protein (Atto425-BSA-biotin) and the acceptor protein were present in the same 
cell (Figure 6.14.d-e). When all three components were present, interactions between the 
FRET donor and the two cassettes labeled proteins were evident (Figure 6.14.f).  
 
a 
   
b 
   
 
Figure 6.14. Studies of protein interactions in COS-7 cells. (a) biotin-BSA-Atto425; (b) streptavidin-
cassette1; (c) avidin-cassette2; (d) biotin-BSA-Atto425 + streptavidin-cassette1; (e) biotin-BSA-Atto425 + 
avidin-cassette2; (f) biotin-BSA-Atto425 + streptavidin-cassette1 + avidin-cassette2. Throughout, excited 
at 458 nm. 
480-520 nm 565-615 nm 640-704 nm 
480-520 nm 565-615 nm 640-704 nm 
biotin-BSA-Atto425 alone 
streptavidin-2 alone 
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Figure 6.14. Continued. 
480-520 nm 565-615 nm 640-704 nm 
480-520 nm 565-615 nm 640-704 nm 
480-520 nm 565-615 nm 640-704 nm 
avidin-2 alone 
biotin-BSA-Atto425 + 
streptavidin-1 
biotin-BSA-Atto425 + 
avidin-2 
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Figure 6.14. Continued. 
 
 
6.5 Conclusions 
 Several through bond energy transfer cassettes 31-33 based on BODIPY 
fragments were prepared. In organic solvents such as MeOH, these cassettes transferred 
energy efficiently from the donor to the acceptors when irradiated in the donor 
absorption region. The overall quantum yields for the cassettes were almost the same as 
the quantum yield of the acceptor fragments alone. All of the cassettes except 32 and 33 
were also soluble in water. Unfortunately, the quantum yields for the cassettes reduced 
dramatically in water. Several cassettes (31c, 31d, 31f, 31g) were almost non-fluorescent 
in aqueous buffer. The energy transfer efficiencies were also lower than that in MeOH. 
No systematic correlation between the behavior in water and cassette structures were 
observed. 
 Interestingly, three cassettes 31a, 31b and 31e still had very good photophysical 
properties in aqueous buffer. Two of them (31b and 31e) were used to monitor protein-
protein interactions. An artificial protein interaction system was built utilizing 
biotin/(strept)avidin interactions to test the water-soluble cassettes. The protein 
interactions with the model system were successfully detected in vitro and in living cells 
using the combination of a FRET donor and two cassettes. 
480-520 nm 565-615 nm 640-704 nm 
biotin-BSA-Atto425 + 
streptavidin-1 + avidin-2 
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CHAPTER VII 
CONCLUSIONS AND OUTLOOK 
 
7.1 Conclusions 
7.1.1 New methodologies for the syntheses of BODIPY and rosamine 
A new synthesis of symmetric BODIPY dyes without meso-substituents was 
discovered (Scheme 7.1.). The kinetics and mechanisms for the new reaction were 
systematically investigated. Possible mechanisms were proposed for the new 
transformation. Series of BODIPYs were easily prepared using the new approach. Some 
of the substrates gave superior yields of desired product compared to conventional 
synthesis. 
 
Scheme 7.1. Illustrative syntheses of symmetric BODIPYs without meso-substituents. (a) Conventional 
synthesis; (b) a  new approach. 
 
a 
NH HN
OHC
+
(i) H+ or LA
(ii) Et3N, BF3OEt2
N
B
F2
N
70 %  
b 
NH
CHO
(i) POCl3, CH2Cl2
25 oC, 12 h
(ii) BF3OEt2, Et3N
25 oC, 12 h
N N
B
F2
92 %  
 
 New methods were developed for the efficient syntheses of rosamine 
derivatives (Scheme 7.2.). Compared with traditional synthesis, the new approach 
described here uses milder conditions but leads to much higher yields with easy 
separation of the desired product. Water-soluble derivatives were also prepared by 
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functionalization of the initial products. The fluorescence properties of these new 
rosamines showed interesting dependence on the amine substituents and the solvent 
media. Several new rosamines were found to be highly cytotoxic toward cancer cells.  
Some of these new rosamines exhibited at least 10-fold lower IC50 values compared 
to Rh123 which is a well studied anti-tumor compound. Further studies revealed that 
the new compounds showed greater cytotoxicity towards oral and nasopharyngeal 
cancer cells compared to immortalized normal cells of the same organ type cancer 
cells which offers potential for the design of new cytotoxic drugs for selective tumor 
cell killing. 
 
Scheme 7.2. Syntheses of rosamine derivatives. (a) Conventional synthesis; (b) a new approach. 
 
a 
HO NR2
CHO
R'
R''
+
strong acid
high temperature
OR2N NR2
R'
R''
conventional synthesis:
10-40 %  
b 
 
 
7.1.2 Syntheses of novel fluorescent compounds 
 Highly fluorescent GFP-chromophore analogs have been successfully 
designed and prepared (Figure 7.1.). The correlation between optical properties and 
structures of these new compounds was investigated. This work provided the first 
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experimental proof that the rigidity of the chromophore inside the protein was 
responsible for its strong fluorescence. Moreover, functional groups were 
incorporated, which not only provided the fluorophores with water-solubility but also 
were amenable to anchor them onto biomolecules. 
 
NH N
N
O
I
458 515 40200 0.0005 492 532 57300 0.86
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absorption (nm), emission (nm), extinction coeff icient (M-1cm-1), quantum yield
in MeOH
almost non-fluorescent highly fluorescent
1c4c
 
Figure 7.1. Highly fluorescent GFP-chromophore analog 1c and its precursor 4c. 
 
 Novel pyronin derivatives with meso-heteroatom substituents (Figure 7.2.) 
have been efficiently prepared. This represents the first synthesis of such dyes. The 
photophysical properties of these compounds are highly dependent on the nature of 
the heteroatom that is attached to the central carbon atom. Series of dyes with 
different emission colors can be easily accessed simply by varying the nucleophiles. 
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Nu
N
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30d
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TfO-
 
 
Figure 7.2. Novel pyronin derivatives. 
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 Series of water-soluble BODIPY dyes with emission above 600 nm were 
prepared. A carboxylic acid was also incorporated into these BODIPYs so that they can 
be used for biomolecular labeling and intracellular imaging. Moreover, these new 
BODIPYs have also been used as acceptors to prepare various water-soluble through 
bond energy transfer cassettes (Figure 7.3.). The cassettes all have complete energy 
transfer and high quantum yields in polar organic solvents (eg MeOH). Several cassettes 
still have good energy transfer and quantum yields in aqueous media and even on 
proteins. Applications of such cassettes in biological studies were also demonstrated. 
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37b 31b
 
 
Figure 7.3. Illustrative examples of water-soluble BODIPY acceptor and through-bond energy transfer 
cassette. 
 
7.1.3 Monitoring of protein-protein interactions in vitro and in living cells 
 One of the major applications of fluorescent dyes is to label biomolecules and 
then study their intracellular localization and interactions with surrounding molecules. 
For instance, the water-soluble through-bond energy transfer cassette 31b was used to 
label several proteins such as BSA, avidin, streptavidin and β-galactosidase. The 
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quantum yield of the cassette was reduced upon attached to proteins. The absorption and 
emission wavelength of these conjugates were very similar to these of the cassette (Table 
7.1.). The fluorescent conjugates were then introduced back into cells such as COS-7 
cells by cell penetrating peptide (eg pep-1, Arg8). These conjugates were easily detected 
by fluorescence microscope. The intracellular localization was also studied. 
 
Table 7.1. Optical properties of cassette and its protein conjugates 
Φ of acceptor 
 Dye/ protein ratio 
λabs 
D 
(nm)
λabs 
A 
(nm)
λemiss 
A 
(nm) 
ex. 
Da 
ex. 
Ab 
E.T.E 
(%)c 
Cassette 31b n/a 501 556 599 0.30 0.32 94 
BSA-cassette 4.0 505 558 604 0.094 0.102 92 
β-Galactosidase-
cassette 4.2 505 556 601 0.11 0.12 92 
Avidin-cassette 1.9 503 554 605 0.09 0.10 90 
Streptavidin-cassette 2.5 502 558 604 0.075 0.080 94 
a Rhodamine 6G (Φ=0.94 in EtOH) ; b Cresyl Violet (Φ=0.54 in MeOH) were used as standards; c energy 
transfer efficiency (E.T.E) was calculated by dividing the quantum yield of acceptor when excited at donor 
by the quantum yield of acceptor when excited at acceptor. 
 
 The water-soluble through-bond energy transfer cassettes were also used to 
detect multiple protein-protein interactions simultaneously (Figure 7.4.). As a proof of 
concept study, an artificial three protein interacting system was built by utilizing the 
biotin/(strept)avidin interactions. Thus, FRET donor (Atto425) labeled BSA was 
functionalized with biotin. Avidin and streptavidin were labeled with two different 
cassettes. The interactions between the Atto425-BSA-biotin and (strept)avidin were 
successfully detected in vitro and in COS-7 cells. 
 
1
A B C D
FRET
donor
FRET
acceptor
and
TBET
donor
TBET
acceptors
which protein does protein 1
interact with?
1B D
FRET
TBETTBET
 
 
Figure 7.4. Scheme for detecting protein-protein interactions. 
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7.2 Outlook 
7.2.1 Rosamine derivatives 
 There is still a lot work to be done in this field. More rosamine derivatives with 
different amine substituents are needed to figure out the origin of the dependence of the 
optical properties on the amine substituents. This can be achieved be employing 
transition metal catalyzed amination, such as Buchwald-Hartwig reaction, of the 3,6-di-
OTf-xanthone (Scheme 7.3.). 
 
Scheme 7.3. New synthesis of rosamine derivatives. 
O
O
TfO OTf
catalyzed
amination  
 
  
The sulfonation reaction as showed in Chapter IV (reaction 4.3) can be further 
exploited to prepare useful water-soluble rosamines. One illustrative example is 
demonstrated in scheme 7.4. 
 
Scheme 7.4. Synthesis of water-soluble rosamines. 
O NR2R2N
HO OH
Cl-
conc'd H2SO4
0 to 25 oC, 12 h
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New rosamine derivatives are needed for further structure-activity relationship 
(SAR) studies (Figure 7.5.). Better anti-tumor candidates could be prepared by 
derivatizing the active hits. For example, compound 11d was found to be highly toxic 
against cancer cells. The bromo/chloro derivatives of 11d can be prepared and used to 
study the halogen effect on the activity. Rosamine 11g was another active compound. 
Furan analog should be used to test the heterocycle effect. Iodination of 11g should lead 
to more active derivatives due to heave atom effect. The unsymmetrical rosamine 22i, 
which had a combination of piperidine and morpholine substituents interestingly had the 
lowest IC50 value among compounds with 2-methyl phenyl at the meso position, alluding 
to the possible importance of an amphilic structure with contrasting hydrophobic and 
hydrophilic halves. New analogs such as 4-IPh or thiophene derivatives should be test 
and compared with 11d and 11g to double check the previous conclusion. 
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Figure 7.5. Rosamine derivatives for anti-tumor activity study. 
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7.2.2 Water-soluble through-bond energy transfer cassettes 
 There are still several problems with the cassettes described in Chapter VI. First, 
the quantum yields of these cassettes are reduced when they are attached to proteins; 
hence they are not optimal for biomolecular labeling. Second, some cassettes have very 
low quantum yields and the energy transfer is not complete in aqueous media. This 
limits their application in biological studies. Third, the emission of the cassettes is below 
700 nm. Thus, these cassettes are still not ideal for in vivo imaging. Further improvement 
is needed to solve these problems. 
 The problem of low quantum yield in water or on protein might be solved by 
improving the water solubility of the cassettes. This can be achieved by incorporating 
more water solubilizing groups into the cassettes. For example, as showed in Figure 7.6., 
a new cassette 49 should have similar absorption and emission wavelength with 31e. But 
it is more soluble in water than 31e thus should give better quantum yield in aqueous 
media and on proteins. Scheme 7.5. describes the synthesis of the new cassette 49. 
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31e
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pH 7.4 PBS Buf fer: Φ: 0.24 , ET: 92%
avidin: Φ: 0.03 , ET: 60%
49
 
Figure 7.6. Water-soluble through-bond energy transfer cassettes. 
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Scheme 7.5. Synthesis of new water-soluble cassette 49. 
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Scheme 7.6. Synthesis of cassette 50. 
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 Another possible water-soluble cassette 50 is showed in Scheme 7.6. In this 
cassette, there are three donor fragments attached to one acceptor thus it can absorb more 
photons and increase the intensity of emission. Since there will be six sulfonic acids and 
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one hexa-ethylene glycol chain in the cassette, it is going to be highly soluble in aqueous 
media and the quantum yield should also be high. 
 
Scheme 7.7. Syntheses of NIR water-soluble BODIPY-BODIPY cassettes 51-52. 
a 
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Scheme 7.7. Continued. 
b 
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 Near IR emitting cassettes are highly desirable for in vivo imaging because their 
emission can penetrate tissue deeper than common dyes thus facilitates detection of the 
labeled targets. Two illustrative examples of such cassettes 51-52 are described in 
Scheme 7.7. BODIPY dyes that are similar to the proposed acceptor fragments have 
been reported.230,238 Therefore, the acceptor parts can be prepared accordingly. 
Incorporation of alkyne functionalities allows subsequent coupling with donor moiety to 
afford the through-bond energy transfer cassettes. There are multiple donor fragments in 
both cassettes thus the brightness of these cassettes will be high. 
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
 
General Experimental Methods 
All reactions were carried out under an atmosphere of dry nitrogen. Glasswares were 
oven-dried prior to use.  Unless otherwise indicated, common reagents or materials were 
obtained from commercial source and used without further purification. All the solvents 
were used after appropriate distillation or purification. 
 
Flash column chromatography was performed using silica gel 60 (230-400 mesh). 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel plates 
with QF-254 indicator and visualized by UV. IR spectra were recorded on a Bruker 
Tensor 27 spectrometer.  Calculations were run with the Gaussian 03 program.  TD-DFT 
was used to calculate the UV absorbance spectra. 
 
1H and 13C spectra were recorded on a Varian 300 (300 MHz 1H; 75 MHz 13C) or Varian 
500 (500 MHz 1H; 125 MHz 13C) spectrometer at room temperature.  Chemical shifts 
were reported in ppm relative to the residual CDCl3 (δ 7.24 ppm 1H; δ 77.0 ppm 13C) 
CD3OD (δ 3.31 ppm 1H; δ 49.0 ppm 13C) or d6-DMSO (δ 2.49 ppm 1H; δ 39.5 ppm 13C). 
19F NMR were acquired on a Varian 300 (300 MHz 1H; 282 MHz 19F) spectrometer. 
CFCl3 was used as an external reference for the 19F NMR spectra.  The gated 1H-
decoupling technique was used to generate proton-coupled 13C NMR. Coupling 
constants (J) were reported in Hertz. 
 
Photophysical Properties and Determination of Quantum Yields 
Absorption spectra were recorded on a Varian 100 Bio UV-Vis spectrophotometer at 
room temperature.  Measurements for the molar extinction coefficients were performed 
according to the following protocol.  2-3 mg of dye was weighed using a digital scale 
(Δw = 0.1 mg), and dissolved into 10 mL of appropriate solvent.  A number of further 
 183
diluted solutions with different dye concentrations (ca: 10-6-10-5 M) were prepared from 
this stock solution. The absorption spectra of these diluted solutions were measured, and 
the absorbance (A) and the concentration (C) were plotted on a graph of A vs C. The 
slope of the above line was the molar extinction coefficient according to the Beer-
Lambert law (A = ε • C • L). 
 
Steady-state fluorescence spectroscopic studies were performed on a Cary Eclipse 
fluorometer at room temperature. The slit width was 5 nm for both excitation and 
emission. The relative quantum yields of the samples were obtained by comparing the 
area under the corrected emission spectrum of the test sample with that of a standard. 
The quantum efficiencies of fluorescence were obtained from three measurements with 
the following equation: 
 
Φx = Φst (Ix/Ist) (Ast/Ax) (ηx2/ηst2)   
 
 
where Φst is the reported quantum yield of the standard, I is the area under the emission 
spectra, A is the absorbance at the excitation wavelength and η is the refractive index of 
the solvent used, measured on a pocket refractometer from ATAGO.  The X subscript 
denotes the test sample, and st denotes standard.   
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APPENDIX B 
EXPERIMENTAL DATA FOR CHAPTER II 
 
Synthesis of compound 2a 
N
H
O
(i) Cl
O
Cl
Et3N, CH2Cl2
25 oC, 2 h
N
O O
N3
2a
(ii) NaN3, DMSO
25 oC, 12 h
 
2-Chloroacetyl chloride (8.8 mL, 0.11 mol) was added dropwise to the solution of N-
methylacetamide (7.3 g, 0.1 mol) and Et3N (15.2 mL, 0.11 mol) in 100 mL CH2Cl2.  The 
solution was stirred at 25oC for 2h, then washed with water (3 x 30 mL) and brine (1 x 
30 mL).  The organic layer was dried over Na2SO4 and evaporated under reduced 
pressure. The residue was dissolved in 100 mL DMSO and NaN3 (13 g, 0.2 mol) was 
added to the resulting solution in one portion.  The reaction mixture was stirred at 25 oC 
for 12 h and then poured into ice water and extracted with EtOAc (3 x 50 mL).  The 
combined extracts were washed with H2O (3 x 30 mL) and brine (1 x 30 mL).  The 
organic layer was dried over Na2SO4 and concentrated under reduced pressure.  The 
crude product was purified by flash chromatography eluting with 1:4 EtOAc/hexane to 
afford 2a (3.0 g, 19 %) as a yellow oil.  1H NMR (300 MHz, CDCl3) δ 4.34 (s, 2H), 3.23 
(s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 173.1, 171.1, 55.5, 31.9, 25.4. MS 
(ESI) m/z calcd for (M+H)+ C5H9N4O2 157.07; found 157.07. 
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13C NMR (CDCl3)
1H NMR (CDCl3)
N
O O
N3
2a
 186
R1 N
H
O
R2
(i) Cl
O
Cl
PhCH3, reflux, 12 h
R1 N
O O
N3
R2
2b - d
(ii) NaN3, DMSO
25 oC, 12 h
 
 
General procedure for the synthesis of α-azido substituted imides 2b-d90 
 
2-Chloroacetyl chloride (1.1 eq.) was added dropwise to a suspension of the amide (1.0 
eq.) in toluene (0.3 M) at 25 oC.  The mixture was heated to reflux for 12 h and then 
evaporated to dryness under reduced pressure.  DMSO was added to the residue to give a 
solution (0.5 M), to which was added NaN3 (2 eq.) in one portion.  After stirring at 25 oC 
for 12 h, the mixture was poured into water and extracted with EtOAc (3 x 30 mL).  The 
combined extracts were washed with H2O (3 x 20 mL) and brine (1 x 20 mL).  The 
organic layer was dried over Na2SO4 and concentrated under reduced pressure.  The 
crude product was purified by flash chromatography to afford 2.   
 
 
Ph N
O O
N3
2b  
 
N-(2-Azidoacetyl)-N-methylbenzamide (2b)  
Prepared according to literature procedure,90 as a white solid (3.66 g, 78 %).  1H NMR 
(300 MHz, CDCl3) δ 7.60-7.45 (m, 5H), 4.38 (s, 2H), 3.21 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 173.6, 171.9, 133.9, 132.6, 128.9, 128.3, 54.5, 35.2.  
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N-(2-Azidoacetyl)-4-iodo-N-methylbenzamide (2c) 
Purified by flash chromatography (4:1 hexanes/EtOAc) to afford 2c (1.48 g, 66 %) as a 
white solid.  1H NMR (300 MHz, CDCl3) δ 7.84 (d, 2H, J = 8.6 Hz), 7.30 (d, 2H, J = 8.6 
Hz), 4.36 (s, 2H), 3.20 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 172.9, 171.7, 138.2, 133.3, 
129.6, 99.9, 54.5, 35.1.  
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 189
N
O O
N3
2d
MeO
 
N-(2-Azidoacetyl)-4-methoxy-N-methylbenzamide (2d) 
Purified by flash chromatography (9:1 hexanes/EtOAc) to afford 2d (1.71 g, 69 %) as a 
yellow oil.  1H NMR (300 MHz, CDCl3) δ 7.59 (d, 2H, J = 9.0 Hz), 6.95 (d, 2H, J = 9.0 
Hz), 4.28 (s, 2H), 3.86 (s, 3H), 3.23(s, 3H); 13C NMR (75 MHz, CDCl3) δ 173.1, 171.7, 
163.4, 131.1, 125.5, 114.1, 55.5, 54.0, 35.2. MS (ESI) m/z calcd for (M+H)+ C11H13N4O3 
249.10; found 249.10. 
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Ph N
H
O O
Cl
NaN3, DMSO
25 oC, 12 h Ph NH
O O
N3
2e  
N-(2-Azidoacetyl)benzamide (2e) 
NaN3 (4.1 g, 62.6 mmol) was added to the solution of N-(2-chloroethanoyl)benzamide 
(6.2 g, 31.3 mmol) (prepared as a white solid with 77 % yield, according to literature 
procedure.239) in 30 mL DMSO.  The mixture was stirred at 25 oC for 12 h and then 
poured into ice water.  The resulting precipitate was filtered and washed with diethyl 
ether to afford 2e (5.9 g, 92 %) as a white solid.  1H NMR (300 MHz, CDCl3) δ 9.38 (br, 
1H), 7.93-7.90 (m, 2H), 7.65-7.50 (m, 3H), 4.58 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 
171.4, 165.7, 133.8, 131.5, 129.2, 127.9, 54.3. 
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R1 N
O O
N3
R2
N
N R2
O
R1
PPh3, PhCH3
25 oC, 12 h
2 3  
 
General procedure for the synthesis of imidazolinones 390 
 
Triphenylphosphine (1.1 eq.) was added to a solution of imide derivatives 2 (1.0 eq.) in 
toluene (0.2 M).  The mixture was stirred at 25 oC for 12 h and then evaporated under 
reduced pressure.  The residue was purified by flash chromatography to afford 3. 
 
 
N
N
O
3a  
1,2-Dimethyl-1H-imidazol-5(4H)-one (3a) 
 
Purified by flash chromatography (1:19 MeOH/EtOAc) to afford 3a (2.5 g, 87 %) as a 
yellow oil.  1H NMR (300 MHz, CDCl3) δ 3.98 (q, 2H, J = 2.4 Hz), 3.00 (s, 3H), 2.15 (t, 
3H, J = 2.4 Hz); 13C NMR (75 MHz, CDCl3) δ 181.1, 163.1, 58.3, 26.3, 15.8.  MS (ESI) 
m/z calcd for (M+H)+ C5H9N2O 113.07; found 113.07. 
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3b  
1-Methyl-2-phenyl-1H-imidazol-5(4H)-one (3b)  
Prepared according to literature procedure,90 as a red solid (1.0 g, 89 %).  1H NMR (300 
MHz, CDCl3) δ 7.63-7.48 (m, 5H), 4.27 (2, 2H), 3.13 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 182.0, 164.9, 131.2, 129.7, 128.8, 128.0, 58.9, 28.6. 
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2-(4-iodophenyl)-1-methyl-1H-imidazol-5(4H)-one (3c) 
Purified by flash chromatography (9:1 CH2Cl2/EtOAc) to afford 3c (1.1 g, 83 %) as a 
yellow solid.  1H NMR (300 MHz, CDCl3) δ 7.85 (d, 2H, J = 8.5 Hz), 7.35 (d, 2H, J = 
8.5 Hz), 4.25 (s, 2H), 3.12 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 181.7, 164.2, 138.1, 
129.6, 129.0, 98.0, 58.8, 28.6. MS (ESI) m/z calcd for (M+H)+ C10H10IN2O 300.98; 
found 300.98. 
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2-(4-Methoxyphenyl)-1-methyl-1H-imidazol-5(4H)-one (3d) 
Purified by flash chromatography (3:2 CH2Cl2/EtOAc) to afford 3d (890 mg, 65 %) as a 
red oil.  1H NMR (300 MHz, CDCl3) δ 7.51 (d, 2H, J = 9.0 Hz), 6.91 (d, 2H, J = 9.0 Hz), 
4.16 (s, 2H), 3.77 (s, 3H), 3.07 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 181.9, 164.3, 
161.6, 129.5, 121.8, 114.0, 58.5, 55.2, 28.5. MS (ESI) m/z calcd for (M+H)+ C11H13N2O2 
205.10; found 205.09. 
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N
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3e  
2-Phenyl-1H-imidazol-5(4H)-one (3e) 
The crude product was washed with diethyl ether to afford pure product 3e (1.5 g, 55 %) 
as a red solid.  1H NMR (500 MHz, CDCl3) δ 11.2 (br, 1H), 7.92-7.91 (m, 2H), 7.53-
7.45 (m, 3H), 4.38 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 185.9, 161.7, 132.0, 129.0, 
128.2, 126.8, 60.2.  MS (ESI) m/z calcd for (M+H)+ C9H9N2O 161.07; found 161.07. 
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Synthesis of compounds Z - 4c and E - 4c 
N
N
O
N
H
CHO
I
+
piperidine
25 oC, 12 h
3c  
NH N
N
O
NH O
N
N
+
Z
E
I
I
Z - 4c E - 4c  
A solution of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde (1.0 eq.) and imidazolinone 3c 
(1.1 eq.) in piperidine (0.2 M) was stirred at room temperature for 12 h.  The reaction 
mixture was diluted with CH2Cl2, washed with water, brine and dried over Na2SO4.  The 
solvents were removed under reduced pressure.  The E and Z isomer can be separated by 
flash chromatography (1:19 to 1:9 EtOAc/Hexanes) and further purified by 
recrystallization from EtOAc/Hexanes.  
N
N
O
I
N
H
CHO +
HBr/TFA, MeOH
25 oC, 30 min
3c  
NH O
N
N
I
E-4c
E
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3,5-Dimethyl-1H-pyrrole-2-carbaldehyde (25 mg, 0.2 mmol) and imidazolinone 3c (60 
mg, 0.2 mmol) were dissolved in 1 mL MeOH then 2 mL TFA and 0.2 mL HBr were 
added.  The solution was stirred at 25 oC for 30 min and a red precipitate formed.  The 
mixture was filtered and the solid was washed with NaHCO3(aq.) then taken into EtOAc. 
The organic layer was washed with NaHCO3(aq.), water and dried over Na2SO4.  The 
solvent was removed under reduced pressure to afford the pure product E-4c as a red 
solid (80 mg, quant.). 
NH N
N
O
NH O
N
N
I
I
1
23
4 5
6
1'
2'3'
4'
5'
Z -4c E-4c
4'
5' 1'
3
2
1
5
46
2'3'
 
Z – 4c: 1H NMR (500 MHz, CDCl3) δ 10.62 (br, 1H), 7.85 (d, 2H, J = 8.6 Hz), 7.48 (d, 
2H, J = 8.6 Hz), 7.17 (s, 1H), 5.87 (d, 1H, J = 2.7 Hz), 3.32 (s, 3H), 2.31 (s, 3H), 2.21 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 169.8, 155.3, 138.1, 138.0, 132.9, 130.6, 129.8, 
129.3, 127.0, 117.1, 112.1, 97.2, 28.9, 13.9, 11.3. From proton-coupled 13C NMR: 3J(H6-
C5) = 3.8 Hz. IR (neat) νC=O 1686 cm-1; λmax abs 458 nm (ε = 40196 M-1cm-1), λmax emiss 515 
nm, Φ = 0.0005 in MeOH;  MS (ESI) m/z calcd for (M+H)+ C17H17IN3O 406.04; found 
406.04. 
E – 4c: 1H NMR (500 MHz, CDCl3) δ 13.01 (br, 1H), 7.80 (d, 2H, J = 8.5 Hz), 7.44 (d, 
2H, J = 8.5 Hz), 7.33 (s, 1H), 5.99 (d, 1H, J = 2.2 Hz), 3.39 (s, 3H), 2.36 (s, 3H), 2.24 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 151.7, 138.2, 137.9, 134.4, 129.5, 129.3, 
129.2, 127.2, 125.6, 113.5, 96.6, 29.1, 14.0, 11.5. From proton-coupled 13C NMR: 3J(H6-
C5) = 8.9 Hz. IR (neat) νC=O 1663 cm-1; λmax abs 458 nm (ε = 48034 M-1cm-1), λmax emiss 515 
nm, Φ = 0.0003 in MeOH;  MS (ESI) m/z calcd for (M+H)+ C17H17IN3O 406.04; found 
406.04. 
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NH N
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I
Z - 4c
NH O
N
NE
I
E - 4c
H - coupled 13C NMR (CDCl3)
H - coupled 13C NMR (CDCl3)
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Photo and thermal isomerization 
NH N
N
O
NH O
N
N
Z
E
I
I
Z - 4c E - 4c
hv
heat
 
A solution of 15 mg of the mixture of E – 4c and Z – 4c in 1 mL of CDCl3 was 
irradiated at 360 nm at room temperature. NMR was taken periodically. 
A solution of 15 mg of the mixture of E – 4c and Z – 4c in 1 mL of d6-DMSO was 
heated to 100oC. NMR was taken periodically after cooled to room temperature. 
General procedure for the synthesis of GFP-chromophore analogs 1 and 5 
N
N
O
R1
N
H
CHO R2+
piperidine
25 oC, 12 h
3  
NH N
N
O
R1
R2
NH O
N
N
R2
R1
+
Z E
4
precipitated as a mixture
BF3•OEt2, Et3N
ClCH2CH2Cl
reflux, 3 h
 
N N
N
O
R1
R2
N O
N
N
R2
R1
+
B
F2
B
F2
1 5  
 
A solution of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde (1.0 eq.) and imidazolinone 3 
(1.1 eq.) in piperidine (0.2 M) was stirred at room temperature for 12 h.  Water was 
added to the solution and yellow precipitate formed.  The mixture was stirred for 10 min 
at room temperature.  The precipitate was collected, washed with water and dried in 
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vacuo to afford a yellow solid.  The solid was dissolved in 1,2-dichloroethane (0.2 M) 
then Et3N (3 eq.) was added.  The reaction mixture was stirred at 25 oC for 15 min then 
BF3•OEt2 (5 eq.) was added.  The mixture was heated to reflux for 3 h and cooled to 
room temperature.  After diluting with dichloromethane, the mixture was washed with 
water and brine.  The organic layer was dried over Na2SO4 and evaporated under 
reduced pressure to give the crude product, which was purified by flash chromatography 
to afford the pure products 1 and 5. 
 
 
N N
N
O
B
F2
1a  
GFP-chromophore analog 1a 
Purified by flash chromatography (3:2 EtOAc/hexanes) to afford 1a (153 mg, 24 %) as a 
yellow solid.  1H NMR (300 MHz, d6-DMSO) δ 7.49 (s, 1H), 6.04 (s, 1H), 3.22 (s, 3H), 
2.64 (s, 3H), 2.31 (s, 3H), 2.19 (s, 3H); 13C NMR (75 MHz, d6-DMSO) δ 160.6, 157.9, 
146.1, 134.6, 128.4, 116.7, 116.5, 116.1, 26.5, 13.8, 12.5, 10.7; 19F NMR (282 MHz, d6-
DMSO) δ 39.43 (q, J = 31.5 Hz); IR (neat) νC=O 1710 cm-1; λmax abs 477 nm (ε = 57286 
M-1cm-1), λmax emiss 485 nm, Φ = 0.89 in MeOH;  MS (ESI) m/z calcd for (M+H)+ 
C12H15BF2N3O 266.13; found 266.13. 
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5a  
GFP-chromophore analog 5a 
Purified by flash chromatography (3:2 EtOAc/hexanes) to afford 5a (350 mg, 54 %) as a 
yellow solid.  1H NMR (500 MHz, d6-DMSO) δ 7.68 (s, 1H), 6.37 (s, 1H), 3.40 (s, 3H), 
2.44 (t, 3H, J = 3.0 Hz), 2.33 (s, 3H), 2.30 (s, 3H); 13C NMR (125 MHz, d6-DMSO) δ 
158.7 (t, J = 5.3 Hz), 156.4, 147.6, 145.1, 133.8, 130.9, 120.9 (2C), 28.4, 16.0 (t, J = 6.2 
Hz), 13.7, 11.5; 19F NMR (282 MHz, d6-DMSO) δ 37.33 (q, J = 18.4 Hz); IR (neat) νC=O 
1622 cm-1; λmax abs 426 nm (ε = 37009 M-1cm-1), λmax emiss 485 nm, Φ = 0.0007 in MeOH; 
MS (ESI) m/z calcd for (M+H)+ C12H15BF2N3O 266.13; found 266.13. 
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N N
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Ph
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F2
1b  
GFP-chromophore analog 1b 
Purified by flash chromatography (1:9 EtOAc/hexanes) to afford 1b (152 mg, 22 %) as a 
red solid.  1H NMR (500 MHz, CDCl3) δ 7.68-7.56 (m, 5H), 7.45 (s, 1H), 6.01 (s, 1H), 
3.22 (s, 3H), 2.34 (s, 3H), 2.23 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 161.0, 153.0, 
151.6, 138.4, 132.1, 130.4, 129.4, 128.8, 124.4, 118.6, 117.7, 116.4, 28.3, 14.4, 11.2; 19F 
NMR (282 MHz, CDCl3) δ 40.92 (q, J = 30.6 Hz); IR (neat) νC=O 1687 cm-1; λmax abs 490 
nm (ε = 58684 M-1cm-1), λmax emiss 521 nm, Φ = 0.87 in MeOH;  MS (ESI) m/z calcd for 
(M+H)+ C17H17BF2N3O 328.14; found 328.14. 
 
 
 
 
 
N N
N
O
Ph
B
F2
1b
19F NMR (CDCl3)
 208
 
 
 
 
N N
N
O
Ph
B
F2
1b
13C NMR (CDCl3)
1H NMR (CDCl3)
 209
 
N O
N
N Ph
B
F2
5b  
GFP-chromophore analog 5b 
Purified by flash chromatography (1:9 EtOAc/hexanes) to afford 5b (430 mg, 63 %) as a 
red solid.  1H NMR (500 MHz, CDCl3) δ 7.66-7.64 (m, 3H), 7.50-7.46 (m, 3H), 6.26 (s, 
1H), 3.63 (s, 3H), 2.58 (t, 3H, J = 3.0 Hz), 2.31 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
160.5, 158.6 (t, J = 5.3 Hz), 147.5, 146.6, 136.0, 130.7, 130.0, 129.1, 128.9, 128.2, 
122.1, 121.3, 30.7, 16.6 (t, J = 6.4 Hz), 11.9; 19F NMR (282 MHz, CDCl3) δ 34.22 (q, J 
= 19.3 Hz) ; IR (neat) νC=O 1640 cm-1; λmax abs 463 nm (ε = 50452 M-1cm-1), λmax emiss 517 
nm, Φ = 0.006 in MeOH;  MS (ESI) m/z calcd for (M+H)+ C17H17BF2N3O 328.14; 
found 328.13. 
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GFP-chromophore analog 1c 
Purified by flash chromatography (1:9 EtOAc/hexanes) to afford 1c (672 mg, 24 %) as 
an orange solid.  1H NMR (300 MHz, CDCl3) δ 7.93 (d, 2H, J = 8.8 Hz), 7.42-7.40 (m, 
3H), 6.01 (s, 1H), 3.21 (s, 3H), 2.34 (s, 3H), 2.21 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
160.7, 152.0, 151.7, 138.9, 138.1, 130.8, 130.5, 123.8, 118.6, 118.0, 116.2, 99.6, 28.3, 
14.4, 11.2; 19F NMR (282 MHz, CDCl3) δ 37.02 (q, J = 27.5 Hz); IR (neat) νC=O 1705 
cm-1; λmax abs 492 nm (ε = 57303 M-1cm-1), λmax emiss 532 nm, Φ = 0.86 in MeOH; MS 
(ESI) m/z calcd for (M+H)+ C17H16BF2IN3O 454.04; found 454.04. 
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GFP-chromophore analog 5c 
Purified by flash chromatography (1:9 EtOAc/hexanes) to afford 5c (1.64 g, 58 %) as a 
red solid.  1H NMR (500 MHz, CDCl3) δ 7.82 (d, 2H, J = 8.5 Hz), 7.64 (s, 1H), 7.39 (d, 
2H, J = 8.5 Hz), 6.28 (s, 1H), 3.62 (s, 3H), 2.58 (t, 3H, J = 3.0 Hz), 2.32 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 161.2, 158.4 (t, J = 6.1 Hz), 147.0, 146.3, 138.1, 136.3, 
130.5, 129.6, 128.6, 122.4, 121.2, 96.4, 30.7, 16.7 (t, J = 6.7 Hz), 11.9; 19F NMR (282 
MHz, CDCl3) δ 34.20 (q, J = 18.9 Hz); IR (neat) νC=O 1610 cm-1; λmax abs 472 nm (ε = 
42669 M-1cm-1), λmax emiss 520 nm, Φ = 0.01 in MeOH;  MS (ESI) m/z calcd for (M+H)+ 
C17H16BF2IN3O 454.04; found 454.03. 
 
 
 
 
 
 
N O
N
N
B
F2
5c
I
19F NMR (CDCl3)
 214
 
 
N O
N
N
B
F2
5c
I
13C NMR (CDCl3)
1H NMR (CDCl3)
 215
N N
N
O
B
F2
1d
OMe
 
GFP-chromophore analog 1d 
Purified by flash chromatography (1:1:3 EtOAc/CH2Cl2/hexanes) to afford 1d (48 mg, 
13 %) as a red solid.  1H NMR (300 MHz, CDCl3) δ 7.65 (d, 2H, J = 8.9 Hz), 7.41 (s, 
1H), 7.06 (d, 2H, J = 8.9 Hz), 5.99 (s, 1H), 3.87 (s, 3H), 3.24 (s, 3H), 2.35 (s, 3H), 2.21 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 162.4, 161.3, 153.4, 150.9, 137.8, 131.3, 130.1, 
118.1, 117.5, 116.7, 116.2, 114.3, 55.4, 28.5, 14.3, 11.1; 19F NMR (282 MHz, CDCl3) δ 
41.17 (q, J = 27.4 Hz) ; IR (neat) νC=O 1664 cm-1; λmax abs 493 nm (ε = 51269 M-1cm-1), 
λmax emiss 521 nm, Φ = 0.85 in MeOH;  MS (ESI) m/z calcd for (M+H)+ C18H19BF2N3O2 
358.15; found 358.15. 
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GFP-chromophore analog 5d 
Purified by flash chromatography (1:1:3 EtOAc/CH2Cl2/hexanes) to afford 5d (144 mg, 
40 %) as a red solid.  1H NMR (500 MHz, CDCl3) δ 7.60 (s, 1H), 7.57 (d, 2H, J = 10.0 
Hz), 6.96 (d, 2H, J = 10.0 Hz), 6.22 (s, 1H), 3.81 (s, 3H), 3.57 (s, 3H), 2.54 (t, 3H, J = 
3.0 Hz), 2.27 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 160.9, 159.6, 158.7 (t, J = 5.5 Hz), 
147.6, 146.1, 135.6, 130.4, 129.6, 121.8, 121.4, 121.2, 114.2, 55.3, 30.6, 16.5 (t, J = 6.4 
Hz) , 11.8; 19F NMR (282 MHz, CDCl3) δ 34.29 (q, J = 18.7 Hz) ; IR (neat) νC=O 1616 
cm-1; λmax abs 455 nm (ε = 38642 M-1cm-1), λmax emiss 528 nm, Φ = 0.03 in MeOH;  MS 
(ESI) m/z calcd for (M+H)+ C18H19BF2N3O2 358.15; found 358.15. 
 
 
 
 
 
 
N O
N
N
B
F2
5d
OMe
19F NMR (CDCl3)
 218
 
 
 
N O
N
N
B
F2
5d
OMe
13C NMR (CDCl3)
1H NMR (CDCl3)
 219
N N
NH
O
Ph
B
F2
1e  
GFP-chromophore analog 1e 
Purified by flash chromatography (1:4 EtOAc/hexanes) to afford 1e (82 mg, 32 %) as a 
red solid.  1H NMR (500 MHz, 1:1 CDCl3/CD3OD) δ 8.02-8.00 (m, 2H), 7.62-7.59 (m, 
1H), 7.55-7.52 (m, 2H), 7.41 (s, 1H), 6.05 (s, 1H), 2.40 (s, 3H), 2.24 (s, 3H); 13C NMR 
(125 MHz, 1:1 CDCl3/CD3OD) δ 163.6, 153.6, 152.0, 138.8, 133.1, 130.8, 129.9 (t, J = 
3.8 Hz), 129.2, 125.4, 119.5, 118.5, 118.4, 14.5 (t, J = 2.4 Hz), 11.2; 19F NMR (282 
MHz, 1:1 CDCl3/CD3OD) δ 41.35 (q, J = 29.1 Hz) ; IR (neat) νC=O 1670 cm-1; λmax abs 
495 nm (ε = 37867 M-1cm-1), λmax emiss 531 nm, Φ = 0.80 in MeOH;  MS (ESI) m/z calcd 
for (M+H)+ C16H15BF2N3O 314.13; found 314.13. 
 
N O
NH
N Ph
B
F2
5e  
GFP-chromophore analog 5e 
Purification was unsuccessful. 
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Synthesis of GFP-chromophore analogs 1f and 5f 
 
NO2
H
NO COOH
N
H
CHO
6
(i) Ac2O, 90 oC, 1.5 h
NH N
O
O
NO290
oC, 1.5 h
(ii)
 
40 % aq. CH3NH2
K2CO3, EtOH
ref lux, 2 h
NH N
N
O
NO2
BF3•OEt2, Et3N
ClCH2CH2Cl
reflux, 3 h
4f  
N N
N
O
NO2
B
F2 N B
F2
O
N
N
NO2
+
1f 5f  
 
A solution of 2-(4-nitrobenzamido) acetic acid (1.48 g, 6.6 mmol) in 10 mL Ac2O was 
heated to 90 oC and stirred for 1.5 h.  To the mixture was added 3,5-dimethyl-1H-
pyrrole-2-carbaldehyde (739 mg, 6 mmol) in one portion at room temperature.  After 
stirring at 90 oC for another 1.5 h, the reaction mixture was cooled to room temperature 
and evaporated to dryness under reduced pressure.  The residue was purified by flash 
chromatography (1:1 CH2Cl2/Hexanes) to give product 6 (860 mg, 46 %) as a red solid.  
NMR analysis of the product indicated that both the E and Z isomers were present in a 
40:60 ratio.  The product was used in the next step without further purification.  1H 
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NMR (500 MHz, CDCl3) Z-6: δ10.30 (s, 1H), 8.33 (d, 2H, J = 9.1 Hz), 8.18 (d, 2H, J = 
9.1 Hz), 7.22 (s, 1H), 5.99 (d, 1H, J = 2.4 Hz), 2.44 (s, 3H), 2.25 (s, 3H); E-6: δ 12.00 (s, 
1H), 8.30 (d, 2H, J = 9.1 Hz), 8.12 (d, 2H, J = 9.1 Hz), 7.42 (s, 1H), 6.07 (d, 1H, J = 2.2 
Hz), 2.41 (s, 3H), 2.29 (s, 3H);  MS (ESI) m/z calcd for (M+H)+ C16H14N3O4 312.10; 
found 312.09. 
 
CH3NH2 (40 % in H2O, 1.9 mL, 22 mmol) was added to the solution of 6 (685 mg, 2.2 
mmol) and K2CO3 (456 mg, 3.3 mmol) in 25 mL EtOH.  The reaction mixture was 
heated to reflux for 2 h, and then cooled to room temperature.  After removal of solvents 
under reduced pressure, the product was purified by flash chromatography (CH2Cl2-
>1:19 EtOAc/CH2Cl2) to afford compound 4f (243 mg, 34 %) as a red solid.  NMR 
analysis of the product indicated that both the E and Z isomers were present in a 48:52 
ratio.  The product was used in the next step without further purification.  1H NMR (500 
MHz, CDCl3) Z-4f: δ 10.58 (s, 1H), 8.36 (d, 2H, J = 8.9 Hz), 7.94 (d, 2H, J = 8.9 Hz), 
7.23 (s, 1H), 5.91 (d, 1H, J = 2.5 Hz), 3.37 (s, 3H), 2.39 (s, 3H), 2.23 (s, 3H); E-4f: δ 
13.12 (s, 1H), 8.32 (d, 2H, J = 8.9 Hz),  7.92 (d, 2H, J = 8.9 Hz), 7.38 (s, 1H), 6.04 (d, 
1H, J = 2.2 Hz), 3.47 (s, 3H), 2.34 (s, 3H), 2.27 (s, 3H); MS (ESI) m/z calcd for (M+H)+ 
C17H17N4O3 325.13; found 325.13. 
 
Et3N (0.34 mL, 2.45 mmol) was added to the solution of 4f (158 mg, 0.49 mmol) in 10 
mL 1,2-dichloroethane.  The resulting solution was stirred at room temperature for 10 
min and BF3•OEt2 (0.49 mL, 3.92 mmol) was added.  The reaction mixture was heated to 
reflux for 3 h then cooled to room temperature.  After removal of solvents under reduced 
pressure, the residue was purified by flash chromatography (1:19 EtOAc/CH2Cl2) to 
afford compound 1f (84 mg, 46 %) as a red solid and 5f (79 mg, 44 %) as a red solid. 
 
For 1f: 1H NMR (500 MHz, CDCl3) δ 8.43 (d, 2H, J = 8.8 Hz), 7.92 (d, 2H, J = 8.8 Hz), 
7.44 (s, 1H), 6.03 (s, 1H), 3.25 (s, 3H), 2.33 (s, 3H), 2.22 (s, 3H); 13C NMR (500 MHz, 
CDCl3) δ 160.3, 153.3, 149.7, 149.4, 140.0, 131.1 (t, J = 2.8 Hz), 130.9, 130.4, 124.0, 
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119.0, 118.5, 115.9, 28.3, 14.4 (t, J = 2.0 Hz), 11.2; 19F NMR (282 MHz, CDCl3) δ 
41.58 (q, J = 28.1 Hz) ; IR (neat) νC=O 1678 cm-1; λmax abs 492 nm (ε = 44003 M-1cm-1), 
λmax emiss 598 nm, Φ = 0.0004 in MeOH;  MS (ESI) m/z calcd for (M+H)+ 
C17H16BF2N4O3 373.13; found 373.11. 
 
For 5f: 1H NMR (500 MHz, CDCl3) δ 8.34 (d, 2H, J = 8.9 Hz), 7.88 (d, 2H, J = 8.9 Hz), 
7.65 (s, 1H), 6.32 (s, 1H), 3.71 (s, 3H), 2.61 (t, 3H, J = 2.9 Hz), 2.34 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 162.9, 158.1 (t, J = 5.0 Hz), 148.1, 148.0, 144.4, 137.1, 135.2, 
130.4, 128.7, 124.2, 123.1, 121.4, 31.0, 16.8 (t, J = 6.5 Hz), 12.0; 19F NMR (282 MHz, 
CDCl3) δ 34.31 (q, J = 18.5 Hz); IR (neat) νC=O 1612 cm-1; λmax abs 472 nm (ε = 35502 
M-1cm-1), λmax emiss 525 nm, Φ = 0.005 in MeOH; MS (ESI) m/z calcd for (M+H)+ 
C17H16BF2N4O3 373.13; found 373.12. 
 224
 
 
 
 
 
6
NH N
O
O
NO2
NH N
N
O
NO24f
1H NMR (CDCl3)
1H NMR (CDCl3)
 225
 
 
 
 
 
 
N N
N
O
NO2
B
F2
1f
13C NMR (CDCl3)
1H NMR (CDCl3)
 226
 
 
 
 
 
 
N N
N
O
NO2
B
F2
1f
N
B
F2
O
N
N
NO2
5f
19F NMR (CDCl3)
19F NMR (CDCl3)
 227
 
 
N
B
F2
O
N
N
NO2
5f
1H NMR (CDCl3)
13C NMR (CDCl3)
 228
Recycle of undesired GFP-chromophore analog 5 
 
N
B
F2
O
N
N
I
1 : 9 H2SO4/TFA
CH2Cl2, 25 oC, 10 min
5c  
NH O
N
N
I (i) ClCH2CH2Cl
reflux, 1 h
(ii) BF3•OEt2, Et3N
reflux, 3 h
 
N
B
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O
N
N
I
N
B
F2
N
N
O
I
+
1c 5c  
Compound 5c (227 mg, 0.5 mmol) was dissolved in 5 mL CH2Cl2 and 5 mL 1:9 
H2SO4/TFA was added.  The solution was stirred at 25 oC for 10 min then poured into 20 
mL ice-water and extracted with CH2Cl2 (3 x 50 mL).  The organic layers were 
combined, washed carefully with saturated NaHCO3 (3 x 30 mL), H2O (1 x 30 mL), 
brine (1 x 30 mL) and dried over Na2SO4.  The solvent was removed under reduced 
pressure to afford an orange solid, which was dried in vacuo and used in the next step 
without further purification. 
The orange solid was dissolved in 10 mL ClCH2CH2Cl. After refluxing for 1 h, the 
solution was cooled to room temperature and Et3N (0.35 mL, 2.5 mmol) was added, 
followed by BF3•OEt2 (0.51 mL, 4.0 mmol) after 10 min.  The reaction mixture was 
heated to reflux for 3 h.  After cooled to room temperature, the solution was diluted with 
30 mL CH2Cl2 and washed with 30 mL H2O, 30 mL brine and dried over Na2SO4.  The 
solvents were removed under reduced pressure and the residue was purified by flash 
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chromatography (EtOAc/Hexanes, 1:9) to afford 1c (64 mg, 28 %) as an orange solid 
and 5c (127 mg, 56 %) as a red solid.   
 
 
Synthesis of GFP-chromophore analog 1g 
 
1g
N
B
F2
N
N
O
I
NaO3SN
B
F2
N
N
O
I
(i) 4 eq. ClSO3H
CH2Cl2
0 oC, 10 min
(ii) NaHCO3(aq.)
1c  
 
ClSO3H (53 μL, 0.8 mmol) was added dropwise to the solution of 1c (91 mg, 0.2 mmol) 
in 2 mL CH2Cl2 at 0 oC.  After stirring at 0 oC for 10 min, the reaction mixture was 
poured into 20 mL ice-water, neutralized with saturated NaHCO3(aq.) and extracted with 
iPrOH/CH2Cl2 (1:1) (3 x 20 mL).  The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure.  The residue was purified by flash chromatography 
(1:9 MeOH/CH2Cl2) to afford the product 1g (102 mg, 92 %) as an orange solid.  1H 
NMR (500 MHz, CD3OD) δ 8.02 (d, 2H, J = 8.4 Hz), 7.61 (s, 1H), 7.56 (d, 2H, J = 8.4 
Hz), 3.20 (s, 3H), 2.55 (s, 3H), 2.43 (s, 3H); 13C NMR (125 MHz, CD3OD) δ 163.1, 
156.7, 149.8, 139.1, 136.2, 132.5, 131.3, 129.3, 125.2, 120.1, 119.9, 100.3, 28.7, 13.6, 
10.9. IR (neat) νC=O  1688cm-1; λmax abs 488 nm (ε = 48132 M-1cm-1), λmax emiss 531 nm, Φ 
= 0.88 in MeOH; MS (ESI) m/z calcd for (M-Na)- C17H14BF2IN3O4S 531.98; found 
531.88. 
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Synthesis of GFP-chromophore analog 1h 
1g
N
B
F2
N
N
O
I
NaO3S
COOH
10mol % PdCl2(PPh3)2
10mol % CuI, 10 eq. Et3N
DMF, 25 oC, 12 h
 
N
B
F2
N
N
O
HO3S
COOH
1h  
Compound 1g (56 mg, 0.1 mmol), PdCl2(PPh3)2 (7 mg, 0.01 mmol) and CuI (2 mg, 0.01 
mmol) were dissolved in 2 mL DMF in a Schlenk tube.  The mixture was freeze-pump-
thawed three times, and then 5-hexynoic acid (56 μL, 0.5mmol) and Et3N (140 μL, 1.0 
mmol) were added.  After stirring at 25 oC for 12 h, the reaction mixture was 
concentrated under reduced pressure.  The residue was dissolved in 20 mL H2O and 
acidified to pH ≈ 2.0 with 1N HCl.  The solution was extracted with iPrOH/CH2Cl2 (1:1) 
(3 x 30 mL).  The organic layer was dried over Na2SO4 and concentrated in vacuo.  The 
crude product was purified by flash chromatography (1:4 MeOH/CH2Cl2) to give the 
desired product 1h as an orange solid (37 mg, 71 %).  1H NMR (500 MHz, CD3OD) δ 
7.74 (d, 2H, J = 8.4 Hz), 7.65 (s, 1H), 7.61 (d, 2H, J = 8.4 Hz), 3.22 (s, 3H), 2.57-2.47 
(m, 10H), 1.96-1.90 (m, 2H); 13C NMR (125 MHz, d6-DMSO) δ 178.0, 160.7, 155.3, 
146.2, 134.2, 133.2, 131.1, 130.1, 127.1, 127.0, 123.4, 117.9, 117.8, 94.3, 79.9, 35.7, 
28.2, 24.9, 18.6, 13.0, 10.4. IR (neat) νC=O  1702, 1593cm-1; λmax abs 488 nm (ε = 35024 
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M-1cm-1), λmax emiss 538 nm, Φ = 0.88 in MeOH; MS (ESI) m/z calcd for (M-H)- 
C23H21BF2N3O6S 516.12; found 516.05. 
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Labeling of streptavidin with 1h 
 
N
B
F2
N
N
O
HO3S
COOH
1h
(i) NHS, DIC, DMF
25 oC, 12 h
(ii) Streptavidin
0.1M pH 8.3 NaHCO3
25 °C, 1 h
 
 
1s
dye:protein 3.0:1.0
N
B
F2
N
N
O
NaO3S
H
N
O
streptav idin
 
 
The solution of 1h (1.9 mg, 3.7 μmol), NHS (2 mg, 18.5 μmol), DIC (3 μL, 18.5 μmol) 
in 0.2 mL DMF was stirred at 25 oC for 12 h.  The above solution (21 μL) was added to 
a solution of 2 mg streptavidin in 0.2 mL 0.1M NaHCO3 buffer (pH = 8.3).  The 
resulting solution was stirred at 25 oC in the dark for 1 h.  The mixture was purified by 
PD-10 desalting column to give the labeled streptavidin 1s.  
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Synthesis of thiol-reactive GFP-chromophore analog 1i 
N
B
F2
N
N
O
I
N
H
PdCl2(PPh3)2, CuI
DIEA, CH2Cl2
25 oC, 12 h
N
B
F2
N
N
O
O
Br
N
HX
O
X= Br, I
1c 7
 
N
B
F2
N
N
O
N
H
HO3S
O I
(i) ClSO3H, CH2Cl2
0 oC, 20 min
(ii) NaI
CH3CN / H2O
25 oC, 24 h
1i  
 
 
A solution of 1c (91 mg, 0.2 mmol) , 2-bromoacetyl propargylamide (176 mg, 1.0 
mmol), PdCl2(PPh3)2 (7 mg, 0.01 mmol) and CuI (2 mg, 0.01 mmol) in 5 mL CH2Cl2 
was degassed and filled with N2 then DIEA (0.17 mL, 1.0 mmol) was added.  The 
reaction mixture was stirred at 25 oC for 12 h then concentrated under reduced pressure.  
The residue was purified by flash chromatography (60 % EtOAc/Hexanes) to afford the 
product 7 (85 mg, 85 %) as a red solid.  1H NMR and MS analysis shows 7 was a 
mixture of two compounds which corresponded to X = Br and I. 1H NMR (500 MHz, 
CDCl3) δ 7.65-7.60 (m, 4H), 7.45 (s, 1H), 6.76 (br, 1H) and 6.33 (br, 1H), 6.03 (s, 1H), 
4.34 (d, 2H, J = 5.4 Hz) and 4.32 (d, 2H, J = 5.4 Hz), 3.92 (s, 2H) and 3.74 (s, 2H), 3.23 
(s, 3H), 2.34 (s, 3H), 2.23 (s, 3H).  MS (ESI) m/z calcd for (M+H)+ C22H21BBrF2N4O2 
501.09; found 501.10 (X = Br); calcd for (M+H)+ C22H21BF2IN4O2 549.08; found 549.08 
(X = I). 
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A solution of the above product 7 (70 mg, 0.14 mmol) in 10 mL CH2Cl2 was cooled to 0 
oC and ClSO3H (38 μL, 0.56 mmol) was added dropwise over 1 min.  The reaction 
mixture was stirred at 0 oC for 20 min then quenched with 1 mL H2O.  The mixture was 
concentrated under reduced pressure and the residue was purified by flash 
chromatography (20 % MeOH/CH2Cl2) to give a red solid.  This intermediate was 
dissolved in 6 mL CH3CN and 4 mL H2O then NaI (63 mg, 0.42 mmol) was added in 
one portion.  The reaction mixture was stirred at 25 oC for 24h then concentrated under 
reduced pressure. The residue was purified by flash chromatography (20 % 
MeOH/CH2Cl2) to afford the product 1i (86 mg, 98 %) as a red solid.  1H NMR (500 
MHz, CD3OD) δ 7.78 (d, 2H, J = 8.3 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63 (s, 1H), 4.26 (s, 
2H), 3.76 (s, 2H), 3.22 (s, 3H), 2.55 (s, 3H), 2.45 (s, 3H); 13C NMR (125 MHz, CD3OD) 
δ 171.1, 163.1, 157.0, 149.5, 136.0, 132.7 (2C), 131.1, 129.2, 128.2, 125.3, 120.0, 119.9, 
88.8, 82.7, 31.0, 28.9, 13.6, 10.9, -2.5. MS (ESI) m/z calcd for (M-H)- C22H19BF2IN4O5S 
627.02; found 626.93. 
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 a 
 
 b 
          
Figure B1. X-ray structures for GFP-chromophore analogs: a 1c and 5c; b 1f and 5f. 
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Table B1. Calculated free energies of E and Z isomers 
NH N
N
O
I
4c
N
N
O
HO
N
N
O
HO
O
A G  
 
Aa Gb,88 4cb 
 Aqueous 
solution Gas phase 
Aqueous 
solution Gas phase DMSO 
Z (Hartree) − - 837.84379 - 837.84976 - 908.160846 - 908.180318 
E (Hartree) − - 837.84114 -837.84715 - 908.162969 - 908.181293 
Energy of  
E vs Z 
(Kcal/mol) 
2.1 1.66 1.64 - 1.33 - 0.61 
 
a Experimental value;91 b calculated with B3LYP/6-31+G** (SDD for I in 4c) 
 
 
 
Table B2. Calculated spectroscopic properties of 4ca 
 
 ΔE, eV λmax, nm Oscillator strength (f) 
 Gas phase 
Z – 4c 2.83 438 0.70 
E – 4c 2.89 430 0.99 
 DMSO 
Z – 4c 2.78 446 (458)b 0.89 
E – 4c 2.81 442 (464)b 1.09 
 
a Calculated with B3LYP/6-31+G** (SDD for I); b data in bold are experimental values 
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a 
                             
HOMO of Z-4c                                                LUMO of Z-4c 
 
b 
                
HOMO of E-4c                                               LUMO of E-4c 
                                      
Figure B2. HOMO and LUMO pictures from B3LYP/6-31+G** (SDD for I) calculation: a Z-4c; and, b 
E-4c. 
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Table B3. Spectroscopic differences between compounds 1 and 5 
N N
N
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N O
N
N
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R11
23
4 5
6
1'
2'3'
4'
5'
1 5
B
F2 B
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strong 19F-13C coupling
19F shift to
higher f ield
1H shif t to lower field
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Trends in chemical shift differences for compounds 5 relative to compounds 1 illustrate that these can be 
used to differentiate between them.  Here the zero line is the chemical shift values for compounds 1, and 
the relative chemical shift difference for the corresponding compound 5 is indicated.  The chemical shift 
differences for the 19F signals shown here are 0.1 x their actual values. 
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Table B3. Continued 
 
νC=O 
(cm-1) 
δC5 
(ppm) 
δF 
(ppm) 
δH6 
(ppm) 
δH4’ 
(ppm) 
δH6’ 
(ppm) 
1a 1710 160.6 39.43 7.49 6.04 2.31 
5a 1622 
158.7 
(t, J = 5.3Hz ) 
37.33 7.68 6.37 
2.44 
(t, J = 3.0Hz ) 
1b 1687 161.0 40.92 7.45 6.01 2.34 
5b 1640 
158.6 
(t, J = 5.3Hz ) 
34.22 7.66 6.26 
2.58 
(t, J = 3.0Hz ) 
1c 1705 160.7 37.02 7.41 6.01 2.34 
5c 1610 
158.4 
(t, J = 6.1Hz ) 
34.20 7.64 6.28 
2.58 
(t, J = 3.0Hz ) 
1d 1664 161.3 41.17 7.41 5.99 2.35 
5d 1616 
158.7 
(t, J = 5.5Hz ) 
34.29 7.60 6.22 
2.54 
(t, J = 3.0Hz ) 
1e 1670 163.6 41.35 7.41 6.05 2.40 
5e - - - - - - 
1f 1678 160.3 41.58 7.44 6.03 2.33 
5f 1612 
158.1 
(t, J = 5.0Hz ) 
34.31 7.65 6.32 
2.61 
(t, J = 2.9Hz ) 
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Table B4. Spectroscopic properties of GFP-chromophore analogs 
 
 
λmax abs 
(nm) 
ε 
(M-1cm-1) 
λmax emiss 
(nm) 
fwhm 
(nm) 
Φa solvent 
1a 477 57286 485 19 0.89 ± 0.01 MeOH 
1a 480 52809 491 21 n.d. CH2Cl2 
5a 426 37009 485 25 0.0007 MeOH 
1b 490 58684 521 46 0.87 ± 0.01 MeOH 
1b 494 42641 530 48 n.d. CH2Cl2 
5b 463 50452 517 64 0.006 MeOH 
1c 492 57303 532 54 0.86 ± 0.02 MeOH 
1c 498 44990 546 53 n.d. CH2Cl2 
5c 463 42669 530 54 0.01 MeOH 
1d 493 51269 521 38 0.85 ± 0.03 MeOH 
1d 496 47448 530 43 n.d. CH2Cl2 
5d 455 38642 528 69 0.03 MeOH 
1e 495 37867 531 48 0.80 ± 0.01 MeOH 
1e 498 44990 546 46 n.d. CH2Cl2 
1f 492 44003 598 120 0.0004 MeOH 
1f 498 n.d 587 53 0.53 ± 0.01 Hexanes 
1f 499 38658 642 150 n.d CH2Cl2 
5f 473 35502 527 73 0.005 MeOH 
5f 486 n.d. 545 97 0.05 Hexanes 
1g 488 48132 531 53 0.88 ± 0.01 MeOH 
1g 481 46461 518 50 0.87 ± 0.01 Phos 7.4b 
1h 488 35024 538 58 0.84 ± 0.01 MeOH 
1h 482 34766 526 56 0.82 ± 0.01 Phos 7.4b 
1s 482 n.d. 529 56 n.d. Phos 7.4b 
a Fluorescein in 0.1M NaOH as standard (Φ = 0.92); b 0.1M lithium phosphate buffer, pH = 7.4 
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APPENDIX C 
EXPERIMENTAL DATA FOR CHAPTER III 
 
Typical procedure for the synthesis of pyrrole-2-carboxaldehyde240 
N
H
(i) POCl3, DMF
ClCH2CH2Cl
(ii) NaOAc, H2O NH
CHO
8a  
POCl3 (5.9 mL, 63.0 mmol) was added dropwise to DMF (4.9 mL, 63.0 mmol) at 0 oC.  
The mixture was warmed to room temperature and stirred for 15 min.  The ice bath was 
replaced to cool the mixture back to 0 °C, then 30 mL of 1,2-dichloroethane was added 
to the mixture.  A solution of 2,4-dimethyl pyrrole (5.0 g, 52.5 mmol) in 50 mL of 1,2-
dichloroethane was added dropwise over 20 min at 0oC.  After the addition was 
complete, the reaction mixture was refluxed for 30 min and then cooled to room 
temperature.  A solution of NaOAc (23.7 g, 289 mmol) in 100 mL of water was added.  
The reaction mixture was again refluxed for 30 min.  The cooled mixture was washed 
with water (1 x 100 mL), saturated Na2CO3 solution (2 x 50 mL) and brine (1 x 50 mL).  
The organic layer was dried over Na2SO4 and the solvents were removed under reduced 
pressure. The residue was purified by flash chromatography (SiO2, 20 % 
EtOAc/Hexanes) to afford the pure product 8a as a light yellow solid (5.8 g, 89 %).  1H 
NMR (300 MHz, CDCl3) δ 9.96 (br, 1H), 9.44 (s, 1H), 5.84 (d, 1H, J = 2.6 Hz), 2.30 (s, 
3H), 2.28 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 175.9, 138.4, 134.7, 128.7, 112.0, 13.2, 
10.6. 
 
8b-8h were prepared using similar method as described for 8a. 
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N
H
CHO
8b  
4,5-Dihydro-1H-benzo[g]indole-2-carbaldehyde (8b) 
Yellow solid (910 mg, 85 %).  1H NMR (300 MHz, CDCl3) δ 10.74 (br, 1H), 9.48 (s, 
1H), 7.71 (d, 1H, J = 7.4 Hz), 7.32-7.19 (m, 3H), 6.84 (d, 1H, J = 2.0 Hz), 2.96 (t, 2H, J 
= 7.5 Hz), 2.78 (t, 2H, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3) δ 178.4, 137.2, 136.7, 
132.5, 128.5, 128.0, 127.4, 127.0, 122.7, 121.7, 120.6, 29.6, 21.3.  MS (ESI) m/z calcd 
for (M+H)+ C13H12NO 198.09; found 198.09. 
 
 
 
 
 
N
H
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N
H
CHO
8c
MeO
 
7-Methoxy-4,5-dihydro-1H-benzo[g]indole-2-carbaldehyde (8c) 
Light green solid (345 mg, 100 %).  1H NMR (300 MHz, CDCl3) δ 10.59 (br, 1H), 9.39 
(s, 1H), 7.61 (d, 1H, J = 8.2 Hz), 6.82-6.78 (m, 3H), 3.81 (s, 3H), 2.91 (t, 2H, J = 7.5 
Hz), 2.74 (t, 2H, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3) δ 177.8, 159.6, 139.3, 137.1, 
132.0, 123.1, 121.4, 120.9, 120.5, 114.5, 112.0, 55.3, 30.0, 21.3.  MS (ESI) m/z calcd for 
(M+H)+ C14H14NO2 228.10; found 228.10. 
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3,5-Diphenyl-1H-pyrrole-2-carbaldehyde (8d) 
White solid (290 mg, 86 %).  1H NMR (300 MHz, CDCl3) δ 10.04 (br, 1H), 9.63 (s, 1H), 
7.70-7.67 (m, 2H), 7.55-7.52 (m, 2H), 7.48-7.33 (m, 6H), 6.72 (d, 1H, J = 2.8 Hz); 13C 
NMR (75 MHz, CDCl3) δ 179.4, 139.1, 138.5, 133.5, 130.4, 129.2, 129.1, 129.0, 128.8, 
128.7, 127.9, 125.3, 109.0.  MS (ESI) m/z calcd for (M+H)+ C17H14NO 248.11; found 
248.11. 
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4-Ethyl-3,5-dimethyl-1H-pyrrole-2-carbaldehyde (8e) 
Brown solid (1.1 g, 85 %).  1H NMR (300 MHz, CDCl3) δ 10.08 (br, 1H), 9.42 (s, 1H), 
2.36 (q, 2H, J = 7.5 Hz), 2.25 (s, 3H), 2.24 (s, 3H), 1.03 (t, 3H, J = 7.5 Hz); 13C NMR 
(75 MHz, CDCl3) δ 175.5, 135.9, 132.2, 127.8, 124.8, 16.9, 15.0, 11.4, 8.7.  MS (ESI) 
m/z calcd for (M+H)+ C9H14NO 152.11; found 152.10. 
 
 
 
 
N
H
CHO
Et 1H NMR (CDCl3)
13C NMR (CDCl3)
 249
N
HEt
CHO
8f  
5-Ethyl-1H-pyrrole-2-carbaldehyde (8f) 
Red solid (1.0 g, 78 %).  1H NMR (300 MHz, CDCl3) δ 10.58 (br, 1H), 9.34 (s, 1H), 
6.92-6.90 (m, 1H), 6.09-6.07 (m, 1H), 2.72 (q, 2H, J = 7.5 Hz), 1.26 (t, 3H, J =7.5 Hz); 
13C NMR (75 MHz, CDCl3) δ 178.2, 145.4, 131.8, 123.4, 108.8, 21.0, 13.1.  MS (ESI) 
m/z calcd for (M+H)+ C7H10NO 124.08; found 124.07. 
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4,5,6,7-Tetrahydro-1H-indole-2-carbaldehyde (8g) 
Yellow solid (960 mg, 78 %).  1H NMR (300 MHz, CDCl3) δ 10.21 (br, 1H), 9.29 (s, 
1H), 6.69 (d, 1H, J = 2.4 Hz), 2.67 (t, 2H, J = 6.1 Hz),  2.51 (t, 2H, J = 6.0 Hz), 1.84-
1.69 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 177.9, 138.9, 131.2, 121.2, 121.1, 23.3, 
23.0, 22.6 (2C: 22.61, 22.59).  MS (ESI) m/z calcd for (M+H)+ C9H12NO 150.09; found 
150.09. 
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4-Acetyl-3,5-dimethyl-1H-pyrrole-2-carbaldehyde (8h) 
Light yellow solid (481 mg, 40 %).  1H NMR (300 MHz, CDCl3) δ 10.20 (br, 1H), 9.62 
(s, 1H), 2.58 (s, 3H), 2.56 (s, 3H), 2.45 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 194.9, 
177.6, 143.1, 134.6, 128.2, 123.7, 31.3, 15.2, 11.4.  MS (ESI) m/z calcd for (M+H)+ 
C9H12NO2 166.09; found 166.09. 
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Typical procedure for the synthesis of symmetric BODIPYs 
 
N
H
CHO
(i) POCl3, CH2Cl2
0 - 25 oC, 12 h
(ii) Et3N, BF3OEt2
25 oC, 12 h
N
B
F2
N
8a 9a  
 
3,5-Dimethyl-1H-pyrrole-2-carbaldehyde 8a (246 mg, 2 mmol) was dissolved in 10 mL 
CH2Cl2 and POCl3 (0.22 mL, 2.4 mmol) was added dropwise over 1 min at 0 oC.  The 
solution was warmed to room temperature slowly and stirred for 12 h.  The mixture was 
cooled to 0 oC and Et3N (1.4 mL, 10 mmol) was added dropwise over 5 min.  After 
stirring for 15 min, BF3OEt2 (2.0 mL, 16 mmol) was added dropwise to the solution over 
5 min.  The reaction mixture was warmed to room temperature and stirred for 12 h.  The 
mixture was passed through a short pad of silica gel eluting with CH2Cl2 to remove the 
polar impurities.  The solvents were removed under reduced pressure.  The residue was 
dissolved in CH2Cl2 and water was added, and the mixture was stirred at room 
temperature overnight. (to decompose excess BF3OEt2 and other impurities).   The 
organic layer was washed with water, brine and dried over Na2SO4.  The solvent was 
removed under reduced pressure and the residue was purified by flash chromatography 
(5 % EtOAc/hexanes) to give the pure product 9a (229 mg, 92 %) as a red solid. 1H 
NMR (CDCl3, 500 MHz) δ 7.01 (s, 1H), 6.02 (s, 2H), 2.51 (s, 6H), 2.22 (s, 6H); 13C 
NMR (CDCl3, 125 MHz) δ 156.7, 141.2, 133.4, 120.0, 119.0, 14.6, 11.2; 19F NMR 
(CDCl3, 282 MHz) δ 30.68 (q, J = 33.5 Hz). HRMS (ESI) m/z calcd for (M+H)+ 
C13H16BF2N2 249.1375; found 249.1373. 
 
9b-9h were prepared using similar methods as described for 9a. 
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BODIPY 9b 
Green solid (360 mg, 91 %).  1H NMR (300 MHz, CDCl3) δ 8.73 (d, 2H, J = 8.0 Hz), 
7.45-7.39 (m, 2H), 7.33-7.23 (m, 4H), 6.98 (s, 1H), 6.76 (s, 2H), 2.90 (t, 4H, J = 7.0 Hz), 
2.72 (t, 4H, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) δ 152.6, 140.5, 136.3, 133.1, 129.7, 
128.3, 128.2, 128.1, 127.5, 124.8, 124.1, 30.5, 22.3; 19F NMR (CDCl3, 282 MHz) δ 
39.67 (q, J = 33.6 Hz).  MS (MALDI) m/z calcd for M+ C25H19BF2N2 396.16; found 
395.88. 
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BODIPY 9c 
Blue solid (194 mg, 85 %).  1H NMR (300 MHz, CDCl3) δ 8.69 (d, 2H, J = 9.0 Hz), 6.95 
(dd, 2H, J = 9.0, 2.8 Hz), 6.86 (s, 1H), 6.78 (d, 2H, J = 2.8 Hz), 6.69 (s, 2H), 3.85 (s, 
6H), 2.87 (t, 4H, J = 6.9 Hz), 2.70 (t, 4H, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 
160.6, 151.9, 142.8, 135.9, 131.9, 129.9 (t, J = 11.1 Hz), 124.2, 122.2, 121.4, 114.3, 
112.4, 55.3, 30.8, 22.3; 19F NMR (CDCl3, 282 MHz) δ 39.15 (q, J = 33.6 Hz).  MS 
(MALDI) m/z calcd for M+ C27H23BF2N2O2 456.18; found 455.88. 
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BODIPY 9d 
Green solid (52 mg, 21 %).  1H NMR (300 MHz, CDCl3) δ 7.98-7.95 (m, 4H), 7.54-7.42 
(m, 17H), 6.73 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 157.8, 145.7, 134.4, 133.3, 132.3, 
129.7, 129.4 (t, J = 3.5 Hz), 129.1, 128.7 (2C), 128.2, 127.7, 119.0; 19F NMR (CDCl3, 
282 MHz) δ 45.58 (q, J = 33.5 Hz).  MS (MALDI) m/z calcd for M+ C33H23BF2N2 
496.19; found 495.93. 
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BODIPY 9e 
Organge solid (227 mg, 75 %).  1H NMR (300 MHz, CDCl3) δ 6.92 (s, 1H), 2.47 (s, 6H), 
2.36 (q, 4H, J = 7.5 Hz), 2.14 (s, 6H), 1.04 (t, 6H, J = 7.5 Hz); 13C NMR (75 MHz, 
CDCl3) δ 154.6, 136.6, 132.4, 131.6, 118.5, 17.3, 14.6, 12.5, 9.4; 19F NMR (CDCl3, 282 
MHz) δ 30.93 (q, J = 33.6 Hz).  MS (MALDI) m/z calcd for M+ C17H23BF2N2 304.19; 
found 303.96. 
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BODIPY 9f 
Orange solid (70 mg, 28 %).  1H NMR (300 MHz, CDCl3) δ 7.05 (s, 1H), 6.94 (d, 2H, J 
=  4.2 Hz), 6.32 (d, 2H, J = 4.2 Hz), 3.02 (q, 4H, J = 7.5 Hz), 1.31 (t, 6H, J = 7.5 Hz); 
13C NMR (75 MHz, CDCl3) δ 164.1, 134.4, 130.1, 127.1, 117.4, 22.0, 12.6; 19F NMR 
(CDCl3, 282 MHz) δ 31.94 (q, J = 33.4 Hz).  MS (MALDI) m/z calcd for M+ 
C13H15BF2N2 248.13; found 247.85. 
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BODIPY 9g 
Red solid (65 mg, 22 %).  1H NMR (300 MHz, CDCl3) δ 6.89 (s, 1H), 6.59 (s, 2H), 3.01 
(t, 4H, J = 6.2 Hz), 2.52 (t, 4H, J = 6.2 Hz), 1.86-1.78 (m, 4H), 1.76-1.68 (m, 4H); 13C 
NMR (75 MHz, CDCl3) δ 158.0, 134.0, 129.3, 125.9, 125.3, 24.7, 23.1, 22.8, 22.3; 19F 
NMR (CDCl3, 282 MHz) δ 27.29 (q, J = 33.5 Hz).  MS (MALDI) m/z calcd for M+ 
C17H19BF2N2 300.16; found 299.91. 
 
 
N
B
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N
9h
O O
 
BODIPY 9h 
Messy reaction, obtained complex mixtures. 
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NH
CHO POCl3, CH2Cl2
25 oC, 12 h NH NH
+
P
O-
O Cl
Cl
108a  
NMR and MS study of the self-condensation reaction: 
Compound 8a (25 mg, 0.2 mmol) was dissolved in 1 mL of CDCl3 and then POCl3 (50 
μL) was added. The reaction was monitored by 1H, 13C and 31P over 10 min intervals at 
room temperature.  
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APPENDIX D 
EXPERIMENTAL DATA FOR CHAPTER IV 
 
Synthesis of 3,6-ditrifylxanthone 16 
O
O
HO OH
Tf2O, Pyr., CH2Cl2
0 to 25 oC, 24 h O
O
TfO OTf
16  
3,6-Dihydroxy-xanthen-9-one (6.85 g, 30 mmol) was dissolved in 150 mL CH2Cl2 and 
pyridine (24.5 mL, 300 mmol) was added slowly over 5 min at 0 oC.  The mixture was 
stirred at 0 oC for 10 min then Tf2O (15 mL, 90 mmol) was added dropwise over 10 min.  
The reaction mixture was warmed to room temperature slowly and stirred for 24 h.  The 
reaction was quenched with water and the organic layer was washed with water (1 x 30 
mL), 1N HCl (3 x 30 mL), brine (1 x 30 mL) and dried over Na2SO4.  The solvents were 
removed under reduced pressure and the residue was recrystallized from 
CH2Cl2/hexanes to afford the pure product as a white crystal (13.2 g, 89 %).  1H NMR 
(500 MHz, CDCl3) δ 8.43 (d, 2H, J = 8.9 Hz), 7.47 (d, 2H, J = 2.3 Hz), 7.33 (dd, 2H, J = 
8.9, 2.3 Hz); 13C NMR (125 MHz, CDCl3) δ 174.5, 156.6, 153.3, 129.6, 121.4, 118.7 (q, 
J = 319.1 Hz), 118.2, 111.4; 19F NMR (282 MHz, CDCl3) δ 104.2 (s). 
 
 
 
 
19F NMR (CDCl3)
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General procedure for the synthesis of 3,6-diamino-xanthen-9-one 
 
O
O
TfO OTf
R2NH, DMSO
90 oC, 12 h O
O
R2N NR2  
 
3,6-Di-triflate-xanthone 16 (1.0 eq.) was dissolved in DMSO (0.2 M) and the 
corresponding amine (10 eq.) was added.  The reaction mixture was heated to 90 oC and 
stirred for 12 h.  After cooling to room temperature, the reaction was quenched with 
water.  The precipitate was collected, washed with saturated Na2CO3 (aq.) and water to 
give the crude product, which was recrystallized from EtOAc/hexanes to afford the pure 
product. 
 
O
O
N N
17  
 
3,6-Di-piperidin-1-yl-xanthen-9-one (17) 
Yellow solid (3.0 g, 89 %).  1H NMR (300 MHz, d6-DMSO) δ 7.86 (d, 2H, J = 9.0 Hz), 
6.98 (dd, 2H, J = 9.0, 2.3 Hz), 6.74 (d, 2H, J = 2.3 Hz), 3.41 (br, 8H), 1.60 (br, 12H); 13C 
NMR (75 MHz, d6-DMSO) δ 173.0, 157.7, 154.8, 126.8, 111.7, 111.3, 98.8, 47.8, 24.8, 
23.9.  MS (ESI) m/z calcd for (M+H)+ C23H26N2O2 363.21; found 363.21. 
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18  
3,6-Di-morpholin-4-yl-xanthen-9-one (18) 
White solid (308 mg, 93 %).  1H NMR (500 MHz, CDCl3) δ 8.14 (d, 2H, J = 9.0 Hz), 
6.86 (dd, 2H, J = 9.0, 2.4 Hz), 6.67 (d, 2H, J = 2.4 Hz), 3.86 (t, 8H, J = 4.9 Hz), 3.33 (t, 
8H, J = 4.9 Hz); 13C NMR (125 MHz, CDCl3) δ 175.1, 158.0, 155.3, 127.7, 114.1, 
111.2, 100.0, 66.5, 47.5.  MS (ESI) m/z calcd for (M+H)+ C21H23N2O4 367.17; found 
367.17. 
 
 
 
 
 
 
1H NMR (CDCl3)
13C NMR (CDCl3)
 274
O
O
N N
BocN NBoc
19  
3,6-Bis-(4-Boc-piperazin-1-yl)-xanthen-9-one (19) 
White solid (680 mg, 60 %).  1H NMR (500 MHz, CDCl3) δ 8.13 (d, 2H, J = 9.0 Hz), 
6.86 (dd, 2H, J = 9.0, 2.3 Hz), 6.66 (d, 2H, J = 2.3 Hz), 3.59 (t, 8H, J = 5.2 Hz), 3.37 (t, 
8H, J = 5.2 Hz), 1.47 (s, 18H); 13C NMR (125 MHz, CDCl3) δ 175.0, 158.1, 155.0, 
154.6, 127.8, 114.0, 111.7, 100.3, 80.2, 47.3(2C), 28.4.  MS (ESI) m/z calcd for (M+H)+ 
C31H41N4O6 565.30; found 565.29. 
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3,6-Di-pyrrolidin-1-yl-xanthen-9-one (20) 
Yellow solid (90 mg, 18 %).  1H NMR (500 MHz, CDCl3) δ 8.08 (d, 2H, J = 8.9 Hz), 
6.50 (dd, 2H, J = 8.9, 2.2 Hz), 6.28 (d, 2H, J = 2.2 Hz), 3.34 (t, 8H, J = 6.6 Hz), 2.01 (t, 
8H, J = 6.6 Hz); 13C NMR (125 MHz, CDCl3) δ 175.0, 158.1, 151.6, 127.6, 111.5, 
109.1, 96.5, 47.6, 25.4.  MS (ESI) m/z calcd for (M+H)+ C21H23N2O2 335.18; found 
335.18. 
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Synthesis of 3-trifyl-6-piperidine-xanthone 
 
O
O
TfO OTf
piperidine
DMSO
25 oC, 1.5 h O
O
TfO N
 
 
3,6-Di-OTf-xanthone (492 mg, 1.0 mmol) was dissolved in 10 mL DMSO and 
piperidine (0.49 mL, 5.0 mmol) was added.  After stirring at 25 oC for 1.5 h, the solution 
was diluted with 30 mL CH2Cl2 and washed with water (3 x 30 mL).  The solvents were 
removed under reduced pressure and the residue was purified by flash chromatography 
(10 % to 20 % EtOAc/Hexanes) to afford the pure product (372 mg, 87 %) as a light 
yellow solid.  Rf = 0.66 (40 % EtOAc/hexanes).  1H NMR (300 MHz, d6-DMSO) δ 8.25 
(d, 1H, J = 8.8 Hz), 7.91 (d, 1H, J = 9.1 Hz), 7.79 (d, 1H, J = 2.4 Hz), 7.50 (dd, 1H, J = 
8.8, 2.4 Hz), 7.07 (dd, 1H, J = 9.1, 2.4Hz), 6.82 (d, 1H, J = 2.4 Hz), 3.50-3.47 (m, 4H), 
1.60 (br, 6H); 13C NMR (75 MHz, d6-DMSO) δ 172.7, 158.2, 155.9, 155.3, 151.9, 128.5, 
127.3, 121.8, 118.4 (q, J = 320.5 Hz), 117.1, 112.1, 111.3, 110.8, 98.2, 47.7, 24.9, 23.9.  
MS (ESI) m/z calcd for (M+H)+ C19H17F3NO5S 428.08; found 428.08. 
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Synthesis of unsymmetrical 3,6-diamino-xanthen-9-one (21) 
 
O
O
TfO N
morpholine
DMSO, 90 oC
12 h O
O
N N
O
21  
 
Morpholine (0.66 mL, 7.5 mmol) was added to the solution of 3-OTf-6-piperidine-
xanthone (321 mg, 0.75 mmol) in 10 mL DMSO. The reaction mixture was heated to 90 
oC and stirred for 12 h. After cooling to room temperature, the solution was diluted with 
30 mL CH2Cl2 and washed with saturated Na2CO3 (aq.) (1 x 30 mL), water (1 x 30 mL) 
and dried over Na2SO4. The solvents were removed under reduced pressure and the 
residue was purified by flash chromatography (40 % EtOAc/Hexanes) to afford the pure 
product 21 (261 mg, 96 %) as a light yellow solid.  Rf = 0.20 (40 % EtOAc/hexanes).  1H 
NMR (500 MHz, CDCl3) δ 8.13 (d, 1H, J = 9.1 Hz), 8.09 (d, 1H, J = 9.1 Hz), 6.86-6.83 
(m, 2H), 6.66 (d, 1H, J = 2.2 Hz), 6.64 (d, 1H, J = 2.2 Hz), 3.85 (t, 4H, J = 4.9 Hz), 
3.39-3.37 (m, 4H), 3.32 (t, 4H, J = 4.9 Hz), 1.66 (br, 6H); 13C NMR (125 MHz, CDCl3) 
δ 175.0, 158.3, 158.0, 155.4, 155.1, 127.7, 127.6, 114.3, 112.8, 111.5, 111.1, 100.1, 
99.4, 66.5, 48.6, 47.6, 25.3, 24.3. MS (ESI) m/z calcd for (M+H)+ C22H25N2O3 365.19; 
found 365.17. 
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Synthesis of rosamines 
O
O
R2N NR2 O
R'
R2N NR2
(i) R'M, THF
0 to 25 oC, 12 h
(ii) 2N HCl
Cl
M = Li or
MgX  
 
A Grignard reagent or Lithium reagent (1.0 mmol) was added dropwise over 1 min to 
the solution of 3,6-diamino-xanthen-9-one (0.2 mmol) in 5 mL THF at 0 oC. After 
stirring for 12 h at room temperature, the reaction mixture was quenched by 2 mL 2N 
HCl (aq.) and stirred for 10 min then diluted with 20 mL CH2Cl2. The organic layer was 
washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by flash chromatography (5% to 10% MeOH/CH2Cl2) to give 
the pure product. 
 
O NN
Me
11a
Cl
 
 
Rosamine 11a 
Purple solid (71 mg, 89 %).  Rf = 0.28 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 8.01 (d, 2H, J = 9.6 Hz), 7.22 (dd, 2H, J = 9.6, 2.5 Hz), 6.77 (d, 2H, J = 2.5 
Hz), 3.66 (br, 8H), 2.87 (s, 3H), 1.72 (br, 12H); 13C NMR (125 MHz, CDCl3) δ 157.6, 
156.4, 156.3, 130.1, 114.8, 114.0, 96.8, 48.8, 25.8, 24.1, 14.8; IR (thin film) 1643, 1597, 
1486, 1401, 1235, 1200 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C24H29N2O 361.2280; 
found 361.2287.   
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Rosamine 11b 
Purple solid (66 mg, 70 %).  Rf = 0.34 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.99 (d, 2H, J = 9.7 Hz), 7.23-7.15 (m, 7H), 6.87 (d, 2H, J = 2.5 Hz), 4.68 (s, 
2H), 3.70 (br, 8H), 1.74 (br, 12H); 13C NMR (125 MHz, CDCl3) δ 158.1, 156.5, 156.3, 
137.1, 130.3, 129.1, 128.1, 127.2, 115.2, 113.9, 97.2, 49.0, 33.3, 25.9, 24.1; IR (thin 
film) 1643, 1594, 1480, 1424, 1397, 1237, 1169 cm-1; HRMS (ESI) m/z calcd for (M-
Cl)+ C30H33N2O 437.2593; found 437.2595.   
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Rosamine 11c 
Green solid (92 mg, 100 %).  Rf = 0.35 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.46-7.45 (m, 3H), 7.21-7.18 (m, 4H), 6.97 (dd, 2H, J = 9.6, 2.5 Hz), 6.79 (d, 
2H, J = 2.5 Hz), 3.60 (br, 8H), 1.62 (br, 12H); 13C NMR (125 MHz, CDCl3) δ 157.9, 
156.4, 156.0, 131.7, 131.3, 130.0, 129.0, 128.6, 114.5, 113.2, 96.9, 48.8, 25.6, 23.7; IR 
(thin film) 1646, 1592, 1483, 1414, 1391, 1235, 1190 cm-1; HRMS (ESI) m/z calcd for 
(M-Cl)+ C29H31N2O 423.2436; found 423.2437.   
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Rosamine 11d 
 
Green solid (105 mg, 90 %) [Made from 4-Iodophenyl magnesium chloride, which was 
prepared from 1,4-di-iodobenzene with iPrMgCl].  Rf = 0.36 (10 % MeOH/CH2Cl2).  1H 
NMR (500 MHz, CDCl3) δ 7.95 (d, 2H, J = 8.4 Hz), 7.27 (d, 2H, J = 9.7 Hz), 7.12 (d, 
2H, J = 8.4 Hz), 7.07 (dd, 2H, J = 9.7, 2.5 Hz), 6.99 (d, 2H, J = 2.5 Hz), 3.73 (br, 8H), 
1.76 (br, 12H); 13C NMR (125 MHz, CDCl3) δ 158.0, 156.2, 155.0, 138.0, 131.5, 131.0, 
130.9, 114.9, 113.1, 97.3, 96.7, 49.1, 25.8, 24.0; IR (thin film) 1644, 1592, 1483, 1420, 
1391, 1235, 1193 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C29H30IN2O 549.1403; 
found 549.1399.  Anal. Calcd for C29H30ClIN2O: C, 59.55; H, 5.17; N, 4.79. Found: C, 
58.00; H, 5.17; N, 4.71.  The elemental analysis data are consistent with the presence of 
one molecule of water per molecules of product. 
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Rosamine 11e 
Green solid (98 mg, 100 %).  Rf = 0.33 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.38 (d, 2H, J = 9.6 Hz), 7.27 (d, 2H, J = 8.8 Hz), 7.08 (d, 2H, J = 8.8 Hz), 
7.04 (dd, 2H, J = 9.6, 2.5 Hz), 6.88 (d, 2H, J = 2.5 Hz), 3.87 (s, 3H), 3.67 (br, 8H), 1.71 
(br, 12H); 13C NMR (125 MHz, CDCl3) δ 161.3, 158.2, 157.0, 156.2, 132.1, 131.2, 
123.5, 114.6, 114.4, 113.5, 97.3, 55.5, 48.9, 25.8, 24.0; IR (thin film) 1644, 1592, 1480, 
1391, 1235, 1191 cm-1;  HRMS (ESI) m/z calcd for (M-Cl)+ C30H33N2O2 453.2542; 
found 453.2546.  
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Rosamine 11f 
Green solid (97 mg, 100 %).  Rf = 0.36 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.50-7.47 (m, 1H), 7.15 (d, 2H, J = 9.5 Hz), 7.08-7.04 (m, 3H), 6.99 (dd, 2H, J 
= 9.5, 2.5 Hz), 6.83 (d, 2H, J =2.5 Hz), 3.65-3.63 (m, 11H),  1.67 (br, 12H); 13C NMR 
(125 MHz, CDCl3) δ 158.3, 156.5, 156.4, 155.2, 132.0 (2C), 130.5, 120.8, 120.4, 114.6, 
114.1, 111.6, 97.2, 55.8, 49.1, 25.9, 24.1; IR (thin film) 1646, 1590, 1480, 1415, 1390, 
1233, 1187 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C30H33N2O2 453.2542; found 
453.2540.   
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Rosamine 11g 
Green solid (69 mg, 74 %).  Rf = 0.25 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.74 (dd, 1H, J = 4.5, 1.7 Hz), 7.63 (d, 2H, J = 9.5 Hz), 7.32-7.30 (m, 2H), 
7.12 (dd, 2H, J = 9.5, 2.5 Hz), 6.92 (d, 2H, J = 2.5 Hz), 3.72 (br, 8H), 1.74 (br, 12H); 13C 
NMR (125 MHz, CDCl3) δ 158.0, 156.3, 149.4, 132.1, 131.9, 130.9, 130.4, 128.3, 114.9, 
113.9, 97.4, 49.1, 25.9, 24.1; IR (thin film) 1642, 1592, 1482, 1415, 1391, 1237, 1192 
cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C27H29N2OS 429.2001; found 429.1995.   
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Rosamine 11h 
Green solid (100 mg, 96 %).  Rf = 0.32 (10 % MeOH/CH2Cl2).  [Made from 2,6-
dimethoxyphenyl lithium, which was prepared from 1,3-dimethoxybenzene with nBuLi]. 
1H NMR (500 MHz, CDCl3) δ 7.49 (t, 1H, J =  8.5 Hz), 7.18 (d, 2H, J = 9.5 Hz), 7.01 
(dd, 2H, J = 9.5, 2.5 Hz), 6.88 (d, 2H, J = 2.5 Hz), 6.71 (d, 2H, J = 8.5 Hz), 3.69-3.67 
(m, 8H), 3.62 (s, 6H), 1.73 (br, 12H); 13C NMR (125 MHz, CDCl3) δ 158.3, 157.4, 
156.5, 153.7, 132.3, 131.7, 114.6, 114.5, 108.4, 104.0, 97.0, 55.9, 48.9, 25.8, 24.1; 
HRMS (ESI) m/z calcd for (M-Cl)+ C31H35N2O3 483.2648; found 483.2656. 
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Rosamine 11i 
Green solid (95 mg, 99 %).  Rf = 0.32 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CD3OD) δ 7.58-7.44 (m, 3H), 7.26-7.16 (m, 7H), 3.79 (br, 8H), 2.07 (s, 3H), 1.82-1.76 
(m, 12H); 13C NMR (125 MHz, CD3OD) δ 159.9, 158.6, 158.2, 137.2, 133.2, 132.7, 
131.9, 131.3, 130.1, 127.3, 116.1, 115.0, 98.2, 50.0, 27.1, 25.3, 19.6; IR (thin film) 1646, 
1588, 1482, 1414, 1389, 1233, 1187 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ 
C30H33N2O 437.2593; found 437.2598.  
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Rosamine 12i 
Green solid (94 mg, 98 %).  Rf = 0.26 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CD3OD) δ 7.59-7.46 (m, 3H), 7.30-7.23 (m, 7H), 3.87-3.85 (m, 8H), 3.79-3.77 (m, 8H), 
2.06 (s, 3H); 13C NMR (125 MHz, CD3OD) δ 160.2, 159.9, 159.1, 137.2, 133.0, 132.8, 
131.9, 131.4, 130.1, 127.3, 116.3, 115.8, 98.6, 67.4, 48.5, 19.6; IR (thin film) 1646, 
1590, 1481, 1415, 1383, 1235, 1190 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ 
C28H29N2O3 441.2178; found 441.2184.  
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Rosamine 13i 
Green solid (47 mg, 53 %).  Rf = 0.28 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CD3OD) δ 7.58-7.45 (m, 3H), 7.26 (d, 1H, J = 7.5 Hz), 7.16 (d, 2H, J = 9.5 Hz), 6.95 
(dd, 2H, J = 9.5, 2.2 Hz), 6.84 (d, 2H, J = 2.2 Hz), 3.63 (br, 8H), 2.15 (br, 8H), 2.06 (s, 
3H); 13C NMR (125 MHz, CD3OD) δ 159.3, 159.1, 156.4, 137.2, 133.4, 132.4, 131.9, 
131.2, 130.1, 127.3, 116.6, 114.7, 97.9, 50.1, 26.3, 19.6; IR (thin film) 1648, 1596, 1413, 
1378, 1344, 1189 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C28H29N2O 409.2280; found 
409.2277.  
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Rosamine 22i 
Green solid (93 mg, 98 %).  Rf = 0.30 (10% MeOH/CH2Cl2).  1H NMR (500 MHz, 
CD3OD) δ 7.58-7.45 (m, 3H), 7.29-7.19 (m, 7H), 3.86-3.81 (m, 8H), 3.74-3.72 (m, 4H), 
2.07 (s, 3H), 1.85-1.75 (m, 6H); 13C NMR (125 MHz, CD3OD) δ 160.3, 159.5, 159.3, 
158.7, 158.6, 137.3, 133.1, 133.0, 132.5, 131.9, 131.3, 130.1, 127.3, 116.8, 115.7, 115.6, 
115.3, 98.7, 98.1, 67.4, 50.2, 48.4, 27.3, 25.3, 19.6; IR (thin film) 1646, 1590, 1480, 
1415, 1387, 1236, 1189 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C29H31N2O2 439.2386; 
found 439.2384.  
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Rosamine 14i 
Purple solid (121 mg, 90 %).  Rf = 0.37 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CD3OD) δ 7.60-7.46 (m, 3H), 7.29-7.22 (m, 7H), 3.84 (br, 8H), 3.67 (br, 8H), 2.06 (s, 
3H), 1.50 (s, 18H); 13C NMR (125 MHz, CD3OD) δ 160.2, 159.9, 158.8, 156.2, 137.2, 
133.0, 132.8, 131.9, 131.4, 130.1, 127.3, 116.4, 115.7, 98.6, 81.9, 47.8 (2C), 28.6, 19.6; 
IR (thin film) 1693, 1646, 1591, 1480, 1413, 1388, 1227, 1161 cm-1; HRMS (ESI) m/z 
calcd for (M-Cl)+ C38H47N4O5 639.3546; found 639.3553.  
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Rosamine 14d 
Green solid (107 mg, 68 %).  Rf = 0.31 (10% MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.94 (d, 2H, J = 8.3 Hz), 7.37 (d, 2H, J = 9.5 Hz), 7.19-7.15 (m, 4H), 7.11 (d, 
2H, J = 8.3 Hz), 3.80 (br, 8H), 3.67-3.65 (m, 8H), 1.45 (s, 18H); 13C NMR (125 MHz, 
CDCl3) δ 158.2, 156.9, 156.8, 154.4, 138.2, 131.8, 131.0, 130.8, 115.4, 114.0, 98.3, 
97.3, 80.7, 47.2(2C), 28.3; IR (thin film) 1694, 1644, 1592, 1479, 1415, 1387, 1226, 
1161 cm-1; HRMS (ESI) m/z calcd for (M-Cl)+ C37H44N4O5 751.2356; found 751.2342.  
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Rosamine 14h 
Purple solid (135 mg, 94 %).  Rf = 0.31 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.50 (t, 1H, J =  8.5 Hz), 7.29 (d, 2H, J = 9.4 Hz), 7.20 (dd, 2H, J = 9.4, 2.5 
Hz), 7.12 (d, 2H, J = 2.5 Hz), 6.71 (d, 2H, J = 8.5 Hz), 3.77 (br, 8H), 3.65-3.63 (m, 8H), 
3.62 (s, 6H), 1.44 (s, 18H); 13C NMR (125 MHz, CDCl3) δ 158.3, 157.4, 157.0, 155.4, 
154.5, 132.5, 132.0, 115.5, 115.0, 108.3, 104.1, 97.8, 80.6, 55.9, 47.0 (2C), 28.3.  HRMS 
(ESI) m/z calcd for (M-Cl)+ C39H49N4O7 685.3601; found 685.3598.  
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ON N
MeO OMe
BocN NBocCl
14h
(i) 1:1 TFA/CH2Cl2
25 oC, 1 h
(ii) NaHCO3
(iii) ion-exchange (Cl) ON N
MeO OMe
HN NHCl
15h  
 
A solution of rosamine 14h (50 mg, 0.07 mmol) in 5 mL TFA/CH2Cl2 (1:1) was stirred 
at room temperature for 1 h.  The solvents were removed with a N2 stream. The residue 
was dissolved in 15 mL iPrOH/CH2Cl2 (1:1) and washed with saturated NaHCO3 (aq.), 
water, and brine then dried over Na2SO4. The solvents were removed under reduced 
pressure.  The residue was dissolved in 10 mL MeOH and 0.5 g Amberlite IRA-400 (Cl) 
ion exchange resin was added. The mixture was stirred at room temperature for 1h and 
filtered through celite.  The solvent was removed under reduced pressure. The ion-
exchange process was repeated twice. The crude product was purified by reverse phase 
MPLC (H2O - 50 % CH3CN/H2O) to give the pure product 15h (30 mg, 83 %) as a 
purple solid. 1H NMR (500 MHz, CD3OD) δ 7.66 (t, 1H, J = 8.6 Hz), 7.44 (d, 2H, J = 
9.3 Hz), 7.37 (dd, 2H, J = 9.3, 2.2Hz), 7.35 (d, 2H, J = 2.2 Hz), 6.94 (d, 2H, J = 8.6 Hz), 
4.10 (t, 8H, J = 5.3 Hz), 3.67 (s, 6H), 3.46 (t, 8H, J = 5.3 Hz); 13C NMR (125 MHz, 
CD3OD) δ 160.0, 158.9, 158.6, 158.5, 134.3, 133.4, 117.1, 116.7, 109.4, 105.5, 99.3, 
56.6, 45.2, 44.1;  HRMS (ESI) m/z calcd for (M-Cl)+ C29H33N4O3 485.2553; found 
485.2557. 
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Synthesis of rosamine 23 
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(i) TFA/CH2Cl2 (1:1)
25 oC, 1 h
(ii)tBu-Bromoacetate
K2CO3, DMF
100 oC, 4 h
14d  
 
O NN
N NCl- CO2tBuButO2C
I
23  
 
Rosamine 14d (39 mg, 0.05 mmol) was dissolved in 2 mL TFA/CH2Cl2 (1:1). The 
solution was stirred at 25 oC for 1 h.  The solvents were removed with nitrogen stream. 
The residue was dissolved in 2 mL DMF then K2CO3 (69 mg, 0.5 mmol) and tert-butyl 
bromoacetate (74 μL, 0.5 mmol) were added. The mixture was heated to 100 oC and 
stirred for 4 h. After cooling to room temperature, the mixture was diluted with CH2Cl2 
and washed with water, dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by flash chromatography (10 % MeOH/CH2Cl2, Rf = 0.28) to 
afford the pure product 23 (31 mg, 76 %) as a purple solid. 1H NMR (500 MHz, CDCl3) 
δ 7.93 (d, 2H, J = 8.4 Hz), 7.29 (d, 2H, J = 9.4 Hz), 7.10-7.06 (m, 6H), 3.79 (br, 8H), 
3.20 (s, 4H), 2.79 (br, 8H), 1.43 (s, 18H); 13C NMR (125 MHz, CDCl3) δ 169.8, 158.2, 
156.8, 156.1, 138.2, 131.6, 131.1, 131.0, 115.0, 113.8, 98.1, 97.0, 82.1, 59.3, 52.2, 47.1, 
28.0; IR (thin film) 1735, 1688, 1644, 1594, 1482, 1391, 1236, 1195, 1152 cm-1; HRMS 
(ESI) m/z calcd for (M-Cl)+ C39H48IN4O5 779.2669; found 779.2671.   
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Synthesis of Rosamine 24 
 
O NN
OHHO
O NN
OMeMeO BBr3, CH2Cl2
-78 to 25 oC
12 h
Cl
11h 24
Cl
 
 
BBr3 (0.19 mL, 2.0 mmol) was added dropwise over 1 min to the solution of 11h (104 
mg, 0.2 mmol) in 4 mL CH2Cl2 at -78 oC.  The solution was warmed to room 
temperature slowly and stirred for 12 h. The reaction was quenched with ice-water and 
the mixture was extracted with 1:1 iPrOH/CH2Cl2 (3 x 15 mL). The organic layer was 
washed with water (1 x 20 mL), brine (1 x 20 mL), dried over Na2SO4 and concentrated 
under reduced pressure. The residue was dissolved in 10 mL MeOH and 0.5 g Amberlite 
IRA-400 (Cl) ion exchange resin was added. The mixture was stirred at room 
temperature for 1h and filtered through celite.  The solvent was removed under reduced 
pressure. The ion-exchange process was repeated twice. The crude product was purified 
by flash chromotagraphy (5 % to 10 % MeOH/CH2Cl2) to afford the product 24 (85 mg, 
87 %) as a green solid. Rf = 0.15 (10 % MeOH/CH2Cl2). 1H NMR (500 MHz, 
CDCl3/CD3OD 1:1) δ 7.44 (d, 2H, J =  9.6 Hz), 7.23 (t, 1H, J = 8.3 Hz), 7.07 (dd, 2H, J 
= 9.6, 2.6 Hz), 6.94 (d, 2H, J = 2.6 Hz), 6.54 (d, 2H, J = 8.3 Hz), 3.71-3.69 (m, 8H), 
1.79-1.74 (m, 12H); 13C NMR (125 MHz, CDCl3/CD3OD 1:1) δ 159.3, 157.4, 156.4, 
156.1, 133.2, 132.5, 115.5, 114.9, 107.4, 107.3, 97.5, 49.4, 26.5, 24.8; HRMS (ESI) m/z 
calcd for (M-Cl)+ C29H31N2O3 455.2335; found 455.2340. 
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Synthesis of Rosamine 25 
O NN
OHHO
O NN
OO COOHHOOC
(i) tBu-Br-Acetate
Cs2CO3, Bu4NI, DMF
25 oC, 12 h
(ii) TFA / CH2Cl2 (1:1)
25 oC, 1 h
24 25
Cl- Cl-
 
 
Rosamine 24 (137 mg, 0.28 mmol), Cs2CO3 (456 mg, 1.4 mmol), Bu4NI (310 mg, 0.84 
mmol) were dissolved in 5 mL DMF and tert-butyl bromoacetate (0.41 mL, 2.8 mmol) 
was added. The reaction mixture was stirred at 25 oC for 12 h then diluted with 30 mL 
CH2Cl2, washed with H2O (3 x 20 mL), brine (1 x 20 mL) and dried over Na2SO4. The 
solvents were removed under reduced pressure and the residue was passed through a 
short pad of silica gel eluting with 5 % MeOH/ CH2Cl2 to give the crude product which 
was used in the next step without further purification. The crude material was dissolved 
in 10 mL TFA/CH2Cl2 (1:1) and stirred at 25 oC for 1 h. The solvents were removed 
with a N2 stream. The residue was dissolved in 30 mL CH2Cl2, washed with H2O (2 x 20 
mL), brine (1 x 20 mL) and dried over Na2SO4.  The solvents were removed under 
reduced pressure. The residue was dissolved in 20 mL MeOH/ CH2Cl2 (1:1) and 1.0 g 
Amberlite IRA-400 (Cl) ion exchange resin was added. The mixture was stirred at room 
temperature for 1 h and filtered through celite.  The solvent was removed under reduced 
pressure. The ion-exchange process was repeated twice. The crude product was purified 
by reverse phase MPLC (H2O – 60 % CH3CN/H2O) to afford the pure product 25 as a 
green solid (128 mg, 75 %). 1H NMR (500 MHz, CDCl3/CD3OD 1:1) δ 7.49 (t, 1H, J = 
8.5 Hz), 7.46 (d, 2H, J = 9.6 Hz), 7.05 (dd, 2H, J = 9.6, 2.5Hz), 6.93 (d, 2H, J = 2.5 Hz), 
6.69 (d, 2H, J = 8.5 Hz), 4.52 (s, 4H), 3.72-3.70 (m, 8H), 1.80-1.75 (m, 12H); 13C NMR 
(125 MHz, CDCl3/CD3OD 1:1) δ 171.0, 159.2, 157.4, 156.9, 154.0, 133.3, 132.7, 115.4, 
114.9, 110.1, 105.7, 97.4, 65.5, 49.4, 26.5, 24.8. HRMS (ESI) m/z calcd for (M-Cl)+ 
C33H35N2O7 571.2444; found 571.2451. 
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Labeling of Avidin with Rosamine 25 
O NN
O O CO2HHO2C
Cl
(i) NHS, DIC
DMF, 25 oC
12 h
(ii) avidin
NaHCO3 buffer
(0.1 M, pH 8.3)
25 oC, 1 h
O NN
O OO2C avidin
H
N
O
25 25-avidin  
 
Rosamine 25 (6.1 mg, 0.01 mmol) and NHS (1.2 mg, 0.01 mmol) were dissolved in 0.3 
mL DMF, then DIC (1.5 μL, 0.01 mmol) was added.  The mixture was stirred at room 
temperature in the dark for overnight. 
 
The above solution (15 μL, 5 eq.) was added to the solution of avidin (6.6 mg, 1 eq.) in 1 
mL sodium bicarbonate buffer (0.1 M, pH 8.3). The mixture was stirred at room 
temperature in the dark for 1h.  The unreacted dye was removed by PD-10 (Sephadex G- 
25) column to afford the labeled avidin.  
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Synthesis of water-soluble rosamines 26 and 27 
O NN
HO OH
X-
conc'd H2SO4
0 to 25 oC, 12 h
24  
O NN
HO OH
Br SO3
O NN
HO OH
HO3S SO3
+
26 27  
Rosamine 24 (68 mg, 0.15 mmol) was dissolved in 2 mL concentrated H2SO4. The 
mixture was stirred at 0 oC for 4 h then warmed to 25 oC and stirred for 12 h. The 
reaction mixture was poured into ice-water and extracted with 1:1 iPrOH/CH2Cl2. The 
organic layer was evaporated to dryness under reduced pressure and the residue was 
purified by flash chromatography (5 to 15 % MeOH/CH2Cl2) to afford product 26 (32 
mg, 35 %) as a purple solid and 27 (39 mg, 42 %) as a green solid. 
26: 1H NMR (300 MHz, 1:1 CD3OD/CDCl3) δ 8.34 (s, 1H), 7.42 (d, 2H, J = 9.6 Hz), 
7.09 (dd, 2H, J = 9.6, 2.4 Hz), 6.93 (d, 2H, J = 2.4 Hz), 3.72-3.69 (m, 8H), 1.76 (br, 
12H); 13C NMR (125 MHz, 1:1 CD3OD/CDCl3) δ 159.1, 157.3, 154.8, 152.9, 132.7, 
130.2, 121.8, 115.3, 115.2, 107.6, 97.7, 49.6, 26.5, 24.7; MS (ESI) m/z calcd for (M+H)+ 
C29H31N2O9S2 615.15; found 615.15. 
 
27: 1H NMR (500 MHz, 1:1 CD3OD/CDCl3) δ 8.05 (s, 1H), 7.38 (d, 2H, J = 9.6 Hz), 
7.07 (dd, 2H, J = 9.6, 2.5 Hz), 6.92 (d, 2H, J = 2.5 Hz), 3.72-3.70 (m, 8H), 1.80-1.75 (m, 
12H); 13C NMR (125 MHz, 1:1 CD3OD/CDCl3) δ 159.2, 157.3, 154.5, 153.2, 152.3, 
133.7, 132.6, 123.3, 115.1 (2 peaks: 115.13, 115.10), 109.1, 101.2, 97.4, 49.4, 26.4, 
24.7; MS (ESI) m/z calcd for (M-H)- C29H28BrN2O6S 611.09; found 611.02. 
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ON N
HN NHCl-
28  
 
1H NMR (500 MHz, CD3OD) δ 7.58-7.55 (m, 1H), 7.52-7.50 (m, 1H), 7.47-7.44 (m, 
1H), 7.27-7.25 (m, 3H), 7.22-7.20 (m, 4H), 3.76 (t, 8H, J = 4.9 Hz), 2.98 (t, 8H, J = 4.9 
Hz), 2.05 (s, 3H); 13C NMR (125 MHz, CD3OD) δ 159.9, 159.5, 158.7, 137.2, 133.0, 
132.7, 131.9, 131.4, 130.1, 127.3, 116.3, 115.5, 98.5, 46.4 (2C), 19.7; HRMS (ESI) m/z 
calcd for (M-Cl)+ C28H31N4O 439.2498; found 439.2500.   
 
 
 
 
1H NMR (CD3OD)
13C NMR (CD3OD)
H2O
 310
0
0.2
0.4
0.6
0.8
1
1.2
450 500 550 600 650
Wavelength (nm)
No
rm
al
iz
ed
 In
te
ns
ity
 Absorption
 Excitation
 
Figure D1. Absorption (10-6 M) and excitation (10-7 M, emission detected at 582 nm) spectra for rosamine 
11i in CH2Cl2. 
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Figure D2. Fluorescence spectra of 11i (10-7 M) at different excitation wavelengths in CH2Cl2. 
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Figure D3. Fluorescence intensity (ex. 562 nm, em. 582nm) of 11i at 1.4 x 10-7 M in a CH2Cl2/MeOH mixed solvent 
system. 
 
 
 
Biological activity studies: 
 
Materials.  ER-Tracker Blue-White DPX, LysoTracker Blue DND-22, rhodamine 123 
(Rh123), Sytox Green were purchased from Molecular Probes, Invitrogen (Oregon, 
USA).  Annexin V-PE Apoptosis Detection Kit 1 BD Biosciences (CA, USA).  Cell 
culture reagents were purchased from Gibco, Invitrogen (Auckland, NZ).  RNase A, 
propidium iodide and MTT were purchased from Sigma (St Loist, USA). 
 
Cell  cultures.  HSC2 oral cavity human squamous carcinoma cells were obtained from 
Health Science Research Resources Bank (Japan).  HK1 cell-line is a gift from the 
University of Hong Kong.  Both cell-lines were grown in MEM medium supplemented 
with 10% FBS.  MCF-7 breast carcinoma and HCT-116 colon carcinoma were obtained 
from American Tissue Culture Collection (Virginia, USA) and maintained in RPMI 
1640 medium supplemented with 10% FBS.  OKF6, an immortalized human oral 
keratinocyte cell-line and NP69, an immortalized human nasopharyngeal epithelial cell-
 312
line were obtained from BWH Cell Culture and Microscopy Core at Harvard Institutes 
of Medicine and the University of Hong Kong respectively, and were maintained in 
keratinocyte serum-free medium supplemented with epidermal growth factor, bovine 
pituitary extract and a final Ca2+ concentration of 0.3 mM. 
 
In vitro proliferation assay.  Approximately 3 000 - 5 000 cells/well exponentially 
growing cells were seeded into 96-well plate and allowed to adhere overnight.  Cells 
were treated with each compound at concentrations ranging from 0.01-10 µM.  At the 
end of incubation period, 15 µl of MTT solution (5.0 mg/ml in PBS) was added and 
incubated for an additional 4 h.  Medium and excessive MTT were aspirated and 
formazan formed was solubilized with 100 µl of DMSO.  Absorbance, as a measurement 
of viable cell number was read at 570 nm with ThermoLabsystems OpsysMR microplate 
spectrometer.  At least three independent experiments were performed and results are 
presented as an average. 
 
Cellular localization.  HSC2 cells grown on round glass coverslips in 12-well plate 
were co-incubated with 100 nM of compound 11 together with organelle-specific 
fluorescence probes.  The endoplasmic reticulum was labeled with 100 nM of ER-
Tracker Blue-White DPX, the lysosomes were stained with 500 nM of LysoTracker Blue 
DND-22, and the mitochrondria was tracked with 100 nM of Rh123 respectively for 15-
30 min of incubation at room temperature.  After incubation, cells were gently rinsed in 
PBS to remove free dyes, and the stained cells were observed using Olympus DSU 
spinning disk confocal microscope configured with a PlanApo ×63 oil objective and 
iXon EM + (Andor Technology) digital camera.  Fluorescent images of X-Y sections at 
0.2 μm were collected sequentially using Olympus CellR software.  Organelle-specific 
fluorescence probes were respectively excited at 365 nm to illuminate ER-tracker and 
LysoTracker, at 494 nm for Rh123 and at 575 nm for compound 11.  
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AnnexinV-FITC apoptosis analysis.  HSC2 cells grown in 60-mm dishes at 50% 
confluency were treated with 0.5 μM of compound 11.  At various treatment intervals, 
floating cells in the medium were pooled together with the adherent cells after 
trypsinization and were washed twice with cold PBS.  The cells were resuspended with 
1X binding buffer at 1 x 106 cells/ml.  A 100μl of cell suspension was transferred to a 5 
ml tube followed by 5 μl of AnnexinV-FITC and 5 μl of propidium iodide (200 μg/ml in 
PBS).  The cells were gently mixed and incubated for 15 min at RT in the dark before 
analysed on a FACSCalibur flow cytometer with 488 nm argon laser.  The fluorescence 
data of 10 000 cells were collected with the FL1 detector with 530/30 band pass filter to 
collect Annexin-FITC fluorescence, and the FL3 detector with a 630 nm long pass filter 
to collect propidium iodide fluorescence.   
 
Cell cycle analysis.  HSC2 cells were treated and collected as above.  Cells were then 
fixed in 70% ice-cold ethanol (v/v in PBS) overnight at 4 ºC.  Following fixation, the 
cells were washed twice in cold PBS.  The pellet was then resuspended in PBS solution 
containing 20 μg/ml RNase A and 1 μM SYTOX Green for 30 min.  The cells were 
analysed on a FACSCalibur flow cytometer with 488 nm argon laser.  The DNA-
SYTOX Green fluorescence of 10 000 cells were collected with the FL1 detector with 
530/30 band pass filter. 
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APPENDIX E 
EXPERIMENTAL DATA FOR CHAPTER V 
 
Compound 29 
O
O
N N
MeO2C CO2Me
29  
 
Synthesized according to the procedure described in Appendix D. Light yellow solid 
(500 mg, 51 %).  1H NMR (500 MHz, CDCl3) δ 8.09 (d, 2H, J = 8.9 Hz), 6.85 (dd, 2H, J 
= 8.9, 2.3 Hz), 6.65 (d, 2H, J = 2.3 Hz), 3.87-3.83 (m, 4H), 3.69 (s, 6H), 3.03-2.98 (m, 
4H), 2.58-2.52 (m, 2H), 2.04-2.00 (m, 4H), 1.87-1.79 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ 175.0, 174.8, 158.1, 154.9, 127.7, 113.5, 111.6, 100.1, 51.8, 47.2, 40.7, 27.5.  
MS (ESI) m/z calcd for (M+H)+ C27H31N2O6 479.22; found 479.23. 
 
 
 
1H NMR (CDCl3)
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Syntheses of Pyronins 30 
O
O
R2N NR2
O
Nu
R2N NR2
(i) Tf2O, CH2Cl2
25 oC, 10 min
(ii) NuH, 30 min
TfO
30  
 
Tf2O (1.0 mmol) was added dropwise to a solution of 3,6-diamino-xanthen-9-one (0.2 
mmol) in 2 mL CH2Cl2 at 25 oC over 1 min.  The reaction mixture was stirred for 10 min 
then the corresponding nucleophile (NuH) was added dropwise over 1 min.  The mixture 
was stirred for 30 min at 25 oC.  (If the reaction was incomplete, another portion of Tf2O 
and nucleophile was added).  The solvents were removed under reduced pressure and the 
residue was purified by flash chromatography (2 % to 10 % MeOH/CH2Cl2) to afford 
the pure product 30. 
13C NMR (CDCl3)
O
O
N N
MeO2C CO2Me
29
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Pyronin 30a 
O
N
N N
TfO
30a  
Red solid (94 mg, 81 %).  Rf = 0.38 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.92 (d, 2H, J = 9.7 Hz), 7.00 (dd, 2H, J = 9.7, 2.7 Hz), 6.65 (d, 2H, J = 2.7 
Hz), 4.05 (br, 4H), 3.56-3.54 (m, 8H), 1.91 (br, 6H), 1.70 (br, 12H); 13C NMR (125 
MHz, CDCl3) δ 160.6, 158.2, 155.1, 129.8, 120.9 (q, J = 322.4 Hz), 112.5, 107.2, 97.8, 
57.0, 48.2, 27.0, 25.4, 24.2, 23.7; 19F NMR (282 MHz, CDCl3) δ 99.2 (s).  MS (ESI) m/z 
calcd for (M-OTf)+ C28H36N3O 430.29; found 430.28. 
 
 
 
19F NMR (CDCl3)
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O
N
N N
TfO
1H NMR (CDCl3)
13C NMR (CDCl3)
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Pyronin 30b 
O
N
N N
TfO
30b  
Red solid (69 mg, 61 %).  Rf = 0.44 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.80 (d, 2H, J = 9.6 Hz), 6.99 (dd, 2H, J = 9.6, 2.7 Hz), 6.67 (d, 2H, J = 2.7 
Hz), 4.04 (q, 4H, J = 7.0 Hz), 3.55-3.53 (m, 8H), 1.70 (br, 12H), 1.40 (t, 6H, J = 7.0 Hz); 
13C NMR (125 MHz, CDCl3) δ 161.7, 158.1, 155.0, 129.6, 120.9 (q, J = 320.1 Hz), 
112.3, 107.8, 97.8, 50.6, 48.2, 25.4, 24.2, 14.1; 19F NMR (282 MHz, CDCl3) δ 99.2 (s).  
MS (ESI) m/z calcd for (M-OTf)+ C27H36N3O 418.29; found 418.28. 
 
 
19F NMR (CDCl3)
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13C NMR (CDCl3)
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Pyronin 30c 
O
HN
N N
TfO
30c  
 
Yellow solid (112 mg, 98 %) [racemic sec-BuNH2 was used as a nucleophile].  Rf = 0.36 
(10 % MeOH/CH2Cl2).  1H NMR (300 MHz, CDCl3) δ 8.42 (d, 1H, J = 9.0 Hz), 8.06 
(br, 2H), 6.91 (dd, 2H, J = 9.6, 2.4 Hz), 6.58 (d, 2H, J = 2.4 Hz), 4.27-4.13 (m, 1H), 3.43 
(br, 8H), 2.07-1.93 (m, 1H), 1.88-1.74 (m, 1H), 1.63 (br, 12H), 1.55 (d, 3H, J = 6.4 Hz), 
0.86 (t, 3H, J = 7.4 Hz); 13C NMR (125 MHz, CDCl3) δ 157.0, 155.0, 154.5, 127.6, 
120.6 (q, J = 320.3 Hz), 112.2, 102.6, 98.1, 56.9, 48.0, 29.7, 25.2, 24.1, 20.2, 10.9; 19F 
NMR (282 MHz, CDCl3) δ 99.1 (s).  MS (ESI) m/z calcd for (M-OTf)+ C27H36N3O 
418.29; found 418.28. 
 
 
 
 
 
 
19F NMR (CDCl3)
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Pyronin 30d 
O
HN
N N
TfO
CO2
tBu
30d  
 
Yellow solid (101 mg, 80 %).  Rf = 0.35 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 8.29 (br, 1H), 7.97 (br, 2H), 6.95 (dd, 2H, J = 9.5, 2.7 Hz), 6.61 (d, 2H, J = 2.7 
Hz), 4.87 (q, 1H, J = 7.0 Hz), 3.49-3.47 (m, 8H), 1.79 (d, 3H, J = 7.0 Hz), 1.66-1.64 (m, 
12H), 1.43 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 170.2, 157.1, 155.2, 153.8, 127.1, 
120.7 (q, J = 320.4 Hz), 112.6, 102.6, 97.9, 83.9, 56.1, 48.0, 27.7, 25.2, 24.1, 18.7; 19F 
NMR (282 MHz, CDCl3) δ 99.2 (s).  MS (ESI) m/z calcd for (M-OTf)+ C30H40N3O3 
490.31; found 490.30. 
 
 
19F NMR (CDCl3)
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Pyronin 30e 
O
S
N N
TfO
Ph
30e  
 
Green solid (28 mg, 23 %).  Rf = 0.29 (10 % MeOH/CH2Cl2).  [1.5 eq Tf2O and 3 eq 
BnSH were used in the reaction and stirred for 3h at 25oC].  1H NMR (500 MHz, CDCl3) 
δ 8.04 (d, 2H, J = 9.6 Hz), 7.16-7.15 (m, 3H), 7.08-7.03 (m, 4H), 6.82 (d, 2H, J = 2.6 
Hz), 4.20 (s, 2H), 3.70-3.68 (m, 8H), 1.75 (m, 12H); 13C NMR (125 MHz, CDCl3) δ 
157.1, 156.4, 155.6, 136.0, 131.4, 128.8, 128.7, 128.0, 120.9 (q, J = 320.3 Hz), 116.9, 
114.8, 97.2, 49.1, 43.2, 25.9, 24.1; 19F NMR  (282 MHz, CDCl3) δ 99.3 (s).  MS (ESI) 
m/z calcd for (M-OTf)+ C30H33N2OS 469.23; found 469.23. 
 
 
 
 
 
19F NMR (CDCl3)
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Pyronin 30f 
O
N
N N
MeO2C CO2Me
TfO
30f  
 
Red solid (120 mg, 86 %).  Rf = 0.36 (10 % MeOH/CH2Cl2).  1H NMR (500 MHz, 
CDCl3) δ 7.91 (d, 2H, J = 9.6 Hz), 7.02 (dd, 2H, J = 9.6, 2.7 Hz), 6.68 (d, 2H, J = 2.7 
Hz), 4.04 (br, 4H), 3.96 (dt, 4H, J = 13.7, 4.0 Hz), 3.65 (s, 6H), 3.23-3.17 (m, 4H), 2.67-
2.61 (m, 2H), 2.03 (dd, 4H, J = 14.0, 3.6 Hz), 1.89 (br, 6H), 1.81-1.74 (m, 4H); 13C 
NMR (125 MHz, CDCl3) δ 174.3, 160.6, 158.0, 154.8, 129.7, 120.8 (q, J = 320.6 Hz), 
112.6, 107.4, 98.2, 57.0, 51.9, 46.3, 40.2, 27.3, 26.9, 23.5; 19F NMR (282 MHz, CDCl3) 
δ 99.2 (s).  MS (ESI) m/z calcd for (M-OTf)+ C32H40N3O5 546.30; found 546.31. 
 
 
 
19F NMR (CDCl3)
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Figure E1. X-Ray Structure of Pyronin 30c 
Empirical formula  C28 H36 F3 N3 O4 S 
Formula weight  567.66 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.2520(19) Å α= 90°. 
 b = 14.376(2) Å β= 106.676(2)°. 
 c = 16.502(3) Å γ = 90°. 
Volume 2784.4(7) Å3 
Z 4 
Density (calculated) 1.354 Mg/m3 
Absorption coefficient 0.175 mm-1 
F(000) 1200 
Crystal size 0.50 x 0.43 x 0.40 mm3 
Theta range for data collection 1.84 to 25.00°. 
Index ranges -14<=h<=14, -17<=k<=17, -19<=l<=19 
Reflections collected 25786 
Independent reflections 4882 [R(int) = 0.0456] 
Completeness to theta = 25.00° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9332 and 0.9175 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4882 / 0 / 354 
Goodness-of-fit on F2 1.101 
Final R indices [I>2sigma(I)] R1 = 0.0864, wR2 = 0.2285 
R indices (all data) R1 = 0.1013, wR2 = 0.2543 
Largest diff. peak and hole 0.893 and -0.336 e.Å-3 
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Figure E2. pH Dependence of Photophysical Properties for 30a 
a.                                                                    b. 
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pH dependence of UV absorbance of 30a under: a acidic; b basic conditions (CH2Cl2, 
7.0 x 10-6 M). Fluorescence pH dependence of 30a under: c acidic; d basic conditions 
(CH2Cl2, 7.0 x 10-7 M). e Fluorescence intensity of 30a under alternating acidic (TFA) 
and basic (Et3N) conditions (CH2Cl2, 7.0 x 10-7 M). 
 
acidic basic acidic basic acidic
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Figure E3. pH Dependence of Photophysical Properties for 30e 
a.                                                                          b. 
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pH dependence of UV absorbance of 30e under: a acidic; b basic conditions (CH2Cl2, 
9.6 x 10-6 M). Fluorescence pH dependence of 30e under: c acidic; d basic conditions 
(CH2Cl2, 1.4 x 10-7 M). e UV absorbance of 30e under alternating acidic and basic 
conditions (CH2Cl2, 9.6 x 10-6 M) [absorbance decreased at λmax with addition of Et3N 
and won’t recover after addition of TFA]. f Fluorescence of 30e under alternating acidic 
and basic conditions (CH2Cl2, 1.4 x 10-7 M). [Completely lost fluorescence within 10 
min after addition of Et3N and did not recover after addition of TFA] 
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Figure E4. Photograph of 16 and 30 in CH2Cl2 Under UV Irradiation 
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APPENDIX F 
EXPERIMENTAL DATA FOR CHAPTER VI 
 
Synthesis of BODIPY donor 35 
I
O
O
CHO
3
N
H
+
(i) TFA, CH2Cl2, 1 h
(ii) chloranil, 0.5 h
(iii) Et3N, BF3OEt2
25 oC, 12 h  
 
I
N
B
F2
N
O
O
3
36 53 %
N3 SO3Na
TBTA, Cu, CuSO45H2O
THF/H2O, 50 oC, 12 h
 
 
 
I
N
B
F2
N
O
O
3
N
NN
SO3Na
35 95 %
N
N
N
Ph
N
3
"TBTA"
tris-(benzyltriazolylmethyl)amine
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I
CHO
OH
O
OTs
3
K2CO3, CH3CN
reflux, 12 h
I
CHO
O
O
3
 
A mixture of 2-hydroxy-4-iodobenzaldehyde (501 mg, 2.02 mmol) and K2CO3 (332 mg, 
2.4 mmol) in 20 mL CH3CN was stirred at 25 oC for 10 min then a solution of 
CH≡CCH2(OCH2CH2)3OTs (685 mg, 2.0 mmol) in 20 mL CH3CN was added. The 
reaction mixture was refluxed for 12 h then cooled to 25 oC and diluted with water. The 
mixture was extracted with EtOAc three times. The organic layer was washed with 
brine, dried over Na2SO4 and evaporated to dryness under reduced pressure. The residue 
was purified by flash chromatography (30 % EtOAc/hexanes) to afford the pure product 
(634 mg, 76 %) as light yellow oil. 1H NMR (300 MHz, CDCl3) δ 10.26 (s, 1H), 7.32-
7.30 (m, 1H), 7.24-7.21 (m, 2H), 4.10-4.07 (m, 2H), 4.04 (d, 2H, J = 2.4 Hz), 3.77-3.74 
(m, 2H), 3.59-3.50 (m, 8H), 2.42 (t, 1H, J = 2.4 Hz); 13C NMR (75 MHz, CDCl3) δ 
188.2, 160.2, 129.7, 128.5, 123.8, 121.9, 102.8, 79.2, 74.4, 70.2, 70.0, 69.8, 68.7, 68.4, 
68.1, 57.7. 
 
1H NMR (CDCl3)
13C NMR (CDCl3)
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(i) TFA, CH2Cl2
r.t., 1 h
(ii) chloranil
(iii) Et3N, BF3OEt2
ClCH2CH2Cl
reflux, 1 h
I
CHO
O
O
3
N
H
+
 
I
O
O
3
N
B
F2
N
36  
 
To a solution of the benzaldehyde derivative (634 mg, 1.52 mmol) and 2,4-
dimethylpyrrole (0.33 mL, 3.2 mmol) in 10 mL CH2Cl2 was added one drop of TFA. 
The solution was stirred at 25 oC for 4 h. Chloranil (411 mg, 1.67 mmol) was added and 
stirring was continued for 1 h. The mixture was passed through a short pad of basic 
alumina eluting with 40 % EtOAc/hexanes. The solvents were removed under reduced 
pressure. The residue was dissolved in 10 mL CH2Cl2 and Et3N (0.63 mL, 4.56 mmol) 
was added followed by BF3OEt2 (0.96 mL, 7.6 mmol) after 10 min. The solution was 
stirred at 25 oC for 12 h then washed with water and brine. The organic layer was dried 
over Na2SO4 and evaporated to dryness. The residue was purified by flash 
chromatography (30 % EtOAc/hexanes) to afford the pure product 36 (508 mg, 53 %) as 
an orange sticky solid.  1H NMR (300 MHz, CDCl3) δ 7.37 (dd, 1H, J = 7.8, 1.4 Hz), 
7.29 (d, 1H, J = 1.4 Hz), 6.80 (d, 1H, J = 7.8 Hz), 5.91 (s, 2H), 4.10 (d, 2H, J = 2.4 Hz), 
4.04-4.02 (m, 2H), 3.64-3.62 (m, 2H), 3.59-3.57 (m, 2H), 3.51-3.49 (m, 2H), 3.38-3.36 
(m, 2H), 3.34-3.32 (m, 2H), 2.46 (s, 6H), 2.37 (t, 1H, J = 2.4 Hz), 1.41 (s, 6H); 13C NMR 
(75 MHz, CDCl3) δ 156.0, 154.9, 142.2, 137.2, 130.9, 130.6 (2 peaks: 130.62, 130.60), 
123.4, 121.4, 120.8, 95.0, 79.4, 74.4, 70.7, 70.3, 69.9, 69.1, 68.8, 68.7, 58.0,14.3, 13.9; 
MS (MALDI) m/z calcd for (M+Na)+ C28H32BF2INaN2O4 659.14; found 659.18. 
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I
O
O
3
N
B
F2
N
N3 SO3Na
TBTA, Cu, CuSO45H2O
THF/H2O, 50 oC, 12 h
 
I
O
O
3
N
B
F2
N
N
NN
SO3Na
35  
 
BODIPY 36 (77 mg, 0.12 mmol), 3-azido-1-propanesulfonic acid, sodium salt (28 mg, 
0.15 mmol), Cu (8 mg, 0.12 mmol), CuSO45H2O (5 mg, 0.02 mmol) and TBTA ligand 
(3 mg, 0.006 mmol) were dissolved in 10 mL THF and 5 ml water. The mixture was 
stirred at 50 oC for 12 h then evaporated to dryness under reduced pressure. The residue 
was purified by flash chromatography (20 % MeOH/CH2Cl2) to afford the product 35 
(95 mg, 95 %) as an orange semi-solid. 1H NMR (500 MHz, CD3OD) δ 8.07 (s, 1H), 
7.53-7.52 (m, 1H), 7.51-7.49 (m, 1H), 6.90 (d, 1H, J = 7.8 Hz), 6.04 (s, 2H), 4.59-4.56 
(m, 4H), 4.14-4.13 (m, 2H), 3.69-3.67 (m, 2H), 3.61-3.59 (m, 2H), 3.53-3.51 (m, 2H), 
3.40-3.38 (m, 2H), 3.35-3.34 (m, 2H), 2.83-2.80 (m, 2H), 2.46 (s, 6H), 2.39-2.33 (m, 
2H), 1.50 (s, 6H); 13C NMR (125 MHz, CD3OD) δ 157.7, 156.4, 144.1, 139.4, 132.5, 
132.2, 132.1, 124.8, 123.2, 122.1, 96.4, 71.9, 71.5, 71.2, 70.8, 70.7, 70.2, 65.0, 50.1, 
27.2, 14.6, 14.4, several peaks account for more than one carbon; 19F NMR (282 MHz, 
CD3OD) δ 31.81-31.02 (m);  MS (ESI) m/z calcd for (M-Na)- C31H38BF2IN5O7S 800.16; 
found 800.16. 
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Synthesis of BODIPY acceptors 
(1) Syntheses of benzaldehyde derivatives 
 
I
OH
CHO
Br CO2Me
K2CO3, DMF
90 oC, 30 min
I
O
CHO
CO2Me
O
CO2Me
I
90 oC
12 h
44  
 
2-Hydroxy-4-iodobenzaldehyde (1.24 g, 5.0 mmol) and K2CO3 (1.38 g, 10.0 mmol) 
were dissolved in 25 mL DMF and stirred for 10 min then methyl bromoacetate (0.7 mL, 
7.5 mmol) was added. The mixture was stirred at 90 oC for 30 min then cooled to room 
temperature and diluted with EtOAc. The mixture was washed with H2O and brine. The 
organic layer was dried over Na2SO4 and evaporated to dryness. The residue was 
purified by flash chromatography (10 to 20 % EtOAc/Hexanes) to afford the product 44 
as white solid (1.41 g, 88 %).  1H NMR (300 MHz, CDCl3) δ 10.44 (s, 1H), 7.49 (d, 1H, 
J = 8.1 Hz), 7.43-7.40 (m, 1H), 7.19 (d, 1H, J = 1.4 Hz), 4.72 (s, 2H), 3.79 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 188.8, 168.0, 159.6, 131.4, 129.4, 124.8, 122.1, 102.8, 65.5, 
52.5. 
 
If the mixture was stirred at 90 oC for 12 h, the reaction gave a different product which 
was found to be a benzofuran derivative in 62 % yield.  1H NMR (300 MHz, CDCl3) δ 
7.91 (s, 1H), 7.57 (dd, 1H, J = 8.2, 1.4 Hz), 7.43 (d, 1H, J = 1.4 Hz), 7.38 (d, 1H, J = 8.2 
Hz), 3.94 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.5, 155.8, 145.5, 133.0, 126.4, 
124.0, 121.6, 113.6, 91.9, 52.5. 
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HO
O H
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Br CO2Me
Ag2O, KI, CH2Cl2
25 oC, 24 h
HO
O
6
CO2Me
 
 
TsCl, Et3N
Me3NHCl, CH3CN
25 oC, 24 h
TsO
O
6
CO2Me
I
OH
CHO
+
 
 
K2CO3, CH3CN
reflux, 12 h
I
O
CHO
O CO2Me
6
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(i) Hexaethylene glycol (8.9 g, 30 mmol) was dissolved in 60 mL dichloromethane and 
Ag2O (7.7 g, 33 mmol) was added in three portions over 10 min. The mixture was 
cooled to 0 oC and stirred for 10min. Bromo-methyl acetate (3.3 mL, 36 mmol) was 
added dropwise to the mixture over 5 min followed by KI (3.0 g, 18 mmol) in one 
portion. The mixture was stirred at 0 oC for 1 h then warmed to room temperature. After 
stirred for 24 h, the mixture was filtered through celite and concentrated under reduced 
pressure. The residue was purified by flash chromatograph (2 to 5 % MeOH/CH2Cl2) to 
afford the product as yellow oil (5.2 g, 49 %) which was used in the next step without 
further purification. 
 
(ii) A solution of HO(CH2CH2O)6CH2CO2Me (2.4 g, 6.8 mmol) and Me3NHCl (67 mg, 
0.7 mmol) in 30 mL acetonitrile was cooled to 0 oC and Et3N (1.9 mL, 13.6 mmol) was 
added then a solution of TsCl (1.7 g, 8.8 mmol) in 20 mL acetonitrile was added 
dropwise over 10 min. The mixture was stirred at 0 oC for 1 h then room temperature for 
24 h. The mixture was diluted with EtOAc, washed with water and brine. The organic 
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layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatograph (2 to 5 % MeOH/CH2Cl2) to afford the pure product as 
yellow oil (2.5 g, 73 %). 1H NMR (300 MHz, CDCl3) δ 7.49 (d, 2H, J = 8.2 Hz), 7.08 (d, 
2H, J = 8.2 Hz), 3.87-3.84 (m, 4H), 3.42-3.26 (m, 25 H), 2.15 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 169.9, 144.0, 132.1, 129.1, 127.0, 69.9, 69.7, 69.6 (2C: 69.64, 69.61), 
69.5, 68.6, 67.7, 67.5, 50.8, 20.7, several peaks account for more than one carbon. 
 
(iii) A solution of 2-hydroxy-4-iodobenzaldehyde (1.1 g, 4.3 mmol) and K2CO3 (774 
mg, 5.6 mmol) in 30 mL CH3CN was stirred at room temperature for 10 min then a 
solution of TsO(CH2CH2O)6CH2CO2Me  in 20 mL CH3CN was added dropwise over 10 
min. After refluxing for 12 h, the mixture was diluted with EtOAc, washed with water 
and brine. The organic layer was dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatograph (2 to 5 % MeOH/CH2Cl2) to 
afford the pure product as yellow oil (2.4 g, 92 %). 1H NMR (300 MHz, CDCl3) δ 10.38 
(s, 1H), 7.45 (d, 1H, J = 8.6 Hz), 7.37-7.34 (m, 2H), 4.19 (t, 2H, J = 4.6 Hz), 4.11 (s, 
2H), 3.86-3.83 (m, 2H), 3.69-3.59 (m, 23 H); 13C NMR (75 MHz, CDCl3) δ 189.0, 
170.8, 160.8, 130.4, 129.1, 124.3, 122.4, 103.1, 70.9, 70.8, 70.5, 70.4, 69.3, 68.5, 51.7, 
several peaks account for more than one carbon. MS (ESI) m/z calcd for (M+Li)+ 
C22H33ILiO10  591.13; found 591.13. 
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2-Hydroxy-5-iodobenzaldehyde (1.24 g, 5.0 mmol) and K2CO3 (1.38 g, 10.0 mmol) 
were dissolved in 25 mL DMF and stirred for 10 min then methyl bromoacetate (0.7 mL, 
7.5 mmol) was added. The mixture was stirred at 90 oC for 30 min then cooled to room 
temperature and diluted with EtOAc. The mixture was washed with H2O and brine. The 
organic layer was dried over Na2SO4 and evaporated to dryness. The residue was 
purified by flash chromatography (20 % EtOAc/Hexanes) to afford the product as white 
solid (1.40 g, 87 %).  1H NMR (300 MHz, CDCl3) δ 10.40 (s, 1H), 8.10 (d, 1H, J = 2.3 
Hz), 7.76 (dd, 1H, J = 8.8, 2.3 Hz), 6.63 (d, 1H, J = 8.8 Hz), 4.73 (s, 2H), 3.79 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 188.0, 168.2, 159.7, 143.9, 137.3, 127.0, 114.9, 84.5, 
65.5, 52.5. 
 
 
 
1H NMR (CDCl3)
13C NMR (CDCl3)
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(2) Syntheses of pyrrole fragments 38-40 
I
OH
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O
3
K2CO3, CH3CN
reflux, 12 h
I
O
O
3
(i) iPrMgCl, THF
0 oC, 1 h
(ii) B(OMe)3
25 oC, 12 h
(iii) 2M HCl(aq)  
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3
N
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Br+
Pd(PPh3)4
2M Na2CO3(aq)
PhCH3/MeOH
80 oC, 24 h  
 
O
O
N
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3
NaOMe
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25 oC, 24 h
O
O
N
H
3
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(i) A solution of 2-iodophenol (3.3 g, 15.0 mmol) and K2CO3 (2.7 g, 19.5 mmol) in 30 
mL CH3CN was stirred at room temperature for 10min then a solution of 
TsO(CH2CH2O)3CH3 (5.3 g, 16.5 mmol) in 20 mL CH3CN was added dropwise over 5 
min. After refluxing for 12 h, the mixture was diluted with EtOAc, washed with water 
and brine. The organic layer was dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatograph (20 to 40 % EtOAc/Hexanes) 
to afford the pure product as yellow oil (5.0 g, 91 %). 1H NMR (300 MHz, CDCl3) δ 
7.72 (dd, 1H, J = 7.8, 1.7 Hz), 7.27-7.21 (m, 1H), 6.79 (dd, 1H, J = 8.2, 1.3 Hz), 6.67 
(td, 1H, J = 7.8, 1.3 Hz), 4.14-4.11 (m, 2H), 3.90-3.87 (m, 2H), 3.80-3.77 (m, 2H), 3.67-
3.61 (m, 4H), 3.53-3.50 (m, 2H), 3.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 157.3, 
139.3, 129.3, 122.6, 112.2, 86.5, 71.8, 71.1, 70.6, 70.4, 69.4, 68.9, 58.9. 
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(ii) A solution of the previous product (366 mg, 1.0 mmol) in 5 mL THF was cooled to 0 
oC and iPrMgCl (2M in THF, 0.70 mL, 1.4 mmol) was added dropwise over 2 min. The 
solution was stirred at 0 oC for 1 h then B(OMe)3 (0.22 mL, 2 mmol) was added. After 
stirring at room temperature for 12 h, the reaction was quenched with 2M HCl at 0 oC 
and stirred for 20 min. The mixture was extracted with EtOAc. The organic layer was 
washed with water, brine and dried over Na2SO4 then concentrated under reduced 
pressure to give the product (212 mg, 75 %) as light yellow oil which was used in the 
next step without further purification. 
 
(iii) Na2CO3 (2M in water, 5.4 mL) was added to a solution of the pyrrole derivative (1.1 
g, 4.5 mmol), arylboronic acid (1.5 g, 5.4 mmol) and Pd(PPh3)4 (104 mg, 0.1 mmol) in 
20 mL PhCH3 and 4 mL MeOH. The mixture was degassed and filled with N2. After 
stirring at 80 oC for 24 h, the mixture was cooled to room temperature and extracted with 
EtOAc. The organic layer was washed with saturated Na2CO3(aq), water, brine and dried 
over Na2SO4 then concentrated under reduced pressure. The residue was purified on 
neutralized (washed with 5% Et3N/Hexanes) silica gel (40 % EtOAc/Hexanes) to afford 
the product 41b (1.7 g, 94 %) as yellow oil which was used in the next step without 
further purification. 1H NMR (300 MHz, CDCl3) δ 7.30-7.28 (m, 1H), 7.26-7.21 (m, 
2H), 6.95-6.80 (m, 2H), 6.18-6.15 (m, 1H), 6.08-6.06 (m, 1H), 4.01-3.98 (m, 2H), 3.69-
3.66 (m, 2H), 3.57-3.47 (m, 8H), 3.32 (s, 3H), 1.24 (s, 9H). 
 
(iv) A solution of 41b (1.8 g, 4.5 mmol) in 20 mL THF and 5 mL MeOH was cooled to 0 
oC and NaOMe (1.2 g, 22.3 mmol) was added in three portions over 15 min. The 
reaction mixture was stirred at room temperature for 24 h then quenched with water at 0 
oC. The mixture was extracted with EtOAc. The organic layer was washed with water, 
brine and dried over Na2SO4 then concentrated under reduced pressure. The residue was 
purified on neutralized (washed with 5% Et3N/Hexanes) silica gel (40 % 
EtOAc/Hexanes) to afford the product 38b (1.2 g, 87 %) as yellow oil. 1H NMR (300 
MHz, CDCl3) δ 10.49 (br, 1H), 7.70-7.67 (m, 1H), 7.14-7.09 (m, 1H), 7.03-6.98 (m, 
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1H), 6.94-6.88 (m, 2H), 6.67-6.65 (m, 1H), 6.32-6.29 (m, 1H), 4.17-4.14 (m, 2H), 3.84-
3.81 (m, 2H), 3.74-3.69 (m, 4H), 3.65-3.61 (m, 2H), 3.53-3.50 (m, 2H), 3.36 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 153.4, 129.1, 126.2, 126.0, 121.8, 121.5, 118.0, 113.3, 108.0, 
105.7, 71.4, 70.1 (2C: 70.14, 70.11), 69.9, 68.9, 67.1, 58.5.  
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(i) A solution of 2-iodophenol (3.3 g, 15.0 mmol) and K2CO3 (2.7 g, 19.5 mmol) in 30 
mL CH3CN was stirred at room temperature for 10min then a solution of 
TsO(CH2CH2O)3CH3 (5.3 g, 16.5 mmol) in 20 mL CH3CN was added dropwise over 5 
min. After refluxing for 12 h, the mixture was diluted with EtOAc, washed with water 
and brine. The organic layer was dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatograph (20 to 40 % EtOAc/Hexanes) 
to afford the pure product as yellow oil (4.5 g, 82 %). 1H NMR (300 MHz, CDCl3) δ 
7.49 (d, 2H, J = 9.0 Hz), 6.64 (d, 2H, J = 9.0 Hz), 4.05-4.02 (m, 2H), 3.81-3.77 (m, 2H), 
3.70-3.66 (m, 2H), 3.64-3.58 (m, 4H), 3.51-3.48 (m, 2H), 3.33 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 158.5, 138.0, 116.9, 82.8, 71.8, 70.7, 70.5, 70.4, 69.4, 67.3, 58.9. 
 
(ii) A solution of the previous product (1.83 g, 5 mmol) in 25 mL THF was cooled to 0 
oC and iPrMgCl (2M in THF, 3.5 mL, 7 mmol) was added dropwise over 5 min. The 
solution was stirred at 0 oC for 1 h then B(OMe)3 (1.2 mL, 10 mmol) was added. After 
stirring at room temperature for 12 h, the reaction was quenched with 2M HCl at 0 oC 
and stirred for 20 min. The mixture was extracted with EtOAc. The organic layer was 
washed with water, brine and dried over Na2SO4 then concentrated under reduced 
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pressure to give the product (915 mg, 64 %) as light yellow oil which was used in the 
next step without further purification. 
 
(iii) Na2CO3 (2M in water, 3.3 mL) was added to a solution of the pyrrole derivative 
(660 mg, 2.7 mmol), arylboronic acid (915 mg, 3.2 mmol) and Pd(PPh3)4 (62 mg, 0.05 
mmol) in 15 mL PhCH3 and 3 mL MeOH. The mixture was degassed and filled with N2. 
After stirring at 80 oC for 24 h, the mixture was cooled to room temperature and 
extracted with EtOAc. The organic layer was washed with saturated Na2CO3(aq), water, 
brine and dried over Na2SO4 then concentrated under reduced pressure. The residue was 
purified on neutralized (washed with 5% Et3N/Hexanes) silica gel (50 % 
EtOAc/Hexanes) to afford the product 41c (1.0 g, 94 %) as yellow oil. 1H NMR (300 
MHz, CDCl3) δ 7.33-7.31 (m, 1H), 7.25 (d, 2H, J = 9.0 Hz), 6.89 (d, 2H, J = 9.0 Hz), 
6.21-6.18 (m, 1H), 6.13-6.11 (m, 1H), 4.16-4.13 (m, 2H), 3.88-3.85 (m, 2H), 3.76-3.73 
(m, 2H), 3.70-3.65 (m, 4H), 3.57-3.54 (m, 2H), 3.38 (s, 3H), 1.37 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 157.9, 149.2, 134.6, 130.2, 126.8, 122.0, 113.8, 113.5, 110.3, 83.2, 77.8, 
70.7, 70.5, 70.4, 69.6, 67.2, 58.9, 27.5. 
 
(iv) A solution of 41c (1.48 g, 3.7 mmol) in 20 mL THF and 5 mL MeOH was cooled to 
0 oC and NaOMe (0.99 g, 18.3 mmol) was added in three portions over 15 min. The 
reaction mixture was stirred at room temperature for 24 h then quenched with water at 0 
oC. The mixture was extracted with EtOAc. The organic layer was washed with water, 
brine and dried over Na2SO4 then concentrated under reduced pressure. The residue was 
purified on neutralized (washed with 5% Et3N/Hexanes) silica gel (40 % 
EtOAc/Hexanes) to afford the product 38c (912 mg, 82 %) as yellow oil. 1H NMR (300 
MHz, CDCl3) δ 9.10 (br, 1H), 7.35 (d, 2H, J = 9.0 Hz), 6.78 (d, 2H, J = 9.0 Hz), 6.74-
6.72 (m, 1H), 6.40-6.38 (m, 1H), 6.24-6.21 (m, 1H), 3.98-3.95 (m, 2H), 3.75-3.71 (m, 
2H), 3.68-3.59 (m, 6H), 3.51-3.48 (m, 2H), 3.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
156.6, 131.4, 125.7, 124.6, 118.1, 114.4, 109.0, 104.1, 71.4, 70.2, 70.1, 70.0, 69.2, 66.8, 
58.4. 
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(i) 6-Hydroxy-1-tetralone (2.11 g, 13.0 mmol) and K2CO3 were dissolved in 30 mL 
CH3CN and stirred for 10 min then a solution hexa(ethelene glycol) monomethyl ether 
tosylate (6.17 g, 13.7 mmol) in 20 mL CH3CN was added. The mixture was refluxed for 
12 h and cooled to room temperature. The reaction mixture was diluted with EtOAc and 
washed with H2O and brine. The organic layer was dried over Na2SO4 and evaporated to 
dryness. The residue was purified by flash chromatography (2 to 5 % MeOH/CH2Cl2) to 
afford the product (4.84 g, 85 %) as yellow oil which was used in the next step without 
further purification. 
 
(ii) A solution of the previous product (4.77 g, 10.8 mmol), NH2OH⋅HCl (2.25 g, 32.4 
mmol) and Et3N (9.0 mL, 64.8 mmol) in 50 mL MeOH was refluxed for 12 h. The 
reaction mixture was diluted with EtOAc and washed with H2O and brine. The organic 
layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by 
flash chromatography (2 to 5 % MeOH/CH2Cl2) to afford the product (4.57 g, 93 %) as 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 9.18 (br, 1H), 7.75 (d, 1H, J = 8.8 Hz), 6.71 
(dd, 1H, J = 8.8, 2.7 Hz), 6.62 (d, 1H, J = 2.7 Hz), 4.10-4.07 (m, 2H), 3.82-3.79 (m, 2H), 
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3.69-3.58 (m, 18 H), 3.51-3.48 (m, 2H), 3.33 (s, 3H), 2.74 (t, 2H, J = 6.6 Hz), 2.66 (t, 
2H, J = 5.9 Hz), 1.85-1.76 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 159.3, 154.6, 141.2, 
125.5, 123.4, 113.5, 113.4, 71.8, 70.7, 70.5, 70.4 (2 peaks: 70.44, 70.36), 69.5, 67.2, 
58.9, 30.0, 23.6, 21.3. (Several peaks account for more than one carbon).  
 
(iii) Product from (ii) (3.1 g, 6.7 mmol) and LiOH (802 mg, 33.4 mmol) were dissolved 
in 50 mL DMSO and ethyne was bubbled in. After stirring at 140 oC for 10 h, the 
mixture was cooled to room temperature and diluted with EtOAc then washed with H2O 
and brine. The organic layer was dried over Na2SO4 and evaporated to dryness. The 
residue was purified by flash chromatography (2 to 5 % MeOH/CH2Cl2) to afford the 
product (1.31 g, 42 %) as yellow oil (some contamination from the starting material), 
which was used in the next step without further purification. 1H NMR (300 MHz, 
CDCl3) δ 9.13 (br, 1H), 7.07 (d, 1H, J = 8.3 Hz), 6.69 (d, 1H, J = 2.4 Hz), 6.61-6.58 (m, 
2H), 5.99-5.97 (m, 1H), 4.00-3.97 (m, 2H), 3.75-3.71 (m, 2H), 3.63-3.54 (m, 18H), 3.47-
3.44 (m, 2H), 3.29 (s, 3H), 2.82-2.77 (m, 2H), 2.66-2.62 (m, 2H). 
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42 73 % (3 steps)  
 
(1) A solution of 5-bromo-2-furaldehyde (1.75 g, 10 mmol) and ethyl azidoacetate (10.3 
g, 80 mmol) in 100 mL EtOH was cooled to 0 oC then sodium ethoxide (15 mL, 20 % in 
EtOH) was added dropwise over 5 min. The reaction mixture was stirred at 10 oC for 1 h 
then quenched with sat’d NH4Cl (aq) at -78 oC. The mixture was diluted with water and 
extracted with Et2O (3 times). The organic layer was washed with brine, dried over 
Na2SO4 and evaporated under reduced pressure. The residue was passed through a short 
pad of silica gel and eluted with 50 % CH2Cl2/hexanes. The product was used for the 
next step without further purification. 
 
(2) A solution of the above product in 30 mL PhCH3 was heated to reflux and stirred for 
20 min then cooled to 25 oC. Et3N (1.7 mL, 12 mmol) and DMAP (122 mg, 1 mmol) 
were added to the reaction mixture followed by a solution of Boc2O (2.62 g, 12 mmol) in 
20 mL CH2Cl2. The mixture was stirred at 25 oC for 12 h then washed with water and 
brine. The organic layer was dried over Na2SO4 and evaporated to dryness under 
reduced pressure. The residue was purified by flash chromatography (5 % Ethyl 
acetate/Hexanes) to afford the pure product 42 (2.6 g, 73 %) as a yellow oil. 1H NMR 
(300 MHz, CDCl3) δ 6.74 (d, 1H, J = 0.8 Hz), 6.55 (d, 1H, J = 0.8 Hz), 4.25 (q, 2H, J = 
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7.2 Hz), 1.54 (s, 9H), 1.28 (t, 3H, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ 160.4, 
147.4, 145.4, 131.0, 127.9, 125.8, 104.9, 103.9, 84.7, 60.8, 27.6, 14.0. 
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To a solution of pyrrole 42 (1.31 g, 3.7 mmol), arylboronic acid (1.26 g, 4.4 mmol) and 
Pd(PPh3)4 (85 mg, 0.07 mmol) in 20 mL PhCH3 and 4 mL MeOH was added Na2CO3 
(2M in water, 4.4 mL). The mixture was degassed and filled with N2. After stirring at 80 
oC for 24 h, the mixture was cooled to room temperature and extracted with EtOAc. The 
organic layer was washed with saturated Na2CO3 (aq), water, brine and dried over Na2SO4 
then concentrated under reduced pressure. The residue was purified by flash 
chromatography (40 % EtOAc/Hexanes) to afford the product 43a (1.33 g, 70 %) as a 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.77 (dd, 1H, J = 7.8, 1.7 Hz), 7.21 (d, 1H, J = 
0.9 Hz), 7.11-7.06 (m, 1H), 6.91-6.85 (m, 1H), 6.80-6.77 (m, 2H), 4.21 (q, 2H, J = 7.1 
Hz), 4.11-4.08 (m, 2H), 3.81-3.78 (m, 2H), 3.65-3.61 (m, 2H), 3.58-3.55 (m, 2H), 3.51-
3.48 (m, 2H), 3.37-3.34 (m, 2H), 3.20 (s, 3H), 1.54 (s, 9H), 1.25 (t, 3H, J = 7.1 Hz); 13C 
NMR (75 MHz, CDCl3) δ 160.3, 155.9, 154.2, 147.7, 143.9, 133.5, 128.4, 125.7, 125.6, 
120.5, 119.4, 111.5, 105.0, 101.2, 83.8, 71.4, 70.3, 70.2, 70.0, 69.1, 67.0, 60.3, 58.4, 
27.4, 13.9. MS (ESI) m/z calcd for (M+H)+ C27H36NO9 518.24; found 518.24. 
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A mixture of pyrrole 43a (211 mg, 0.41 mmol) and NaOH (163 mg, 4.1 mmol) in 3 mL 
ethylene glycol was heated to 150 oC in the microwave under N2 and stirred for 30 min. 
The reaction mixture was cooled to 25 oC and diluted with water then extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and evaporated to 
dryness under reduced pressure. The residue was purified on neutralized silica gel 
(washed with 5 % Et3N/Hexanes) eluted with 60 % EtOAc/Hexanes to afford the pure 
product 40a (103 mg, 73 %) as brown oil. 1H NMR (300 MHz, CDCl3) δ 8.68 (br, 1H), 
7.95 (dd, 1H, J = 7.8, 1.7 Hz), 7.34 (s, 1H), 7.16-7.10 (m, 1H), 7.04-6.99 (m, 1H), 6.91-
6.87 (m, 1H), 6.75-6.73 (m, 1H), 6.17-6.15 (m, 1H), 4.22-4.18 (m, 2H), 3.90-3.87 (m, 
2H), 3.75-3.64 (m, 6H), 3.57-3.54 (m, 2H), 3.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
153.8, 151.6, 147.3, 127.0, 126.7, 125.3, 121.7, 121.0, 120.4, 112.2, 100.1, 91.3, 71.7, 
70.5, 70.4, 70.2, 69.6, 67.3, 58.7. 
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To a solution of compound 42 (2.59 g, 7.23 mmol), arylboronic acid (3.07 g, 10.8 mmol) 
and Pd(PPh3)4 (162 mg, 0.14 mmol) in 40 mL PhCH3 and 8 mL MeOH was added 
Na2CO3 (2M in water, 10.8 mL). The mixture was degassed and filled with N2. After 
stirring at 80 oC for 24 h, the mixture was cooled to room temperature and extracted with 
EtOAc. The organic layer was washed with saturated Na2CO3 (aq), water, brine and dried 
over Na2SO4 then concentrated under reduced pressure. The residue was purified by 
flash chromatography (40 % EtOAc/Hexanes) to afford the product 43b (4.42 g, 96 %) 
as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.51 (d, 2H, J = 9.0 Hz), 6.82 (d, 2H, J = 
9.0 Hz), 6.78 (s, 1H), 6.66 (s, 1H), 4.22 (q, 2H, J = 7.0 Hz), 4.04-4.01 (m, 2H), 3.75-3.72 
(m, 2H), 3.63-3.60 (m, 2H), 3.58-3.52 (m, 4H), 3.44-3.41 (m, 2H), 3.25 (s, 3H), 1.54 (s, 
9H), 1.26 (t, 3H, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) δ 160.3, 159.7, 158.7, 147.8, 
144.5, 133.1, 125.2, 125.1, 123.3, 114.6, 105.4, 94.9, 84.1, 71.5, 70.4, 70.2 (2 peaks: 
70.24, 70.16), 69.3, 67.1, 60.4, 58.6, 27.5, 14.0. 
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A mixture of pyrrole (2.38 g, 4.6 mmol) and NaOH (1.84 g, 46 mmol) in 50 mL ethylene 
glycol was heated to 150 oC in the microwave under N2 and stirred for 30 min. The 
reaction mixture was cooled to 25 oC and diluted with water then extracted with EtOAc. 
The organic layer was washed with brine, dried over Na2SO4 and evaporated to dryness 
under reduced pressure. The residue was purified on neutralized silica gel (washed with 
5 % Et3N/Hexanes) eluted with 60 % EtOAc/Hexanes to afford the pure product (1.28 g, 
81 %) as a gray solid. 1H NMR (300 MHz, CDCl3) δ 8.36 (br, 1H), 7.49 (d, 2H, J = 8.8 
Hz), 6.80 (d, 2H, J = 8.8 Hz), 6.72-6.70 (m, 1H), 6.41 (s, 1H), 6.15-6.13 (m, 1H), 4.01-
3.98 (m, 2H), 3.79-3.76 (m, 2H), 3.74-3.63 (m, 6H), 3.55-3.52 (m, 2H), 3.35 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 157.5, 155.4, 147.8, 125.9, 125.3, 124.4, 120.0, 114.6, 
92.9, 91.5, 71.7, 70.6, 70.4, 70.3, 69.6, 67.1, 58.8. 
 369
 
 
 
 
 
 
O
H
N
O
O
3
1H NMR (CDCl3)
13C NMR (CDCl3)
 370
(3) Syntheses of BODIPYs 47 
I
O
CHO
CO2Me
+
(i) TFA, CH2Cl2
25 oC, 1 h
(ii) chloranil
(iii) Et3N, BF3OEt2
ClCH2CH2Cl
reflux, 1 h
N
H
OMe
44 38a  
 
N
B
F2
N
I
MeO OMe
O CO2Me
47a  
 
Compound 44 (320 mg, 1 mmol) and pyrrole 38a (346 mg, 2 mmol) were dissolved in 
10 mL CH2Cl2 and one drop of TFA was added. The solution was stirred at room 
temperature until TLC showed the complete consumption of the aldehyde (around 1 h). 
Chloranil (246 mg, 1 mmol) was added and stirring was continued for 30 min. The 
mixture was passed through a short pad of basic alumina eluting with CH2Cl2. The 
solvents were removed under reduced pressure. The residue was dissolved in 20 mL 1,2-
dichloroethane and Et3N (0.42 mL, 3 mmol) was added followed by BF3OEt2 (0.63 mL, 
5 mmol) after 10 min. The solution was refluxed for 1 h then cooled to room 
temperature. The reaction mixture was washed with water and brine. The organic layer 
was dried over Na2SO4 and evaporated to dryness. The residue was purified by flash 
chromatography (20 to 40 % EtOAc/Hexanes) to afford the product (480 mg, 69 %) as 
red solid.  1H NMR (500 MHz, CDCl3) δ 7.74-7.72 (m, 2H), 7.46 (dd, 1H, J = 7.9, 1.3 
Hz), 7.32-7.29 (m, 2H), 7.17 (d, 1H, J = 1.3 Hz), 7.12 (d, 1H, J = 7.9 Hz), 6.98-6.95 (m, 
2H), 6.89 (d, 2H, J = 8.3 Hz), 6.78 (d, 2H, J = 4.3 Hz), 6.53 (d, 2H, J = 4.3 Hz), 4.65 (s, 
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2H), 3.76 (s, 3H), 3.75 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 168.6, 157.5, 156.0, 
155.4, 138.2, 135.7, 133.4, 131.9 (t, J = 5.3 Hz), 130.6, 130.4, 129.1, 123.5, 122.2, 
121.9, 121.3, 120.2, 110.8, 95.7, 65.3, 55.7, 52.3; 19F NMR (282 MHz, CDCl3) δ 43.69 
(dq, 1F, J = 97.2, 30.8 Hz), 40.81 (dq, 1F, J = 97.2, 30.8 Hz); MS (ESI) m/z calcd for 
(M+H)+ C32H27BF2IN2O5  695.10; found 695.11. 
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Purple sticky solid (352 mg, 15 %), prepared from benzaldehyde 45 (1.22 g, 2.1 mmol) 
and pyrrole 38b (1.31 g, 4.3 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 7.80 (d, 2H, J = 7.8 Hz), 7.43-7.40 (m, 2H), 7.29-7.26 
(m, 2H), 7.08 (d, 1H, J = 7.8 Hz), 6.99-6.96 (m, 2H), 6.88 (d, 2H, J = 8.3 Hz), 6.68-6.65 
(m, 4H), 4.15-4.03 (m, 8H), 3.72-3.44 (m, 45H), 3.30 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ 170.8, 157.1, 156.7, 155.1, 138.3, 135.6, 133.0, 131.9 (t, J = 6.1 Hz), 130.5, 
129.6, 128.7, 123.2, 122.6, 122.1, 120.5, 112.3, 95.9, 71.8, 71.0, 70.8 (2 peaks: 70.83, 
70.82), 70.6, 70.5 (5 peaks: 70.55, 70.54, 70.52, 70.49, 70.46), 70.4 (2 peaks: 70.43, 
70.38), 70.3 (2 peaks: 70.30, 70.26), 69.4, 69.3, 69.1, 68.5, 68.1, 58.9, 51.7, several 
peaks account for more than one carbon; 19F NMR (282 MHz, CDCl3) δ 49.00-48.31 (m, 
1F), 38.57-37.91 (m, 1F); MS (MALDI) m/z calcd for (M+Na)+ C56H74BF2IN2NaO17  
1245.40; found 1245.34. 
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Blue sticky solid (915 mg, 64 %), prepared from benzaldehyde 45 (683 mg, 1.17 mmol) 
and pyrrole 38c (715 mg, 2.34 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 7.82 (d, 4H, J = 8.8 Hz), 7.40-7.37 (m, 2H), 7.01 (d, 1H, 
J = 7.8 Hz), 6.92 (d, 4H, J = 8.8 Hz), 6.67 (d, 2H, J = 4.4 Hz), 6.52 (d, 2H, J = 4.4 Hz), 
4.15-4.13 (m, 4H), 4.11 (s, 2H), 4.07-4.06 (m, 2H), 3.84-3.83 (m, 4H), 3.72-3.38 (m, 
41H), 3.34 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 170.8, 159.8, 158.0, 157.0, 137.6, 
136.4, 132.8, 130.9 (t, J = 4.2 Hz), 129.6, 129.5, 125.1, 123.1, 121.8, 120.2, 114.3, 95.9, 
71.8, 70.8, 70.7 (2 peaks: 70.73, 70.68), 70.5 (3 peaks: 70.51, 70.48, 70.45), 70.4 (5 
peaks: 70.43, 70.40, 70.39. 70.37, 70.35), 70.3, 70.2 (2 peaks: 70.24, 70.20), 69.5, 69.1, 
69.0, 68.4, 67.2, 58.9, 51.7, (several peaks account for more than one carbon); 19F NMR 
(282 MHz, CDCl3) δ 44.80 (dq, 1F, J = 94.8, 32.1 Hz), 43.30 (dq, 1F, J = 94.8, 32.1 
Hz); MS (MALDI) m/z calcd for M+ C56H74BF2IN2O17  1222.41; found 1222.36. 
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Red solid (345 mg, 50 %), prepared from benzaldehyde 46 (320 mg, 1.0 mmol) and 
pyrrole 38a (346 mg, 2.0 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 7.76-7.70 (m, 4H), 7.33-7.30 (m, 2H), 6.99-6.96 (m, 2H), 
6.90 (d, 2H, J = 8.3 Hz), 6.82 (d, 2H, J = 4.3 Hz), 6.64 (d, 1H, J = 8.5 Hz), 6.57 (d, 2H, J 
= 4.3 Hz), 4.64 (s, 2H), 3.75 (s, 6H), 3.73 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 169.0, 
157.5, 155.5, 140.2, 139.3, 137.3, 135.6, 131.8 (t, J = 5.0 Hz), 130.6, 129.1, 125.9, 
122.2, 121.8, 120.1, 113.9, 110.8, 83.0, 65.0, 55.7, 52.2, several peaks account for more 
than one carbon; 19F NMR (282 MHz, CDCl3) δ 43.98 (dq, 1F, J = 97.2, 30.6 Hz), 40.75 
(dq, 1F, J = 97.2, 30.6 Hz); MS (MALDI) m/z calcd for M+ C32H26BF2IN2O5  694.09; 
found 694.30. 
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Blue solid (604 mg, 88 %), prepared from benzaldehyde 44 (320 mg, 1.0 mmol) and 
pyrrole 39a (338 mg, 2.0 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 8.77 (d, 2H, J = 8.0 Hz), 7.45 (dd, 1H, J = 7.8, 1.5 Hz), 
7.44-7.40 (m, 2H), 7.31-7.28 (m, 2H), 7.24-7.23 (m, 2H), 7.17 (d, 1H, J = 1.5 Hz), 7.06 
(d, 1H, J = 7.8 Hz), 6.48 (s, 2H), 4.61 (s. 2H), 3.74 (s, 3H), 2.88 (t, 4H, J = 7.2 Hz),  
2.65 (t, 4H, J = 7.2 Hz); 13C NMR (125 MHz, CDCl3) δ 168.5, 156.1, 152.4, 140.5, 
136.3, 134.3, 133.4, 132.9, 130.5, 129.6, 128.3, 128.2 (2 peaks: 128.245, 128.172), 
127.5, 124.8, 124.0, 121.5, 95.3, 65.4, 52.3, 30.5, 22.3; 19F NMR (282 MHz, CDCl3) δ 
40.65-39.12 (m); MS (MALDI) m/z calcd for M+ C34H26BF2IN2O3  686.10; found 
686.02. 
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Green solid (330 mg, 80 %), prepared from benzaldehyde 44 (160 mg, 0.5 mmol) and 
pyrrole 39b (205 mg, 1.0 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 8.73 (d, 2H, J = 8.9 Hz), 7.43 (dd, 1H, J = 7.9, 1.3 Hz), 
7.17 (d, 1H, J = 1.3 Hz), 7.05 (d, 1H, J = 7.9 Hz), 6.95 (dd, 2H, J = 8.9, 2.7 Hz), 6.77 (d, 
2H, J = 2.7 Hz), 6.41 (s, 2H), 4.60 (s, 2H), 3.86 (s, 6H), 3.73 (s, 3H), 2.85 (t, 4H, J = 7.1 
Hz), 2.63 (t, 4H, J = 7.1 Hz); 13C NMR (125 MHz, CDCl3) δ 168.6, 160.5, 156.2, 151.7, 
142.8, 135.9, 133.5, 132.2, 131.9, 130.5, 130.0 (t, J = 10.9 Hz), 124.4, 124.2, 121.6 (2 
peaks: 121.61, 121.58), 114.3, 112.4, 95.0, 65.5, 55.3, 52.3, 30.9, 22.3; 19F NMR (282 
MHz, CDCl3) δ 40.11-39.42 (m, 1F), 39.19-38.50 (m, 1F); MS (MALDI) m/z calcd for 
M+ C36H30BF2IN2O5  746.13; found 746.03. 
 381
 
 
 
 
 
 
 
 
 
N
B
F2
N
I
O CO2Me
MeO OMe
1H NMR (CDCl3)
13C NMR (CDCl3)
19F NMR (CDCl3)
 382
N
B
F2
N
I
O
O O OO
O CO2Me
6 6
6
47g  
 
Green sticky solid (984 mg, 47 %), prepared from benzaldehyde 45 (800 mg, 1.4 mmol) 
and pyrrole 39c (1.3 g, 2.8 mmol) using similar conditions as described for 47a. 
 
1H NMR (500 MHz, CDCl3) δ 8.63 (d, 2H, J = 9.0 Hz), 7.33-7.30 (m, 2H), 6.95 (d, 1H, 
J = 7.8 Hz), 6.89 (dd, 2H, J = 9.0, 2.8 Hz), 6.74 (d, 2H, J = 2.8 Hz), 6.28 (s, 2H), 4.14-
4.12 (m, 4H), 4.08 (s, 2H), 4.02-4.00 (m, 2H), 3.82-3.80 (m, 4H), 3.67-3.34 (m, 65H), 
3.29 (s, 6H), 2.79-2.76 (m, 4H), 2.57-2.54 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 
170.6, 159.5, 157.0, 151.2, 142.4, 135.6, 132.7 (2 peaks: 132.74, 132.72), 131.5, 130.0 
(t, J = 10.6 Hz), 129.3, 123.8, 123.7, 121.7, 121.3, 114.7, 112.7, 95.1, 71.6, 70.7, 70.6 (2 
peak: 70.59, 70.56), 70.3 (4 peaks: 70.35, 70.32, 70.28, 70.26), 70.2 (2 peaks: 70.21, 
70.17), 70.1, 70.0 (2 peaks: 69.99, 69.95), 69.3, 69.1, 68.9, 68.3, 67.1, 58.8, 51.5, 30.6, 
22.1, (several peaks account for more than one carbon); 19F NMR (282 MHz, CDCl3) δ 
40.80-40.16 (m, 1F), 38.38-37.75 (m, 1F); MS (MALDI) m/z calcd for M+ 
C72H102BF2IN2O23  1538.60; found 1538.53. 
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Green sticky solid (391 mg, 75 %), prepared from benzaldehyde 45 (233 mg, 0.4 mmol) 
and pyrrole 40a (294 mg, 0.85 mmol) using similar conditions as described for 47a. 
 
1H NMR (300 MHz, CDCl3) δ 7.87 (dd, 2H, J = 7.8, 1.7 Hz), 7.41-7.38 (m, 2H), 7.33-
7.27 (m, 4H), 7.06 (d, 1H, J = 7.8 Hz), 7.02-6.95 (m, 4H), 6.07 (s, 2H), 4.31-4.28 (m, 
4H), 4.10 (s, 2H), 4.09-4.06 (m, 2H), 4.00-3.96 (m, 4H), 3.84-3.81 (m, 4H), 3.77-3.74 
(m, 4H), 3.68 (s, 3H), 3.66-3.32 (m, 30H), 3.30 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
170.8, 164.3, 157.1, 156.3, 152.4, 150.5, 139.9, 136.9, 133.1, 130.9, 129.6, 127.1, 123.0, 
121.9, 120.9, 119.0, 112.2, 101.9, 100.4, 95.7, 71.7, 70.9, 70.8, 70.7 (2 peaks: 70.72, 
70.68), 70.4, 70.3 (2 peaks: 70.32, 70.29), 70.2, 70.1, 69.4, 69.0, 68.4, 67.8, 58.8, 51.6, 
several peaks account for more than one carbon; 19F NMR (282 MHz, CDCl3) δ 29.09-
28.65 (m); MS (MALDI) m/z calcd for M+ C60H74BF2IN2O19 1302.40; found 1302.16. 
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Green sticky solid (1.18 g, 41 %), prepared from benzaldehyde 45 (1.3 g, 2.23 mmol) 
and pyrrole 40b (1.58 g, 4.57 mmol) using similar conditions as described for 47a. 
 
1H NMR (300 MHz, CDCl3) δ 7.67 (d, 4H, J = 8.8 Hz), 7.38-7.34 (m, 2H), 7.02 (d, 1H, 
J = 7.8 Hz), 6.91 (d, 4H, J = 8.8 Hz), 6.78 (s, 2H), 6.04 (s, 2H), 4.13-4.10 (m, 4H), 4.09 
(s, 2H), 4.05-4.02 (m, 2H), 3.83-3.79 (m, 4H), 3.70-3.36 (m, 41H), 3.31 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 170.7, 167.7, 160.4, 157.0, 153.1, 149.5, 139.3, 136.4, 133.0, 
129.5, 126.9, 122.9, 122.4, 121.8, 115.0, 102.1, 95.7, 93.8, 71.7, 70.7 (2 peaks: 70.72, 
70.65), 70.4 (2 peaks: 70.42, 70.35), 70.3, 70.2, 70.1 (2 peaks: 70.11, 70.08), 69.4, 69.0, 
68.9, 68.4, 67.4, 58.8, 51.6, several peaks account for more than one carbon;  19F NMR 
(282 MHz, CDCl3) δ 28.75-28.48 (m); MS (MALDI) m/z calcd for (M-F)+ 
C60H74BFIN2O19 1283.40, found 1283.30; calcd for M+ C60H74BF2IN2O19 1302.40, found 
1302.29; calcd for (M+Na)+ C60H74BF2INaN2O19 1325.39, found 1325.28. 
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(4) Syntheses of BODIPYs 48 
Typical procedures: 
N
B
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MeO OMe
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I
MeO OMe
O CO2Me
TMS
PdCl2(PPh3)2
CuI, Et3N
CH2Cl2, 25 oC
24 h
48a47a  
 
BODIPY 47a (208 mg, 0.3 mmol), trimethylsilylacetylene (0.4 mL, 3.0 mmol), 
PdCl2(PPh3)2 (11 mg, 0.02 mmol), CuI (3 mg, 0.02 mmol) were dissolved in 20 mL 
CH2Cl2 then Et3N (0.4 mL, 3.0 mmol) was added. After stirring at room temperature for 
24 h, the reaction mixture was evaporated to dryness under reduced pressure. The 
residue was purified by flash chromatography (20 to 30 % EtOAc/Hexanes) to afford the 
product 48a (184 mg, 92 %) as red solid.  1H NMR (500 MHz, CDCl3) δ 7.74-7.72 (m, 
2H), 7.34 (d, 1H, J = 7.8 Hz), 7.32-7.29 (m, 2H), 7.22 (dd, 1H, J = 7.8, 1.3 Hz), 6.98-
6.95 (m, 2H), 6.93 (d, 1H, J = 1.3 Hz), 6.89 (d, 2H, J = 8.3 Hz), 6.76 (d, 2H, J = 4.3 Hz), 
6.53 (d, 2H, J = 4.3 Hz), 4.67 (s, 2H), 3.75 (s, 9H), 0.28 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 168.9, 157.5, 155.3 (2 peaks: 155.33, 155.26), 138.7, 135.7, 132.2, 131.9 (t, J 
= 5.4 Hz), 130.5, 129.1, 125.6, 124.9, 124.2, 122.1, 122.0, 120.2, 114.9, 110.8, 104.0, 
96.2, 65.2, 55.7, 52.3, -0.1; MS (MALDI) m/z calcd for M+ C37H35BF2N2O5Si  664.24; 
found 664.31. 
 389
 
 
 
 
N
B
F2
N
MeO OMe
O CO2Me
TMS
1H NMR (CDCl3)
13C NMR (CDCl3)
 390
N
B
F2
N
O
O O
O CO2Me
O O
3 3
6
TMS
48b  
 
Purple semi-solid (271 mg, 86 %), prepared from 47b (322 mg, 0.26 mmol).  1H NMR 
(500 MHz, CDCl3) δ 7.80-7.78 (m, 2H), 7.30 (d, 1H, J = 7.7 Hz), 7.27-7.24 (m, 2H), 
7.17 (dd, 1H, J = 7.7, 1.5 Hz), 7.12 (d, 1H, J = 1.5 Hz), 6.97-6.94 (m, 2H), 6.88-6.86 (m, 
2H), 6.65-6.63 (m, 4H), 4.12-4.03 (m, 8H), 3.70-3.42 (m, 45 H), 3.28 (s, 6H), 0.26 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 170.7, 156.6, 156.3, 154.8, 138.6, 135.6, 131.8 (t, J 
= 5.6 Hz), 131.7,  130.4, 128.6, 125.5, 123.9 (2 peaks: 123.93, 123.88), 122.4, 122.0, 
120.4, 115.4, 112.2, 104.1, 95.8, 71.7, 70.9, 70.7, 70.5, 70.4 (4 peaks: 70.45, 70.44, 
70.38, 70.37), 70.3 (3 peaks: 70.34, 70.32, 70.28), 70.2, 70.1, 69.3, 69.0, 68.9, 68.4, 
68.0, 58.8, 51.6, -0.2, several peaks account for more than one carbon; 19F NMR (282 
MHz, CDCl3) δ 48.72 (dq, 1F, J = 96.9, 31.7 Hz), 38.18 (dq, 1F, J = 96.9, 31.7 Hz); MS 
(MALDI) m/z calcd for (M+Na)+ C61H83BF2N2NaO17Si  1215.54; found 1215.47. 
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Blue semi-solid (819 mg, quant.), prepared from 47c (840 mg, 0.69 mmol).  1H NMR 
(500 MHz, CDCl3) δ 7.79 (d, 4H, J = 9.0 Hz), 7.19 (d, 1H, J = 7.8 Hz), 7.11 (dd, 1H, J = 
7.8, 1.2 Hz), 7.07 (d, 1H, J = 1.2 Hz), 6.88 (d, 4H, J = 9.0 Hz), 6.61 (d, 2H, J = 4.3 Hz), 
6.48 (d, 2H, J = 4.3 Hz), 4.09-4.07 (m, 4H), 4.06 (s, 2H), 4.05-4.03 (m, 2H), 3.79-3.77 
(m, 4H), 3.67-3.43 (m, 35H), 3.40-3.37 (m, 4H), 3.34-3.32 (m, 2H), 3.29 (s, 6H), 0.21 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 170.5, 159.6, 157.6, 156.1, 137.9, 136.2, 131.4, 
130.7 (t, J = 4.2 Hz), 129.4, 125.3, 124.9, 123.8, 123.6, 119.9, 115.2, 114.0, 103.9, 95.6, 
71.6, 70.6, 70.5 (2 peaks: 70.50, 70.46), 70.3, 70.2 (4 peaks: 70.23, 70.20, 70.17, 70.16), 
70.1 (3 peaks: 70.14, 70.12, 70.07), 70.0, 69.9,  69.3, 68.8, 68.7, 68.2, 67.0, 58.7, 51.4, -
0.4, (several peaks account for more than one carbon); 19F NMR (282 MHz, CDCl3) δ 
45.12 (dq, 1F, J = 96.3, 31.7 Hz), 43.13 (dq, 1F, J = 96.3, 31.7 Hz); MS (MALDI) m/z 
calcd for (M-F)+ C61H83BFN2O17Si  1173.55; found 1173.55. 
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Red solid (194 mg, 83 %), prepared from 47d (245 mg, 0.35 mmol).  1H NMR (500 
MHz, CDCl3) δ 7.75-7.72 (m, 2H), 7.55-7.51 (m, 2H), 7.34-7.28 (m, 2H), 6.99-6.94 (m, 
2H), 6.91-6.87 (m, 2H), 6.79-6.76 (m, 3H), 6.54 (d, 2H, J = 4.3 Hz), 4.67 (s, 2H), 3.75 
(s, 6H), 3.73 (s, 3H), 0.23 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 168.8, 157.5, 155.6, 
155.4, 138.2, 135.8, 134.3, 131.9, 130.5, 129.2, 123.7, 122.1, 122.0, 120.2, 116.1, 111.6, 
110.9, 103.7, 94.2, 65.1, 55.7, 52.2, -0.1, (one carbon is ambiguous, some peak accounts 
for two carbons); 19F NMR (282 MHz, CDCl3) δ 43.88 (dq, 1F, J = 96.8, 30.6 Hz), 40.64 
(dq, 1F, J = 96.8, 30.6 Hz); MS (MALDI) m/z calcd for M+ C37H35BF2N2O5Si  664.24; 
found 664.12. 
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Blue solid (174 mg, 88 %), prepared from 47e (206 mg, 0.3 mmol).  1H NMR (500 
MHz, CDCl3) δ 8.78 (d, 2H, J = 8.0 Hz), 7.44-7.40 (m, 2H), 7.31-7.28 (m, 3H), 7.24-
7.20 (m, 3H), 6.94 (d, 1H, J = 1.3 Hz), 6.46 (s, 2H), 4.63 (s, 2H), 3.73 (s, 3H), 2.88 (t, 
4H, J = 7.2 Hz), 2.64 (t, 4H, J = 7.2 Hz), 0.27 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
168.8, 155.4, 152.3, 140.5, 136.4, 134.8, 132.8, 132.1, 129.6, 128.4, 128.3, 128.2, 127.5, 
125.4, 125.0, 124.9, 124.8, 115.1, 104.0, 96.1, 65.3, 52.3, 30.5, 22.4, -0.1;  19F NMR 
(282 MHz, CDCl3) δ 40.67-39.08 (m); MS (MALDI) m/z calcd for M+ 
C39H35BF2N2O3Si  656.25; found 656.16. 
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Blue solid (124 mg, 87 %), prepared from 47f (149 mg, 0.2 mmol).  1H NMR (500 MHz, 
CDCl3) δ 8.73 (d, 2H, J = 9.0 Hz), 7.27 (d, 1H, J = 7.6 Hz), 7.19 (dd, 1H, J = 7.6, 1.2 
Hz), 6.95 (dd, 2H, J = 9.0, 2.7 Hz), 6.93 (d, 1H, J = 1.2 Hz), 6.77 (d, 2H, J = 2.7 Hz), 
6.39 (s, 2H), 4.62 (s, 2H), 3.86 (s, 6H), 3.72 (s, 3H), 2.85 (t, 4H, J = 7.1 Hz), 2.63 (t, 4H, 
J = 7.1 Hz), 0.27 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 168.9, 160.5, 155.6, 151.6, 
142.7, 136.0, 132.8, 132.2, 131.8, 130.0 (t, J = 11.2 Hz), 125.2, 125.1, 124.2, 121.6, 
115.3, 114.3, 112.3, 104.1, 95.9, 65.4, 55.3, 52.2, 30.9, 22.4, -0.1, (one carbon is 
ambiguous, some peak accounts for two carbons); MS (MALDI) m/z calcd for M+ 
C41H39BF2N2O5Si 716.27; found 716.13. 
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Green sticky solid (566 mg, 80 %), prepared from 47f (724 mg, 0.47 mmol).  1H NMR 
(500 MHz, CDCl3) δ 8.64 (d, 2H, J = 9.0 Hz), 7.19 (d, 1H, J = 7.7 Hz), 7.11 (dd, 1H, J = 
7.7, 1.3 Hz), 7.06 (d, 1H, J = 1.3 Hz), 6.90 (dd, 2H, J = 9.0, 2.6 Hz), 6.76 (d, 2H, J = 2.6 
Hz), 6.27 (s, 2H), 4.16-4.14 (m, 4H), 4.09 (s, 2H), 4.05-4.03 (m, 2H), 3.84-3.84 (m, 4H), 
3.69-3.35 (m, 65H), 3.31 (s, 6H), 2.81-2.78 (m, 4H), 2.59-2.56 (m, 4H), 0.23 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 170.7, 159.6, 156.3, 151.2, 142.5, 135.8, 133.3, 131.5 (2 
peaks: 131.54, 131.52), 129.7 (t, J = 10.7 Hz), 124.9, 124.7, 123.9 (2 peaks: 123.92, 
123.88), 121.4, 115.4, 114.7, 112.7, 104.2, 95.4, 71.7, 70.8, 70.7, 70.6, 70.4 (3 peaks: 
70.42, 70.39, 70.35), 70.3 (3 peaks: 70.34, 70.28, 70.27), 70.2 (2 peaks: 70.24, 70.18), 
70.1, 70.0, 69.4, 68.9, 68.4, 67.2, 58.8, 51.6, 30.7, 22.1, -0.2, (several peaks account for 
more than one carbon); 19F NMR (282 MHz, CDCl3) δ 40.84-40.19 (m, 1F), 38.31-37.65 
(m, 1F); MS (MALDI) m/z calcd for M+ C77H111BF2N2O23Si  1508.74; found 1508.68. 
 401
 
 
 
 
 
 
 
N
B
F2
N
O
O O OO
O CO2Me
6 6
6
TMS
1H NMR (CDCl3)
13C NMR (CDCl3)
19F NMR (CDCl3)
 402
N
B
F2
N
O
O CO2Me
6
O O
O O
OO
3 3
TMS
48h  
 
Green semi-solid (443 mg, quant.), prepared from 47h (458 mg, 0.35 mmol).  1H NMR 
(300 MHz, CDCl3) δ 7.87 (dd, 2H, J = 7.9, 1.7 Hz), 7.32-7.26 (m, 5H), 7.17-7.11 (m, 
2H), 7.01-6.94 (m, 4H), 6.05 (s, 2H), 4.30-4.27 (m, 4H), 4.10-4.07 (m, 4H), 3.99-3.96 
(m, 4H), 3.83-3.80 (m, 4H), 3.76-3.73 (m, 4H), 3.67 (s, 3H), 3.65-3.31 (m, 30H), 3.29 (s, 
6H), 0.25 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.7, 164.2, 156.3, 156.2, 152.3, 
150.4, 140.0, 137.3, 131.9, 130.8, 127.1, 125.4, 124.0, 123.8, 120.9, 119.0, 115.5, 112.1, 
104.1, 101.9, 100.4, 95.8, 71.7, 70.9, 70.7 (3 peak: 70.74, 70.69, 70.65), 70.4, 70.3 (2 
peaks: 70.33, 70.28), 70.2, 70.1, 69.4, 68.9, 68.7, 68.4, 67.7, 58.8, 51.6, -0.2, (several 
peaks account for more than one carbon); 19F NMR (282 MHz, CDCl3) δ 29.01-28.63 
(m); MS (MALDI) m/z calcd for (M-F)+ C65H83BFN2O19Si 1253.54, found 1253.49; 
calcd for (M+Na)+ C65H83BF2NaN2O19Si 1295.53, found 1295.47. 
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Green semi-solid (1.08 g, 94 %), prepared from 47i (1.18 g, 0.91 mmol).  1H NMR (300 
MHz, CDCl3) δ 7.67 (d, 4H, J = 8.9 Hz), 7.26 (d, 1H, J = 7.7 Hz), 7.15-7.12 (m, 1H), 
7.09-7.08 (m, 1H), 6.92 (d, 4H, J = 8.9 Hz), 6.78 (s, 2H), 6.02 (s, 2H), 4.14-4.10 (m, 
4H), 4.09 (s, 2H), 4.08-4.05 (m, 2H), 3.83-3.79 (m, 4H), 3.70-3.27 (m, 47H), 0.24 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 170.7, 167.6, 160.4, 156.3, 153.1, 149.4, 139.4, 
136.9, 131.8, 126.9, 125.4, 124.0, 123.7, 122.5, 115.4, 115.0, 104.1, 102.1, 95.8, 93.8, 
71.7, 70.8, 70.7, 70.5, 70.4, 70.3, 70.2, 70.1 (2 peaks: 70.12, 70.07), 69.4, 68.9, 68.8, 
68.4, 67.4, 58.8, 51.5, -0.2, (several peaks account for more than one carbon); 19F NMR 
(282 MHz, CDCl3) δ 28.66-28.39 (m); MS (MALDI) m/z calcd for (M-F)+ 
C65H83BFN2O19Si 1253.54, found 1253.58; calcd for M+ C65H83BF2N2O19Si 1272.54, 
found 1272.58; calcd for (M+Na)+ C65H83BF2NaN2O19Si 1295.53, found 1295.54. 
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(5) Syntheses of BODIPYs 37 
Typical procedures: 
N
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K2CO3
MeOH/THF/H2O
25 oC, 24 h N
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MeO OMe
O CO2H
48a 37a  
 
BODIPY 48a (66 mg, 0.1 mmol) and K2CO3 (69 mg, 0.5 mmol) were dissolved in 5 mL 
MeOH + 5 mL THF + 1 mL H2O. After stirring at room temperature for 24 h, the 
reaction mixture was diluted with H2O, acidified with 2 M HCl and extracted with 
CH2Cl2. The organic layer was washed with H2O, brine and dried over Na2SO4 then 
evaporated to dryness. The residue was purified by flash chromatography (2 to 5 % 
MeOH/CH2Cl2) to afford the product 37a (49 mg, 85 %) as red solid.  1H NMR (500 
MHz, CDCl3) δ 7.69-7.68 (m, 2H), 7.35-7.34 (m, 1H), 7.30-7.26 (m, 2H), 7.23-7.21 (m, 
1H), 6.98 (s, 1H), 6.95-6.92 (m, 2H), 6.86-6.85 (m, 2H), 6.72 (br, 2H), 6.48 (br, 2H), 
4.59 (s, 2H), 3.69 (s, 6H), 3.13 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 172.1, 157.4, 
155.5, 155.1, 138.3, 135.6, 132.3, 131.8, 130.6, 129.1, 125.1, 124.7, 124.4, 122.3, 121.8, 
120.2, 115.4, 110.9, 82.6, 79.1, 65.1, 55.7; 19F NMR (282 MHz, CDCl3) δ 43.73 (dq, 1F, 
J = 97.6, 30.7 Hz), 40.83 (dq, 1F, J = 97.6, 30.7 Hz); MS (ESI) m/z calcd for (M-H)- 
C33H24BF2N2O5  577.17; found 577.21. 
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Purple semi-solid (191 mg, 76 %), prepared from 48b (271 mg, 0.23 mmol).  1H NMR 
(500 MHz, CDCl3) δ 7.79 (d, 2H, J = 7.6 Hz), 7.32 (d, 1H, J = 7.6 Hz), 7.28-7.24 (m, 
2H), 7.20-7.19 (m, 1H), 7.16 (br, 1H), 6.97-6.94 (m, 2H), 6.87 (d, 2H, J = 8.3 Hz), 6.66 
(br, 4H), 4.12-4.02 (m, 6H), 3.83 (s, 2H), 3.70-3.68 (m, 6H), 3.58-3.41 (m, 36H), 3.28 
(s, 6H), 3.21 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 174.9, 156.6, 156.4, 155.0, 138.5, 
135.6, 131.8, 130.5, 128.6, 124.6, 124.2, 124.1, 122.5, 122.0, 120.5, 115.7, 112.3, 82.8, 
78.7, 71.7, 70.7, 70.5 (2 peaks: 70.51, 70.46), 70.3, 70.0, 69.8, 69.7 (3 peaks: 69.74, 
69.71, 69.66), 69.6, 69.5, 69.3, 69.0, 68.9, 68.8, 68.0, 58.8, (several peaks account for 
more than one carbon); 19F NMR (282 MHz, CDCl3) δ 49.43 (dq, 1F, J = 97.6, 32.4 Hz), 
37.58 (dq, 1F, J = 97.6, 32.4 Hz); MS (ESI) m/z calcd for (M-H)- C57H72BF2N2O17  
1105.49; found 1105.45. 
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Blue semi-solid (512 mg, 67 %), prepared from 48c (815 mg, 0.69 mmol).  1H NMR 
(500 MHz, CDCl3) δ 7.82 (d, 4H, J = 9.0 Hz), 7.25 (d, 1H, J = 7.8 Hz), 7.18-7.16 (m, 
1H), 7.14-7.13 (m, 1H), 6.92 (d, 4H, J = 9.0 Hz), 6.66 (d, 2H, J = 4.3 Hz), 6.52 (d, 2H, J 
= 4.3 Hz), 4.14-4.12 (m, 4H), 4.09-4.07 (m, 2H), 4.00 (s, 2H), 3.84-3.82 (m, 4H), 3.72-
3.69 (m, 4H), 3.66-3.51 (m, 26H), 3.48-3.46 (m, 2H), 3.44-3.42 (m, 4H), 3.38-3.36 (m, 
2H), 3.34 (s, 6H), 3.19 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 173.4, 159.8, 157.9, 
156.3, 137.9, 136.4, 131.7, 130.9 (t, J = 4.2 Hz), 129.7, 125.0, 124.6, 124.2, 124.1, 
120.2, 115.7, 114.3, 82.8, 78.7, 71.8, 70.7, 70.6, 70.5, 70.4, 70.1, 69.9 (2 peaks: 69.93, 
69.88), 69.8 (2 peaks: 69.83, 69.80), 69.7, 69.6, 69.5, 69.3, 68.9 (2 peaks: 68.93, 68.85), 
67.2, 58.9, (several peaks account for more than one carbon); 19F NMR (282 MHz, 
CDCl3) δ 45.00 (dq, 1F, J = 94.9, 32.0 Hz), 43.19 (dq, 1F, J = 94.9, 32.0 Hz); MS (ESI) 
m/z calcd for (M-H)- C57H72BF2N2O17  1105.49; found 1105.50. 
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Red solid (83 mg, 95 %), prepared from 48d (100 mg, 0.15 mmol).  1H NMR (500 MHz, 
CDCl3) δ 7.68 (d, 2H, J = 7.3 Hz), 7.52-7.47 (m, 2H), 7.29-7.26 (m, 2H), 6.94-6.91 (m, 
2H), 6.85 (d, 2H, J = 8.4 Hz), 6.77-6.73 (m, 3H), 6.48 (br, 2H), 4.53 (s, 2H), 3.68 (s, 
6H), 3.02 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 173.1, 157.4, 155.6, 155.5, 138.0, 
135.7, 134.7, 131.8, 130.6, 129.2, 123.7, 122.3, 121.8, 120.2, 115.1, 112.1, 110.9, 82.3, 
77.4, 65.1, 55.7, (one carbon is ambiguous, some peak accounts for two carbons); 19F 
NMR (282 MHz, CDCl3) δ 43.97 (br, 1F), 40.56 (br, 1F); HRMS (ESI) m/z calcd for 
(M-H)- C33H24BF2N2O5  577.1746; found 577.1743. 
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Blue solid (36 mg, 80 %), prepared from 48e (52 mg, 0.08 mmol).  1H NMR (500 MHz, 
CDCl3) δ 8.77 (d, 2H, J = 8.1 Hz), 7.43-7.40 (m, 2H), 7.31-7.27 (m, 3H), 7.24-7.21 (m, 
3H), 6.99 (s, 1H), 6.43 (s, 2H), 4.60 (s, 2H), 3.15 (s, 1H), 2.84 (t, 4H, J = 7.0 Hz), 2.60 
(t, 4H, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3) δ 172.9, 155.2, 152.5, 140.5, 136.3, 
134.3, 133.0, 132.3, 129.7, 128.4, 128.3, 128.2, 127.5, 125.4, 125.2, 124.7, 124.4, 115.5, 
82.6, 78.9, 64.9, 30.5, 22.3;  19F NMR (282 MHz, CDCl3) δ 40.14-39.64 (m); MS (ESI) 
m/z calcd for (M-H)- C35H24BF2N2O3  569.18; found 569.17. 
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Blue solid (63 mg, quant.), prepared from 48f (72 mg, 0.1 mmol).  1H NMR (500 MHz, 
CDCl3) δ 8.72 (d, 2H, J = 8.9 Hz), 7.29-7.27 (m, 1H), 7.22-7.21 (m, 1H), 6.98-6.93 (m, 
3H), 6.75 (br, 2H), 6.36 (br, 2H), 4.56 (s, 2H), 3.83 (s, 6H), 3.14 (s, 1H), 2.82-2.79 (m, 
4H), 2.59-2.56 (m, 4H); 13C NMR (125 MHz, CDCl3) δ172.8, 160.6, 155.3, 151.8, 
142.8, 135.8, 132.4, 132.2, 132.0, 130.0 (t, J = 10.9 Hz), 125.5, 125.3, 124.2, 124.1, 
121.5, 115.7, 114.2, 112.4, 82.7, 78.8, 65.1, 55.3, 30.8, 22.3; 19F NMR (282 MHz, 
CDCl3) δ 39.50 (br); MS (ESI) m/z calcd for (M-H)- C37H28BF2N2O5 629.21; found 
629.18.
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Green sticky solid (315 mg, 80 %), prepared from 48g (416 mg, 0.28 mmol).  1H NMR 
(500 MHz, CDCl3) δ 8.64 (d, 2H, J = 9.1 Hz), 7.22 (d, 1H, J = 7.7 Hz), 7.14 (d, 1H, J = 
7.7 Hz), 7.10 (s, 1H), 6.91 (dd, 2H, J = 9.1, 2.5 Hz), 6.77 (d, 2H, J = 2.5 Hz), 6.29 (s, 
2H), 4.17-4.15 (m, 4H), 4.06-4.05 (m, 2H), 3.85-3.83 (m, 4H), 3.80 (s, 2H), 3.70-3.37 
(m, 62H), 3.32 (s, 6H), 3.18 (s, 1H), 2.81-2.78 (m, 4H), 2.60-2.56 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 174.5, 159.7, 156.4, 151.4, 142.5, 135.8, 133.1, 131.7, 131.6, 129.8 
(t, J = 11.0 Hz), 125.0, 124.2, 124.1, 123.9, 121.4, 115.8, 114.8, 112.8, 82.9, 78.4,71.8, 
70.7, 70.5, 70.4 (4 peaks: 70.43, 70.43, 70.40, 70.35), 69.7, 69.5 (2 peaks: 69.53, 69.48), 
69.4 (2 peaks: 69.44, 69.35), 68.9, 68.7, 67.2, 58.9, 30.7, 22.2, (several peaks account for 
more than one carbon); 19F NMR (282 MHz, CDCl3) δ 41.09-40.38 (m, 1F), 38.23-37.58 
(m, 1F); MS (MALDI) m/z calcd for (M+Na)+ C73H101BF2NaN2O23  1445.68; found 
1445.79. 
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Syntheses of through-bond energy transfer cassettes 
(1) Syntheses of cassettes 31a-g 
Typical procedures: 
N
B
F2
N
MeO OMe
O CO2H
N N
B
F2
N3
NaO3S SO3Na
+
34 37a  
 
N
N
N
Ph
N
3
Cu, CuSO4.5H2O
THF/H2O (1:1), 25 oC
24 h N
B
F2
N
O
OMe
CO2H
N
NN
NF2B
N
SO3Na
NaO3S
MeO
31a 75 %  
 
BODIPY donor 34 (6 mg, 0.01 mmol), BODIPY acceptor 37a (11 mg, 0.02 mmol), 
TBTA ligand (0.5 mg, 0.001 mmol), Cu (0.6 mg, 0.01 mmol) and CuSO4⋅5H2O (0.3 mg, 
0.001 mmol) were dissolved in 5 mL THF + 1 mL H2O and stirred at room temperature 
for 24 h. The solvents were removed under reduced pressure and the residue was 
 421
purified by MPLC on reverse phase silica gel (H2O to 50 % CH3CN/H2O) to afford the 
product (9 mg, 75 %) as red solid.  1H NMR (500 MHz, d6-DMSO) δ 9.68 (s, 1H), 8.23 
(d, 2H, J = 8.4 Hz), 7.70-7.65 (m, 4H), 7.56 (d, 1H, J = 7.7 Hz), 7.49 (d, 2H, J = 7.7 Hz), 
7.40-7.37 (m, 2H), 7.18 (br, 2H), 7.09 (d, 2H, J = 8.4 Hz), 6.98-6.95 (m, 2H), 6.57 (d, 
2H, J = 4.2 Hz), 4.58 (s, 2H), 3.74 (s, 6H), 2.67 (s, 6H), 1.63 (s, 6H); 13C NMR (125 
MHz, d6-DMSO) δ 157.3, 154.6, 154.4, 147.2, 142.1, 139.4, 137.9, 137.1, 135.2, 134.8, 
132.8, 132.5, 131.1, 130.8, 130.4, 130.0, 129.5, 122.1, 121.7, 121.4, 120.7, 120.6, 119.7, 
111.3, 94.4, 55.6, 45.3, 13.9, 12.8, (due to poor solubility, several carbon did not show 
up); MS (ESI) calcd for (M-2Na)2- C52H41B2F4N7O11S2  m/z 550.62, found 550.58; calcd 
for (M-2Na-H)3- C52H40B2F4N7O11S2  m/z 366.74, found 366.73. 
 
MS
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31b  
 
Red solid (46 mg, 78 %), prepared from donor 34 (20 mg, 0.035 mmol) and BODIPY 
acceptor 37b (43 mg, 0.039 mmol).  1H NMR (500 MHz, d6-DMSO) δ 9.69 (s, 1H), 8.22 
(d, 2H, J = 8.4 Hz), 7.87 (s, 1H), 7.77 (d, 1H, J = 7.9 Hz), 7.71 (d, 2H, J = 8.2 Hz), 7.63 
(d, 2H, J = 7.5 Hz), 7.58 (d, 1H, J = 7.9 Hz), 7.38-7.35 (m, 2H), 7.11 (d, 2H, J = 8.4 Hz), 
6.99-6.96 (m, 2H), 6.89 (d, 2H, J = 4.3 Hz), 6.77 (d, 2H, J = 4.3 Hz), 4.32 (s, 2H), 4.12 
(br, 4H), 3.81 (s, 2H), 3.66 (br, 6H), 3.54-3.32 (m, 36H), 3.12 (s, 6H), 2.67 (s, 6H), 1.63 
(s, 6H); 13C NMR (125 MHz, d6-DMSO) δ 173.3, 156.9, 156.7, 154.7, 154.4, 147.1, 
142.1, 139.5, 137.9, 137.1, 135.3, 134.8, 133.3, 132.6, 131.3, 130.8, 130.0, 129.5, 129.4, 
122.7, 122.3, 121.5, 120.7, 120.0, 117.2, 112.7, 109.8, 71.3, 70.1, 69.9, 69.8 (2 peaks: 
69.81, 69.78), 69.7 (3 peaks: 69.71, 69.69, 69.66), 69.6, 69.3, 68.7, 68.6, 68.4, 68.0, 
58.0, 14.0, 12.8. (7C are ambiguous, several peaks account for more than one carbon).  
MS (ESI) m/z calcd for (M-2Na)2- C76H89B2F4N7O23S2  M/Z: 814.78; found 814.71. 
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Blue solid (54 mg, 80 %), prepared from donor 34 (23 mg, 0.040 mmol) and BODIPY 
acceptor 37c (49 mg, 0.044 mmol).  1H NMR (500 MHz, d6-DMSO) δ 9.69 (s, 1H), 8.21 
(d, 2H, J = 8.2 Hz), 7.87-7.83 (m, 5H), 7.76 (d, 1H, J = 7.8 Hz), 7.70 (d, 2H, J = 8.2 Hz), 
7.56 (d, 1H, J = 7.8 Hz), 7.05 (d, 4H, J = 8.8 Hz), 6.90 (d, 2H, J = 4.3 Hz), 6.81 (d, 2H, J 
= 4.3 Hz), 4.30 (s, 2H), 4.18-4.16 (m, 4H), 3.77-3.75 (m, 6H), 3.64 (br, 2H), 3.60-3.35 
(m, 36H), 3.22 (s, 6H), 2.67 (s, 6H), 1.63 (s, 6H); 13C NMR (125 MHz, d6-DMSO) δ 
173.7, 159.8, 157.1, 156.9, 154.7, 147.1, 142.1, 139.5, 138.8, 137.9, 137.1, 136.2, 134.8, 
133.2, 132.6, 131.0, 130.4, 130.0, 129.5, 124.6, 122.3, 120.8, 120.7, 117.3, 114.4, 109.9, 
71.3, 70.0 (2 peaks: 70.01, 69.96), 69.8 (2 peaks: 69.82, 69.76), 69.7, 69.6 (2 peaks: 
69.64, 69.62), 69.1, 68.9, 68.6, 68.4, 67.3, 58.1, 14.0, 12.8, (several peaks account for 
more than one carbon); MS (ESI) calcd for (M-2Na)2- C76H89B2F4N7O23S2  m/z 814.78; 
found 814.75. 
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Red solid (11 mg, 48 %), prepared from donor 34 (11 mg, 0.02 mmol) and BODIPY 
acceptor 37d (17 mg, 0.03 mmol). 1H NMR (500 MHz, CD3OD) δ 8.61 (br, 1H), 8.17-
8.15 (m, 1H), 8.00-7.95 (m, 3H), 7.51-7.43 (m, 4H), 7.25 (d, 1H, J = 8.7 Hz), 7.18-7.15 
(m, 2H), 6.98 (br, 2H), 6.89-6.87 (m, 2H), 6.69 (br, 2H), 6.46-6.45 (m, 2H), 4.59 (s, 2H), 
3.68 (s, 6H), 2.80 (s, 6H), 1.77 (s, 6H); Due to poor solubility, 13C NMR with good 
resolution could not be obtained; MS (ESI) calcd for (M-2Na)2- C52H41B2F4N7O11S2  m/z 
550.62, found 550.59; calcd for (M-2Na+H) - C52H42B2F4N7O11S2  m/z 1102.25, found 
1102.23. 
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Green solid (36 mg, 60 %), prepared from donor 34 (30 mg, 0.053 mmol) and BODIPY 
acceptor 37e (36 mg, 0.063 mg).  1H NMR (500 MHz, d6-DMSO) δ 9.59 (s, 1H), 8.59 
(d, 2H, J = 8.2 Hz), 8.22 (d, 2H, J = 8.5 Hz), 7.68 (d, 2H, J = 8.5 Hz), 7.59-7.57 (m, 2H), 
7.46-7.42 (m, 3H), 7.39-7.35 (m, 4H), 6.99 (s, 2H), 4.32 (s, 2H), 2.89-2.86 (m, 4H), 2.66 
(br, 10H), 1.61 (s, 6H); 13C NMR (125 MHz, d6-DMSO) δ 154.3, 150.8, 146.6, 141.7, 
140.3, 139.1, 137.4, 136.6, 136.1, 135.7, 134.4, 132.5, 132.2, 129.5, 129.1, 128.4, 127.3, 
126.9, 126.8, 125.6, 120.4, 117.4, 108.6, 45.4, 29.4, 21.3, 13.6, 12.4. (6C are ambiguous, 
several peaks account for more than one carbon). MS (ESI) m/z calcd for (M-2Na)2- 
C54H41B2F4N7O9S2  M/Z: 546.63; found 546.61. 
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31f  
 
Green solid (14 mg, 35 %), prepared from donor 34 (19 mg, 0.033 mmol) and BODIPY 
acceptor 37f (32 mg, 0.051 mg).  1H NMR (500 MHz, d6-DMSO) δ 9.64 (s, 1H), 8.54 (d, 
2H, J = 9.0 Hz), 8.23 (d, 2H, J = 8.4 Hz), 7.68 (d, 2H, J = 8.4 Hz), 7.65 (s, 1H), 7.60 (d, 
1H, J = 7.7 Hz), 7.46 (d, 1H, J = 7.7 Hz), 7.02 (dd, 2H, J = 9.0, 2.0 Hz), 6.97 (d, 2H, J = 
2.0 Hz), 6.78 (s, 2H), 4.51 (s, 2H), 3.84 (s, 6H), 2.86-2.83 (m, 4H), 2.66 (s, 6H), 2.64-
2.60 (m, 4H), 1.62 (s, 6H); 13C NMR (125 MHz, d6-DMSO) δ 172.0, 160.4, 157.0, 
154.6, 150.4, 147.4, 143.0, 142.1, 139.5, 137.9, 137.1, 135.6, 134.9, 134.8, 132.4, 132.3, 
131.6, 130.0, 129.5, 129.1, 125.4, 122.6, 120.8, 120.6, 120.5, 116.7, 114.3, 112.7, 109.5, 
55.4, 30.1, 21.6, 14.0, 12.8, (one carbon is ambiguous, some peak might account for two 
carbons); MS (ESI) calcd for (M-2Na)2- C56H45B2F4N7O11S2 m/z 576.64; found 576.62. 
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Green solid (30 mg, 25 %), prepared from donor 34 (34 mg, 0.06 mmol) and BODIPY 
acceptor 37g (111 mg, 0.078 mg).  1H NMR (500 MHz, 1:1 CDCl3/CD3OD) δ 8.83 (br, 
1H), 8.63-8.62 (m, 2H), 8.06 (br, 2H), 7.70 (br, 1H), 7.48 (br, 3H), 7.29 (br, 1H), 6.86-
6.80 (m, 4H), 6.41 (s, 2H), 4.15 (br, 6H), 3.94-3.85 (m, 8H), 3.72-3.34 (m, 66H), 2.80 
(br, 10H), 2.60 (br, 4H), 1.77 (s, 6H); 13C NMR (125 MHz, 1:1 CDCl3/CD3OD) δ 160.5, 
157.9, 156.8, 151.9, 148.3, 143.7, 142.4, 138.4, 136.8, 135.6, 135.0, 133.2, 132.4, 131.0, 
130.4, 125.2, 124.5, 122.1, 121.7, 120.1, 118.3, 115.2, 113.8, 72.0, 71.2, 70.9, 70.6, 
70.5, 70.3, 70.2, 70.1, 67.9, 59.2, 31.4, 22.9, 14.6, 14.0, (due to poor solubility, 22C are 
ambiguous, several peaks might account for more than one carbon); MS (ESI) m/z calcd 
for (M-2Na)2- C92H117B2F4N7O29S2 M/Z: 972.87, found 972.86; calcd for (M-2Na-H)3- 
C92H116B2F4N7O29S2  M/Z: 648.26, found 648.22. 
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(2) Syntheses of cassettes 32-33 
Typical procedures: 
N
B
F2
N
O
MeO OMe
CO2H
NN
N
B
F2
ONaO3SNN
N
B
F2
ONaO3S
N
B
F2
N
O
MeO OMe
CO2H
I
+
PdCl2(PPh3)2
CuI, Et3N
DMF, 25 oC
12 h
1g
37a
32
 
 
A solution of donor 1g (14 mg, 0.025 mmol), BODIPY acceptor 37a (20 mg, 0.035 
mmol), PdCl2(PPh3)2 (2 mg, 0.003 mmol) and CuI (0.6 mg, 0.003 mmol) in 3 mL DMF 
was degassed and filled with N2 then Et3N (35 μL, 0.25 mmol) was added. The reaction 
mixture was stirred at 25 oC for 24 h then concentrated under reduced pressure. The 
residue was purified by flash chromatography (20 % MeOH/CH2Cl2) to afford the 
product 32 (20 mg, 79 %) as a red solid.  1H NMR (500 MHz, d6-DMSO) δ 7.89-7.84 
(m, 3H), 7.67 (s, 1H), 7.47 (br, 3H), 7.37-7.30 (m, 4H), 7.17 (s, 1H), 7.08-7.07 (m, 4H), 
6.95 (br, 2H), 6.56 (br, 2H), 4.48 (s, 2H), 3.73 (s, 6H), 3.11 (s, 3H), 2.41 (s, 3H), 2.33 (s, 
3H);  13C NMR (500 MHz, d6-DMSO) δ 171.3, 160.7, 157.3, 156.4, 155.0, 154.7, 146.4, 
140.1, 140.0, 135.0, 134.4, 133.5, 132.2, 131.4, 131.1, 130.9, 130.4, 130.2, 127.2, 125.6, 
124.6, 124.1, 123.0, 122.3, 121.3, 119.8, 118.1, 117.9, 115.5, 111.4, 91.8, 89.4, 66.9, 
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55.6, 28.2, 13.0, 10.5; MS (ESI) m/z calcd for (M-Na)- C50H38B2F4N5O9S 982.25; found 
982.25. m/z calcd for (M-Na-H)2- C50H37B2F4N5O9S 490.62; found 490.62. 
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Blue sticky solid (45 mg, 45 %), prepared from BODIPY donor 35 (46 mg, 0.056 mmol) 
and BODIPY acceptor 37c (75 mg, 0.068 mmol).  1H NMR (500 MHz, CD3OD) δ 7.97 
(s, 1H), 7.92 (d, 4H, J = 8.8 Hz), 7.40-7.30 (m, 5H), 7.20 (d, 1H, J = 7.5 Hz), 7.00 (d, 
4H, J = 8.8 Hz), 6.77 (d, 2H, J = 4.3 Hz), 6.69 (d, 2H, J = 4.3 Hz), 6.05 (s, 2H), 4.58-
4.54 (m, 4H), 4.18-4.16 (m, 8H), 4.09 (s, 2H), 3.84-3.82 (m, 4H), 3.70-3.30 (m, 54H), 
2.80-2.77 (m, 2H), 2.48 (s, 6H), 2.37-2.31 (m, 2H), 1.52 (s, 6H); 13C NMR (125 MHz, 
CD3OD) δ 173.0, 161.6, 159.3, 158.2, 157.3, 156.5, 144.1, 139.8, 139.7, 137.9, 133.2, 
132.6, 132.4, 131.2, 131.1, 127.0, 126.7, 126.5, 126.3, 126.0, 125.3, 125.2, 125.0, 122.1, 
121.6, 116.6 (2 peaks: 116.62, 116.58), 115.5, 91.2, 90.9, 73.0, 72.0, 71.8 (2 peaks: 
71.83, 71.76), 71.6 (2 peaks: 71.64, 71.57), 71.4, 71.3 (2 peaks: 71.30, 71.26), 71.1 (3 
peaks: 71.13, 71.09, 71.08), 71.0, 70.9, 70.8, 70.7, 70.5, 70.3, 70.2, 68.9, 68.7, 64.9, 
59.1, 52.4, 50.0, 49.1, 27.3, 14.7, 14.4, (4C are ambiguous, several peaks might account 
for more than one carbon). 
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Spectroscopic properties of through-bond energy transfer cassettes 31-33 
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Figure F1. Spectra for cassette 31a, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F2. Spectra for cassette 31b, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F3. Spectra for cassette 31c, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F4. Spectra for cassette 31d, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F5. Spectra for cassette 31e, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F6. Spectra for cassette 31f, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F7. Spectra for cassette 31g, in MeOH: a absorbance and, b fluorescence; in 0.1 M phosphate 
buffer (pH 7.4): c absorbance and, d fluorescence. (10-6 M for absorbance and 10-7 M for fluorescence). 
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Figure F8. a Normalized absorbance and, b fluorescence of cassette 32 in MeOH (10-6 M for absorbance 
and 10-7 M for fluorescence). 
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Figure F9. a Normalized absorbance and, b fluorescence of cassette 33 in MeOH (10-6 M for absorbance 
and 10-7 M for fluorescence). 
 
 
 
Table F1. Photophysical properties of cassette 33 
 
log(εmax) Φ of acceptor 
solvent 
λabs D 
(nm) 
λabs A 
(nm) 
λemiss A
(nm) D A Ex. Da Ex. Ab 
E.T.E (%)c 
MeOH 503 586 625 4.97 4.78 0.63 0.67 94 
 
a Rhodamine 6G (Φ = 0.94 in EtOH); and b Cresyl Violet (Φ = 0.54 in MeOH) were used as standards; c 
energy transfer efficiency (E.T.E) was calculated by dividing the quantum yield of acceptor when excited 
at donor by the quantum yield of acceptor when excited at acceptor. 
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Protein-protein interaction studies: 
(1) Syntheses of fluorescently labeled proteins: 
Cassette 1 refers to BODIPY cassette 31b; Cassette 2 refers to BODIPY cassette 31e 
 
Synthesis of 1-Streptavidin 
Cassette 1 (1.0 mg, 0.6 μmol) was dissolved in 100 μL dry DMF and NHS (0.4 mg, 3.5 
μmol), DIC (0.5 μL, 3.2 μmol) were added. The reaction mixture was stirred at room 
temperature for 24 h. 
The activated cassette 1 solution (35 μL, 5 eq.) was added to the solution of streptavidin 
(2.2 mg, 1 eq.) in 0.5 mL sodium bicarbonate buffer (0.1 M, pH 8.3). The solution was 
stirred at room temperature in the dark for 30 min. The unreacted cassette 1 was 
removed by SephadexTM G-25 (PD-10) desalting column. 
 
Synthesis of 1-Bovine Serum Albumin (BSA) 
The activated cassette 1 solution (63 μL, 5 eq.) was added to the solution of BSA (5 mg, 
1 eq.) in 1 mL sodium bicarbonate buffer (0.1 M, pH 8.3). The solution was stirred at 
room temperature in the dark for 30 min. The unreacted cassette 1 was removed by 
SephadexTM G-25 (PD-10) desalting column. 
 
Synthesis of 2-Avidin 
Cassette 2 (1.0 mg, 0.9 μmol) was dissolved in 100 μL dry DMF and NHS (0.5 mg, 4.3 
μmol), DIC (0.7 μL, 4.5 μmol) were added. The reaction mixture was stirred at room 
temperature for 24 h. 
The activated cassette 2 solution (100 μL, 5 eq.) was added to the solution of avidin (12 
mg, 1 eq.) in 1.0 mL sodium bicarbonate buffer (0.1 M, pH 8.3). The solution was stirred 
at room temperature in the dark for 30 min. The unreacted cassette 2 was removed by 
SephadexTM G-25 (PD-10) desalting column. 
 
Synthesis of Atto-425-BSA 
A solution of Atto 425-NHS ester (1.0 mg, 6 eq.) in 100 μL DMF was added to the 
solution of BSA (22 mg, 1 eq.) in 2.0 mL sodium bicarbonate buffer (0.1 M, pH 8.3). 
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The solution was stirred at room temperature in the dark for 30 min. The unreacted Atto 
425- NHS was removed by SephadexTM G-25 (PD-10) desalting column. 
 
Synthesis of Atto-425-BSA-Biotin 
A solution of biotin NHS ester (0.7 mg, 10 eq.) in 100 μL DMF was added to the 
solution of Atto-425-BSA (13 mg, 1 eq.) in 1.0 mL sodium bicarbonate buffer (0.1 M, 
pH 8.3). The solution was stirred at room temperature in the dark for 30 min. The 
unreacted biotin-NHS was removed by SephadexTM G-25 (PD-10) desalting column. 
 
Determination of Dye/Protein Ratios 
(i) measure the absorbance of the protein-dye conjugate at 280 nm (A280) and at the λmax 
for the dye (Amax) 
(ii) correct for the contribution of the dye to the absorbance at A280: 
Aprotein = A280 – Amax * (A280 free dye/Amax free dye) 
(iii) Dye/protein ration = (Amax/εdye) / (Aprotein/εprotein) 
 
Determination of Biotin/Protein Ratios 
(i) HABA/avidin reagent (Sigma, H2153) was reconstituted with 10 mL deionized water. 
In a 1 mL cuvette, pipette 0.9 mL HABA/avidin reagent solution, read A500 HABA/avidin. 
Add 0.1 mL sample, mix by inverting the cuvette, wait for 5 min then read A500 
HABA/avidin+samples. 
(ii) sample blank: dilute 0.1 mL sample with 0.9 mL water and read A500 sample blank. 
(iii) ΔA500 = 0.9A500 HABA/avidin + A500 sample blank - A500 HABA/avidin+samples 
(ΔA500 should be in the range of 0.1-0.4. If a change greater than this is observed, the 
sample should be diluted and measure again, as this indicates there is more biotin present 
than avidin) 
(iv) μmol biotin/ml sample = 10 * (ΔA500/34) 
(v) biotin/protein ratio = (μmol biotin/ml sample) / (μmol protein/ml sample) 
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Figure F10. Absorbance and fluorescence spectra for 1-streptavidin in 0.1 M phosphate buffer (pH 7.4). 
λmax abs(D): 502 nm;  λmax abs(A): 556 nm; λemiss(A): 604 nm;  
 
dye/protein ratio = 2.5 : 1.0 
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Figure F11. Absorbance and fluorescence spectra for 1-BSA in 0.1 M phosphate buffer (pH 7.4). λmax 
abs(D): 505 nm;  λmax abs(A): 558 nm; λemiss(A): 604 nm;  
 
dye/protein ratio = 4.0 : 1.0 
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Figure F12. Absorbance and fluorescence spectra for 2-avidin in 0.1 M phosphate buffer (pH 7.4). λmax 
abs(D): 505 nm;  λmax abs(A): 642 nm; λemiss(A): 655 nm;  
 
dye/protein ratio = 1.6 : 1.0 
 
(Some energy leakage from the donor was observed when cassette 2 was attached to 
avidin.) 
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Figure S13. Absorbance and fluorescence spectra for Atto-425-BSA in 0.1 M phosphate buffer (pH 7.4). 
λmax abs: 437 nm;  λemiss(A): 482 nm;  
 
dye/protein ratio = 5.2 : 1.0 
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Figure F14. Absorbance and fluorescence spectra for Atto-425-BSA-biotin in 0.1 M phosphate buffer (pH 
7.4). λmax abs: 435 nm;  λemiss(A): 481 nm;  
 
biotin/protein/dye ratio = 6.6 : 1.0 : 5.2 
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(2) In-vitro three protein interactions 
Experiment (ii) (the key experiment): 
In a fluorescence cuvette, 1-streptavidin (3.0 x 10-7 M) and 2-avidin (9.0 x 10-7 M) were 
pretreated with BSA (1.8 x 10-5 M) in 0.1 M phosphate buffer (pH 7.4).  The mixture 
was incubated in the dark for 20 min, and then Atto-425-BSA-biotin (2.0 x 10-7 M) was 
added.  These relative concentrations were used to give similar fluorescence intensities. 
Fluorescence (ex. 430 nm) of the solution was taken after 10 min. The solution was also 
excited at 488 nm to obtain the fluorescence after FRET (F488 after). 
 
0
50
100
150
200
250
300
400 450 500 550 600 650 700 750 800
Wavelength (nm)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
Figure F15. Fluorescence spectra for exp. (ii) after FRET (ex. 430 nm) 
 
The following strategies were used to deduce the approximate fluorescence of the 
reaction mixture before FRET: 
(i) Streptavidin (3.0 x 10-7 M), avidin (9.0 x 10-7 M) and BSA (1.8 x 10-5 M) were mixed 
in 0.1 M phosphate buffer (pH 7.4) for 20 min, then Atto-425-BSA-biotin (2.0 x 10-7 M) 
was added. The mixture was incubated for 10 min then excited at 430 nm to obtain the 
emission spectrum before FRET for Atto-425-BSA-biotin (Fbaseline-1).  This gives a 
baseline for one component (Atto-425-BSA-biotin). 
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(ii) Practically it is impossible to prepare BSA-biotin which has the same biotin/protein 
ratio and biotin distribution as the Atto-425-BSA-biotin used.  However, it is necessary 
to correct the fluorescence of the cassettes involved in the protein-protein interaction for 
the presence of the BSA-biotin.  Consequently, we made the assumption that the 
percentage correction for the presence of BSA-biotin would be almost the same when 
the sample was irradiated at 430 nm and at 488 nm.  Thus, the following steps were used 
to correct the baseline for the 1-streptavidin and 2-avidin:       
    (a) 1-streptavidin (3.0 x 10-7 M), 2-avidin (9.0 x 10-7 M) were pretreated with BSA 
(1.8 x 10-5 M) in 0.1 M phosphate buffer (pH 7.4) for 20 min. Fluorescence of this 
solution was taken when excited at 430 nm (F430) and 488 nm (F488 before).  
    (b) Since Atto-425-BSA-biotin is not excited at 488 nm, the fluorescence changes 
observed between F488 after and  F488 before (“before” and “after” refer to FRET) should be 
caused by environmental changes and/or interactions between 1-streptavidin and 2-
avidin under the experimental conditions. This then can be used to correct the F430 for 
the same change and obtain the baseline for 1-streptavidin and 2-avidin according to: 
 
Fbaseline-2 = F430 x (F488 after / F488 before) 
 
(iii) The approximate fluorescence of the reaction mixture before FRET was then the 
sum of the two components defined above:  
 
Fbaseline = Fbaseline-1 + Fbaseline-2 
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Figure F16. Fluorescence spectra for exp. (ii) before FRET (ex. 430 nm) 
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Figure F17. Fluorescence spectra for exp. (ii) before and after FRET (ex. 430 nm) 
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Experiment (i) (control): 
In a fluorescence cuvette, 1-streptavidin (3.0 x 10-7 M) and 2-avidin (9.0 x 10-7 M) were 
pretreated with BSA (1.8 x 10-5 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was 
incubated in the dark for 20 min, and then Atto-425-BSA (2.0 x 10-7 M) was added. 
Fluorescence (ex. 430 nm) of the solution was taken after 10 min. The baseline for this 
experiment was obtained using similar methods as described for experiment (ii). 
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Figure F18. Fluorescence spectra for exp. (i), before and after FRET (ex. 430 nm) 
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Experiment (iii) (biotin block): 
In a fluorescence cuvette, 1-streptavidin (3.0 x 10-7 M) and 2-avidin (9.0 x 10-7 M) were 
pretreated with BSA (1.8 x 10-5 M) and biotin (1.0 x 10-4 M) in 0.1 M phosphate buffer 
(pH 7.4). The mixture was incubated in the dark for 20 min, and then Atto-425-BSA-
biotin (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) of the solution was taken 
after 10 min. The baseline for this experiment was obtained using similar methods as 
described for experiment (ii). 
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Figure F19. Fluorescence spectra for exp. (iii), before and after FRET (ex. 430 nm) 
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Experiment (iv) (selective binding): 
In a fluorescence cuvette, 1-BSA (3.0 x 10-7 M) and 2-avidin (9.0 x 10-7 M) were 
pretreated with BSA (1.8 x 10-5 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was 
incubated in the dark for 20 min, and then Atto-425-BSA-biotin (2.0 x 10-7 M) was 
added. Fluorescence (ex. 430 nm) of the solution was taken after 10 min. The baseline 
for this experiment was obtained using similar methods as described for experiment (ii). 
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Figure F20. Fluorescence spectra for exp. (iv), before and after FRET (ex. 430 nm) 
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Figure F21. Overall fluorescence changes at 480 nm, 606 nm and 654 nm for exp (i)-(iv). (excited at 430 
nm) 
 
Data presented in Figure F21 represents the overall fluorescence changes.  The next step 
in the process is to deconvolute the components of these changes that are due to 
interaction of Atto 425 with cassette 1 and cassette 2.  To do this it is important to 
understand that fluorescence at 480 nm should be due to the FRET-donor (Atto 425), 
since cassette 1 and cassette 2 do not fluorescence at 480 nm.  However, fluorescence 
observed at 606 nm for the protein-protein interactions had components from cassette 1 
and from Atto 425, but not from cassette 2 which does not emit at this wavelength.  
Similarly, fluorescence observed at 654 nm had components from both cassettes and 
from Atto 425.  Thus the following steps were taken for deconvolution (throughout: 
excited at 430 nm): 
(i) The emission at 480 nm was measured to reveal the fluorescence from Atto 
425.   
(ii) The value from step (i) was used to deduce the fluorescence from Atto 425 at 
606 nm. 
(iii) The value from step (ii) was subtracted from the observed value at 606 nm to 
reveal the fluorescence intensity attributed to cassette 1 alone. 
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(iv) The values from (i) and (iii) were used to deduce the fluorescence of Atto 
425 and of cassette 1 at 654 nm. 
(v) The values from step (iv) were subtracted from the observed value at 654 nm 
to reveal the fluorescence intensity attributed to cassette 2 alone. 
 
Mathematically, an illustrative correction procedure is described for experiment (ii): 
(1) Fluorescence changes at 480 nm is due to fluorescence changes of FRET donor 
(Atto-425-BSA-biotin), since 1-streptavidin and 2-avidin do not emit at 480 nm. 
 
(2) (a) Fluorescence intensity of 1-streptavidin at 606 nm before FRET (Fbefore, 1-streptavidin, 
606) can be read from the baseline (Fbaseline-2) described above;  
 
  (b) The fluorescence intensity of 1-streptavidin after FRET is given by: 
 
Fafter, 1-streptavidin, 606 =  Fafter, 606 – Fafter, 480 * (F606/F480)Atto-425-BSA-biotin 
 
where Fafter, 606, Fafter, 480 are the fluorescence intensity for the reaction mixture after 
FRET at 606nm and 480nm, respectively; (F606/F480) Atto-425-BSA-biotin is the ratio of 
fluorescence intensity at 606nm and 480nm for Atto-425-BSA-biotin;  
 
      (c) The percentage fluorescence change for 1-streptavidin at 606nm is given by: 
  
(Fafter, 1-streptavidin, 606 - Fbefore, 1-streptavidin, 606) * 100 / Fbefore, 1-streptavidin, 606 
 
(3)  (a) Fbefore, 654 is read from the baseline value Fbaseline-2 as described above, then that 
value is applied to the following equation to obtain the fluorescence intensity of 2-avidin 
at 654 nm before FRET: 
  
Fbefore, 2-avidin, 654 = Fbefore, 654 – Fbefore, 1-streptavidin, 606 * (F654/F606)1-streptavidin 
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where Fbefore, 1-streptavidin, 606 is the fluorescence intensity of 1-streptavidin at 606 nm before 
FRET; (F654/F606)1-streptavidin is the ratio of fluorescence intensity at 654 nm and 606 nm 
for 1-streptavidin; 
 
       (b) The fluorescence intensity of 2-avidin at 654 nm after FRET is calculated from: 
 
Fafter, 2-avidin, 654 =  
Fafter, 654 – Fafter, 480 * (F654/F480) Atto-425-BSA-biotin - Fafter, 1-streptavidin, 606 * (F654/F606)1-streptavidin 
 
where (F654/F480) Atto-425-BSA-biotin is the ratio of fluorescence intensity at 654 nm and 480 
nm for Atto-425-BSA-biotin; 
 
       (c) The percentage fluorescence change for 2-avidin at 654nm is calculated from: 
  
(Fafter, 2-avidin, 654 - Fbefore, 2-avidin, 654) * 100 / Fbefore, 2-avidin, 654 
 
Similar corrections were made to experiment (i), (iii) and (iv). The data shown in Figure 
F22 are that after all these corrections were applied. 
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Figure F22. Fluorescence changes for Atto 425 (480 nm), cassette 1 (606 nm) and cassette 2 (654 nm) in 
exp (i)-(iv) 
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FRET Efficiency  
The stoichiometry of BSA-biotin/avidin/streptavidin complexes formed in the 
experiments (i)-(iv) was impossible to determine.  Consequently, the FRET efficiency 
for the reaction was calculated for the overall energy transfer, which is the energy 
transfer from the FRET donor (Atto425) to cassettes 1 and 2. 
 
FRET efficiency (E) was calculated from: 
 
E = 1- Fafter / Fbefore 
 
where Fafter and Fbefore are the FRET donor (Atto 425) fluorescence intensity after and 
before FRET, respectively. 
 
 
Table F2. FRET efficiency for experiments (i)-(iv) 
 
 experiment (i) experiment (ii) experiment (ii) experiment (iv) 
FRET 
efficiency (%) 
15 74 16 50 
 
 
 467
(3) In-vitro two protein interactions 
(i) In a fluorescence cuvette, 1-streptavidin (3.0 x 10-7 M) was pretreated with BSA (9.0 
x 10-6 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 
20 min, and then Atto425-BSA-biotin (2.0 x 10-7 M) was added. Fluorescence (ex. 430 
nm) of the solution was taken after 10 min. The baseline for this experiment was 
obtained using similar methods as described above. 
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Figure F23. Fluorescence spectra for exp. (i), before and after FRET (ex. 430 nm) 
 468
(ii) In a fluorescence cuvette, 1-streptavidin (3.0 x 10-7 M) was pretreated with BSA (9.0 
x 10-6 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 
20 min, and then Atto425-BSA (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) of 
the solution was taken after 10 min. The baseline for this experiment was obtained using 
similar methods as described above. 
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Figure F24. Fluorescence spectra for exp. (ii), before and after FRET (ex. 430 nm) 
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(iii) In a fluorescence cuvette, 2-avidin (9.0 x 10-7 M) was pretreated with BSA (9.0 x 10-
6 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 20 
min, and then Atto425-BSA-biotin (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) 
of the solution was taken after 10 min. The baseline for this experiment was obtained 
using similar methods as described above. 
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Figure F25. Fluorescence spectra for exp. (iii), before and after FRET (ex. 430 nm) 
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(iv) In a fluorescence cuvette, 2-avidin (9.0 x 10-7 M) was pretreated with BSA (9.0 x 10-
6 M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 20 
min, and then Atto425-BSA (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) of the 
solution was taken after 10 min. The baseline for this experiment was obtained using 
similar methods as described above. 
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Figure F26. Fluorescence spectra for exp. (iv), before and after FRET (ex. 430 nm) 
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(v) In a fluorescence cuvette, 1-BSA (3.0 x 10-7 M) was pretreated with BSA (9.0 x 10-6 
M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 20 
min, and then Atto425-BSA-biotin (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) 
of the solution was taken after 10 min. The baseline for this experiment was obtained 
using similar methods as described above. 
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Figure S27. Fluorescence spectra for exp. (v), before and after FRET (ex. 430 nm) 
 472
(vi) In a fluorescence cuvette, 1-BSA (3.0 x 10-7 M) was pretreated with BSA (9.0 x 10-6 
M) in 0.1 M phosphate buffer (pH 7.4). The mixture was incubated in the dark for 20 
min, and then Atto425-BSA (2.0 x 10-7 M) was added. Fluorescence (ex. 430 nm) of the 
solution was taken after 10 min. The baseline for this experiment was obtained using 
similar methods as described above. 
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 Figure F28. Fluorescence spectra for exp. (vi), before and after FRET (ex. 430 nm) 
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(4) Ex vivo protein-protein interaction studies 
a. Cell culture 
COS-7 cells (American Type Culture Collection) were cultured as subconfluent 
monolayers on 75 cm2 culture flask with vent caps in DMEM supplemented with 10 % 
fetal bovine serum (FBS) in a humidified incubator at 37 ºC with 5 % CO2.  Cells grown 
to subconfluence were enzymatically dissociated from the surface with trypsin and 
plated 2-3 days prior to the experiments in Lab-Tek two well chambered coverglass 
slides (Nunc).  
 
b. Fluorescence microscopy 
Protein interactions were studied on living COS7 cells using a Zeiss 510 META NLO 
Multiphoton Microscope System consisting of an Axiovert 200 MOT microscope.  
Digital images of streptavidin-1 (acceptor 1), avidin-2 (acceptor 2) and biotin-BSA-
Atto425 (FRET donor) were captured with a 40x / 1.3 oil objective with the following 
filter sets: Excitation 458 nm; Emission BP 480-520 for BSA-Atto425 (FRET donor); 
Emission BP 565-615 for streptavidin-1 (acceptor 1);  and Emission BP 640-704 for 
avidin-2 (acceptor 2).   
 
The protein:carrier complexes were pre-formed at room temperature in ACAS medium 
for 30 min by mixing (in a mol:mol ratio) the labeled protein and the carrier, Pep-1 
(Active Motif).  The different complexes were formed as follows: 
- FRET donor (biotin-BSA-Atto425) : Pep-1 : 1:20 mol:mol ratio of 
protein:carrier  
- Streptavidin-1 (acceptor 1) : Pep-1 : 1:15 mol:mol ratio of protein:carrier 
- Avidin-2 (acceptor 2) : Pep-1 : 1:10 mol:mol ratio of protein:carrier 
- Streptavidin-1 (acceptor 1) : Avidin-2 (acceptor 2) : Pep-1 : 1:3:50 mol:mol 
ratio of protein:carrier 
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c. Ex-vivo three protein interactions 
First, the FRET donor was imported inside COS-7 cells by treating the cells with the 
FRET donor (biotin-BSA-Atto425) : Pep-1 complex.  After a 10 min incubation period 
at 37 °C, the cells were washed several times with PBS, then the Streptavidin-1 
(acceptor 1) : Avidin-2 (acceptor 2) : Pep-1 complex was added, and the cells were 
incubated for another 10 min at 37 °C.  The cells were washed several times with PBS 
buffer and then put on the stage of the Zeiss 510.   
 
Energy Transfer data in COS-7 cells loaded with FRET donor (biotin-BSA-Atto425), 
Streptavidin-1 and Avidin-2 were collected using 458 nm excitation wavelength.  
Emission of FRET donor (biotin-BSA-Atto425) (blue channel; donor signal) was 
collected using a BP 480-520 emission filter whereas emissions of Streptavidin-1 and 
Avidin-2  (FRET channel; acceptor signals) were collected using a BP 565-615 and BP 
640-704 filters, respectively.  Donor bleed through signal to the FRET channel was 
calculated by measuring the FRET channel signal resulting from COS cells loaded only 
with the donor. Acceptor bleed through to the FRET channel was calculated by 
measuring the FRET channel signal resulting from COS cells loaded with Streptavidin-1 
and Avidin-2 alone.  
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a 
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Figure F29. Three protein interactions in living cells (biotin-BSA-Atto425 + Streptavidin-1 + Avidin-2): 
a DIC and fluorescence images of cells; b overlay 
480-520 nm 565-615 nm 640-704 nm 
480-520 nm 
565-615 nm 640-704 nm 
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d. Ex-vivo two protein interactions (donor and acceptor 1; donor and acceptor 2) 
As described above, cells were first treated with the FRET donor (10 min at 37 °C), 
followed by the Acceptor 1 or Acceptor 2 (10 min at 37 °C).   
a 
  
  
b 
   
Figure F30. Two protein interactions in living cells (biotin-BSA-Atto425 + Streptavidin-1): a DIC and 
fluorescence images of cells; b overlay 
480-520 nm 
565-615 nm 640-704 nm 
480-520 nm 565-615 nm 640-704 nm 
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Donor and Acceptor 2: 
  
  
Figure F31. Two protein interactions (biotin-BSA-Atto425 + Avidin-2): DIC and fluorescence images of 
cells. 
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e. Ex-vivo control experiments  
Energy Transfer data in untreated COS-7 cells i.e. cell autofluorescence and in cells 
loaded uniquely with FRET donor (biotin-BSA-Atto425), Streptavidin-1 and Avidin-2 
were collected  using 458 nm excitation wavelength.  Emission of FRET donor (biotin-
BSA-Atto425) (blue channel; donor signal) was collected using a BP 480-520 emission 
filter whereas emissions of Streptavidin-1 and Avidin-2  (FRET channel; acceptor 
signals) were collected using BP 565-615 and BP 640-704 emission filters, respectively.  
Donor bleed through signal to the FRET channel was calculated by measuring the FRET 
channel signal resulting from COS cells loaded only with the donor. Acceptor bleed 
through to the FRET channel was calculated by measuring the FRET channel signal 
resulting from COS cells loaded with Streptavidin-1 and Avidin-2 alone. 
  
  
Figure F32. Cell autofluorescence 
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565-615 nm 640-704 nm 
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Figure F33. Biotin-BSA-Atto425 (FRET Donor) only 
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Figure F34. Streptavidin-1 (Acceptor 1) only 
565-615 nm 640-704 nm 
480-520 nm 
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Figure F35. Avidin-2 (Acceptor 2) only 
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